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The transmission of Trypanosoma brucei, the causative agent of human African 
trypanosomiasis, depends upon the development in the bloodstream of 'stumpy 
forms' from non-transmissible 'slender forms'. In stumpy forms many mRNAs are 
downregulated and translation is generally repressed. However, a small subset of 
genes escape this repression and are upregulated, presumably as an adaptation for 
transmission. To understand the basic of this, regulatory sequences within the 3'UTR 
of a major stumpy-enriched transcript (an ESAG9 gene) have been characterised. 
This identified a signal responsible for gene silencing in slender forms and gene 
activation when cells develop to stumpy forms.  
 
An investigation was made of upstream open reading frames (uORFs) as a 
mechanism for the control of stumpy form gene expression. No evidence was found 
of uORF control, but one gene investigated was found to produce two transcripts 
through trans-splicing at different sites. These transcripts, which were found to 
exhibit some differential abundance between life-cycle stages, would generate a long 
and short form (from an internal ATG) of the encoded protein. Both are predicted to 
contain a UBA/TS-N (ubiquitin associated) domain, however, the longer form of the 
protein is also predicted to contain a transmembrane helix and cleavable signal 
peptide, suggesting a different localisation. However, ectopic expression of either 
protein form with a Ty epitope tag resulted in the same protein localisation.  
 
Additionally, the transcripts of two translational protein homologues, TbeIF4E4 and 
TbeIF6, were identified as upregulated in stumpy forms. Radiolabelled-methionine 
experiments and polysome analysis showed that overexpression or RNAi-mediated 
ablation of TbeIF6 resulted in a decrease in protein synthesis and decrease in 
translation. Unlike its archaeal homologue, TbeIF6 protein was not induced by cold-
shock treatment.  
 
Finally, to identify which transcripts escape translational repression in stumpy forms 
an analysis was made of polysome-associated transcripts by RNA-sequencing. This 
identified potentially interesting genes for further investigation, and showed that 
14 
many procyclic-enriched transcripts were also enriched in stumpy form polysome-
associated RNA, confirming these cells as preadapted for transmission. Together, 
this work has characterised a 3’UTR regulatory element in a stumpy-enriched 
transcript, examined alternative trans-splicing of another transcript, investigated two 
translational protein homologues and identified transcripts that escape translational 
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Trypanosoma brucei species are unicellular protozoan parasites belonging to Phylum 
Euglenozoa, Order Kinetoplastida, and Family Trypanosomatidae (Vickerman, 
1994). Trypanosomes are extremely ancient protists, likely diverged from the 
eukaryotic lineage soon after the early eukaryote cell had acquired the mitochondrion 
through endosymbiosis (Gray, 1992).  
 
The trypanosomatids include, among others, T. brucei, T. cruzi and Leishmania 
species, which also comprise the group termed the ‘TriTryps’. All of these cause 
neglected tropical disease; human African trypanosomiasis (HAT) and Nagana in the 
case of T. brucei, Chagas disease, also known as American trypanosomiasis, in the 
case of T. cruzi, and the spectrum of Leishmaniasis disease in the case of the 
Leishmania species. 
 
Chagas disease is found mainly in Latin America and human infection principally 
occurs by transmission of T. cruzi through the faeces of triatomine bugs. It is 
estimated that 10 million people worldwide are infected with T. cruzi 
(http://www.who.int/mediacentre/factsheets/fs340/en/index.html). Leishmaniasis is a 
spectrum of diseases covering cutaneous, mucocutaneous, and the most serious, 
visceral forms of the disease. Leishmania parasites are transmitted to human hosts by 
the bite of a sandfly, which then proliferate in the phagolysosome of macrophages 
after phagocytosis. 
 
The studies presented in this thesis concern T. brucei, the causative agent of HAT 
and Nagana in cattle. 
 
1.1.1 Impact of African trypanosomiasis 
HAT, also known as African sleeping sickness, is caused by infection with the T. 
brucei subspecies, T. b. gambiense and T. b. rhodesiense. Recent estimates puts the 
prevalence of the disease between 50 000-70 000 cases (Brun et al., 2009), and 
disease is limited to sub-Saharan Africa, due to the distribution of the parasite vector, 




Figure 1.1 Map of Africa with the epidemiological status of HAT in countries where 
the disease is considered endemic. Figure taken from Simarro et al. (2008). 
 
Infection with T. b. gambiense is found in west and central Africa, where it causes a 
chronic infection accounting for more than 90% of disease cases, whereas T. b. 
rhodesiense infection is found in eastern and southern Africa, causing an acute 
infection accounting for less than 10% of cases (Simarro et al., 2008).  
 
The disease mostly affects rural areas, where it causes a great economic burden. A 
measure of disease burden, disability-adjusted life year (DALY) was estimated in 
2002 at 1.54 million DALYs lost to HAT (Fevre et al., 2008). The individual 
household economic burden of a case of HAT is high, including the costs of care at 
home and at hospitals, of seeking diagnosis, medical fees, and transport costs, as well 
as income lost by the infected individual and their carers (reviewed in (Boelaert et 
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al., 2010). This is also the case even when diagnostics and drugs are provided free of 
charge and causes a delay in the uptake of treatment. Also having a great economic 
impact is the infection of cattle with the subspecies T. b. brucei, which is non-
pathogenic to man, but limits agricultural production, food resources and the 
economic growth of the affected countries (Simarro et al., 2008). 
 
1.1.2 Human African Trypanosomiasis (HAT) disease 
HAT is characterised by two stages of disease progression. At the initial, 
haemalymphatic, stage parasites are present in the bloodstream and lymphatic 
system. The symptoms are wide ranging and include intermittent fever, 
splenomegaly, malaise, adenopathies, cardiovascular manifestations, and pruritus 
(Vincendeau and Bouteille, 2006). One specific symptom that is characteristic of 
infection is swollen cervical lymph nodes.  
 
The second, meningoencephalitic, stage occurs when the parasite enters the central 
nervous system (CNS) by crossing the blood-brain barrier. At this stage neurological 
symptoms develop gradually, including the characteristic alteration of the circadian 
sleep/wake cycle, resulting in daytime somnolence and nocturnal insomnia, that 
gives the disease its name, sleeping sickness. The general signs of the first stage 
remain and other symptoms can include sensory disturbances, psychiatric disorders 
such as confusion or aggression, and tremor (Vincendeau and Bouteille, 2006). 
Ultimately, if left untreated, the infection results in coma and death. 
 
Chronic infection, caused by T. b. gambiense infection, results in an infection 
without the appearance of symptoms for months or years, often until the advanced 
disease stage, in comparison to the acute infection, caused by T. b. rhodesiense, 
where symptoms of the first stage are apparent after a few weeks or months (Simarro 
et al., 2008). 
 
Within disease control programmes, a three step method is used for diagnosis, based 
on screening, diagnostic confirmation, and staging (Brun et al., 2009). For the 
screening of populations at risk of T. b. gambiense infection, the card agglutination 
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test for trypansomiasis (CATT) is used widely. CATT is a serological test that is fast, 
practical and reported to be 87-98% sensitive and 93-95% specific (Brun et al., 
2009). However, due to incomplete sensitivity, microscopic examination of blood or 
lymph samples to detect the presence of parasites is required, especially for those 
individuals with suspected infections but negative CATT results. Staging of the 
disease is then required, because HAT treatment differs for the first and second 
stages. Lumber puncture is required to assess cerebrospinal fluid for the presence of 
more than 5 white blood cells/µl, parasites, or elevated protein levels (>370 mg/L), 
which confirms disease progression to the second stage (Brun et al., 2009). 
 
1.1.3 HAT treatment 
There are four drugs registered to treat HAT, these are suramin, pentamidine, 
melarsoprol, and eflornithine. Selection of drug for treatment is based on the disease 
stage and subspecies of trypanosome responsible for infection (see Table 1.1), each 
drug suffers from difficulty in administration and often toxicity. Indeed, melarsoprol, 
an arsenical, results in the death of up to 5% of those treated with the drug, due to the 
related toxicity (Barrett, 2010). 
 
Table 1.1 The four drug treatments in use to treat HAT and their main adverse 
reactions (table taken from (Brun et al., 2009). 
 
 
The administration and toxicity drug problems, together with evidence of drug 
resistance, means that there is a desperate need for the development of new drugs. 
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However, the recent entry of fexinidazole and other compounds into preclinical or 
clinical trials offers hope for new HAT treatments (Barrett, 2010). Additionally, the 
recent development of an genome-scale RNA interference (RNAi) target sequencing 
(RIT-seq) screen approach to identifying the molecular components contributing to 
current drug efficacy and resistance should provide a powerful tool to assist the 




As well as causing disease of medical importance, trypanosomes are interesting to 
study due to unique aspects of their cell biology. For example, RNA editing was first 
discovered in trypanosomes (Benne et al., 1986), where uridines are inserted and 
deleted in mitochondrial transcripts. Subsequently, different types of RNA editing, 
such as adenosine-to-inosine RNA editing, have been discovered in various other 
organisms. Additionally, trypanosomes use RNA polymerase I (Pol I) for 
transcription of some protein-coding genes and polycistronic gene expression, these 
features being unique or unusual for a eukaryote. Linked to this, trypanosomes 
greatly rely on the post-transcriptional regulation of gene expression (discussed in 
Section 1.7) making these organisms particular suitable to study this type of gene 
regulation. Being an evolutionarily early-branching eukaryote, unicellular, with a 
published genome sequence, availability of RNAi as a tool to study gene function, 
and easy to culture in vitro, also make T. brucei a particularly useful system for 
scientific study. 
 
1.2.1 Lifecycle of T. brucei 
T. brucei exhibits a digenetic lifecycle, taking place in the mammalian host and the 
arthropod vector, the tsetse fly. The parasite alternates between proliferative and 
non-proliferative states and undergoes great morphological and metabolic changes 
(Vickerman, 1985), in addition to major changes in gene expression (Clayton, 2002), 
in order to adapt to the different environments. The developmental cycle of T. brucei 




Figure 1.2 Schematic diagram depicting the developmental cycle of T. brucei in the 
mammalian host and tsetse fly vector, with changes in cell surface, mitochondrion, 
glycosomes, receptor mediated endocytosis, and relative size of developmental stage 
shown. However, it should be noted that this schematic diagram is missing detail on 
the long and short epimastigote forms that are present in the tsetse fly (Van Den 
Abbeele et al., 1999). Asterisks indicate proliferative stages. Figure taken from 
Vickerman (1985). 
 
Mammalian infection occurs through the bite of a tsetse fly (Glossina species) 
harbouring T. brucei parasites during a bloodmeal, and deposition of infective 
metacyclic form trypanosomes in the dermal connective tissue from the fly’s salivary 
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glands (Vickerman, 1985). From here trypanosomes enter the lymphatic and blood 
systems and, as mentioned above, at a later stage of the disease they cross the blood-
brain barrier to enter the CNS. Trypanosomes transform into slender forms that 
express variant surface glycoproteins (VSG), a glycoprotein that coats the surface of 
the mammalian form trypanosomes, and also the metacyclic form in preparation for 
transmission to the mammalian host. Slender forms are the proliferative stage in the 
mammal, and multiplication occurs by binary fission. These forms possess a simple 
mitochondrion that is devoid of cristae as the parasite uses the abundant blood 
glucose as an energy source for glycolysis (Ryley, 1962).  
 
At the peak of parasitaemia, a proportion of the slender form population irreversibly 
differentiate into stumpy forms in response to a density-dependent parasite-derived 
signal, via an intermediate form. Stumpy forms, which have a shortened, broader 
cellular morphology, are non-proliferative, cell cycle arrested in G1 or G0 (Shapiro 
et al., 1984), show increased mitochondrial activity (Priest and Hajduk, 1994) and 
are preadapted for transmission to the tsetse fly. Stumpy forms represent an 
important stage in the parasite lifecycle as their division-arrest enables the control of 
parasite numbers, therefore prolonging host survival and transmission probability, 
and also allows the coordination of morphological changes with cell cycle re-entry 
upon tsetse transmission (Matthews, 2005). 
 
Upon another tsetse fly bloodmeal, bloodstream trypanosomes are ingested by the 
tsetse fly. Here, while slender forms die or differentiate into stumpy forms in the 
anterior midgut, stumpy forms differentiate into procyclic forms (Vickerman, 1985). 
The VSG coat is lost and replaced with the insect form surface coat, procyclin 
(Roditi et al., 1989). The procyclic form is again proliferative and changed 
morphologically to become long and thinner. Additionally, the mitochondrion 
develops cristae and possesses functional cytochrome-mediated electron transport 
and all citric acid cycle enzymes are present as the preferred energy source shifts to 
proline (Priest and Hajduk, 1994). To complete the lifecycle back to the infective 
metacyclic form, the parasites must migrate to the salivary glands and pass through a 
number of different developmental stages (see Figure 1.2). These developmental 
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stages also include long and short epimastigote forms (Van Den Abbeele et al., 
1999) which are not depicted in Figure 1.2. Additionally, although genetic exchange 
has long been demonstrated to take place in T. brucei (Jenni et al., 1986), a recent 
report now provides evidence for meiosis occurring in the tsetse salivary gland 
within a newly described meiotic developmental lifecycle stage (Peacock et al., 
2011). 
 
The phenomenon of antigenic variation in bloodstream form trypanosomes is 
particularly important to the trypanosome lifecycle, as this process enables the 
parasites to escape the host immune system and thus survive in the mammalian 
bloodstream. Antigenic variation is achieved through the expression of a dense 
variant surface glycoprotein (VSG) coat on the trypanosome surface membrane, the 
molecular identity of which they change periodically to avoid clearance of the 
parasite by host antibody-mediated killing (reviewed in (McCulloch, 2004). To 
obtain the expression of a single VSG protein at any one time in a trypanosome cell, 
only one of about 20 telomeric VSG expression sites (ES) is transcribed at a time 
from a subnuclear body, the expression site body (ESB) (Navarro and Gull, 2001); 
reviewed in (McCulloch, 2004). Within the bloodstream expression sites (BES), 
expression site-associated genes (ESAGs) are co-transcribed with the VSG (Hertz-
Fowler et al., 2008). The control of transcriptional switching between VSG genes is 
probably by epigenetic regulation, in part by a histone methyltransferase, DOTB1 
(Figueiredo et al., 2008).  
 
1.2.2 Cell biology 
The trypanosome cell has a strictly organised cell structure containing precisely 
positioned single copy organelles, these being the kinetoplast, mitochondrion, 
nucleus, flagellum and flagellar pocket (Matthews, 2005). The cell biology exhibits 
many developmental changes throughout the trypanosome lifecycle (reviewed in 
(Matthews, 2005). The cell structure is defined by the microtubule cytoskeleton, 
producing an elongated cell shape (see Figure 1.3). The flagellum is responsible for 
the motility of the trypanosome and extends along the extracellular surface posterior 
to anterior, originating intracellularly from a basal body that is connected to the 
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kinetoplast (reviewed in (Vaughan and Gull, 2003). The site where the flagellum 
originates from, termed the flagellar pocket, is a plasma membrane invagination and 
the only site of exo- and endocytosis (Overath and Engstler, 2004).  
 
 
Figure 1.3 T. brucei cell ultrastructure. A simplified representation of the major 
trypanosome cell structural feature locations. Figure taken from Matthews, 2005. 
 
Trypanosomes possess two DNA-containing structures, the kinetoplast, which holds 
the mitochondrial DNA and the nucleus, which holds the nuclear DNA. During the 
cell cycle both must be replicated and thus the cell cycle is tractable by the number 
of these two structures present in the cell (Sherwin and Gull, 1989). Cells in G1 or 
G0 have one kinetoplast and one nucleus (1K1N), cells in G2/M possess a 2K1N 
configuration, and post-mitotic cells have a 2K2N configuration (Sherwin and Gull, 
1989). Thus, analysis of cells using a DNA stain, such as 4,6-diamidino-2-
phenylindole (DAPI), allows the cell cycle stage to be determined. During the cell 
cycle, each organelle must be replicated as well and this is also performed in a well-
ordered manner (Woodward and Gull, 1990; Bangs, 2011). For example, the 
emergence from the flagellar pocket of the short daughter flagellum during flagellum 
replication is one of the earliest events in cell duplication. In the procyclic form, the 
growth of the daughter flagellum tracks along the length of the old flagellum guided 
by a special connective structure, the flagellar connector, at the distal tip of the 
daughter flagellum (Moreira-Leite et al., 2001). 
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1.3 Trypanosome differentiation 
 
1.3.1 Slender to stumpy differentiation 
As mentioned above, slender forms differentiate into stumpy forms in response to a 
density-dependent parasite-derived signal. This signal is termed stumpy induction 
factor (SIF) and is currently unidentified. Although the identity and signalling 
pathway are unknown, some details have been determined. 
 
It has been shown that slender to stumpy differentiation can proceed independently 
of host cues and involves a density dependent mechanism, and additionally that SIF 
is of low relative molecular mass and released by trypanosomes (Vassella et al., 
1997). The cyclic AMP (cAMP) signalling pathway has been implicated in the 
transduction of the SIF signal, due to the findings that treatment with a membrane-
permeable cAMP derivative or the phosphodiesterase inhibitor, etazolate, results in 
induction of stumpy morphology and growth arrest similarly to SIF, and also that SIF 
results in an increase in intracellular cAMP (Vassella et al., 1997).  
 
The membrane permeable cAMP analog used in that study, 8-(4-chlorophenylthio)-
cAMP (pCPTcAMP), was also shown to cause the differentiation to stumpy forms of 
monomorphic culture-adapted bloodstream forms (Breidbach et al., 2002). 
Monomorphic strains are so called because they have lost the ability to differentiate 
to stumpy forms in the host, as opposed to pleomorphic strains that have not 
(Matthews et al., 2004). This study therefore indicates that in monomorphic strains 
this inability may result from a failure in the SIF signalling pathway rather than in 
the differentiation process itself (Breidbach et al., 2002). 
 
Additionally, it has been shown that slender forms differentiate into ‘stumpy-like’ 
forms through treatment with a hydrolysable cAMP analog, 8-pCPT-2’-O-Me-
cAMP, which also has an antiproliferative effect, neither of which were observed 
with hydrolysis-resistant, membrane permeable cAMP analogs (Laxman et al., 
2006). This suggested that it is the metabolic products derived from the membrane 
permeable cAMP analogs that cause differentiation to stumpy-like forms rather than 
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the analogs themselves, and therefore, transformation may not be mediated directly 
by cAMP (Laxman et al., 2006). 
 
Other chemical treatments can also generate stumpy-like forms. For example, the 
transformation of slender forms to intermediate and stumpy forms has been reported 
with difluoromethylornithine (DFMO) treatment, which causes depletion of 
intracellular polyamines (Giffin and McCann, 1989). Also, the cysteine proteinase 
inhibitor, Z-Phe-Ala-CHN2, caused the induction of stumpy-like forms, which was 
proposed to be triggered by prevention of cell cycle progression (Scory et al., 2007). 
Finally, treatment with troglitazone treatment reportedly caused a similar 
differentiation to stumpy-like forms, although cell cycle arrest in G1/G0 was not 
observed (Denninger et al., 2007).  
 
Signalling by two protein kinases has also been implicated in slender to stumpy 
differentiation. Specifically, depletion of the MAP kinase 5 (MAPK5) resulted in 
increased sensitivity to SIF (Domenicali Pfister et al., 2006) and deletion of the ZFK 
kinase also resulted in an increased rate of slender to stumpy form differentiation 
(Vassella et al., 2001). 
 
1.3.2 Stumpy to procyclic differentiation 
It has been shown that monomorphic slender forms can be induced to differentiate to 
procyclic forms in vitro when stimulated with two triggers, a decrease in temperature 
from 37°C to 27°C and the addition of cis-aconitate at a high concentration (Czichos 
et al., 1986). Subsequently, it was determined that a further cold shock of 20°C 
confers increased sensitivity to micromolar concentrations of cis-aconitate and citrate 
that is more similar to the concentration likely encountered by the trypanosome in 
the tsetse bloodmeal environment (Engstler and Boshart, 2004). It was also proposed 
that the cold shock induces the expression of a cell-surface receptor for citrate/cis-
aconitate, this being dependent on previous cell cycle arrest and differentiation to 
stumpy form cells (Engstler and Boshart, 2004). 
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Recently, the PAD (proteins associated with differentiation) family of carboxylate-
transporter proteins were shown to be required for perception of the citrate/cis-
aconitate differentiation signal (Dean et al., 2009). One member of the family, 
PAD1, was enriched in stumpy forms, and another, PAD2, was enriched in procyclic 
forms with cold shock causing upregulation and relocation of the protein to the cell 
surface in stumpy forms (Dean et al., 2009), consistent with the predicted properties 
of the putative cell-surface receptor for citrate/cis-aconitate (Engstler and Boshart, 
2004).  
 
Also important in the signalling pathway are two phosphatases, TbPTP1 and 
TbPIP39. TbPTP1 acts as a molecular brake in bloodsteam forms, inhibiting 
differentiation to procyclic forms (Szoor et al., 2006). Downstream of this, TbPIP39 
is negatively regulated by TbPTP1, but becomes phosphorylated and activated 
during differentiation, enhancing stumpy to procyclic form differentiation (Szoor et 
al., 2010). Additionally, many changes in gene expression also accompany 
development to procyclic forms, which are discussed in more detail in Section 1.7.2. 
 
1.4 Gene expression in stumpy forms 
 
Many trypanosome genes have been found to exhibit differential gene expression in 
different lifecycle stages, these genes being identified individually or by 
transcriptomic analysis. Of particular importance to this project are genes that have 
been identified as enriched in stumpy forms. A number of microarray analyses 
(Kabani et al., 2009; Jensen et al., 2009; Queiroz et al., 2009), as well as an RNA 
sequencing study (Nilsson et al., 2010), have been performed that included RNA 
extracted from stumpy forms and identified stumpy-enriched, as well as other 
lifecycle stage-enriched, transcripts. These types of analyses have resulted in the 
identification of many genes that would be interesting for further study. This is 
particularly true for the stumpy form lifecycle stage, because as discussed below, 
these cells show translational repression, and so any transcripts upregulated here are 
likely to be important for stumpy form biology. 
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1.4.1 Translational repression in stumpy forms 
Between the well-studied stages, the proliferative slender and procyclic forms and 
the non-proliferative stumpy form, there are major changes in protein translation. 
Stumpy forms show a dramatically reduced level of protein synthesis with respect to 
slender or procyclic forms, as revealed by analysis of newly synthesised proteins 
with radiolabelled methionine incorporation (Brecht and Parsons, 1998). A decrease 
in protein synthesis was also observed in cells induced to stumpy-like forms with 
difluoromethylornithine treatment (Bitonti et al., 1988). Brecht and Parsons (1998) 
showed that there was no difference in the ability of transcripts from the different 
lifecycle stages to be translated in vitro using a rabbit reticulocyte translation system. 
Therefore, the transcripts themselves were not responsible for the decreased protein 
synthesis, although, importantly the authors noted that there may be changes in the 
interaction of the mRNA cap with the trypanosome cap binding protein in stumpy 
forms that were undetectable in the in vitro system due to the unique trypanosome 
cap 4 structure (Bangs et al., 1992). The decrease in protein synthesis in stumpy 
forms was also not attributable to differing poly(A) tail lengths, as these showed no 
significant variation in length between the lifecycle stages. Through the analysis of 
polysome profiles, a well-established method for determining global translation, it 
was observed that stumpy forms exhibited a greatly reduced level of polysome-
associated transcripts (Brecht and Parsons, 1998). Thus, the reduced protein 
synthesis in this lifecycle stage is due to a repression of translation.  
 
While there is a decrease in the levels of protein synthesis in stumpy forms compared 
to slender forms, two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) of 
35S-labelled proteins showed that the majority of those synthesised are the same, with 
only some being stage-specific (Shapiro and Kimmel, 1987). As stumpy forms are 
preadapted for transmission to the tsetse fly, presumably they must express proteins 
that enable this preadaptation. Therefore, although translation is repressed in stumpy 
forms, a small subset of transcripts must escape this repression to generate proteins 
enriched in stumpy forms.  
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1.4.2 Stumpy form enriched proteins 
Some important genes have been found to exhibit stumpy form specific expression. 
For example, the PAD1 protein mentioned above, is specifically expressed in stumpy 
forms and is also enriched in this lifecycle stage at the level of the mRNA (Dean et 
al., 2009).  
 
Additionally, the expression-site-associated gene (ESAG) 9 family mRNAs are 
strongly enriched in stumpy forms (Barnwell et al., 2010; Jensen et al., 2009); see 
Figure 1.4). These proteins were found to be secreted by stumpy form trypanosomes 
and thus are implicated in infection chronicity or parasite transmission (Barnwell et 
al., 2010). In that study, one member of this family was determined to be present in 
two expression sites of T. brucei EATRO 2340 and was also named ‘ESAG9-EQ’ 
because it was the gene most similar to ESAG9 genes in T. equiperdum (a 
trypanosome species which parasitizes horses) (Florent et al., 1991). 
 
 
Figure 1.4 Expression of five ESAG9 genes in monomorphic slender (EATRO Sl) 
and pleomorphic stumpy forms of T. brucei EATRO 2340 GUTat 7.2 (EATRO St) 
and pleomorphic stumpy forms of T. b. brucei AnTat1.1 (AnTat St). As controls, an 
ESAG2-specific probe and a constitutively expressed transcript (Tb11.02.3640) were 
hybridised with the same RNA samples. Ethidium bromide staining of rRNA 
indicates lane loading. Tb927.5.4620 is also named ‘ESAG9-EQ’. Figure taken from 
Barnwell et al. (2010). 
 
 
Another protein exhibiting stumpy form enriched expression is the homologue of 
aconitase, TbACO. The expression of TbACO was lowest in slender forms, 8-fold 
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enriched in stumpy forms, and increased 4-fold further in procyclic forms (Saas et 
al., 2000). However, the TbACO mRNA showed only minor lifecycle changes in 
abundance, indicating regulation through translational or post-translational 
mechanisms (Saas et al., 2000). Aconitase is an enzyme that catalyses the conversion 
of citrate to isocitrate via the intermediate of cis-aconitate, which as citrate and cis-
aconitate can trigger differentiation to the procyclic form, makes this protein of 
interest. 
 
1.5 Eukaryotic translation 
 
Translation of eukaryotic mRNAs is believed to occur through the scanning 
mechanism of translational initiation. This mechanism proposes that the small 
ribosomal subunit (40S) is recruited to the mRNA at the 5’ end and then migrates 
linearly along the mRNA until an AUG codon is encountered (reviewed in (Kozak, 
2002). However, two secondary mechanisms allow initiation at downstream AUG 
codons in some mRNAs, reinitiation and context-dependent leaky scanning, and 
additionally internal ribosome entry sites (IRES). These mechanisms are discussed 
below in Section 1.6. 
 
Eukaryotic translation initiation (see Figure 1.5; reviewed in (Sonenberg and 
Hinnebusch, 2009) begins with recruitment to the mRNA of the preassembled 43S 
preinitiation complex (PIC). The PIC comprises of the 40S ribosomal subunit, Met-
tRNAi (methionyl tRNA specialised for initiation), eukaryotic initiation factor (eIF) 
2, eIF1, eIF1A, eIF3 and eIF5 (Pestova et al., 1998). The eIF2 and Met-tRNAi are 
preassembled prior to PIC formation in the ternary complex (TC), where eIF2 is in 
its GTP-bound form (Choi et al., 1998). Loading on to the ribosome is mediated by 
the eIF4F complex, which consists of eIF4E, the cap binding factor, and eIF4A, an 
RNA helicase, both bound to the scaffolding protein, eIF4G (Gingras et al., 1999). 
Thus, eIF4E is responsible for 5’ cap recognition and through it’s binding to eIF4G, 
which binds to eIF3, the recruitment of the PIC, and eIF4A is presumed to unwind 
secondary structure present in the mRNA to assist scanning (LeFebvre et al., 2006; 
Marsden et al., 2006). Scanning downstream proceeds until an AUG codon is placed 
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in the P (peptidyl) decoding ribosome site, which base-pairs with the Met-tRNAi 
anticodon. This results in GTP hydrolysis in the ternary complex stimulated by 
eIF5B, and eIF2-GDP is released along with other initiation factors, allowing the 
large ribosomal subunit (60S) to join, thus forming the 80S ribosome (Pestova et al., 
2000; Lee et al., 2002). Protein synthesis therefore begins when the appropriate 
aminoacyl-tRNA enters into the A (aminoacyl) site and the first peptide bond is 
synthesised (reviewed in (Leung et al., 2011).   
 
 
Figure 1.5 Schematic diagram of eukaryotic cap-dependent translation initiation and 
its regulation by eIF2α kinases and other signalling pathways. Figure taken from 
Sonenberg and Hinnebusch (2009). 
 
Translation progresses with polypeptide chain elongation through the entry into the 
A site of an aminoacyl-tRNA associated with a GTP-bound elongation factor (EF), 
until correct base-pairing to the codon at the A site triggers GTP hydrolysis, peptide 
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bond formation and translocation of the ribosome to the following codon (reviewed 
in (Leung et al., 2011). This process repeats until a stop codon is encountered in the 
A site, which is recognised by release factors (RFs), causing hydrolysis of the 
polypeptidyl-tRNA, releasing the nascent protein chain and subsequently 
dissociation of the ribosome (reviewed in (Leung et al., 2011). 
 
A single mRNA can have multiple associated ribosomes engaged in translation; this 
structure is referred to as a polyribosome or polysome (Warner et al., 1963). 
Circularisation of the mRNA can be mediated by interaction of eIF4G with poly(A) 
binding protein (PABP) which links the cap and poly(A) tail of the mRNA (Wells et 
al., 1998). This could allow reinitiation of dissociated ribosomes on the mRNA cap 
post-termination (Rajkowitsch et al., 2004).  
 
The translation initiation factors, eIF4E and eIF2, as well as eIF5A and eIF6, are 




The structure of eIF4E resembles a cupped hand, consisting of a curved, antiparallel 
8-stranded β sheet backed by 3 long α helices (Marcotrigiano et al., 1997). Cap 
binding occurs through the concave basal surface, where conserved tryptophan side-
chains are important for recognition (Marcotrigiano et al., 1997).  
 
eIF4E represents a molecule thought to be important for determining translation rates 
due to its critical role in mRNA cap recognition and recruitment of the ribosome 
through its interaction with eIF4G and because it is believed to be present in limiting 
concentrations (Duncan et al., 1987). Consequently, eIF4E activity is regulated 
through multiple mechanisms (reviewed in(Raught and Gingras, 1999). 
 
Firstly, eIF4E expression is regulated through transcriptional control by the 
transcription factor, c-Myc, and p53 (Zhu et al., 2005). Also, phosphorylation status 
of eIF4E appears to correlate with translation rate, although this is not always 
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observed (reviewed in(Raught and Gingras, 1999). eIF4E is phosphorylated at 
Ser209 by mitogen-activating protein kinase (MAPK)-interacting serine/threonine 
kinase (Mnk) 1 and 2, substrates of extracellular signal-related kinase (ERK) or p38 
mitogen-activated protein (MAP) kinases (Pyronnet et al., 1999). 
 
Additionally, the 4E-BP (eIF4E-binding proteins) family of repressor proteins 
regulate eIF4E, through binding to eIF4E and preventing formation of a functional 
eIF4F complex by inhibiting binding to eIF4G (Haghighat et al., 1995). 
Phosphorylation also regulates the activity of the 4E-BPs, as phosphorylation results 
in dissociation of the protein from eIF4E (Pause et al., 1994). Another level of 
control results from the eIF4E homologous protein (4EHP), which shows homology 
to eIF4E and binds specifically to capped RNA (Rom et al., 1998), but does not 
interact with eIF4G (Joshi et al., 2004), again preventing formation of a functional 
eIF4F complex.  
 
1.5.2 eIF2 
Downregulation of general protein synthesis in response to starvation, stress, or viral 
infections in mammalian cells is mediated by phosphorylation of the α subunit of 
eIF2 (Hershey, 1991). Following translation initiation, exchange of GDP for GTP in 
the inactive eIF2-GDP complex to reform the active ternary complex is catalysed by 
eIF2B. Phosphorylation of Ser-51 of eIF2α inhibits the recycling of eIF2 by binding 
to eIF2B and sequestering it, therefore, preventing translation initiation (Rowlands et 
al., 1988). 
 
A number of kinases have been found to phosphorylate eIF2α in mammalian cells. 
These include protein kinase R, which is activated upon double-stranded RNA 
binding (Kostura and Mathews, 1989), and protein kinase R-like ER kinase (PERK), 
which is activated by the ER stress of accumulation of unfolded proteins (Harding et 
al., 1999). Although general protein synthesis is repressed by eIF2α 
phosphorylation, a subset of mRNAs are still actively translated, this being mediated 





eIF5A is a protein shown to promote translation elongation in yeast (Saini et al., 
2009). This is the only known protein to contain the unusual amino acid hypusine 
(Nε-(4-amino-2-hydroxybutyl)lysine) in eukaryotes and archaea (Cooper et al., 
1983).  
 
Hypusine is synthesised only as a posttranslational modification of one specific 
lysine residue of eIF5A through the activities of two enzymes in a two-step process 
(Murphey and Gerner, 1987; Park et al., 1982; Park et al., 2006). The first enzymatic 
reaction involves the transfer of the aminobutyl moiety of spermidine to form an 
intermediate, deoxyhypusine, catalysed by deoxyhypusine synthase (DHS). 
Deoxyhypusine hydroxylase (DOHH) then hydroxylates this intermediate to form 
hypusine. The presence of hypusine is essential for eIF5A function, as it is required 
for the association of eIF5A with ribosomes (Jao and Chen, 2006). 
 
1.5.4 eIF6 
eIF6 is a protein that functions as an anti-association factor, as it prevents association 
of the 40S and 60S subunits by binding to 60S, thus preventing 80S formation 
(Russell and Spremulli, 1980). Although termed a translation initiation factor, the 
protein does not function as a true initiation factor, as it is not required for yeast 
translation in in vitro assays (Si and Maitra, 1999). Rather, its function in translation 
appears to be mediated by its anti-association activity preventing translation. 
Nonetheless, a role for eIF6 has been reported in yeast in 60S biogenesis, because 
depletion of eIF6 in this organism resulted in impaired processing of pre-rRNA 
precursors that are the constituents of 60S subunits (Basu et al., 2001). 
 
eIF6 is found in both Archaea and Eukarya, but not in Eubacteria, where 
transcription and translation are coupled (Miluzio et al., 2009). Yeast and human 
eIF6 proteins share 72% identity (Si et al., 1997). The structures have been 
determined for archaeal (Methanococcus jannaschii) aIF6 and Saccharomyces 
cerevisiae eIF6 by X-ray crystallography and demonstrate that IF6 possesses a 
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phylogenetically conserved unique protein structure termed ‘pentein’ (Groft et al., 
2000). This pentein structure is a pentameric fold consisting of five quasi identical 
α/β subdomains arrayed around a five-fold axis of pseudosymmetry. Phylogenetic 
analysis of known eIF6 and aIF6 sequences suggested an origin from a common 
ancestor before divergence of the archaeal and eukaryotic kingdoms (Groft et al., 
2000). 
 
Recently, the crystal structure of the 60S subunit from Tetrahymena thermophila in 
complex with eIF6 has been determined (Klinge et al., 2011). This structure 
demonstrated that eIF6 binds through the larger of its flat surfaces to the ribosomal 
protein, RPL23, of the 60S subunit, where it would prevent 40S binding. In yeast, 
release of eIF6 binding to the 60S is promoted by elongation factor-like 1 (Efl1p) 
(Senger et al., 2001), and the homologue of Schwachman-Bodian-Diamond 
syndrome (SBDS) protein, Sdo1 (Menne et al., 2007). In mammals, eIF6 interacts 
with RACK1 (receptor for activated protein kinase C [PKC] 1) in the cytoplasm and 
phosphorylation of eIF6 by PKC is believed to mediate dissociation (Ceci et al., 
2003). 
 
Investigation of eIF6 heterozygous mice revealed that mammalian eIF6 is required 
for efficient translation initiation while ribosome biogenesis was unaffected, and 
additionally that eIF6 regulates translation in response to extracellular signals 
(Gandin et al., 2008). In yeast, eIF6 is essential for cell growth (Si and Maitra, 
1999), and mice heterozygous for eIF6 exhibited decreased growth, while eIF6 
knockout was lethal (Gandin et al., 2008), demonstrating the essential role of this 
protein. 
 
eIF6 protein is found in both the cytoplasm, where its anti-association activity 
prevents translation, and in the nucleolus, where it is involved in 60S biogenesis 
(reviewed in (Miluzio et al., 2009) (see Figure 1.6). Localisation is controlled by the 
phosphorylation status of eIF6 at Ser-174 and Ser-175, where nuclear export is 
dependent on phosphorylation by a nuclear isoform of casein kinase 1 (CK1) 
(Biswas et al., 2011). 
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Figure 1.6 Schematic diagram depicting eIF6 in ribosome biogenesis in the nucleus 
and translational control in the cytosol. eIF: eukaryotic initiation factor; PABP: 
poly(A)-binding protein. Figure taken from Miluzio et al. (2009). 
 
eIF6 has also been implicated in controlling the expression of specific genes. In 
Xenopus laevis, eIF6 is believed to be involved in a mechanism acting on the specific 
translation of transcripts regulating cell survival, upstream of B-cell lymphoma gene-
2 (Bcl-2)/Bcl-2-associated X protein (Bax) (De Marco et al., 2010). eIF6 has also 
been reported to be involved microRNA (miRNA) silencing and RNAi. Human eIF6 
was found to associate with the RNA-induced silencing complex (RISC), and 
depletion of eIF6 in human or Caenorhabditis elegans decreases miRNA-mediated 
silencing (Chendrimada et al., 2007). In Fenneropenaeus chinensis and 
Marsupenaeus japonicus, eIF6 interacts with TRBP (trans-activation response RNA-
binding protein), a component of RISC (Wang et al., 2009; Wang et al., 2012). 
Knockdown of eIF6 or TRBP in M. japonicus impaired the double-stranded RNA 
(dsRNA)-induced RNAi pathway (Wang et al., 2012). Additionally, eIF6 may 
selectively regulate the protein synthesis of β-catenin mRNA (Ji et al., 2008). 
 
In Archaea, aIF6 has been characterised in Sulfolobus solfataricus, where it also 
shows anti-association activity by binding to 50S ribosomal subunits and preventing 
formation of 70S ribosomes (Benelli et al., 2009). Although a role for mammalian 
eIF6 in G1/S phase progression through the cell cycle was identified (Gandin et al., 
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2008), aIF6 was found to uniformly expressed in the cell cycle. However, aIF6 
protein was found to be upregulated following both cold- and heat shock, indicating 
that it may negatively regulate protein synthesis under unfavourable environmental 
conditions (Benelli et al., 2009). 
 
1.5.5 Control of the scanning mechanism of translation initiation 
A number of mechanisms have been identified that affect the scanning mechanism of 
translation initiation; these are GC-rich 5’UTRs, leaky scanning, upstream open 
reading frames (uORFs) and IRES. GC-rich 5’UTRs are highly structured which 
prevents the ribosome from traversing the 5’UTR, therefore inhibiting translation 
initiation (reviewed in Kozak, 2002).  
 
Recognition of an AUG start codon is enhanced by the context of the surrounding 
sequence. In mammals, the optimal context is GCCRCCaugG, where R (position -3) 
represents a purine and is the most important position functionally (Kozak, 1986) 
and the G in position +4 contributes strongly too (Kozak, 1997). If the first AUG is 
in a strong context, translation initiates there, however, if it is in a weak context, 
leaky scanning can result whereby scanning continues to a downstream AUG for 
initiation and can therefore result in production of two proteins from one transcript 
(reviewed in Kozak, 2002). 
 
An uORF is a small ORF present at the 5’ end of a transcript upstream from the main 
ORF. The presence of an uORF can affect the translation of the main ORF through 
two mechanisms. The scanning ribosome can initiate translation on the AUG of the 
uORF, causing translation of the uORF peptide which results in reinitiation of 
scanning, believed to be due to the 40S ribosome remaining bound to the mRNA 
(Kozak, 2002). Alternatively, it can inhibit translation of the main ORF by 
translation of the uORF peptide causing stalling of the ribosome. For example, the 
arginine attenuator peptide encoded by an uORF present in yeast CPA1 mRNA 
causes ribosome stalling on the uORF termination codon (Gaba et al., 2005). 
However, for reinitiation to occur the 40S subunit must reacquire the ternary 
complex and therefore the length between the stop codon of the uORF and the AUG 
42 
of the main ORF is an important determinant of whether this occurs (reviewed in 
(Hinnebusch, 1997). This is the mechanism by which phosphorylation of eIF2α is 
thought to allow the expression of certain transcripts while causing global translation 
inhibition, i.e. through reduction of the pool of ternary complexes, thus controlling 
the reinitiation ability of ribosomes on the main ORF or an additional downstream 
uORF. The perhaps best characterised example of this is the translation of GCN4 in 
yeast (reviewed in Hinnebusch, 1997) and it has also been demonstrated for 
GADD34 (growth arrest DNA-inducible gene 34) in mammals (Lee et al., 2009).  
 
An IRES is a structural element that can cause the initiation of translation by direct 
recruitment of ribosomes to an AUG present in an internal site of the mRNA and is 
therefore independent of the cap binding complex, eIF4F. The first example of IRES 
was idenitifed in picornaviral mRNAs (Jang et al., 1988). 
 
1.6 Gene expression in Trypanosoma brucei 
 
1.6.1 Genome organisation 
The genome of T. brucei has been sequenced and published (Berriman et al., 2005), 
in addition to those of T. cruzi (El-Sayed et al., 2005) and L. major (Ivens et al., 
2005). The T. brucei genome is organised into 11 megabase-sized chromosomes and 
an unspecified number of small and intermediate-sized chromosomes that encode 
sequences with similarity to megabase chromosome subtelomeric regions. The genes 
on the megabase chromosomes are arranged in long, nonoverlapping gene clusters 
which are transcribed as polycistrons.  
 
The polycistronic transcription units (PTUs) are marked at the boundaries by four 
histone variants and composed of arrays of sometimes more than 100 genes, but with 
no evidence of functionally related gene clusters as seen for prokaryotic operons 
(Siegel et al., 2009). Transcription is carried out by RNA polymerase II (Pol II), 
except for the major surface glycoprotein genes (the procyclins and VSGs), which 
are transcribed by Pol I (Gunzl et al., 2003). For Pol II-expressed genes, no 
promoters have been identified, with the exception of the splice leader (SL) RNA 
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(Gilinger and Bellofatto, 2001), whereas Pol I promoters have been identified. 
Instead, probable Pol II transcription start sites show strong enrichment of histones 
H4K10ac, H2AZ, H2BV, and the bromodomain factor BDF3 (Siegel et al., 2009). 
Thus, while Pol II-expressed genes are likely regulated at the post-transcriptional 
level, Pol I-expressed genes are subject to different regulatory mechanisms for gene 
expression at the transcriptional level. 
 
1.6.2 Trans-splicing and polyadenylation 
Monocistronic mRNAs are obtained from polycistronic RNA precursors by the two 
processes of trans-splicing, at the 5’ end, and cleavage/polyadenylation of the 3’ end. 
The trans-splicing reaction involves the addition of a 39 nucleotide (nt) splice leader 
RNA to the 5’ splice acceptor site (SAS) (Agabian, 1990). The splice leader RNA 
also possesses a modified 5’ mRNA cap structure, termed cap 4 and in some aspects 
is unique to trypanosomatids, which generates a functional mRNA (Bangs et al., 
1992). Hypermethylated cap 4 also has methylation of the first four nucleotide 
positions, this hypermethylation is required for efficient translation rates (Zamudio et 
al., 2009). Similarly to cis-splicing, the trans-splicing acceptor site is an AG 
dinuceotide downstream of a polypyrimidine tract (Huang and Van der Ploeg, 1991; 
Matthews et al., 1994). The polyadenylation site (PAS) has no known consensus 
signal, but instead is linked to trans-splicing of the downstream gene, occurring 100-
400nt upstream from the polypyrimidine tract (Matthews et al., 1994; Benz et al., 
2005).  
 
Trans-splicing, therefore, overcomes the restriction that only the 5’ open reading 
frame would be translated in the polycistron by the scanning mechanism of initiation, 
through the separation of individual mRNAs. Cis-splicing is extremely rare, but does 
occur in T. brucei for at least two genes, poly(A)-polymerase (Mair et al., 2000) and 
a DNA/RNA helicase (Berriman et al., 2005). Identification of introns in other T. 
brucei genes appears unlikely as an RNA-seq study did not identify any new 
examples, although, the authors reported that the methodology did not provide a 
reliable way to identify introns (Siegel et al., 2010). 
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1.6.3 Identification of splicing and polyadenylation sites 
An analysis of known SAS and PAS sites in T. brucei cDNAs found that in general 
trans-splicing occurs at the first AG dinucleotide following a polypyrimidine tract of 
8-25nt, resulting in a median 5’UTR length of 68nt and mean length of 129nt (Benz 
et al., 2005). Additionally, polyadenylation occurs between 80 and 140nt 
downstream of the polypyrimidine tract, at a position of one or more A residues, 
resulting in a median 3’UTR length of 348nt and mean length of 587nt. These data 
were then used to generate a predictive algorithm for processing sites for most 
protein coding genes in the T. brucei genome (Benz et al., 2005).  
 
Since that study, four studies have been recently published which used 
Illumina/Solexa high-throughput RNA sequencing to determine SAS and PAS sites 
in T brucei on a genome wide scale (Siegel et al., 2010; Nilsson et al., 2010; Kolev 
et al., 2010; Veitch et al., 2010). These studies varied in the T. brucei strains 
analysed and used varying approaches to sequencing. For example, Siegel et al. 
(2010) used in vitro cultured T. b. brucei slender monomorphic bloodstream and 
procyclic forms with RNA-seq, Nilsson et al. (2010) used T. b. brucei slender and 
stumpy (monomorphic and pleomorphic) bloodstream forms, and procyclic forms 
with a novel approach termed spliced leader trapping (SLT), Kolev et al. (2010) used 
T. b. rhodesiense procyclic forms, and Veitch et al. (2010) used T. b. gambiense 
slender bloodstream and procyclic forms with a digital gene expression approach 
(which relies on the restriction enzyme, NlaIII).  
 
Siegel et al. (2010) identified the SAS for 6959 genes and the PAS for 5948 genes, 
noting that most genes have between one and three alternative SAS and PAS are 
more dispersed. Additionally, the paper observed that for 488 genes the SAS was 
identified downstream from the originally assigned ATG start codon, meaning that a 
subsequent in-frame ATG must be used for the true coding sequence. Nilsson et al. 
(2010) identified the SAS for 85% of the annotated protein-coding genes, with more 
than 2500 alternative splicing events being identified that appear to be lifecycle 
stage-regulated in many cases. The data from all the studies confirmed that the major 
splice acceptor dinucleotide is AG and that the SAS is preceded 14-43nt upstream by 
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a polypyrimidine tract (Siegel et al., 2011). The observed median 3’UTR length was 
reported as 400nt and 388nt (Siegel et al., 2010; Kolev et al., 2010). The high 
abundance of alternative SAS and alternative PAS site usage found in these studies 
was surprising and the authors noted that this could represent a means for generating 
the same protein but with differing properties (for example, the inclusion/exclusion 
of targeting signals for different cellular localisations) and a means for regulating 
gene expression (Siegel et al., 2011), which has also been previously proposed 
(Helm et al., 2008). 
 
1.7 Regulation of gene expression in T. brucei  
 
Due to the transcription of almost all trypanosome protein-coding genes by Pol II in 
polycistronic transcription units and the observation that co-transcribed genes do not 
share common patterns of regulation, regulation of gene expression is believed to 
occur at the post-transcriptional level (Clayton & Shapira, 2007). Post-transcriptional 
control of gene expression can be made at various levels in eukaryotes, such as the 
regulation of splicing and polyadenylation, mRNA stability and degradation, RNA 
interference, translation, and protein stability. Studies of the mechanisms of 
trypanosome post-transcriptional control have so far focused more on the 
characterisation of 3’UTR elements, RNA binding proteins and mRNA degradation 
and these appear to be particularly important. 
 
1.7.1 Characterisation of 3’UTR elements 
The most well characterised trypanosome 3’ untranslated region (3’UTR) is that of 
procyclin. Procyclin is the major surface antigen expressed in the lifecycle stages 
present in the tsetse fly and this stage-specific expression is conferred by the 3’UTR 
(Berberof et al., 1995). There were three elements in the 3’UTR identified to be 
responsible for this control; two positive elements, one within the first 40nt of the 
3’UTR and also a conserved 16-mer (loops I and III), which prevent transcript 
degradation, and a negative element (loop II) (Furger et al., 1997). The structure of 
the 3’UTR of EP1 procyclin was determined experimentally to be composed of three 
domains, two of which form stable structures corresponding to loops I and III 
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(Drozdz and Clayton, 1999). The 3’UTR of the GPEET procyclin also confers 
regulation by glycerol and hypoxia (Vassella et al., 2000).   
 
Additionally, investigation has been made of the 3’UTRs of the nuclear-encoded 
mitochondrial cytochrome oxidase (COX) complex components. These components 
are developmentally regulated, being enriched in the procyclic form at the mRNA 
level (Mayho et al., 2006). The COX mRNAs exhibit differential mRNA stability 
and for at least three subunits the 3’UTRs possess regulatory regions contributing to 
translational control (Mayho et al., 2006). This study also identified a 26-mer 
sequence in one of the 3’UTRs that is overrepresented in procyclic-enriched 
transcripts.  
 
Other 3’UTRs conferring developmental gene expression control (reviewed in 
(Clayton, 2002) include an amino acid transporter (AATP11) that is enriched in 
procyclic forms (Robles and Clayton, 2008), phosphoglycerate kinase transcripts 
(Blattner and Clayton, 1995), and VSG mRNA that is expressed specifically in 
bloodstream forms (Berberof et al., 1995). 
 
1.7.2 RNA-binding proteins 
Due to their reliance on post-transcriptional control of gene expression, kinetoplastid 
genomes show an enrichment in genes encoding RNA-binding proteins compared to 
unicellular organisms that rely on transcriptional control (Ivens et al., 2005). In T. 
brucei, a particularly well characterised set of RNA-binding proteins are the three 
zinc finger protein (ZFP) proteins, one of which, TbZFP3, enhances differentiation to 
procyclic forms and shows a polysome association that is developmentally regulated 
(Paterou et al., 2006). This protein shows specific association with the EP1 and 
GPEET procyclin isoform transcripts and therefore provided the missing link 
between the regulatory regions defined in these mRNAs (see above) and translation 
of these transcripts (Walrad et al., 2009). 
 
Other examples in T. brucei include the RNA helicase, DHH1, which is important 
for the correct expression of many developmentally regulated genes (Kramer et al., 
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2010); the RNA-binding protein PUF (Pumilio/Fem-3) 9, which stabilises a set of 
transcripts during S-phase (Archer et al., 2009); RNA-binding proteins ALBA3 and 
4, implicated in differentiation of mesocyclic to epimastigote insect forms (Subota et 
al., 2011); and the RNA-binding protein, TbDRBD3, which binds to and promotes 
the stability of a subset of developmentally regulated mRNAs encoding membrane 
proteins (Estevez, 2008). Therefore, in trypanosomes RNA-binding proteins can 
regulate the expression of specific sets of mRNAs during particular cellular 
processes. 
 
1.7.3 mRNA degradation 
The decay of mRNAs is achieved by removal of the poly(A) tail by the PAN2/PAN3 
complex, CCR4/CAF1/NOT complex, or poly(A)-specific ribonuclease (PARN), and 
then 3’-5’ exonucleolytic digestion or decapping and 5’-3’ exonucleolytic digestion 
(reviewed in (Parker and Song, 2004). In T. brucei, a complex containing CAF1 and 
NOT proteins was identified and CAF1 was shown to possess deadenylation activity 
with its depletion resulting in delayed deadenylation and degradation of mRNAs 
(Schwede et al., 2008). Additionally, T. brucei PARN-1 has been shown to be a 
functional deadenylase and responsible for the degradation of a subset of mRNAs 
(Utter et al., 2011). In yeast, the exosome is complex composed 3’-5’ 
riboexonucleases responsible for most 3’-5’ exonucleolytic digestion and T. brucei 
possesses a simplified exosome complex, being composed of fewer proteins (Estevez 
et al., 2001). Depletion of the major 5’-3’ exoribonuclease, XRNA, resulted in the 
stabilization of most unstable mRNAs (Manful et al., 2011). Taken together, these 




In eukaryotes, RNA interference (RNAi) and related small-RNA-mediated pathways 
play an important role in the silencing of gene expression, initiated by small RNAs 
(~20-30nt) with sequences complementary to regions of the transcripts they regulate 
(reviewed in (Jinek and Doudna, 2009). T. brucei possesses the RNAi pathway, 
being one of the first organisms where it was discovered (Ngo et al., 1998), and 
48 
homologues of RNAi proteins, namely two Dicer-like enzymes (TbDCL1 and 
TbDCL2) (Patrick et al., 2009) and an Argonaute (AGO) protein (TbACO1) 
(Durand-Dubief and Bastin, 2003; Atayde et al., 2011). TbDCL2 is nuclear and 
involved in the endogenous RNAi response to retroposons and repeats, whereas 
TbDCL1 is mostly cytoplasmic and proposed to be involved in processing any 
cytoplasmic dsRNA (Patrick et al., 2009).  
 
RNAi in T. brucei is involved in the suppression of two classes of retroposon, INGI 
(Kimmel et al., 1987) and SLACS (Spliced Leader Associated Conserved Sequence) 
(Aksoy et al., 1990) transcripts (Shi et al., 2004). Prolonged culture of T. brucei 
deficient in RNAi results in genomic rearrangements of SLACS, supporting the 
hypothesis that this pathway serves to control the spread of retroposons in the 
genome (Patrick et al., 2008). The RNAi pathway has not been implicated the 
control of expression of any other transcripts. 
 
1.7.5 Translation 
To date, there have been few studies examining components of the translational 
machinery in T. brucei. The proteins studied thus far are members of eIF4F cap-
binding complex (Freire et al., 2011; Dhalia et al., 2006) and three potential eIF2α 
kinases (TbeIF2K1-3; Moraes et al., 2007).  
 
T. brucei contains four homologues of eIF4E, TbeIF4E1-4 (Clayton and Shapira, 
2007), which have been investigated to some extent. One study has reported that 
TbeIF4E1 and 2 localise to the nucleus and cytoplasm, while TbeIF4E3 and 4 are 
cytoplasmic, but all are constitutively expressed across bloodstream and procyclic 
stages (Freire et al., 2011). Additionally, through RNAi-mediated ablation, 
TbeIF4E3 or TbeIF4E1 and 2 together were found to be essential for procyclic form 
viability, whereas TbeIF4E1, 3 and 4 were found to be essential in the bloodstream 
form. Knockdown of TbeIF4E3 alone, or TbeIF4E1 and 2, or TbeIF4E1 and 4 
resulted in translation inhibition as assessed by radiolabelled methionine 
incorporation. TbeIF4E1, 2 and 4 were found to bind a cap analogue, but not 
TbeIF4E3, and TbeIF4E3 and 4 were found to interact with T. brucei eIF4G 
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homologues (Freire et al., 2011). However, the characterisation of each of the 
homologues in this paper are limited by two main criticisms, firstly, the cap-binding 
efficiency was assessed through binding to m7 cap, and not the significantly different 
trypanosome cap 4, meaning that this cap-binding analysis had limited biological 
relevance. Secondly, a direct role in translation initiation was not demonstrated, as 
the authors did not perform sucrose density polysome analysis to identify where the 
proteins migrate using their antibodies to the homologues or the effects on translation 
of TbeIF4E RNAi knockdown.  
 
Leishmania major also possesses four homologues of eIF4E, LmEIF4E1-4, which 
are well conserved with the T. brucei homologues (Dhalia et al., 2005) and better 
characterised. LmEIF4E1 and 4 bind m7GTP and cap 4, and interact with 
mammalian 4EBP1, LmEIF4E1 is more abundant in the amastigote lifecycle stage, 
LmEIF4E2 binds mainly to cap 4 and comigrates with polysomal fractions on 
sucrose gradients, whereas LmEIF4E3 bound mainly to m7GTP and comigrated with 
80S ribosomes (Yoffe et al., 2006). Additionally, LmEIF4E4 was found to interact 
with an eIF4G homologue, LeishIF4G-3 (Yoffe et al., 2009; Zinoviev et al., 2011). 
Interestingly, in Leishmania a novel non-conserved 4E-Interacting Protein has been 
identified which binds to LmEIF4E1 in promastigotes but not amastigotes, and so 
was proposed to be involved in a switch between cap-dependent and independent 
translation (Zinoviev et al., 2011). 
 
Two homologues of eIF4A, a member of the cap-binding complex along with eIF4E 
and eIF4G, have also been studied. TbEIF4AI is a very abundant and predominately 
cytoplasmic protein, whose depletion dramatically reduced protein synthesis and 
prevented cell proliferation, and TbEIF4AIII is a nuclear protein, whose depletion 
also stopped cell proliferation but with slower kinetics (Dhalia et al., 2006). 
 
As noted previously, the presence of multiple copies of eIF4F subunits in the 
typanosomatids may reflect their association with different life-cycle stages or the 
translation of specific mRNA subsets (Dhalia et al., 2005). This could make these 
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proteins particularly interesting to study in the context of life-cycle stage dependent 
translation. 
 
Three potential eIF2α kinases were identified in T. brucei, and one, TbeIF2K2, was 
characterised to be a transmembrane glycoprotein expressed in bloodstream and 
procyclic forms (Moraes et al., 2007). This protein was capable of phosphorylating 
yeast and mammalian eIF2α at Ser-51 and localised mainly to the membrane of the 
flagellar pocket, which is the site of exo- and endocytosis, suggesting that it may 
have a role in a sensing mechanism (Moraes et al., 2007).  
 
Interestingly, it was recently shown that in T. cruzi, nutritional stress results in 
increased levels of Tc-eIF2α phosphorylation and inhibition of global translation 
initiation, and also that Tc-eIF2α phosphorylation is required for parasite 
differentiation to infective forms (Tonelli et al., 2011). In Leishmania, eIF2α 
phosphorylation has also been associated with decreased protein synthesis and 
differentiation (Lahav et al., 2011). Phosphorylation of eIF2α and inhibition of 
translation have been shown to control sporozoite latency in Plasmodium, through 
the action of an eIF2α kinase, IK2 (Zhang et al., 2010), possibly with a Puf protein, 
Puf2 (Muller et al., 2011). Additionally, eIF2α phosphorylation by another eIF2α 
kinase, PfeIK1, is involved in the stress response to amino acid starvation (Fennell et 
al., 2009) In T. brucei, however, eIF2α phosphorylation is not associated with stress 
response of heat shock (Kramer et al., 2008). 
 
Therefore, studies so far indicate that T. brucei appears to contain homologues of the 
main translational protein machinery. 
 
1.8 Project aims 
 
To date, gene expression studies in trypanosomes have focussed entirely on the 
proliferative life-cycle stages in mammalian hosts (bloodstream slender forms) or the 
tsetse mid-gut (procyclic forms). Nothing is known about gene expression control in 
non-proliferative stumpy forms. However, here, translational control is likely to be 
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very important because most mRNAs are translationally repressed in this quiescent 
cell-type, though a small subset of mRNAs are known to be highly expressed, likely 
to assist survival of the stumpy form, or to preadapt this parasite for transmission to 
the Tsetse mid-gut. Such transcripts, therefore, provide an excellent model for the 
escape of translational repression, although the regulatory mechanisms are unknown. 
 
Therefore, the question to be addressed in this work was how are translation and the 
escape from translational arrest in stumpy form T. brucei controlled? The specific 
aims of this work were to: 
 
• Determine what signals control the expression, or escape from translational 
arrest, of genes expressed in stumpy forms 
• Investigate if mechanisms such as uORFs are involved in the control of the 
escape from repression, or repression, of genes expressed in stumpy forms 
• Investigate if specific translational proteins are involved in translational 
control in stumpy forms 






























































2.1 Bioinformatic analysis 
 
2.1.1 Basic bioinformatic tools 
The sequenced Trypanosomatid genomes and associated gene entry annotations were 
accessed through the TriTryp database (http://tritrypdb.org/tritrypdb/).  
 
Multi-alignment of DNA sequences or protein sequences were performed online 
using the ClustalW2 programme (Multiple Sequence Alignment tool, version 2.1) 
from the EMBL-EBI web server (http://www.ebi.ac.uk/Tools/msa/clustalw2/) with 
the default settings (Larkin et al., 2007).  
 
Protein-protein BLAST (Basic Local Alignment Search Tool; (Altschul et al., 1990) 
searches were performed online using the EMBL-EBI web server 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) with the default settings, or accessed through 
the TriTryp database web server (http://tritrypdb.org/tritrypdb/) for the interrogation 
of T. brucei annotated genes alone. 
 
For prediction of RNA secondary structure the Srna application module of the freely 
available web-based software package Sfold (Ding et al., 2004) was used with the 
default settings (http://sfold.wadsworth.org/cgi-bin/index.pl).  
 
Annotated chromosome sequences of the T. brucei TREU 927/4 genome were 
viewed using Artemis software available from the Wellcome Trust Sanger Institute 
(http://www.sanger.ac.uk/resources/software/artemis/). Predicted splice sites (Benz 
et al., 2005) were included by using the ‘Read an Entry’ option in Artemis. 
 
Protein structure homology modelling was performed using SwissModel (Arnold et 
al., 2006; Kiefer et al., 2009) using the ‘Automated Mode’ 
(http://swissmodel.expasy.org/). Models were then viewed using the Swiss-
PdbViewer application (available from http://spdbv.vital-it.ch/). 
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2.1.2 Identification of potential uORFs 
For computational identification of potential uORFs present in the T. brucei TREU 
927/4 genome, firstly, for all annotated genes in the published genome the 100 
nucleotide of 5’ intergenic sequence immediately preceding the start codon of each 
annotated gene, was obtained from the database 
(http://www.genedb.org/genedb/tryp/) using the ‘list download’ facility. These 
sequences were then translated into amino acid sequence using the ExPASy tool, 
http://searchlauncher.bcm.tmc.edu/seq-util/Options/sixframe.html, or 
http://biotools.umassmed.edu/cgi-bin/biobin/transeq. A PERL script was then used to 
identify within these sequences of a methionine codon followed by a stop codon with 
at least two amino acid residues in between, this being designated as a potential 
uORF sequence (PERL script written and executed by Pankaj Barua, University of 
Edinburgh). 
 
2.1.3 Basic GO term analysis 
A Gene Ontology (GO) term search was performed with a SQL query (Appendix 2; 
written by Christiane Hertz-Fowler, Wellcome Trust Sanger Institute, Hinxton) 
containing the IDs of the genes of interest using http://www.berkeleybop.org/goose. 
The frequency of each GO term returned for a group of genes was determined using 
the ‘pivot table’ function in Microsoft Office Excel and used for comparison of terms 
returned for different groups of genes.  
 
2.1.4 GO Toolbox analysis 
The GO-Stats online tool (http://genome.crg.es/GOToolBox/) (Martin et al., 2004) 
was used to find enriched and depleted GO terms associated with the gene lists under 
investigation compared to those associated with the whole T. brucei genome. For 
each gene list a GTB file was generated using the Create Dataset tool 
(http://genome.crg.es/cgi-bin/GOToolBox/gotbx-dataset-form.cgi). Within this tool 
the ‘Trypanosoma brucei GeneDB version’ was selected as the corresponding 
annotation set, all three (biological process, molecular function, cellular component) 
ontologies were selected, and the other settings remained at default. The GTB file 
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was then used as input in the GO-Stats tool, ‘hypergeometric’ selected as the 
statistical test and ‘Bonferroni’ selected as the correction. 
 
2.1.5 Regulatory Sequence Analysis Tools (RSAT) analysis 
To detect possible regulatory sequences in a set of genes the online Regulatory 
Sequence Analysis Tools (RSAT; http://rsat.scmbb.ulb.ac.be/rsat/) was used, as these 
tools detect over-represented oligonucleotides in sets of DNA sequences. The 
‘sequence retrieval’ tool at TriTrypDB (http://tritrypdb.org/tritrypdb/) was used to 
obtain the specified amount of genomic sequence upstream/downstream of the 
translation start/stop codon of each gene ID in the gene set under investigation. The 
retrieved sequences were used in the ‘oligo-analysis (words)’ RSAT tool, with the 
parameters remaining at the default settings, except that the oligomer length chosen 
was 8 and Markov model selected. The output from this was then transferred to the 
‘string-based pattern matching (dna-pattern)’ tool as input, and again the parameters 
remained at their default settings, except that ‘matching statistics’ was also selected 
as output returned. Again this output was used as input in the ‘feature map’ tool, the 
parameters again remained at default.  
 
For investigation with the ESAG9-EQ element sequence (see Section 3.9.3), the 
RSAT DNA-pattern matching tool was used. The default settings were used, except 
the ‘direct only’ option for strand searched was selected, ‘start’ as the origin, 
allowing 2 substitutions in the pattern, and also ‘match scores’ and ‘matching 
statistics’ were selected in the output options. 
 
2.1.6 Additional protein prediction programmes 
The Pfam 24.0 database (http://pfam.sanger.ac.uk) sequence search was used with 
the protein sequence of interest using the default parameters (including the default 
value of 1.0 for the E-value) to identify potential protein domains within a sequence 
(Finn et al., 2010). The SignalP 3.0 server (www.cbs.dtu.dk/services/SignalP) was 
used to predict the presence and location of signal peptide cleavage sites within 
amino acid sequences used as input with the default settings, ‘Eukaryotes’ selected 
as the organism group and ‘Both’ selected as the method (Bendtsen et al., 2004b). 
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The PSORT server (http://psort.hgc.jp/) was used to assess iPSORT, WoLF PSORT, 
and PSORT II programmes (Nakai and Horton, 1999). For iPSORT prediction, ‘non-
plant protein’ was selected and for WoLF PSORT prediction, ‘animal’ was selected 
as the organism type. The SecretomeP 2.0 server 
(http://www.cbs.dtu.dk/services/SecretomeP/) was used with the ‘Mammalian’ 
setting to predict non-classical protein secretion (Bendtsen et al., 2004a). The 
TMHMM server v. 2.0 (http://www.cbs.dtu.dk/services/TMHMM/) was used to 
predict transmembrane helices (Krogh et al., 2001). The TargetP 
(http://www.cbs.dtu.dk/services/TargetP/) programme (Emanuelsson et al., 2000) 
was used with ‘Non-plant’ selected as the organism group, ‘Perform cleavage site 




The monomorphic trypanosome strains used in this work were T. b. brucei Lister 427 
(bloodstream form), T. b. brucei 427-449 (bloodstream and procyclic forms), and T. 
b. brucei ‘single marker’ cell line (bloodstream form). The pleomorphic trypanosome 
strains used in this work were T. b. brucei AnTat 1.1 and T. b. brucei AnTat 1.1 
90:13.  
 
The T. b. brucei Lister 427 cell line was the most commonly used cell line in this 
study and details of its lineage can be found on the website of Prof. George Cross 
(http://tryps.rockefeller.edu/DocumentsGlobal/lineage_Lister427.pdf). The T. b. 
brucei 427-449 cell line is the Lister 427 cell line that has been previously 
engineered to possess stable integration of the pHD449 construct (Biebinger et al., 
1997). Therefore, these cells express the tetracycline (Tet) repressor and were used 
for inducible, ectopic protein expression. The T. b. brucei Lister 427 ‘single marker’ 
bloodstream cell line (from Dr Achim Schnaufer, University of Edinburgh) expresses 
the Tet repressor (TetR) and T7 RNA polymerase (Wirtz et al., 1999) and was, 




The T. b. brucei AnTat 1.1 cell line was used for murine infections to obtain slender, 
intermediate and stumpy form populations to obtain RNA samples for Illumina 
digital tag sequencing. The T. b. brucei AnTat 1.1 90:13 cell line (Engstler and 
Boshart, 2004) was used for transfection of pleomorphic cells with CAT reporter 
gene constructs (see Section 3.9) and RNAi constructs (see Section 4.9.2). 
 
2.2.1 Laboratory culture 
Monomorphic bloodstream form T. brucei were maintained at logarithmic 
concentrations at 37°C with 5% CO2 in HMI-9 medium (Hirumi and Hirumi, 1989) 
containing 20% foetal calf serum (FCS; Fetal Bovine Serum Gold, PAA) and 
penicillin-streptomycin (100 Units/ml Penicillin, 100 µg/ml Streptomycin; 
Invitrogen) using vented flasks. Procyclic form T. brucei were kept at 27°C in SDM-
79 medium (Cross and Manning, 1973) containing ~15% FCS, 0.1% hemin and 
penicillin-streptomycin (100 Units/ml Penicillin, 100 µg/ml Streptomycin; 
Invitrogen) using non-vented flasks. The additions to both media were sterilised by 
passing through a single-use syringe filter (0.20 µm; Sartorius Stedim Biotech) into 
the medium. 
 
When cultured in vitro following transfection (see Section 2.2.4), pleomorphic 
bloodstream form T. b. brucei cells were kept in HMI-9 in monomorphic 
bloodstream form conditions. The medium used was always pre-warmed to 37°C, the 
time out of 37°C incubation was minimised and the cell density was maintained 
below 1 x 106 cells/ml were possible. 
 
For storage of trypanosome cells, 10 ml of the cell culture in exponential-phase 
growth was pelleted at 2000 rpm for 10 minutes and resuspended in 1 ml of the 
appropriate medium with 7% glycerol. This was then transferred into a cyrovial tube 
and put at -80°C. For longer term storage the cryovial was transferred into liquid 
nitrogen storage. To thaw the cells, the cryovial was placed briefly in a 42°C water 
bath until thawed, then the culture transferred into 9 ml of medium appropriate for 
the life-cycle stage and 24 hours later any necessary selective drugs for the cell line 
were added.  
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Unless otherwise stated, cell concentration was determined by a 1:40 dilution of the 
cell culture in Coulter Isoton II Diluent (Beckman Coulter) using a Z2 Coulter 
Particle Count and Size Analyzer (Beckman Coulter) measuring the range of 2.5-7 
microns. 
 
The single marker cell line was maintained with 2.5 µg/ml G418 Disulphate 
(Melford); the 427-449 cell line was maintained with 0.5 µg/ml phleomycin 
(Invitrogen). Induction of RNAi or ectopic protein expression from transfectant cell 
lines with pQuadra, pALC14 or pHD451-Ty plasmids was performed using 10 µg/ml 
or 1 µg/ml Tetracycline (Sigma; dissolved in ethanol for a stock solution). 
 
2.2.2 Purification of trypanosomes from murine blood 
The mice used in this study were the MF1 strain and male. Each mouse was infected 
with trypanosomes in a maximum volume of 0.2 ml by intraperitonal (IP) injection. 
If infected for the harvest of a stumpy form population, the mouse was injected (IP) 
with 250 µl cyclophosphamide (25 mg/ml) the day prior to infection. If necessary, 
the infection was monitored by microscopic examination of a small volume of blood 
obtained by tail-snip of the infected mouse, then the blood from trypanosome-
infected mouse was collected by heart puncture. The blood was allowed to pass 
through a diethylaminoethyl (DEAE) cellulose (DE-52) anion exchange column 
(Lanham and Godfrey, 1970) equilibrated with PSG (pH7.8, see Appendix 1). Note 
that all animal work was performed by Prof. Keith Matthews, Deborah Hall or Julie 
Wilson in accordance with their Home Office licences. 
 
2.2.3 Transfection of monomorphic trypanosomes 
Prior to transfection, 15 µg of the construct was linearised in a 50 µl NotI (Promega) 
restriction enzyme digest incubated overnight at 37°C. Linearisation was confirmed 
by comparison of 1 µl of the digest to uncut vector on a 1% w/v agarose gel made 
with TAE (Tris-acetate EDTA) buffer. The remaining digest solution was purified 
using Nucleospin Extract II (Macherey-Nagel) according to the manufacturer’s 
instructions, except that the elution step was performed four times, each with 50 µl 
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of elution buffer. The DNA was ethanol precipitated by adding 20 µl of 3M sodium 
acetate and 550 µl 100% ethanol, briefly vortexing the solution and incubating at -
80°C overnight. Then, the solution was centrifuged at 14000 rpm for 10 minutes at 
4°C and the pellet was allowed to air-dry before resuspension with 5 µl 1mM Tris-
HCl pH8, 0.1mM EDTA.  
 
For transfection, 4 x 107 logarithmically-growing trypanosomes were pelleted at 
2000 rpm for 10 minutes and resuspended in 100 µl transfection buffer (either 
AMAXA Nucleofector solution [Lonza] or Ingenio Electroporation Solution 
[Mirus]) with the purified DNA. The resuspended cells were added to an 
AMAXA/Mirus cuvette and transfected using an AMAXA Nucleofector machine 
(Lonza) with programme X-001 or Z-001 (Burkard et al., 2007; Schumann Burkard 
et al., 2011). Following transfection, cells were allowed to recover in HMI-9 
overnight, before selection of transfectants 24 hours post-transfection using serial 
dilutions (neat, 1:10, 1:100, 1:1000) of the cells in HMI-9 containing the selective 
drug. As a control, the parental cell line was also used for serial dilutions with HMI-
9 containing the selective drug to ensure lethality of the drug for cells not possessing 
the transfected construct. 
 
For transfections with the CAT449 plasmid, transfectants were selected and 
maintained with 0.5 or 2.5 µg/ml phleomycin (Invitrogen); 2 µg/ml hygromycin B 
(InvivoGen) for the pHD451-Ty plasmid; 0.5 µg/ml puromycin (Calbiochem) for the 
pALC14 plasmid; and 2.5 µg/ml phleomycin for the pQuadra plasmid. 
 
2.2.4 Transfection of pleomorphic trypanosomes 
Preparation of NotI-digested DNA for transfection was performed as for transfection 
of monomorphic cells (section 2.2.3). Mice were infected with the AnTat1.1 90:13 
cell line and during slender parasitaemia the blood was collected by heart puncture 
(as described in Section 2.2.2).  
 
The blood sample was transferred into 25 ml of HMI-9 medium (pre-warmed to 
37°C, as was all the HMI-9 medium used for pleomorphic cell culture). These flasks 
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were left to stand upright at 37°C for a few hours to allow the red blood cells to 
settle. The media containing the trypanosome cells was removed, without disturbing 
the settled red blood cells, transferred into a flask of 25 ml of HMI-9, and another 25 
ml of HMI-9 added to the settled blood cells. Again, these flasks were left to stand 
upright at 37°C. The following day, without disturbing the settled red blood cells, the 
media containing the trypanosome cells (about 75 ml) was transferred from both 
flasks into a fresh flask. The cell concentration was determined using a 
haemocytometer and the culture divided for the number of transfections to be 
performed. Cells were pelleted at 2000 rpm for 8 minutes and the supernatant 
discarded. The cells were resuspended with 80 µl AMAXA Nucleofector solution 
(Lonza) with the linearised DNA to be transfected. A negative control using sterile, 
distilled water instead of DNA was also performed in parallel. The resuspended cells 
were transferred to a cuvette (Lonza) and transfected using an AMAXA 
Nucleofector machine (Lonza) with programme X-001. The cells were then 
transferred into 25 ml of HMI-9 medium and 37°C. 
 
A few hours following transfection, the cells were transferred into 24-well culture 
plates (Greiner Bio-one), in four different cell concentrations (1 ml of culture in each 
well). The following day, 1 ml of HMI-9 medium containing the selective drug at 
double the final concentration was added to each well. A range of different drug 
concentrations was applied for each cell concentration. For selection of transfectant 
cells with phleomycin, the drug concentration range was 1-2 µg/ml. As a control, 
cells in HMI-9 medium lacking the selective drug were also included in a culture 
plate. Further dilutions of cells in selective media were made later if necessary. 
Following the death of all the control cells not transfected with DNA, each well 
containing surviving transfectant cells was diluted into a larger culture volume (5 ml) 
with selective drug. Two surviving cultures were used to infect a mouse (as 
described in Section 2.2.2).  For this, cells were pelleted from a small volume of the 
cell culture (typically 1 ml) by centrifugation at ~9000 rpm for ~4 minutes using a 
microfuge, and resuspended in about 200 µl HMI-9 medium for injection. 
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2.2.5 Differentiation to ‘stumpy-like’ form using 8-pCPT-2’-O-Me-cAMP 
8- (4- Chlorophenylthio)- 2’- O- methyladenosine- 3’, 5’- cyclic monophosphate (8-
pCPT-2’-O-Me-cAMP; Biolog Life Science Institute) dissolved in DMSO (Dimethyl 
sulfoxide) to a concentration of 10 mM (briefly vortexed to ensure all the compound 
had dissolved) was added to a 25 ml cell culture (~5 x105 cells/ml concentration) to 
give a final concentration of 10 µM. As a control, to an identical cell culture the 
same volume of DMSO alone was added. Following incubation at 37°C for 48 hours, 
5 ml of each culture was used to generate cell lysate samples for use in a CAT 
ELISA assay (as described in Section 2.6) and the remaining culture used for RNA 
extraction and then Northern blot analysis (as described in Section 2.4).  
 
2.2.6 Differentiation to procyclic form using cis-aconitate 
Monomorphic bloodstream form trypanosomes were induced to differentiate to 
procyclic forms in vitro in HMI-9 medium using 6 mM cis-aconitate (Sigma) and 
incubation at 27°C in 24-well culture plates (Greiner Bio-one). In parallel, a control 
was performed of cells untreated with cis-aconitate, this being performed for cells 
induced and uninduced for RNAi or ectopic protein expression, with each treatment 
condition performed in triplicate. Differentiation was assessed 72 hours post-
induction for cells stained positive for EP-procyclin (see Section 2.8.3).  
 
2.2.7 Cold shock treatment 
The T. b. brucei Lister 427 cell line was used and cell lysate samples taken for 
Western blot analysis as described in Section 2.7. A cell lysate sample was taken at 0 
hours, then the cells split into three groups and transferred to three temperatures 
(37°C, 27°C and 20°C). Cell lysate samples were taken at various time-points up to 5 





All oligonucleotides were obtained from Sigma-Aldrich and resuspended with 
distilled water. A list of the names and sequences of oligonucleotides (primers) used 
in this study can be found in Table 2.1. 
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Table 2.1 List of oligonucleotides (primers) used in this study. 
 
 
Number Name Sequence (5'-3')
1 M13 Forward GTAAAACGACGGCCAGT
2 M13 Reverse CAGGAAACAGCTATGAC
3 Aconitase 5’UTR F2 gtgctcgagtggggtcttggtccag
4 Aconitase 5’UTR R2 cccaagcttacacaagactccctcttc
5 Aconitase 3’UTR F2 ggcggatcccggaacaccgaaacctg
6 Aconitase 3’UTR R2 ggggaagaccttgctggtttgctttttcggg
7 Aconitase 3'UTR 400nt F cgggcggatccctaactacatatttggtacatg
8 Aconitase 3'UTR 300nt F gcgcggatccagctgacttggtgcc
9 Aconitase 3'UTR 200nt F ggcggatccgcgacggcttaacgag
10 Aconitase 3'UTR 100nt F gggggcggatccggtgacaaaaacctttg
11 Aconitase 3'UTR 850nt R ccgaagaccttgctgGTTCCCTCTACCTTATGC
12 ESAG9-EQ 3’UTR F2 cccggatccaaatcattaccgcaattcc
13 ESAG9-EQ 3’UTR R2 cccgaagaccttgctgttatcacgttccc
14 ESAG9-EQ 3’UTR 350nt F ggccggatccaacaccgcatgatg
15 ESAG9-EQ 3’UTR 300nt F ggcccggatccctgctttcaatgaag
16 ESAG9-EQ 3’UTR 250nt F ggcgcggatccagaggatcgaataac
17 E3d R ggggTCTAGAgttccatccacatgatcttcattg
18 E3d F ggggTCTAGAactaatgtaatcataagtagcgtacatgag
19 ADAPT dT GGCCACGCGTCGACTAGTACTTTTTTTTTTTTTTT
20 AUAP GGCCACGCGTCGACTAGTAC
21 CAT 3 cCGTGGCCAATATGGACAACTTC
22 CAT 4 GGTGCTGATGCCGCTGGCG
23 Aldolase 1.1 F gggGGATCCTGCCCATTTAGTTAG
24 Aldolase 1.1 R gcTCTAGACGAGACAAGGGAAAAGC
25 Aldolase 1.2 F ggggTCTAGATGTCTTTTCCGTGGAAAGGTTC
26 Aldolase 1.2 R GAAGACcttgctgGGGCACGAATCCCC
27 E3eI F ggatctagagttgtggagagac
28 E3eI R gggtctagagttattcgatcctc
29 E3eI F2 ctagggttgtggagagacaagataagaggatcgaataact
30 E3eI R2 ctagagttattcgatcctcttatcttgtctctccacaacg
31 E3eI GeneArt F CGTCAAGGCCACGTGTC
32 E3eI GeneArt R GAGGCCAGTCTTGTGCTC
33 Tb09.211.2300 5'UTR F cccctcgagcgatgtgacttaatg
34 Tb09.211.2300 5'UTR R2 cccaagcttcaccacaaccacac
35 Tb11.47.0019 5'UTR F cccctcgagtgttgttgttgttg
36 Tb11.47.0019 5'UTR R2 cccaagcttcacacgcaaagg
37 ESAG9-EQ 5’UTR F2 cccctcgaggtttacaatccaac
38 ESAG9-EQ 5’UTR R2 cccaagcttttttccccccgac
39 Tb09m F ggtggtgtgatatatacgtgtttggttggtg
40 Tb09m R caccaaccaaacacgtatatatcacaccacc
41 Tb11m F ctcatccgccgtcacgaggatagaaagg
42 Tb11m R cctttctatcctcgtgacggcggatgag
43 EQm F gtggtattttgtacgatttgttagtttacgtcggggg
44 EQm R cccccgacgtaaactaacaaatcgtacaaaataccac
45 Splice leader CTATTATTAGAACAGTTTCTGTACTATATTG
46 Tb09 a2 cCAAAACTGTAGGAAATGGTATCG
47 Tb09 b2 CAGCATTTCTAAGCATGGGATC
 
  a 
63 
 
a Restriction enzyme site sequences are underlined 
48 Tb11 a2 ccCTCTAGCCGAGATGTTG
49 Tb11 b2 cGCTGACCCGAGATCATC
50 Tb09 a gccTTGCCGAACACACTAACCAA
51 Tb09 b gccCAGGTGCCATATATCGAAAC
52 Tb11 a ccgAACAACAAAAGGCCTTCCCTC
53 Tb11 b gggTCAACTGTCATCTCCGCAAC
54 as077 GCATAATGCCACTGCGCTTT
55 as076 GAAGTTCGCTCCATGAACCT
56 Tb09 a F gggTACCAATGTGATGGTTGGTTAGTGTGTTCGGCAA
57 Tb09 a R gggTACCATAGAGTTGGGCGAAAAGAAGTAAGGGAACA
58 Tb11 a F gggTACCAATGTGATGGAGGGAAGGCCTTTTGTTGTT
59 Tb11 a R gggTACCATAGAGTTGGACGGCACGTTGGAGGTAATA
60 Tb09 b F gggTACCAATGTGATGGCGGTGAGGCTCAGAAGGTAG
61 Tb09 b R gggTACCATAGAGTTGGGTGAGTTCTTCCTGAAGCGG
62 Tb11 b F gggTACCAATGTGATGGGTTGCGGAGATGACAGTTGA
63 Tb11 b R gggTACCATAGAGTTGGTGATCAGGGTCGATTTGTGA
64 Tb11 long 451 F3 cCTCGAGATGTGTGTCTGTTTGTGTTGTC
65 Tb11 451 R ccGGATCCAGAGCTATCTTTGTTCACAATG
66 Tb11 short 451 F cccAAGCTTATGAATGTTTTTGATTCCAACAGC
67 Tb11a 1.1 F gggaagcttAGGGAAGGCCTTTTGTTGTT
68 Tb11a 1.1 R gggtctagaACGGCACGTTGGAGGTAATA
69 Tb11a 1.2 F gggctcgagACGGCACGTTGGAGGTAATA
70 Tb11a 1.2 R gggggatccAGGGAAGGCCTTTTGTTGTT
71 Tb11b 1.1 F gggaagcttGTTGCGGAGATGACAGTTGA
72 Tb11b 1.1 R gggtctagaTGATCAGGGTCGATTTGTGA
73 Tb11b 1.2 F gggctcgagTGATCAGGGTCGATTTGTGA
74 Tb11b 1.2 R gggggatccGTTGCGGAGATGACAGTTGA
75 TbeIF4E1 F gggTACCAATGTGATGGaaagctggtgggaagttgtg
76 TbeIF4E1 R gggTACCATAGAGTTGGgctgtgaagatgggtttcgt
77 TbeIF4E2 F ggcTACCAATGTGATGGGCAGCAACTGCTACACCAAA
78 TbeIF4E2 R gggTACCATAGAGTTGGCTTAACTTCCAGTCTCGCCG
79 TbeIF4E3 F gggTACCAATGTGATGGGTTGGGGATGTTGAGTGCTT
80 TbeIF4E3 R gggTACCATAGAGTTGGTCGACGGTTTTCCTTTCATC
81 TbeIF4E4 F gggTACCAATGTGATGGAGCAACAGCAAACAGTGGTG
82 TbeIF4E4 R gggTACCATAGAGTTGGAGGGTTTCGTCATGTTGGAG
83 TbK1 F ggcTACCAATGTGATGGATCGTCCGGTACTACGATGC
84 TbK1 R gggTACCATAGAGTTGGATTTTCGTTGCCACCTTGTC
85 TbK2 F gggTACCAATGTGATGGCCTCGTTGGCTTTGGTATGT
86 TbK2 R gggTACCATAGAGTTGGGAAAGAGTTGTGGCATGGGT
87 TbK3 F ggcTACCAATGTGATGGTGGTGTTTTGTACGCCGTTA
88 TbK3 R gggTACCATAGAGTTGGTGACCTTGTGTCGTCAGAGC
89 1770 pQ F gggTACCAATGTGATGGTCTGACGATGTGGGTGTGTT
90 1770 pQ R ggcTACCATAGAGTTGGTCTGCAATGGATGTACGGAA
91 4900 pQ F ggcTACCAATGTGATGGCGATGGAACATGACATACGC
92 4900 pQ R gggTACCATAGAGTTGGGTTTCAGTCCCTCTTCGCTG
93 INGI F AAGGCCGCAGATTTACCACAG
94 INGI R AGCGACGTTTCTTCGCAGTC
95 1770 451 F GGCAAGCTTATGACACTGCGTACGCGCTTCGAGAGCTC
96 1770 451 R GGGGATCCTGCCAGTTCATCCACCAACGTATCGCGC
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2.3.2 Plasmids 
The T. brucei expression vector, pHD449 (Biebinger et al., 1997), was previously 
modified through replacement of the tetracycline resistance cassette present in this 
plasmid with the chloramphenicol acetyltransferase (CAT) coding region, to create 
the plasmid, CAT449 (Mayho et al., 2006). This plasmid contains the phleomycin 
resistance gene (BLE). The pQuadra vector system (Inoue et al., 2005) was used for 
RNAi-mediated transcript ablation and is outlined in the schematic diagram shown in 
Appendix 2. Alternatively, pALC14 (Bochud-Allemann and Schneider, 2002) was 
used for RNAi-mediated transcript ablation. For ectopic overexpression of protein 
with a Ty epitope tag at the C terminus, the pHD451 vector that had been previously 
modified to include a Ty epitope tag sequence downstream of insertion site was used 
(Hendriks et al., 2001). Each of these plasmids can be linearised with a NotI 
restriction enzyme digestion reaction (see Section 2.3.7). 
 
The commercially available plasmid, pGEM-T Easy (Promega), was used for 
ligation with each PCR amplicon and following small-scale plasmid preparation (see 
Section 2.3.10) was sequenced (The Genepool, University of Edinburgh) with M13 
forward and reverse primers (see Table 2.1) to establish insertion copy number, 
orientation and sequence. 
 
2.3.4 Genomic DNA extraction 
Genomic DNA was extracted from trypanosomes using DNeasy Blood & Tissue kit 
(Qiagen) according to the manufacturer’s instructions for Animal Blood (Spin-
Column Protocol), except that a lower amount of RNase was added (about 15 µl 10 
mg/ml RNase per sample). 
 
2.3.5 PCR amplification 
DNA sequences were amplified in a polymerase chain reaction (PCR) using either 
GoTaq Hot Start polymerase (Promega) or the Expand High Fidelity PCR system 
(Roche). In both cases, the total reaction volume was 50 µl, containing 2 µl of each 
of a forward primer (25 µM), reverse primer (25 µM; see Table 2.1 for sequences), 
and genomic DNA as template. When using the GoTaq Hot Start polymerase, 
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reactions were made according to the manufacturer’s instructions, containing 10u/µl 
GoTaq Hot Start polymerase (Promega) and 3 µl 25mM MgCl2 (Promega).  When 
using the Expand High Fidelity polymerase, the reaction was made according to the 
manufacturer’s instructions using the Expand High Fidelity buffer containing MgCl2 
(Roche). A reaction containing water instead of genomic DNA (water control) and 
another reaction containing forward and reverse primers previously determined to 
result in a product (positive control) were performed in parallel with the 
experimental reaction(s). PCR cycles started with a denaturing step of 95°C for 5 
minutes, then 30 cycles of 95°C for 30 seconds (20 seconds for the Expand High 
Fidelity PCR system), 45 seconds (30 seconds for the Expand High Fidelity PCR 
system) at the annealing temperature, and 72°C for 2 minutes, followed by a single 
step of 72°C for 4 minutes.  
 
The product from each PCR reaction was analysed on an agarose gel (typically 1 or 
1.2% w/v) made with TAE buffer containing ethidium bromide (0.4 µg/ml), after 
electrophoresis at ~120 volts. If products of various molecular weights were 
observed, the product of the correct molecular weight was excised from the agarose 
gel and purified using the Nucleospin Extract II kit (Macherey-Nagel) according to 
the manufacturer’s instructions. Each PCR amplicon was then ligated (using either 
the PCR reaction directly or purified gel product) into the pGEM-T Easy plasmid 
(see Sections 2.3.2 and 2.3.9). 
 
2.3.6 Oligonucleotide annealing reaction 
Both oligonucleotides (each 100µM) to be annealed were mixed with distilled water 
and annealing buffer (final concentration: 10mM Tris, pH7.5-8.0, 50mM NaCl, 1mM 
EDTA) to obtain a final concentration of 25µM of each oligonucleotide. This was 
incubated at 90-95°C for 4 minutes, then allowed to slowly cool to room temperature 
over a period of about 45-60 minutes and transferred to 4°C. 
 
2.3.7 Restriction enzyme digest 
Plasmids were digested in double-enzyme digest reactions using 0.2u of each 
restriction enzyme per µl of reaction, compatible buffer, plasmid and BSA (New 
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England Biolabs). All restriction enzymes were obtained from Promega, except for 
BbsI, which was obtained from New England Biolabs. Reactions were incubated at 
37°C, usually overnight but at least for a minimum of 4 hours. The products of the 
digest were examined on an agarose gel as above (Section 2.3.5), with the product 
for ligation being excised and purified using the Nucleospin Extract II kit 
(Macherey-Nagel) according to the manufacturer’s instructions. 
 
2.3.8 CIAP treatment 
The pQuadra3 plasmid required Calf Intestinal Alkaline Phosphatase (CIAP) 
treatment following digestion before use in a ligation reaction. The DNA was added 
to a reaction containing 0.01u of CIAP (Promega) per µl of reaction performed 
according to the manufacturer’s instructions, except that the Stop buffer was not used 




Ligation of digested and purified DNA for insertion and vector was performed in a 
10 µl reaction with T4 DNA ligase (Promega) according to the manufacturer’s 
instructions, using 1µl of vector, 7.5 µl of DNA for insertion, and buffer (T4 DNA 
ligase 10X buffer or 2X Rapid Ligation buffer, both Promega). Except ligation using 
the pQuadra vector system contained 0.5 µl of pQuadra3 plasmid, 2 µl of pQuadra1 
plasmid and 5.5 µl of DNA for insertion. A negative control reaction was performed 
in parallel, which included distilled water instead of the insert DNA in the reaction. 
Reactions were incubated either overnight at 4°C or at room temperature for a 
minimum of 4 hours. 
 
2.3.10 Transformation of bacteria and small-scale plasmid preparation 
Transformation of Escherichia coli XL1-blue bacteria (genotype: SupE44, hsdR17, 
recA1, endA1, gyrA46, thi, relA1, lac, F’ [proAB+, lacIq, lacZDM15, Tn10(tetr)]) 
was performed with each ligation reaction. 100 µl of competent bacterial cells were 
incubated with 5 µl of ligation reaction on ice for 30 minutes. The cells were then 
heat-shocked at 42°C for 30 seconds. Either 100-250 µl of LB (Luria Bertani)-broth 
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was added to the cells and they were allowed to recover by incubation with shaking 
at 37°C for up to 45 minutes and then plated out on LB-Agar plates containing 100 
µg/ml amplicilin, or they were plated out immediately following the heat-shock step. 
The plates were incubated at 37°C overnight.  
 
Individual colonies were selected, transferred into 3 ml LB-broth with 100 µg/ml 
amplicilin, and incubated overnight at 37°C with shaking. 1.5 ml of the cell culture 
was pelleted at 13 000 rpm for 5 minutes and resuspended with 100 µl of Solution I 
(see Appendix 1). 200 µl of Solution II (see Appendix 1) was added, mixed by 
inversion several times and incubated for 4-5 minutes at room temperature. Then, 
150 µl of ice-cold Solution III (see Appendix 1) was added, again mixed by 
inversion and incubated on ice for 5 minutes. The sample was centrifuged at 13 000 
rpm for 15 minutes and to the supernatant 900 µl of ice-cold 100% ethanol was 
added, the solution mixed by inversion several times and incubated on ice for a 
minimum of 20 minutes. Following this, the sample was centrifuged at 13 000 rpm 
for 10 minutes and then the pellet was washed with 70% ethanol. After removal of 
the supernatant, the pellet was allowed to air-dry and then resuspended with 40 µl 
distilled water and 1 µl ribonuclease A (10 mg/ml; Sigma). 
 
2.3.11 Large-scale plasmid preparation 
For plasmid amplification, 200 µl of the bacterial culture used for the small-scale 
plasmid preparation was added to 200 ml LB-broth containing 100 µg/ml Amplicilin 
and incubated overnight at 37°C with shaking. DNA extraction and preparation was 
performed using the Qiagen Plasmid Midi kit according to the manufacturer’s 
instructions. The purified plasmid pellet was resuspended with 200 µl TE buffer. 
 
2.3.12 Site-directed mutagenesis 
To perform site-directed mutagenesis of an uORF start codon from ATG to ACG, the 
QuikChange XL Site-Directed Mutagenesis Kit (Stratagene) was used according to 
the manufacturer’s instructions. Briefly, the CAT449 plasmid containing the 
sequence to be mutagenised was used in a mutant strand synthesis reaction with the 
cognate two complimentary oligonucleotides containing the appropriate T to C 
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mutation. The primers that were used are numbers 39-44 in Table 2.1, which had 
been obtained from Sigma Aldrich as purifications by polyacrylamide gel 
electrophoresis (PAGE). The amplification product was then digested with DpnI 
restriction enzyme. Following digestion, 2 µl was used in a transformation of 
supplied XL-10-Gold ultracompetent cells, as per the manufacturer’s instructions, 
except that LB-broth was used instead of NZY+ broth and LB-Agar plates containing 
100 µg/ml amplicilin were used. Resulting colonies were screened to confirm the 
desired mutation following small-scale plasmid preparation, as described above 
(Section 2.3.10), and sequencing (The GenePool, University of Edinburgh) using 
primer numbers 33 and 34, or 35 and 36, or 37 and 38 (see Table 2.1), as appropriate. 
 
2.4 Northern blot analysis 
 
All apparatus used for electrophoresis, blotting, hybridisation and detection were 
cleaned thoroughly by washing with detergent, rinsing with ultra pure water, rinsing 
with 70% ethanol, and rinsing with ultra pure water.  
 
2.4.1 RNA extraction 
RNA extraction was performed using the Qiagen RNeasy kit according to the 
manufacturer’s instructions. Logarithmically growing trypanosomes were pelleted at 
2000 rpm for 10 minutes, resuspended with 600 µl RLT buffer (Qiagen) containing 
β-mercaptoethanol (10 µl β-mercaptoethanol for 1 ml RLT buffer) and stored 
overnight at -80°C. The sample was thawed and vortexed for 1 minute, then RNA 
was purified using the manufacturer’s instructions for ‘animal cell spin’ RNA 
purification. Elution of RNA was performed with 30 or 40 µl nuclease-free water. 
RNA concentration was determined using a NanoDrop Spectrophotometer ND-1000.  
 
For the bloodstream form monomorphic cell total RNA sample for use with Illumina 
digital tag RNA sequencing, trypanosomes were washed twice with filter-sterilised 
PSG prior to RNA extraction as described above. This was identical for the stumpy 
form total RNA sample for use with Illumina digital tag RNA sequencing, except 
that the trypanosomes were only washed once following purification of the cells 
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from murine blood (as described in Section 2.2.2). Also, for the Illumina digital tag 
RNA sequencing samples, the optional on-column DNase-treatment (RNase-Free 
DNase Set, Qiagen) was included in the Qiagen RNeasy kit protocol for ‘animal cell 
spin’ RNA purification. 
 
2.4.2 Electrophoresis of RNA samples 
An RNA gel was made as follows, firstly, 2.4 g of agarose was completely dissolved 
in 160 ml distilled water, then 20 ml of 10X MOPS buffer (see Appendix 1) and 6ml 
of 37% formaldehyde were added. The solution was gently mixed and then allowed 
to set in a gel tray. 
 
Equivalent amounts of RNA were loaded per lane (in the range of 0.5-2.5 µg per 
lane, in a maximum volume of 8 µl), each with 9 µl of formamide, 3 µl of 37% 
formaldehyde, 2 µl of 10X MOPS buffer and 2 µl of RNA loading buffer (see 
Appendix 1). Immediately prior to loading, the samples were heated at 65°C for 5 
minutes. The gel was electrophoresed at 150V for 90 minutes in MOPS buffer (1X 
concentration). The gel was then stained with 25 µl ethidium bromide (10 mg/ml) in 
200 ml 1X MOPS for 15 minutes with gentle agitation at room temperature. To 
destain the gel, three washes were performed with distilled water, for a total time of 
about 1 hour 45 minutes. The UV transilluminator setting of a GBOX (Syngene) was 
used to visualise the rRNA bands and a photograph was taken, so later the amount of 
rRNA in each lane could be quantified using GeneTools software (Syngene). 
 
2.4.3 Blotting 
RNA was transferred on to a nylon membrane using the upward capillary transfer 
method. A raised platform was created in a plastic container containing 10X SSC 
(see Appendix 1), on top of this platform a piece of chromatography paper (pre-wet 
in 10X SSC) was placed with two ends of the paper submersed in the 10X SSC 
liquid below. The gel containing the electrophoresed RNA was then placed on top 
(so that the open-wells of the gel contacted the filter paper). Saran wrap was used to 
cover this apparatus and the gel to prevent evaporation of the liquid, and a window 
slightly smaller than the size of the gel cut out of the saran wrap on the top of the gel. 
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Positively-charged nylon membrane (Roche) (pre-wet in 10X SSC) was placed on 
top of the gel, followed by two layers of chromatography paper (pre-wet in 2X SSC) 
slightly larger than the size of the membrane. Air bubbles were then removed from 
the layers by rolling a 10 ml pipette over the top while applying mild downward 
pressure. Finally, several layers of paper tissue were placed on top, followed by a 
Perspex plate, then a weight of about 500 g, all placed to ensure equal distribution of 
weight downwards on to the gel. The transfer was allowed to take place overnight. 
The following day RNA was cross-linked on to the membrane at 0.12 joules using 
UV-light (UV Crosslinker, Uvitec). The cross-linked membrane was kept dry and 
stored at room temperature in the dark until prehybridisation and the remainder of 
the Northern blot analysis protocol. 
 
2.4.4 Riboprobe generation 
Primers to amplify around a 200-400 nucleotide region of sequence specific to the 
gene of interest were designed using the freely available RNAit programme 
(http://trypanofan.path.cam.ac.uk/software/RNAit.html). These were used in a 
standard PCR with genomic DNA and the product of the correct size ligated into 
pGEM-T easy plasmid for sequencing as outlined in Section 2.3.5 above. The small-
scale preparation of the plasmid that contained insert of the correct sequence was 
used as template in a standard PCR (two 50 µl reactions; see Section 2.3.5) with M13 
forward and reverse primers (2 µl of each at 10 µM concentration per 50 µl reaction; 
Table 2.1). 5 µl of the product of this reaction was electrophoresed in a standard 
agarose gel (see Section 2.3.5). The remainder of the reaction was purified using the 
Nucleospin Extract II kit (Macherey-Nagel), or if multiple products were observed, 
the remainder of the reaction was used to gel-excise the product of the correct size, 
and this was purified using the same kit (see Section 2.3.5). 
 
1 µg of the purified PCR product was used in a 20 µl reaction with either SP6 or T7 
polymerase (Roche), depending of the orientation of the insert in the pGEM-T easy 
plasmid, to generate the anti-sense sequence, using a DIG RNA labeling kit (Roche) 
according to the manufacturer’s instructions and including the optional DNase 
treatment step. After stopping the reaction by the addition of 2 µl of 0.2M EDTA 
71 
(pH8.0), 2.5 µl of 4M lithium chloride and 75 µl of cold 100% ethanol was added. 
This was mixed and incubated at -80°C for a minimum time period of overnight, 
then centrifuged for 15 minutes at 12 000 g at 4°C. The pellet was washed with 70% 
ethanol, then air-dried for 10 minutes and resuspended with 50 µl of distilled water 
and 1 µl of RNase inhibitor (Promega). The riboprobe was stored at -80°C and 
checked before use by electrophoresis on a standard agarose gel (see Section 2.3.5). 
 
2.4.5 Riboprobe hybridisation and detection 
The membrane was incubated for 1 hour at the hybridisation temperature (68°C) with 
10 ml of hybridisation buffer (see Appendix 1). 2 µl of a riboprobe was added to 100 
µl of hybridisation buffer and denatured by boiling for about 8 minutes. This was 
added to 7 ml of hybridisation buffer (pre-warmed to the hybridisation temperature) 
and added to the membrane after removal of the solution not containing the 
riboprobe. The membrane was incubated overnight at the hybridisation temperature. 
The following day, the membrane was washed for around 30 minutes with 2X 
SSC/0.1% SDS twice, and then once with 0.5X SSC/0.1% SDS for around 45 
minutes, with each wash being at the hybridisation temperature. Then, the following 
steps were performed at room temperature with gentle agitation, using freshly 
cleaned boxes at each step; the membrane was blocked for 1 hour with 50 ml Maleic 
acid buffer (see Appendix 1) containing 1% DIG block solution (see Appendix 1), 
incubated for 30 minutes with 50 ml Maleic acid buffer containing 1% DIG block 
solution and 2 µl anti-DIG antibody (Anti-Digoxigenin-AP Fab fragments, Roche), 
then washed for 10 minutes with 50 ml Maleic acid buffer containing 0.3% Tween-
20 (Fisher Scientific) three times, and finally incubated for 2 minutes in detection 
buffer (100 mM Tris-HCl pH 9.5, 100 mM NaCl). 
 
The membrane was incubated for 2 minutes in Bag W with an appropriate amount of 
CDP-star (25 mM Roche; 1:100 dilution with detection buffer) for the membrane 
size (usually 0.5 ml or 1 ml). CDP-star solution was removed by applying slight 
pressure across the outside of the Bag W with tissue. The Bag W was then heat-
sealed and incubated for 15 minutes at 37°C, before being cut to remove the sealing 
and exposed either to X-ray film or using a GBOX (Syngene; for signal 
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quantification by normalisation to the rRNA, see Section 2.4.2). In both cases the 
Bag W was taped down around the cut edges to prevent drying of the membrane. 
Following exposure, the Bag W edges were re-sealed and the membrane was stored 
at -20°C. If the membrane was re-exposed using the alternative exposure method the 
membrane was re-processed from the step of incubation in detection buffer. 
 
2.5 Splice leader addition site and polyadenylation site mapping 
 
Throughout the following procedure autoclaved eppendorf tubes, filter pipette tips 
and nuclease-free water were used where appropriate.  
 
RNA was prepared from the various cell lines as described in 2.4.1 and used in a 
cDNA reaction as follows. 2 µg of RNA was mixed with nuclease-free water to give 
a volume of 22 µl, to this the following was added in the given order: 2 µl of primer, 
8 µl of AMV RT 5X buffer (Promega), 2 µl of RNase inhibitor (RNasin, Promega), 4 
µl of 2.5mM dNTPs, 2 µl of AMV reverse transcriptase (Promega), and DTT (0.1M, 
1 µl per 100 µl). The primer used was either random hexamers (Promega) for 
5’RACE, or an oligo-dT 3’ primer containing an adapter sequence (primer 19, see 
Table 2.1) for 3’RACE. The reaction was incubated at 37°C for 10 minutes, then 
42°C for 1 hour. An identical reaction was also performed in parallel for each RNA 
sample, termed an ‘RT minus’ control reaction that contained nuclease-free water 
instead of reverse transcriptase, to control for the amplification of contaminating 
genomic DNA in the subsequent PCR reactions. Additionally, another control 
reaction was performed in parallel, which was identical except for that nuclease-free 
water was used instead of an RNA sample. 
 
The first PCR was a standard reaction, performed using GoTaq Hot Start polymerase 
(Promega) and 50°C annealing temperature (see Section 2.3.5) with 2 µl of each 
cDNA reaction or control cDNA reaction. A second (nested) PCR was then 
performed as described for the first PCR but with 2 µl of each first PCR instead of 
cDNA reaction. Also performed in parallel with each PCR was a negative control 
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reaction, which was identical except for the addition of water instead of cDNA 
template. 
 
See Sections 3.4.1 and 4.4.3 for the primers used in mapping PAS and SAS. A 
schematic diagram of the procedure used to map SASs is shown in Figure 4.5 (A). 
 
2.6 CAT ELISA 
 
2.6.1 Cell lysis 
For the chloramphenicol acetyltransferase (CAT) enzyme-linked immunosorbant 
assay (ELISA) logarithmically growing cells were used at a concentration of 1-4 x 
106. For this protocol, a CAT ELISA kit (Roche) was used according to the 
manufacturer’s instructions. Where possible, samples from cell lines possessing 
different CAT constructs to be compared were processed together. To allow 
normalisation of values to cell number at the end of the assay, cell cultures were 
counted directly before the following procedure. 5ml of the culture was pelleted and 
washed 3 times with chilled phosphate buffered saline (PBS); centrifugations were 
performed at 2000 rpm for 10 minutes at 4°C and cell pellets resuspended inbetween 
centrifugations. To lyse the cells, 1 ml of CAT ELISA lysis buffer (Roche) was 
added, the pellet resuspended and incubated for 25 minutes at room temperature. 
Following the incubation, lysed cells were centrifuged as above and two 500 µl 
aliquots of supernatant were snap-frozen in liquid nitrogen and stored at -80°C for 
later use in the ELISA. 
 
2.6.2 ELISA 
Cell lysate samples were thawed on ice and from each 500 µl aliquot two samples 
were used for replicates. Standard dilutions were prepared according to the 
manufacturer’s instructions, each in duplicate and the results used to generate a 
calibration curve. Any dilutions of samples were made with sample buffer. Of each 
standard dilution or cell lysate sample, 200 µl was added to a well of an anti-CAT 
antibody-coated ELISA microplate and incubated at 37°C for one hour. Following 
incubation, each well was washed with 250 µl washing buffer 5 times. Then, 200 µl 
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of anti-CAT antibody conjugated to digoxigenin solution was added and the 
microplate incubated and washed as above. Next, 200 µl of anti-DIG-peroxidase 
antibody solution was added and again the microplate was incubated and washed as 
above. Finally, 200 µl of peroxidise substrate was added and the absorbance of each 
sample at 405 nm was measured using a BioTek ELx808 ELISA microplate reader. 
 
2.6.3 CAT ELISA data analysis 
The absorbance readings were recorded with Gen5 software (BioTek) and this was 
also used to generate a calibration curve. The r2 value obtained was greater than 0.99 
in each CAT ELISA assay, except for one instance when it was 0.977. The 
background absorbance value was determined as the mean of duplicate samples of 
sample buffer alone. This value was subtracted from the experimental absorbance 
values and the mean of duplicate samples calculated. This value was then divided by 
the cell concentration measured when the samples were generated (see Section 
2.6.1).  
 
2.7 Western blot analysis 
 
2.7.1 Protein sample preparation 
Trypanosome cultures were counted and then centrifuged at 2000 rpm for 10 
minutes. The pellet was washed with 5 ml PBS and then resuspended with boiling 
Laemmli buffer (62.5 mM Tris-HCl pH6.8, 2% SDS, 10% glycerol, bromophenol 
blue [2 mg in 100ml], 5% β-mercaptoethanol) to give 0.4 x 106 cells/ml. Protein 
samples were then boiled for 3 minutes and stored at -20°C.  
 
2.7.2 Electrophoresis of protein samples 
Different percentage SDS-PAGE gels were made according to the component 
concentrations in Appendix 1. First a running gel was allowed to set between 1.5 mm 
glass plates, to about 1-1.5 cm from the top, with 70% ethanol added above the 
running gel solution. The 70% ethanol was removed, a stacking gel solution added 
above the running gel and a 10- or 15-well 1.5 mm comb inserted into the top of the 
space between the plates before allowing the stacking gel to set. Protein samples 
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were boiled for 5 minutes prior to loading on the SDS-PAGE gel. The samples were 
electrophoresed in running buffer (25 mM Tris-HCl pH8.3, 192 mM glycine, 0.1% 
SDS) at 150V until the dye-front started to run out of the base of the gel. 
 
2.7.3 Semi-dry transfer of proteins 
Electrophoresed proteins were transferred on to PVDF membrane (Immobilon-P, 
Millipore) using the semi-dry transfer method. In a Semi-dry Transfer Cell (Bio-Rad) 
a piece of extra thick blot paper (Bio-Rad) wet in semi-dry transfer buffer (see 
Appendix 1) was placed. On top of this the PVDF membrane was added (prior to this 
the membrane had been placed in methanol for about 15 seconds, then in distilled 
water for about 2 minutes and then semi-dry transfer buffer for about 5 minutes), and 
then the SDS-PAGE gel (which had been rinsed with distilled water). Finally, 
another piece of extra thick blot paper wet in semi-dry transfer buffer was placed on 
top and any air bubbles between the layers removed by rolling across the top of the 
blot paper using 10 ml pipette and applying slight downward pressure. The transfer 
was performed at 0.14 Amp (constant) for 90 minutes. Visualisation of transferred 
proteins was achieved by brief incubation of the membrane with Ponceau stain (0.4% 
Ponceau S [Sigma], 3% trichloroacetic acid [TCA]), then background staining 
removed by brief washes with distilled water. An image of the bands visible on the 
stained membrane was obtained with an Epson Perfection V200 Photo scanner. The 
membrane was then fully destained with PBS containing 0.1% Tween-20 (Fisher 
Scientific). 
 
For membranes for use with the eIF6 antibody (BD Biosciences), the procedure 
outlined above was followed, except for the following modifications: the semi-dry 
transfer was at 1.2 mAmp/cm2 for 1 hour and the Ponceau stain was removed 
entirely with distilled water. 
 
2.7.4 Antibody hybridisation and detection 
Typically, membranes were blocked by incubation with PBS containing 0.1% 
Tween-20 (Fisher Scientific) and 5% w/v non-fat dry milk (Marvel) for either 1 hour 
at room temperature or overnight at 4°C. The membrane was then incubated with the 
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primary antibody diluted in PBS containing 0.1% Tween 20 and 5% dry milk 
(Marvel) for 1 hour at room temperature with agitation. Following this the membrane 
was washed with PBS containing 0.1% Tween-20 for 30 minutes with agitation, 
changing the buffer every 10 minutes. Next, the membrane was incubated with the 
secondary antibody diluted in PBS containing 0.1% Tween 20 and 5% dry milk 
(Marvel) for 1 hour at room temperature with agitation. Again, the membrane was 
then washed with PBS containing 0.1% Tween 20 for 30 minutes with agitation, 
changing the buffer every 10 minutes. The ECL Plus Western Blotting Detection 
System (GE Healthcare) was used according to the manufacturer’s instructions to 
detect bound antibody. Fluorescent signal was detected using a GBOX (SynGene) 
and GeneSnap software (SynGene) or by exposure to X-ray film.  
 
For detection of eIF6 protein with the eIF6 antibody (BD Biosciences), the following 
protocol was followed. The membrane was blocked by incubation with blocking 
buffer (10 mM Tris pH7.5, 100 mM NaCl, 0.1% Tween 20, 5% w/v non-fat dry milk 
[Marvel]) for either 1 hour at room temperature or overnight at 4°C. The membrane 
was then incubated with the primary antibody diluted in blocking buffer for 1 hour at 
room temperature with agitation. Following this the membrane was washed with 
wash buffer (10 mM Tris pH7.5, 100 mM NaCl, 0.1% Tween 20) for 30 minutes 
with agitation, changing the buffer every 5-10 minutes. Next, the membrane was 
incubated with the secondary antibody diluted in blocking buffer for 1 hour at room 
temperature with agitation. Again, the membrane was then washed with wash buffer 
for 30 minutes with agitation, changing the buffer every 5-10 minutes. The ECL Plus 
Western Blotting Detection System (GE Healthcare) was then used to detect bound 
antibody as outlined above. 
 







Table 2.2. Dilution of antibodies used in Western blot analysis, immunofluorescence 
microscopy and fluorescence-activated cell sorting (FACS). 
 
Antibody Dilution 
Western blot analysis  
BB2 1:5 
α-eIF6 (BD Bioscience) 1:1000 
α-mouse IgG-HRP (Sigma) 1:5000 
α-rabbit IgG-HRP (Sigma) 1:5000 
Immunofluorescence microscopy  
BB2 1:50 
α-mouse-FITC (Sigma) 1:200 
Fluorescence-activated cell sorting (FACS)  
α-EP-procyclin 1:500 





2.8.1 Methanol-fixation of cells and DAPI staining for microscopy 
Typically, 1 ml of cell culture was centrifuged at 7000 rpm for 3 minutes using a 
microfuge. The supernatant was removed to leave about 40 µl and the cells 
resuspended in this remaining solution. About 20 µl of this cell solution was spread 
on to a glass microscope slide using the side of a pipette tip and allowed to air-dry, 
before the slide was immersed in ice-cold methanol for storage at -20°C. 
 
The methanol-fixed cell slides were rehydrated in PBS for 10 minutes. Then the slide 
was incubated for 2 minutes in a humidity chamber with 50 µl of DAPI (1 µg/ml). 
The slide was washed once in PBS for 5 minutes and a coverslip was fixed to each 
slide with 50 µl of PDA (p-phenylenediamine; 10 mg/ml) and mowiol (see Appendix 
1) mix (50 µl PDA and 500 µl mowiol). This was left to dry at room temperature for 
around 1-2 hours, then transferred to 4°C for storage in the dark. Slides were 
analysed on an Axioskop 2 plus microscope (Zeiss) and micrographs captured using 
QCapture software (QImaging).  
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2.8.2 Paraformaldehyde-fixation of cells and antibody staining for microscopy 
For each slide, 1 x 107 cells were centrifuged at 1000 rpm for 10 minutes, the pellet 
washed with 5 ml vPBS (see Appendix 1), and centrifuged again at 1000 rpm for 10 
minutes. The pellet was resuspended with 3 ml vPBS and 1 ml of 8% 
paraformaldehyde and incubated for 10 minutes at 4°C. Cells were pelleted at 2000 
rpm for 10 minutes, washed with 5 ml vPBS and re-pelleted. The cells were 
resuspended in about 150 µl vPBS, spread on a polysine microscope slide, and left 
for 20 minutes in a humidity chamber. The liquid was poured off the slide, 200 µl of 
PBS with 0.1% Triton X-100 (Sigma) added and incubated for 2 minutes. After 
being washing twice for 5 minutes in PBS, the slide was then incubated for 10 
minutes in a humidity chamber with 150 µl PBS containing 2% BSA (Bovine Serum 
Albumin; PAA). Then, stained with 150 µl of primary antibody diluted in PBS with 
2% BSA for 60 minutes in a humidity chamber. Following three washes of 10 
minutes in PBS, the slide was stained with 150 µl of secondary antibody diluted in 
PBS with 2% BSA for 60 minutes in a humidity chamber, and again washed three 
times for 10 minutes with PBS. The slide was then stained with 50 µl DAPI (1 
µg/ml) for 2 minutes in a humidity chamber, washed for 5 minutes with PBS and a 
coverslip fixed with 50 µl of PDA and mowiol as above (see Section 2.8.1). Slides 
were analysed on an Axioskop 2 plus microscope (Zeiss), micrographs captured 
using QCapture software (QImaging) and images processed using ImageJ 
(http://imagej.nih.gov/ij) and Adobe Photoshop. 
 
For the dilutions of the antibodies used in this study see Table 2.2. 
 
2.8.3 Fluorescence-activated cell sorting 
Cells were induced to differentiate as described in Section 2.2.6. As a positive 
control for procyclin expression, 1 ml of an in vitro procyclic form cell culture was 
used. Centrifugations in the following procedure were performed at 2000 g for 5-10 
minutes. For each cell culture 1 ml was transferred to a FACS tube (5ml Polystyrene 
Round-Bottom Tube; BD Falcon) and the cells washed twice with PBS. The cells 
were then resuspended with 500 µl of fix solution (PBS with 2% formaldehyde, 
0.05% gluteraldehyde) and incubated overnight at 4°C. Again, the cells were washed 
79 
twice with PBS, resuspended with 200 µl of blocking solution (PBS with 2% BSA) 
and incubated for 30 minutes at 4°C. After a wash step with PBS, the cells were 
resuspended with 200 µl of primary antibody (diluted in blocking solution; for 
antibody dilution see Table 2.2) and incubated at 4°C for hour. This wash and 
incubation step was repeated with the secondary antibody (diluted in blocking 
solution). Finally, the cells were washed with PBS and resuspended with ~500 µl of 
PBS and stored overnight at 4°C until the remainder of the protocol.  
 
About 15-30 minutes prior to cell analysis, 10 µl of DAPI (1 µg/ml) was added to the 
cell sample. Cell analysis was performed using a BD FACS LSR II flow cytometer 
(BD Biosciences) and BD FACSDiva software. Data analysis was performed using 
FlowJo software (with assistance from Martin Waterfall, University of Edinburgh; 
see Section 5.7). 
 
2.9 Polysome analysis 
 
2.9.1 Harvest and lysis of cells 
For the Illumina digital tag sequencing experiment: 
For the 427 bloodstream monomorphic cell samples, cells were grown in 20 flasks of 
50 ml culture volumes to a cell density of 1-2 x106 cells/ml. The cells were incubated 
with cycloheximide (100 µg/ml) for 10 minutes at 37°C. Then, pelleted by 
centrifugation at 2500 rpm for 10 minutes and washed twice in ice-cold PSG 
containing 100 µg/ml cycloheximide. Groups of 5 flasks were pooled after the first 
pelleting step to give 4 samples for polysome analysis. 
 
For the stumpy cell sample, AnTat1.1 cells were purified from the blood of five mice 
6 days post-infection as described in Section 2.2.2, cell density was determined and 
then the cells were incubated with cycloheximide (100 µg/ml) for 10 minutes at 
37°C. The cells were then pelleted by centrifugation at 2500 rpm for 10 minutes and 
washed once with ice-cold PSG containing 100 µg/ml cycloheximide.  
 
For the RNAi/ectopic protein expression experiments:  
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At 24 or 48 hours prior to cell harvest, tetracycline (1 or 10 µg/ml) was added to 250 
ml of cells at a concentration to provide a cell concentration of ~1-3 x106 cells/ml at 
the time of cell harvest. As a control, an identical group of cells were established that 
were untreated with tetracycline (uninduced control), which was processed in 
parallel with the induced cells. At the time of cell harvest, cells were incubated with 
cycloheximide (100 µg/ml) for 10-15 minutes at 37°C. The cells were pelleted by 
centrifugation at 2500 rpm for 10 minutes at 4°C and washed twice in ice-cold PBS 
containing 100 µg/ml cycloheximide.  
 
For both types of experiment: 
Each cell pellet was then resuspended with 750 µl of polysome buffer (120mM 
NaCl, 40mM TrisHCl pH7.0, 2mM MgCl2) containing 100 µg/ml cycloheximide, 
0.75 µl RNase inhibitor (RNasin, Promega), protease inhibitor cocktail (1 tablet per 
15 ml polysome buffer; Roche) and 0.1mM DTT (DL-Dithiothreitol; Sigma). The 
samples were then snap-frozen in liquid nitrogen and stored at -80°C for later use. 
 
On the day of sucrose gradient preparation and fractionation, cell samples were lysed 
(unthawed) through sonication for ~3-6 minutes in a water bath with sonication 
(Bandelin Sonorex) with brief periods of vortexing. 5 µl of sample was removed to 
confirm cell lysis by microscopic examination. Cell lysates were then centrifuged at 
12 000 rpm for 4 minutes at 4°C and the supernatant transferred to a fresh eppendorf 
tube containing 1 µl of RNase inhibitor (RNasin). 
 
2.9.2 Sucrose gradient preparation 
50% and 15% sucrose solutions (w/v; sucrose in polysome buffer) were sterilized 
through a single-use syringe filter (0.20 µm; Sartorius Stedim Biotech) and 
completed with 100 µg/ml cycloheximide, 0.5 µl/ml RNase inhibitor (RNasin, 
Promega), protease inhibitor cocktail (1 tablet per 50 ml polysome buffer; Roche) 
and 0.1mM DTT. Gradients were poured using a Hoefer SG 50 Gradient Maker 
(Amersham Biosciences), magnetic stirrer and MasterFlex C/L peristaltic pump 
(Cole-Parmer) into Polyallomer centrifuge tubes (14 x 95 mm; Beckman) and stored 
at 4°C (not longer than a couple of hours) until ultra-centrifugation and fractionation.  
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2.9.3 Ultra-centrifugation and fractionation 
Cell lysate was layered on to the top of a 15-50% sucrose gradient. Samples were 
centrifuged in a pre-cooled Beckman L-60 Ultracentrifuge at 40 000 rpm for 2 hours 
at 4°C, using a SW40 rotor. The gradient centrifuge tube was pierced with a Brandel 
Tube Piercer and Fluorinert FC-77 (Sigma-Aldrich) pumped through as the high-
density chase solution with a Brandel Syringe Pump. The gradient was then 
separated into fractions using a Foxy R1 machine (Teledyne Isco) and the optical 
density read at 254 nm throughout fractionation on a UA-6 Absorbance Detector 
(Teledyne Isco). One fraction was taken for every 13 drops and the sensitivity 
typically set to 1 or 2. PeakTrak software (Teledyne Isco, Inc.) was used to record 
the absorbance output. 
 
2.9.4 RNA and protein extraction from gradient fractions 
RNA extraction was made using the Qiagen RNeasy kit. Following fractionation, 3.5 
ml of Buffer RLT with β-mercaptoethanol (10 µl β-mercaptoethanol per 1 ml RLT 
buffer) was added to each polysome fraction and transferred to -80°C overnight. 
After thawing, 2.5 ml of 100% ethanol was added and mixed. RNA was extracted 
from each fraction sample using a separate RNeasy column and according to the 
manufacturer’s instructions for the ‘RNA cleanup’ protocol, including the on-column 
DNase treatment (RNase-Free DNase Set, Qiagen). RNA was eluted from each 
column with 30 or 40 µl nuclease-free water and stored at -80°C. RNA concentration 
was determined using a NanoDrop Spectrophotometer ND-1000 and for the Illumina 
digital tag sequencing experiment, 10% of each sample was examined on an RNA 
gel (see Section 2.4.2). 
 
2.10 [35S]-methionine labelling 
 
The radiolabelled methionine experiments were performed by Dr Terry Smith 
(University of St. Andrews) similarly to previously reported (Smith et al., 2009). 
Cells were pelleted, washed with methionine-free minimal essential media and 
resuspended with 2 ml of the same media to a concentration of 1 x 107 cells/ml. Cells 
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were labelled for one hour at 37°C with 10 mCi [35S]-methionine in an orbital shaker 
water bath.  
 
For use with SDS-PAGE, a volume of 1 ml was pelleted, washed with trypanosome 
dilution buffer (TDB; 25 mM KCl, 400 mM NaCl, 5 mM MgSO4, 100 mM 
Na2HPO4, NaH2PO4, 100 mM glucose), resuspended with pre-heated SDS-PAGE 
sample buffer and boiled for 5 minutes. A 10% SDS-PAGE gel and Coomassie blue 
staining was used to visualise the proteins. The gel was then destained, soaked in 
En3hance (NEN) for 30 minutes, washed twice with water, soaked in 10% glycerol, 
dried and exposed to XAR-5 film at -70°C.  
 
For radiolabel incorporation quantification, the remaining 1 ml was split into 
triplicate samples, these being centrifuged, washed with TDB, then resuspended with 
TCA. The protein pellet was washed and reconstituted with 1% SDS, the 
incorporation quantified scintillation counting. 
 
2.11 Illumina digital tag RNA sequencing  
 
To determine the quantitative expression levels of mRNA, Illumina digital tag RNA 
sequencing was used. For this, RNA samples were sequenced by Eurofins MWG 
Operon from short-insert (17+4 bp) DNA libraries using Illumina HiSeq 2000 
sequencing. Eurofins MWG Operon also prepared the library prior to sequencing 
using the workflow shown in the schematic diagram in Figure 2.1. Following binding 
of the short-insert cDNA library to the flow cell, the Cluster Station isothermally 
amplifies the cDNA constructs by bridge PCR to create clonal clusters of ~1000 
copies each. These template clusters are then directly sequenced using sequencing by 
synthesis technology and four fluorescently labelled, reversibly terminated 




Figure 2.1 Schematic diagram outlining the workflow of library preparation for 
Illumina digital tag sequencing by Eurofins MWG Operon. The isolation of mRNAs 
was achieved with oligo (dT) magnetic beads (blue circle), the first strand of oligo 
(dT) bound cDNA was synthesised from the mRNA by reverse transcription, the 
mRNA degraded by RNase, then the second strand cDNA was synthesised. The 
cDNA was cleaved at NlaIII restriction enzyme site sequences (CATG; shown in 
turquoise) through digestion with NlaIII. Adapter 1 (shown in dark blue) was ligated 
to the digested end. The Adapter 1 contains sequence that together with the start of 
the NlaIII sequence forms an MmeI restriction enzyme site sequence. MmeI cuts 
20/18nt downstream from the MmeI site, so digestion with MmeI, therefore, creates a 
17nt sequence flanked by Adapter 1 and the NlaIII restriction site sequence. 3’ 
fragments were removed by precipitation of the magnetic beads. An Adapter 2 
sequence (shown in red) was then ligated to the site of MmeI cleavage, resulting in a 
17 bp tag sequence of the original mRNA molecule. The Adapters 1 and 2 contain 
sequence used for linear PCR amplification (15 cycles) of each 17 bp tag sequence. 
Each of the amplified cDNA constructs were gel purified and then bound to the flow 
cell on the Ilumina Cluster Station via complementary sequences present in the 










































To date, nothing is known about the mechanisms of control of gene expression in 
stumpy form T. brucei. However, the control of gene expression is important in this 
life-cycle stage since there is a repression of gene expression for most transcripts, 
except a small subset of genes that escape this repression. Regulation of gene 
expression in trypanosomatids is believed to operate at the post-transcriptional level 
and several examples where 3’UTRs are important to life-cycle stage-dependent 
control of expression have been identified (reviewed in Clayton, 2002 and see 
Section 1.6). To investigate if signals present within the UTRs are important for 
control of the expression of stumpy-enriched genes, two genes that exhibit increased 
expression at this lifecycle stage where chosen for UTR analysis. These two genes 
were ESAG9-EQ and aconitase. Analysis was made of the expression level of a 
reporter gene under the control of the different UTR sequences to assess any gene 
regulation conferred by those sequences. The aim of these experiments was to ask:  
 
1. Is each UTR responsible for repression of gene expression in slender forms, and if 
so, are there specific sequences within the UTR that contribute to this?  
 
2. Is each UTR responsible for alleviation of gene expression repression in stumpy 
forms, and again, if so, are there specific sequences within the UTR that contribute to 
this? 
 
3.1 CAT reporter gene assay 
 
A CAT reporter assay approach was used to assess the contributions of a given 5' or 
3'UTR to the control of gene expression. This approach has previously been used 
successfully to map 3'UTR control elements of COX genes (Mayho et al., 2006). 
The approach uses the expression vector, CAT449, which is illustrated in Figure 3.1. 
The CAT449 plasmid is a modified pHD449 plasmid (Biebinger et al., 1997), such 
that the Tetracycline repressor sequence present in pHD449 is replaced with the 
chloramphenicol acetyltransferase (CAT) coding region (Mayho et al., 2006), which 




Figure 3.1 Schematic diagram of the sub-cloning strategy for 5’/3’UTR analysis with CAT reporter gene assay. A. Diagram of the region of 
CAT449 vector with the chloramphenicol acetyl transferase (CAT), phleomycin resistance (BLER), and β-tubulin genes and flanking 5’ and 
3’UTRs (TUB: tubulin, ACT: actin). Aldolase (ALD) 5’UTR and truncated 3’UTR (ΔALD) flank the CAT gene, the ΔALD 3’UTR conferring 
constitutive expression; replacement of these with an experimental UTR used the XhoI and HindIII (5’UTR) or BamHI and BbsI (3’UTR) 
restriction enzyme sites. B. Representation of a deletion series for an experimental 3’UTR. Forward primers were designed to create ~50nt 
sequential deletions along the UTR from the 5’ end. Bent arrows indicate where PCR primers were designed to amplify from, containing the 







Hence, as with pHD449, digestion with NotI results in linearisation of the CAT449 
vector in the tubulin targeting sequence and, consequently, integration into the T. 
brucei genome is through the β-tubulin locus. The β-tubulin locus consists of a 
repetitive array of β-tubulin and α-tubulin genes on chromosome 1. After plasmid 
integration, the CAT reporter gene is consequently transcribed by read-through Pol II 
transcription of this locus. This is potentially important, because the same machinery 
is being used to transcribe the CAT reporter gene as the endogenous gene whose 
regulation is under investigation. As a result, any regulatory elements present in the 
sequence under examination should be able to function effectively in the reporter 
gene assay. Although one gene investigated, ESAG9-EQ, may also be transcribed by 
Pol I as it is present in expression sites (Barnwell et al., 2010).  
 
3.1.1 Generation of CAT449-based constructs 
Flanking the CAT gene in the CAT449 vector are the aldolase 5’ UTR and truncated 
aldolase 3’UTRs. The truncated aldolase 3’UTR provides constitutive CAT gene 
expression (Mayho et al., 2006), since it is not developmentally regulated (Biebinger 
et al., 1997). Investigation of experimental 5'UTRs was made by replacement of the 
aldolase 5'UTR through XhoI and HindIII restriction enzyme sites, and of 
experimental 3’UTRs by replacement of the truncated aldolase 3’UTR through 
BamHI and BbsI restriction sites (see Figure 3.1 A). In each case, UTR replacement 
was achieved by amplification of the relevant DNA sequence by PCR using primers 
containing the appropriate restriction enzyme site sequences for insertion. Each 
amplicon was initially sub-cloned into the pGEM T-easy vector (see Sections 2.3.9 
and 2.3.10). After sequence verification, this was followed by digestion from pGEM 
T-easy with those restriction enzymes and ligation into similarly digested, purified 
CAT449 plasmid (see Sections 2.3.7 and 2.3.9). Each plasmid construct was 
amplified by large-scale plasmid preparation and, following linearisation with NotI, 
transfected into the T. b. brucei monomorphic bloodstream form strain Lister 427 
(see Sections 2.3.11 and 2.2.3). Like pHD449, CAT449 contains the phleomycin 
resistance gene (BLER), so phleomycin (0.5 – 2.5 µg /ml) was used to select for 
successful transfectants. Selection with phleomycin was made on serial dilutions of 
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transfected cells, to allow clonal selection, with a control of drug-treated parental 
(non-transfected) cells being included to confirm drug sensitivity (see Section 2.2.3). 
Only after all control cells were dead from the drug action were transfectant clones 
isolated. 
 
3.1.2 Determining CAT mRNA and protein levels 
Assessment of CAT protein levels in successful transfectant cell lines was made 
through CAT ELISA assays using a CAT ELISA kit (Roche) according to the 
manufacturer’s instructions (see Section 2.6). Each sample analysed in the assay was 
present in duplicate on the CAT ELISA plate from which the mean was calculated. 
Experimental replicates refer to the repetition of the whole CAT ELISA assay from a 
repeated generation of samples. In each assay, a sample from the cell line obtained 
from transfection with the unmodified CAT449 plasmid (referred to as the 
‘unmodified vector’ construct) was included to allow comparison of results from 
assays performed at different times. As such, in each assay the value obtained for the 
unmodified vector cell line was arbitrarily adjusted to 100%, and the other values 
adjusted to the percentage of this value. 
 
Assessment of CAT mRNA levels in successful transfectant cell lines was made 
through northern blot analysis (see Section 2.4). To detect CAT mRNA, a 
digoxygenin-labelled probe designed against the CAT coding region was used from 
laboratory stocks. Again, an RNA sample from the cell line obtained from 
transfection with unmodified CAT449 plasmid was included in each northern blot to 
allow comparison of results between various blots. As previously seen (Mayho et al., 
2006), the use of the CAT probe with RNA samples obtained from cells transfected 
with the CAT449 vector results in the detection of three bands. The smallest of these 
is the CAT mRNA; the larger two are presumed to be processing intermediates of the 
CAT mRNA (see Figure 3.3 for an example). 
 
As mentioned above, the truncated aldolase 3’UTR in CAT449 gives constitutive 
CAT reporter gene expression. Thus any experimental 5' or 3'UTR which causes 
repression of gene expression in slender forms would cause a decrease in CAT 
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expression relative to the unmodified CAT449 vector. Therefore, if the 5' and/or 
3'UTRs of ESAG9-EQ or aconitase contribute to gene regulation, it would be 
expected that insertion of that sequence would result in a decrease in CAT 
expression, as expression of both of these genes is repressed in slender forms in vivo.  
 
For any UTR that conferred repression of gene expression in slender forms, 
subsequent analysis involved creation of a deletion series to delineate any regions of 
that UTR that were responsible for the repression. To produce a deletion series, PCR 
reactions were carried out with primers to create ~100nt or ~50nt sequential 
deletions. Therefore, for a 5’UTR deletion series, the same forward primer would be 
used as for the ‘full-length’ construct but with reverse primers complementary to 
sequence ~100/50nt sequentially along the length of the 5’UTR. Similarly, for a 
3’UTR deletion series, the same reverse primer would be used as for the ‘full-length’ 
construct but with forward primers complementary to sequence ~100/50nt 
sequentially along the length of the 3’UTR. Thus, deletions were made from the 3’ 
end of a 5’UTR and from the 5’ end of a 3’UTR, to maintain the regulatory 
SAS/PAS signals present respectively. A schematic of a 3’UTR deletion series is 
shown in Figure 3.1 (B).  
 
3.2 Is the aconitase 5'UTR or 3'UTR responsible for control of gene expression? 
 
It has been shown previously that the T. brucei aconitase (TbACO) protein is 
enriched in stumpy forms compared to slender forms (Saas et al., 2000). However, 
only minor changes in the transcript abundance between the lifecycle stages were 
observed, which suggests that expression of the TbACO protein is regulated at the 
translational or post-translation level (Saas et al., 2000). To investigate if either the 
5’ or 3’UTR of the transcript were responsible for this regulation, the 5’ or 3’UTR 
present in the CAT449 vector were replaced, as described above, with 500nt of 




3.2.1 Analysis of the 5’ & 3’ UTR  
For TbACO the nearest upstream gene annotated in the T. brucei TREU 927 genome 
sequence is Tb927.10.14010 and the nearest downstream gene annotated is 
Tb927.10.13990. The intergenic region between the stop codon of Tb927.10.14010 
and the start codon of TbACO is 1982 bp. The intergenic region between the stop 
codon of TbACO and the start codon of Tb927.10.13990 is 2649 bp. These 









































Figure 3.2 continues on the following page 
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B 
3’UTR(s)                                              ______________ 
TAGcggaacaccgaaacctgttcctcagagaataagcctgtgaattagtgaggggcgtagcaagggat 
__Possible IRE___               400nt(s) 
atctttgtttaccgcttccgtattcatcgttattgctaactacatatttggtacatggttgggtgtgt 
                                                            300nt(s) 
ggggcggctactaccgccacatcgtgagacgaggtagaagcgccgtttaactgtctcccctttggcca
gctgacttggtgccatgccgcacatttgttccaacgagggttgaagaggatgcaaaaaaaaaaaaaga 
                            200nt(s) 
ggtaaaaacgaggttcgacgacgctattatggcgacggcttaacgagatcagaacgttattgttattg 
                                                          100nt(s) 
ttatttatttatttattttttgaggaagcaaaacgggaaaaggggatctatggatattaatggtgaca
aaaacctttgtcggtgaacgtggacgatgcgtaaaacaatggaaggctctggatcggtcgcaacaccc 










Figure 3.2 Intergenic regions for Tb927.10.14000 (TbACO). A. The genomic 
sequence from the stop codon of the nearest upstream annotated gene, 
Tb927.10.14010, to the start codon of TbACO. B. The genomic sequence from the 
stop codon of TbACO to the start codon of the nearest downstream annotated gene, 
Tb927.10.13990. Because this intergenic region is 2649bp in length, only the first 
900nt of the sequence is shown. The possible iron-response element (IRE) sequence 
is indicated by the line. Sequences are in the 5’ to 3’ direction. Red font: stop codon, 
red highlight: start codon, grey highlight: start (s) or end (e) of each sequence used to 
generate the construct named above that residue, ag: SAS (Saas et al., 2000), a: PAS 
(Siegel et al., 2010). 
 
Ideally, the whole of each intergenic region would be used for analysis in the 
CAT449 vector to ensure that all endogenous regulatory signals were included. 
However, due to the extended length of each of the upstream and downstream 
intergenic regions a shorter region was chosen for analysis. Primers 3 and 4 (see 
Table 2.1) were used to amplify the 500nt region upstream of the TbACO start codon 
and primers 5 and 6 were used to amplify the 500nt region downstream of the 
TbACO stop codon (Figure 3.2) using T. b. brucei Lister 427-449 genomic DNA. 
These were used to replace the 5’ or 3’UTR of the CAT gene in CAT449 to generate 
the ‘5’UTR’ and ‘3’UTR’ constructs respectively.  
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The 5’ splice acceptor site (SAS) for TbACO has been previously determined to be 
at position -100 relative to the first ATG by 5’RACE analysis (Saas et al., 2000; 
marked on sequence in Figure 3.2 A). 3’RACE analysis in the same study revealed 
two polyadenylation sites (PAS) for TbACO, as PCR products obtained from this 
were 500 and 810 bp. Therefore, 500nt was chosen as the length for analysis of the 
5’ and 3’UTRs as this length of sequence should contain the signals for splice-leader 
addition and polyadenylation respectively. 
As described above, stable transfectant cell lines generated with the ‘5’UTR’ and 
‘3’UTR’ constructs (Figure 3.3 A) in T. b. brucei monomorphic bloodstream form 
strain Lister 427 were selected with 0.5 µg/ml phleomycin. These were then used to 
assess CAT mRNA abundance by northern blot analysis and CAT protein abundance 
through CAT ELISA assays. For each construct, two biological replicates 
(independently derived clones) were examined in CAT ELISA assays. The mean of 
the biological replicates for each construct is shown in Figure 3.3 (B). Three 
biological replicates for each construct were examined by northern blot analysis and 
this result is shown in Figure 3.3 (C). 
 
As shown in Figure 3.3 (B) the 5’UTR and 3’UTR constructs resulted in vastly 
different levels of CAT protein expression. For the 5’UTR construct, the CAT 
protein level was only reduced to 80% (±8.8%) of CAT expression seen for the 
unmodified vector. However, replacement of the truncated aldolase 3’UTR in the 
3’UTR construct resulted in a dramatic reduction in CAT protein expression to 4.7% 
(±0.75%) of CAT expression with the unmodified vector. 
 
In contrast, the CAT mRNA expression pattern (Figure 3.3 C) appeared to be 
different to the CAT protein expression pattern for the 5’UTR and 3’UTR construct 
clones. The 5’UTR clones show a high CAT mRNA level with respect to the 
unmodified vector clone, similar to the CAT protein level seen for this construct. 
Similarly, the 3’UTR clones showed abundant CAT mRNA with respect to the 









Figure 3.3 Analysis of TbACO 5’ and 3’UTR using a CAT reporter gene assay.  A. 
Schematic of sequences analysed with the ‘5’UTR’ and ‘3’UTR’ constructs, with the 
locations of known trans-splicing processing. SAS: 5’ splice-acceptor site. B. CAT 
ELISA assay results from two independently derived clones for each of the 5’UTR 
and 3’UTR constructs, and one clone of the unmodified vector. Two experimental 
replicates were performed for each clone. The mean ± standard error for biological 
replicates is shown. C. Northern blot analysis using a digoxygenin-labelled RNA 
probe against the CAT coding region with RNA samples from three independently 
derived clones for each of the 5’UTR or 3’UTR constructs and one clone of 
unmodified vector as a control. Ethidium bromide staining of rRNA is shown in the 





Also apparent in Figure 3.3 (C) is a size difference between the CAT mRNA derived 
from the 5’UTR clones and in the 3’UTR clones. This is likely due to the locations 
of mRNA processing sites for the CAT transcript in each case. The predicted SAS 
location would generate a transcript with a short 5’UTR for the 5’UTR construct, of 
a similar length to the aldolase 5’UTR from the unmodified vector. In contrast, the 
PAS used in the 3’UTR construct was expected to produce a longer 3’UTR than that 
produced with the truncated aldolase 3’UTR present in the 5’UTR and unmodified 
vector constructs. Therefore, the CAT mRNA would run at a higher molecular weight 
in the 3’UTR construct RNA samples, as was observed in Figure 3.3.  
 
The relatively abundant CAT mRNA derived from both the 5’UTR and 3’UTR 
constructs was expected because, as mentioned above, endogenous TbACO shows 
little developmental regulation of RNA levels between life-cycle stages, with instead 
regulation being made at the protein levels (Saas et al., 2000).  
 
This supports what was observed for the 3’UTR construct clones: low CAT protein 
expression but high CAT mRNA expression. Therefore, it would appear that there 
are regulatory elements present within the 500nt downstream sequence for TbACO 
that cause repression of gene expression in slender forms. Thus, the 3’UTR was 
selected for further analysis. 
 
3.2.2 3’UTR deletion series 
From the data presented in Figure 3.3 it would appear that the majority of repression 
of TbACO expression in bloodstream forms is mediated through the 3’UTR, 
although some minor contribution may be made by the 5’UTR. Therefore, the next 
step was to generate a deletion series of the 3’UTR sequence to further define the 
regulatory regions responsible for this repression. Initially, constructs of sequential 
100nt deletions were designed to generate the constructs ‘400nt’, ‘300nt’, ‘200nt’ 
and ‘100nt’ (see Figure 3.2). Primers 7, 8, 9 and 10 were used in PCR reactions each 




Additionally, to further define any regulatory regions, the predicted RNA secondary 
structures of the sequences used for analysis of the 5’ and 3’UTR were analysed. For 
this the freely available web-based software package Sfold (Ding et al., 2004) was 
used (see Section 2.1.1). Sfold is a programme that uses an algorithm that produces a 
statistical sample of RNA secondary structures according to the Boltzmann 
distribution for a given sequence. The output predictions from the Sfold ‘Srna’ 
programme gives centroid structures that are each produced from a cluster of similar 
predicted structures. The ensemble centroid structure is considered as the single 
structure that best represents the central tendency of the set of the entire collection of 
structures sampled (Ding et al., 2005). The ensemble centroid structures for the 
sequences used in the 5’UTR (from the mapped SAS, Saas et al., 2000) and 3’UTR 
constructs are given in Figure 3.4 A and B respectively.  
 
As the 3’UTR sequence used for the RNA secondary structure prediction with Sfold 
was 500nt and so relatively long, the predicted folding consisted of a number of 
smaller structures. One potentially interesting predicted structure was observed in the 
Sfold for the 3’UTR sequence, this being the structure outlined in a box in Figure 3.4 
B (an enlargement of the structure is shown in Figure 3.4 C). This is because it 
appears to bear some similarity to an iron response element (IRE), which is a stem-
loop structure. In metazoans, iron regulatory proteins, IRP1 and IRP2, regulate iron 
homeostasis post-transcriptionally by binding to IREs present in the mRNAs of 
genes involved in iron metabolism. Binding of an IRP to an IRE present in a 5’UTR 
represses translation of that transcript and binding to an IRE present in a 3’UTR can 
suppress mRNA degradation (reviewed in Volz, 2008). A schematic of an IRE 
secondary structure and the three-dimensional structure of an IRE bound by an IRP 
is shown in Figure 3.4 (D; taken from Volz, 2008). By comparison of Figure 3.4 C 
and D, it can be observed that the possible IRE in the TbACO 3’UTR shares 
similarity to the conserved canonical IRE stem-loop structure, in that it possesses a 
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Figure 3.4 Predicted RNA secondary structures for TbACO 5’ and 3’UTRs. A. Sfold predicted secondary RNA structure for TbACO upstream 
sequence used in 5’UTR construct from the mapped splice addition site (Saas et al., 2000). B. Sfold predicted secondary RNA structure for 
TbACO downstream sequence used in 3’UTR construct. The 5’ and 3’ ends are indicated as well as the start of each deletion series sequence 
(see Figure 3.2). C. Enlargement of boxed region from B. showing the possible iron response element (IRE) structure. Asterisks indicate 
sequence with similarity to human mAco IRE sequence given in Volz (2008). D. Figure from Volz (2008) showing schematic of secondary 




triplet of unpaired nucleotides (AUA) at the apical loop and two un-paired 
nucleotides (C and U) along the length of the stem. However, the structure is lacking 
the un-paired nucleotide below the apical loop, the two un-paired nucleotides are 
located further from the apical loop, and the highly conserved signature sequence of 
the apical loop (CAGUGX, where X = U, C, or A; Volz, 2008) is different 
(GAUAU-).  Yet it was also noticed that part of the sequence of the possible IRE in 
the TbACO 3’UTR is similar to part of the primary sequence of a human 
mitochondrial aconitase IRE (A-UcUUUGU; Volz, 2008); this is indicated in Figure 
3.4 (C) with asterisks. 
 
Although the similarity between this sequence and the canonical IRE sequence is 
low, the possibility that this predicted structure functions as an IRE provided a lead 
for further investigation. As such, the 400nt deletion construct discussed above 
would be particularly interesting because this involves deletion of this potential IRE 
sequence, along with other sequence (see Figure 3.4 B).  
 
3.2.3 TbACO PAS identification 
During the course of this work a study was published that, through high-throughput 
RNA sequencing of in vitro cultured bloodstream form and procyclic form T. brucei, 
identified the SAS and PAS for ~7000 and ~6000 genes respectively (Siegel et al. 
2010). From the results of that study, two PASs were identified for TbACO, these 
being at positions +516nt and +843nt relative to the TbACO stop codon (see Figure 
3.2 B), this being approximately consistent with the earlier study by Saas et al. 
(2000). As noted earlier, neither of these PAS locations are within the sequence used 
for the 3’UTR construct, since that sequence stops at +500nt, just short of the first 
PAS identified. Thus there could be another explanation for why low CAT protein 
expression was seen using the 3’UTR construct; the use of an inappropriate PAS 
would cause the CAT RNA to not be expressed highly as the signals needed for 
appropriate polyadenylation of CAT RNA would be absent. Therefore, it could be 
that another site is chosen for polyadenylation that is not optimal and affects the 
translation efficiency of the transcript, resulting in lower CAT protein expression. 
Consequently, it was necessary to repeat the analysis of the 3’UTR by including 
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850nt of downstream sequence instead of 500nt. This length would ensure correct 
processing of the CAT transcript by including both endogenous PAS sites at +516nt 
and +843nt and thus any repression of gene expression would be due to regulatory 
regions within the sequence investigated. To make this construct, named ‘850nt’, 
primer 11 was used in a PCR reaction with primer 5. 
 
Unfortunately, at this point we became aware that another laboratory was also 
investigating the regulation of TbACO gene expression through analysis of the 5’ 
and 3’UTR in a similar manner. Therefore, this work on the TbACO 5’ and 3’UTR 
was ceased. Consequently, the creation of the 3’UTR deletion series constructs and 
850nt construct were not completed and the effects of these sequences on gene 
expression were not analysed. Instead, the 5’ and 3’UTRs of another gene 
upregulated in stumpy forms, ESAG9-EQ, was analysed for control of gene 
expression in this study. The results for this will be presented in the remainder of this 
chapter. 
 
3.3 Is the ESAG9-EQ 3’UTR responsible for the control of gene expression? 
 
ESAG9-EQ (Tb927.5.4620) is so-called because it was the T. brucei ESAG9 
sequence that was found to be most similar to the T. equiperdum ESAG9 sequences 
(Barnwell et al. 2010; Florent et al. 1991). ESAG9 proteins are a family whose 
mRNAs are strongly developmentally regulated, being highly enriched in stumpy 
forms compared to slender forms (Barnwell et al. 2010). To investigate if either the 
5’ or 3’UTR of the transcript were responsible for this developmental regulation the 
5’ or 3’UTR sequences present in the CAT449 vector were replaced, as described 
earlier (Section 3.1.1), with sequence either upstream or downstream of the ESAG9-
EQ gene, respectively. The results of the analysis of the ESAG9-EQ 5'UTR are given 
in Chapter 4, whereas the results of analysis of the ESAG9-EQ 3'UTR are given in 
the rest of this chapter.  
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3.3.1 Analysis of the ESAG9-EQ full-length 3’UTR and 3’UTR deletion series 
For ESAG9-EQ the nearest downstream gene annotated in the T. b. brucei TREU 
927 genome sequence is Tb927.5.4630. The intergenic region between the stop 
codon of ESAG9-EQ and the start codon of Tb927.5.4630 is 3057 bp, which is 
shown in Figure 3.5. One polyadenylation site for ESAG9-EQ has been previously 
mapped from cDNA to locate at position +217 bp relative to the ESAG9-EQ stop 
codon (Keith Matthews, unpublished observations) (see Figure 3.5). To include any 
regulatory sequences up to, and beyond, the polyadenylation site, 400nt of the 
downstream sequence was used for analysis. Therefore, for cloning of the 3’UTR of 
ESAG9-EQ, primers 12 and 13 were used to amplify by PCR 400nt of sequence 
downstream of the ESAG9-EQ stop codon, this creating the 'full-length’ 3’UTR 
construct. Initially, PCRs were performed using genomic DNA from T. b. brucei 
strain Lister 427-449 as template. However, these reactions were unsuccessful, 
possibly due to the absence of ESAG9-EQ in the ESAG9 gene repertoire of this 
strain, or strain differences in the sequence regions where primers were designed to 
anneal. However, success was achieved by using genomic DNA from T. b. brucei 
EATRO 2340 as template instead. 
 
A 
3’UTR(s)                                          350nt(s) 
TAGaaatcattaccgcaattccatggaatactgtgaaaacgtctattgagattaacaccgcatgatga
g 










                                                               
gacacgaggcaaggtgagaaacaggcgacaaccttaacaatattattattaattaaacaaggaaattt
a 










Figure 3.5 Downstream intergenic region for Tb927.5.4620 (ESAG9-EQ). A. The 
genomic sequence from the stop codon of the ESAG9-EQ gene to the start codon of 
the nearest downstream annotated gene, Tb927.5.4630, is shown. Because this 
intergenic region is 3057 bp in length, only the first 400nt of the sequence is shown. 
The regulatory element sequence is indicated by the line. The sequence is shown in 
the 5’ to 3’ direction. Red font: stop codon, red highlight: start codon, grey highlight: 
start (s) or end (e) of each sequence used to generate the construct named above that 
residue, a: polyadenylation site (PAS) mapped previously from cDNA (+217 bp 
relative to ESAG9-EQ stop codon), pink highlight: PASs from 5’RACE of e clones 
B3, B4, and C2 (see section 3.4.1). B. Schematic diagram showing replacement of 
the truncated aldolase 3’UTR (ΔALD 3’UTR) in the CAT449 plasmid with each of 




As for TbACO, a deletion series was constructed by substituting the forward primer 
of the PCR reaction with one complementary to sequence either about 50nt, 100nt, or 
150nt downstream of the ESAG9-EQ stop codon (primers 14, 15, and 16, see Table 
2.1 and Figure 3.1 B) these being used with primer 13, to generate the sequences 
used for the 3’UTR constructs ‘350nt’, ‘300nt’, and ‘250nt’, respectively (see Figure 
3.5). As the mapped PAS was located at +217 bp, all the deletion series constructs 
were expected to maintain the PAS signal present in the full-length 3’UTR construct. 
As before, stable transfectant cell lines were generated using T. b. brucei 
monomorphic bloodstream form strain Lister 427, these being selected with 0.5 
µg/ml phleomycin. Thereafter, clonal selection for each construct transfection was as 
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described above (Section 3.1), although, initially only one clone (biological 
replicate) was analysed for each of the full-length, 350nt, 300nt, and 250nt 
constructs. Data for the CAT mRNA and protein derived from the resulting clones is 
shown in Figure 3.6 (A and B). 
 
In comparison to the unmodified vector, the full-length ESAG9-EQ 3’UTR construct 
conferred repression of CAT expression at the level of protein (Figure 3.6 A; 26% 
±1.7% of CAT protein expression of the parental clone) and at the level of mRNA 
(Figure 3.6 B; 27% the level of CAT mRNA expression of the unmodified vector). 
The data presented in Figure 3.6 (A) for the full-length construct is the mean of 5 
biological replicates (independently derived clones). Because expression of ESAG9-
EQ mRNA is repressed in slender forms (Barnwell et al., 2010, see Figure 1.4), a 
repression of CAT expression was expected from any sequence that contributes to 
developmental expression. Thus, from Figure 3.6, it can be concluded that the 
ESAG9-EQ 3'UTR contributes to the repression of gene expression in slender forms. 
Because the level of both CAT RNA and CAT protein were low, this demonstrates 
that the control of ESAG9-EQ expression in slender forms is likely to be generated at 
the level of mRNA abundance, contrasting with TbACO where translational control 
appears important. 
 
Interestingly, investigation of the deletion series constructs revealed that the 
repression seen with the intact 3'UTR was then lost with the 350nt and 250nt 
constructs, where CAT protein expression increased to 83% and 73% respectively. 
However, repression was retained with the 300nt construct, since CAT protein 
expression remained at 26% of that seen for the unmodified vector (Figure 3.6 A). 
Figure 3.6 (B) shows that for each deletion construct construct, the RNA expression 
level matched the pattern of protein expression, such that CAT mRNA expression 
increased with the 350nt deletion construct (75% the level CAT mRNA of the 
unmodified vector), decreased with the 300nt construct (53%) and increased again 
with the 250nt construct (151%). Therefore, this supports the level of RNA as being 







Normalisation (%):    100     27     75      53    151    94      66   135 
 
Figure 3.6 Analysis of the ESAG9-EQ 3’UTR using a CAT reporter gene assay. A. 
CAT protein expression from the constructs shown as a percentage of expression 
from one clone of unmodified vector (control). The number of biological replicates 
(independently derived clones) used was: Full-length: 5, 350nt, 300nt, 250nt, eΔ 





standard error of biological replicates is shown on the graph. At the left of the graph 
are schematic representations of the sequence analysed in each construct, with the 
polyadenylation site location indicated with ‘A’ and the regulatory element location 
indicated by the red line. B. Northern blot analysis using a digoxygenin-labelled 
RNA probe against the CAT coding region, with RNA from the unmodified vector, 1 
biological replicate of each of the full-length, 350nt, 300nt, and 250nt constructs, and 
3 biological replicates of the eΔ construct. The lower panel shows the ethidium 
bromide-staining of the rRNA present in each sample analysed to indicate the 
loading of each lane. Shown below are the values of mRNA quantitation following 
normalisation to rRNA as a percentage of that obtained for the unmodified vector. 
 
By northern blot analysis (Figure 3.6 B) size differences were observed in the CAT 
mRNAs derived from the full-length, 350nt, 300nt and 250nt constructs in 
comparison to the unmodified vector and each other. As for the TbACO 5’ and 
3’UTR constructs, this is likely to be due to differences in UTR length between the 
constructs, with each of the ESAG9-EQ 3’UTR-based mRNAs using the same PAS 
in each construct. 
 
3.3.2 Possible regulatory regions within the ESAG9-EQ 3’UTR  
On initial examination, these results could indicate that there is a region that 
negatively regulates expression that is lost with the first 50nt deletion (350nt), a 
region that positively regulates expression lost with the next 50nt deletion (300nt), 
and again a region that negatively regulates expression that is lost with the final 50nt 
deletion (250nt). However, it is also possible that there may be a structure or 
structures present within the 3'UTR that are responsible for the results observed. 
Therefore, to investigate the potential RNA structures of the full-length and deletion 
series 3'UTRs, the Sfold programme, Srna, was used to analyse each 3’UTR 






































Figure 3.7 RNA secondary structure predictions for ESAG9-EQ 3’UTR sequences. The Sfold (http://sfold.wadsworth.org/cgi-bin/index.pl) 
software package Srna was used with the sequences used for construct generation extending to the mapped PAS. Shown are the Ensemble 
Centroid structures generated. A. Full-length 3’UTR construct sequence. B. 350nt 3’UTR construct sequence. C. 300nt 3’UTR construct 
sequence. D. 250nt 3’UTR construct sequence. E. Enlargement of boxed region in A. Boxes indicate the regulatory element structure. 
 




The Sfold ensemble centroid RNA structure prediction for each construct is provided 
in Figure 3.7. Interestingly, the two constructs that confer repression of CAT gene 
expression, the full length 3’UTR and 300nt 3'UTR, are predicted to possess a stem-
loop structure that is absent from the other two ensemble centroid structures, either 
because it is not predicted to form (350nt 3'UTR construct) or because some of the 
sequence forming the structure has been deleted (250nt 3'UTR construct). The 
structure is indicated with boxes in Figure 3.7 (A and C) and an enlargement of the 
structure is shown in Figure 3.7 (E). This structure, therefore, represents a candidate 
for the regulatory element responsible for repression of gene expression caused by 
the ESAG9-EQ 3'UTR, and was termed the ESAG9-EQ 'element'. Consequently, the 
next step was to investigate this element in more detail. 
 
3.4 Element deletion 
 
To assess whether the element structure identified from the Sfold analysis was 
responsible for the repression of CAT gene expression observed with the constructs 
in which it is predicted to form, the sequence for the element structure was deleted 
from the full-length 3’UTR sequence. Hence, if this structure was responsible for 
repression of gene expression, its deletion from the construct would result in an 
increase in CAT gene expression, due to an alleviation of the repressive signal. 
 
The sub-cloning strategy for this deletion construct replaced the element sequence 
with an XbaI restriction site (see Figure 3.8). To achieve this, two PCR reactions 
were performed using the PCR product that was used to create the full-length 
construct as template; one reaction with primers 17 and 12 to amplify the region of 
the full-length 3’UTR sequence upstream of the element sequence, the other with 
primers 18 and 13 to amplify the region of the full-length 3’UTR sequence 
downstream of the element sequence. The two PCR amplicons were used in a single 
ligation reaction with BamHI- and BbsI-digested CAT449 vector. The resulting 
construct was termed ‘element deletion’ or ‘eΔ’. For this construct, three 
independently derived clones (biological replicates) were analysed instead of one as 




Figure 3.8 Schematic diagram showing the sub-cloning strategy used for generating 
the ESAG9-EQ element deletion (eΔ) 3’UTR construct. Two PCR reactions were 
performed using the full-length ESAG9-EQ 3’UTR as template and primers 
(indicated with bent arrows; see Table 2.1 for the sequences) numbers 12 and 17, and 
13 and 18, for two PCRs. Primer 12 contained the BamHI restriction enzyme site 
sequence; primer 13 contained the BbsI sequence; primers 17 and 18 contained the 
XbaI sequence. These reactions amplified the sequence upstream and downstream of 
the ESAG9-EQ element sequence (indicated by the red box). Then the PCR products 
were cloned into the pGEM T-easy plasmid, digested with the appropriate restriction 
enzymes, and purified (see Section 2.3). These were then used in a ligation reaction 
with CAT449 plasmid that had been digested with BamHI and BbsI and purified (see 
Section 2.3.9), in order to replace the truncated aldolase 3’UTR present in this 












             
Figure 3.9 continues on the following page 
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Figure 3.9 RNA secondary structure predictions for ESAG9-EQ element deletion and element insertion 3’UTR sequences. The Sfold 
(http://sfold.wadsworth.org/cgi-bin/index.pl) software package Srna was used with the sequences used for construct generation. Shown are the 
Ensemble Centroid structures generated. A. Element deletion (eΔ) construct sequence extending to the mapped PAS. B. Truncated aldolase 
3’UTR sequence. C. Element insertion (eI) construct sequence. Black box indicates the regulatory element structure, blue and orange boxes 


















The sequence used for the eΔ 3’UTR sequence was also analysed by Sfold to verify 
that the predicted folding of this deleted 3’UTR would not differ significantly from 
that predicted for the full-length 3’UTR. The ensemble centroid structure obtained 
for the eΔ 3’UTR sequence is shown in Figure 3.9 (A). In comparison to the 
ensemble centroid structure obtained for the full-length 3’UTR sequence (see Figure 
3.7 A), it is clear that the predicted folding of both sequences is very similar, with 
only minor alterations to the folding evident around the region of the element 
deletion. This meant that any change in CAT expression levels between the full-
length and eΔ 3’UTR constructs should be due to the deletion of the element 
sequence, or its predicted structure, and not due to any other changes in the predicted 
structure of the 3’UTR.  
 
In comparison to the full-length construct, two of the three clones analysed of the eΔ 
construct gave some alleviation of the repression of CAT mRNA and protein 
expression (Figure 3.6 A and B, clones B3 and B4; 44% and 36% of the unmodified 
vector CAT protein expression, 94% and 66% of the unmodified vector CAT mRNA 
expression, respectively). The third clone, however, exhibited a much greater CAT 
mRNA and protein expression (Figure 3.6 A and B, clone C2; 95% of the 
unmodified vector CAT protein expression, 135% of the unmodified vector CAT 
mRNA expression). The reason for this difference between the clones is unclear. One 
possible explanation is that either clones B3 and B4 or clone C2 possessed an 
incorrect 3’UTR sequence. This could be possible if the full-length 3’UTR amplicon 
contaminated the ligation reaction for the eΔ CAT449 construct. In this case, the 
DNA used for transfection would accidentally contain both the full-length and eΔ 
CAT449 constructs. This is a possibility, since the CAT mRNA under the control of 
either of these UTRs would run at approximately the same molecular weight, as is 
observed with CAT mRNA from the full-length and eΔ construct clones (Figure 3.6 
B). Therefore, it was considered important to confirm the CAT 3’UTR sequence 
present in each transfectant line, this being carried out by 3’RACE for each of the 
three eΔ clones.  
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3.4.1 Investigation of possible causes of the aberrant result for clone C2 
3’RACE involved generation of cDNA from each RNA sample using an oligo-dT 3’ 
primer containing an adapter sequence (primer 19, see Table 2.1 and Section 2.5; 
Mayho et al., 2006). This cDNA was then used as template in a PCR reaction with a 
CAT gene-specific primer (primer 21) and a primer consisting of the adapter 
sequence (primer 20). A second PCR amplification was performed with another CAT 
gene-specific primer (primer 22), complementary to CAT gene sequence 
downstream from primer 21, and primer 20 again. This second amplification 
therefore generated a nested PCR product to increase specificity. The main PCR 
product from each reaction was then gel-excised and ligated into pGEM T-Easy 
vector. Following transformation and small-scale plasmid preparation, two bacterial 
colonies were sequenced with M13 forward and reverse primers (primers 1 and 2), 
for each of the B3, B4 and C2 clones.  
 
The sequences returned from 3’RACE showed that all three clones contained the 
correct, deleted, 3’UTR sequence downstream of the CAT gene sequence. 
Additionally, the 3’RACE sequencing also provided the PAS location for each clone, 
these being shown in Figure 3.10 (A) as filled circles. There were found to be three 
different PAS locations and each being also indicated on the sequence in Figure 3.5. 
As can be seen, the PASs for each clone were located close to each other, although 
for each there was minor variation between results from the two bacterial colonies 
from the same clone. One PAS was located further downstream than the rest; this 
was one of the sequences obtained from clone B3. However, this does not explain the 
difference in CAT gene expression because the clone showing more abundant 
expression was clone C2, the PASs for which matched those from clone B3 and 
clone B4.  
 
As the 3’UTR sequences were confirmed as correct for each eΔ clone and there was 
no significant difference in PAS location between the clones, another explanation 
may be that this was just an erroneous result that is not repeatable. To investigate this 
result, RNA and protein samples were collected again from each clone after the cell 
lines were revived from storage at -80°C. CAT ELISA assay and northern blot 
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analysis was repeated with these new samples. However, the results obtained were 
the same as that presented in Figure 3.6 (data not shown), indicating that the original 

























































Figure 3.10 Investigation of the aberrant result obtained for the element deletion (eΔ) construct clone C2. A. Polyadenylation site (PAS) 
locations identified by 3’RACE in the 3’UTR of the three element deletion (eΔ) construct clones (B3, B4 and C2). PAS locations identified by 
3’RACE are indicated by filled circles; these locations are also shown on the sequence in Figure 3.5. The PAS location previously mapped for 
ESAG9-EQ cDNA (Keith Matthews, unpublished observations; see Section 3.3.1) is indicated by ‘A’. B. Northern blot analysis using a 
digoxygenin-labelled RNA probe against the CAT coding region, with RNA from the unmodified vector, full-length and eΔ (clones B3, B4 and 
C2) clones as shown in Figure 3.6 (B), as well as four additional clones (C2, C3, C4 and C5) of the full-length construct and four additional 
clones (B3*, B4*, C1* and C2*) of the eΔ construct. The lower panel shows the ethidium bromide-staining of the rRNA present in each sample 
analysed to indicate the loading of each lane. 
B 
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3.4.2 Additional full-length and eΔ  3’UTR construct clones 
Finally, it was hypothesised that the unusual expression level observed with the eΔ 
clone C2 may have been caused by integration of the construct into a different 
location of the β-tubulin locus, an alternative locus, or by multiple integration of the 
construct into the β-tubulin locus. To investigate whether the result for clone C2 was 
indeed an odd result, the full-length and eΔ 3’UTR constructs were re-transfected to 
generate 4 additional and independently derived clones for each construct. CAT 
mRNA and protein expression was assessed again for these new clones; i.e. full-
length clones C2, C3, C4 and C5, and eΔ clones B3*, B4*, C1*, and C2*. All the 
new full-length clones gave similar CAT protein expression to that obtained from the 
first clone analysed; therefore, the mean of all 5 of these biological replicates is 
shown in Figure 3.6 (A). Similarly, all the new eΔ clones gave similar CAT protein 
expression to that obtained for clones B3 and B4, indicating that the result for clone 
C2 was an odd result. Hence, the mean of the 6 biological replicates (i.e. excluding 
the data obtained from clone C2) is presented in Figure 3.6 (A) as eΔ (53% ±5.2% of 
the CAT protein expression from unmodified vector). The result of the northern blot 
analysis with RNA from the original and new full-length and eΔ clones is provided 
in Figure 3.10 (B). As can be seen, the CAT mRNA levels are similar for the new 
clones as the original clones for each construct, except clone C2 which has a much 
greater CAT mRNA expression (262% of the level of CAT mRNA expression of the 
unmodified vector), further confirming this as an odd cell line. It is possible that this 
is due to integration location or multiple integration of the construct into the β-
tubulin locus. However, further experiments, such as southern blot analysis of 
genomic DNA obtained from each clone, would be needed to confirm this. 
 
From the data obtained from multiple clones of the full-length and eΔ 3’UTR 
constructs (presented in Figure 3.6), it would appear that deletion of the element 
sequence, and therefore, predicted structure, causes some alleviation of CAT gene 
expression at the RNA level, therefore, suggesting that it contributes to the 
repression of gene expression in slender forms. However, comparison of the data 
obtained from the full-length, 250nt and eΔ 3’UTR constructs in Figure 3.6 (A), 
shows that the 250nt construct alleviates repression more than the eΔ 3’UTR 
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construct, indicating that the element is not fully responsible repression. Instead, 
additional regulatory region(s) must contribute. 
 
3.5 Insertion of the element into an unrelated 3'UTR 
 
To confirm the negative regulatory function of the element deleted in the eΔ 3’UTR 
construct, the element was inserted into an unrelated 3’UTR sequence. Specifically, 
the stem-loop element sequence was inserted into the truncated aldolase 3’UTR 
sequence that is present in the CAT449 vector, to generate an ‘element insertion’ or 
‘eI’ 3’UTR construct.  
 
A number of potential different placements of the element sequence within the 
truncated aldolase 3'UTR sequence were analysed using Sfold to identify the location 
that resulted in the least disruption to the structures already present. This was carried 
out to minimise the chance that any change in CAT expression was caused by a 
change in overall structure, rather than insertion of the element. Figure 3.9 (B) shows 
the ensemble centroid structure predicted for the truncated aldolase 3’UTR. As can 
be seen there are three prominent stem-loop structures predicted and two loops of 
sequence without predicted folding. Thus, it was thought that these sequences 
without predicted structure would be less likely to contribute to gene regulation and 
so insertion of the element sequence in various positions along these sequences was 
tested. Figure 3.9 (C) shows the ensemble centroid structure predicted for the 
location chosen and, so, the eI 3’UTR sequence. This maintains two of the three 
prominent stem-loop structures predicted in the truncated aldolase 3’UTR (blue and 
orange boxed regions in Figure 3.9 B and C), however, the third predicted prominent 
stem-loop was not predicted to form. The element structure was also predicted to 
form (indicated with a black box in Figure 3.9 C). However, in order to obtain this 
construct it was necessary to include a palindromic sequence at the 5’ and 3’ ends of 
the stem-loop element sequence to assist its predicted folding. For this, the XbaI 




3.5.1 Sub-cloning of the eI 3’UTR construct 
Sub-cloning of the eI sequence to create this construct proved difficult. The initial 
sub-cloning strategy involved three PCR reactions using the unmodified vector or 
full-length 3’UTR construct DNA as template; one reaction with primers 23 and 24 
(see Table 2.1) to amplify the region of the truncated aldolase 3’UTR sequence 
upstream of the site for element insertion (‘aldolase 1.1’), another with primers 25 
and 26 to amplify the region of the truncated aldolase 3’UTR sequence downstream 
of the site for element insertion (‘aldolase 1.2’), the third with primers 27 and 28 to 
amplify the element sequence. Primers 24, 25, 27 and 28 contained the XbaI 
restriction site sequence, primer 23 contained the BamHI restriction site sequence, 
and primer 26 contained the BbsI restriction site sequence. Thus, after insertion of 
each PCR product into pGEM T-easy vector, digestion of the sequences with these 
three restriction enzymes, and then ligation of the three digested sequences in one 
ligation reaction with BamHI- and BbsI-digested CAT449 vector, the eI construct 
would be generated. However, it became clear that this strategy would not work, 
because the element sequence PCR product was very short in length and one ligation 
reaction with all three digested sequences would not be successful. Moreover, 
ligation of two digested products into pGEM T-easy vector, then digestion of this for 
ligation of the third digested product would not work either due to the presence of 
two XbaI restriction sites in the eI sequence.  
 
Therefore, a second sub-cloning strategy was attempted. This used the aldolase 1.1 
and 1.2 pGEM T-easy constructs generated above, but instead of generation of the 
element sequence through PCR, an approach with complementary oligonucleotide 
sequences was used. To circumvent the problem of two XbaI restriction sites 
mentioned above, one of the XbaI restriction sites was changed so that one 
nucleotide of the sequence was mutated to another nucleotide. Thus, the sequence 
would not be recognised for digestion by XbaI but would still assist the folding of the 
element structure. After analysis using Sfold of different mutations of the last 
nucleotide in the upstream XbaI restriction site in the eI sequence, the mutation 
found to least affect the predicted folding was A-to-G. The complementary 
oligonucleotide sequences designed were primers 29 and 30 (see Table 2.1). The 
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strategy involved annealing of these oligonucleotides together in an annealing 
reaction (see Section 2.3.6) to generate the element sequence with overhangs 
compatible for insertion into XbaI digested sequences (see Figure 3.11). Then, a 
ligation reaction would be performed with the annealed oligonucleotides and XbaI-
digested aldolase 1.1 pGEM T-easy vector. This construct would then be digested 
with XbaI and PstI and ligated with XbaI- and PstI-digested aldolase 1.2 pGEM T-
easy vector. However, despite numerous attempts, ligation of annealed 
oligonucleotides into XbaI-digested aldolase 1.1 pGEM T-easy vector was always 
unsuccessful. This was hampered by the inability to confirm successful annealing of 
the complementary oligonucleotides, due to the short length of their sequence and 
the presence of overhangs preventing the ligation into pGEM T-easy vector for 
sequencing. It is likely that annealing was unsuccessful due to the relatively extended 
length of the oligonucleotides and the element sequence, which may have caused the 
formation of hairpins in the oligonucleotides or annealing of the oligonucleotides so 
that the correct overhangs for insertion into XbaI digested sequences were not 
present. Therefore, this cloning strategy was abandoned. 
 
 
     5’ ctagggttgtggagagacaagataagaggatcgaataact 3’ 
            |||||||||||||||||||||||||||||||||||| 
         3’ ccaacacctctctgttctattctcctagcttattgagatc 5’ 
 
Figure 3.11 Annealed complementary oligonucleotides for an eI 3’UTR sub-cloning 
strategy. The sequence is the identified ESAG9-EQ element sequence with 
nucleotides added at both 5’ and 3’ ends to create overhangs compatible for insertion 
of the annealed oligonucleotides into XbaI-digested DNA (grey highlight).  
 
 
A strategy involving mutagenesis of the truncated aldolase 3’UTR was then 
considered. This would consist of mutagenesis to insert the element sequence with 
flanking XbaI restriction enzyme sites into the truncated aldolase 3’UTR using the 
QuikChange XL Site-Directed Mutagenesis kit (Stratagene). However, due to the 
extended length of the sequence for the insert and the restrictions on design of the 
primers for successful mutagenesis, primers could not be designed according to the 
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guidelines for mutagenesis, even using only a third of the insert sequence at a time. 
Therefore, this approach was not initiated.  
 
Finally, the eI 3’UTR sequence, with flanking BamHI and BbsI restriction enzyme 
sites for ligation into BamHI- and BbsI-digested CAT449 vector, was synthesised by 
a commercial company, GENEART AG (Germany; GENEART services presently 
being offered through www.invitrogen.com), in their pMA-T vector. However, 
digestion of this construct with BamHI and BbsI produced insufficient amount of 
digested insert DNA for gel-purification and use in a ligation reaction. Attempts to 
transform E. coli XL-blue bacteria with the plasmid were unsuccessful, as DNA 
obtained from transformed bacterial colonies ran on agarose gels at a much lower 
molecular weight. Possibly this was due to incompatibility of the plasmid and the 
bacterial strain. Consequently, a PCR reaction was performed with primers 31 and 
32, using the pMA-T plasmid sequence as template, to amplify the region of the 
plasmid containing the eI sequence. The eI sequence was verified after insertion into 
pGEM T-easy and following BamHI and BbsI digestion was inserted into BamHI- 
and BbsI-digested CAT449 vector. As for the previous constructs analysed, T. b. 
brucei monomorphic bloodstream form strain Lister 427 were then transfected with 
the construct, although the selection of stable transfectant clones used 2.5 µg/ml 
phleomycin. Four independently derived clones (biological replicates) of the eI 
construct were analysed. 
 
3.5.2 Element insertion causes a small decrease in CAT reporter gene expression 
The four eI construct clones analysed each resulted in very limited repression of 
CAT protein expression in comparison to the unmodified vector (Figure 3.6 A), 
giving a mean CAT protein expression of 90% ±6.0 of the expression from the 
unmodified vector. The CAT mRNA expression for each of the four eI construct 
clones is shown in Figure 3.12. The CAT mRNA expression level was also reduced 
with this construct, as the mean level of CAT mRNA expression for the clones was 
67% of that of the unmodified vector (52%, 49%, 51% and 114% for clones D1, D4, 





Figure 3.12 Analysis of the CAT mRNA level obtained with the element insertion 
(eI) construct in a CAT reporter gene assay. Northern blot analysis using a 
digoxygenin-labelled RNA probe against the CAT coding region, with RNA from 
the unmodified vector and 4 biological replicates of the eI construct (clones D1, D4, 
C5, and C6). The lower panel shows the ethidium bromide-staining of the rRNA 
present in each sample analysed to indicate the loading of each lane. 
 
 
As described above, the only difference between the 3’UTR downstream of the CAT 
gene in the eI construct and the unmodified vector is the insertion of the regulatory 
element sequence. Therefore, it is likely that the element sequence is responsible for 
this repression. The repression seen, however, was very minor and much less than 
seen with the full-length 3’UTR construct or as great as the extent of repression 
release seen with the eΔ 3’UTR construct compared to the full-length 3’UTR 
construct. This could be due to an inability of the element sequence to form the 
predicted structure (see Figure 3.7 E). Another possibility is that additional sequence 
of the ESAG9-EQ 3’UTR surrounding the element sequence is needed for the 
element’s negative regulatory function or that regulatory proteins that bind the 
element sequence are unable to due to the secondary structure present in this 3’UTR. 
However, the small repression of gene expression seen with the eI construct does 
support the negative regulatory function of the element sequence, even out of the 




3.6 Additional 3’UTR deletion series cell lines 
 
With the odd result obtained from one clone of the eΔ construct (clone C2, see 
Section 3.4), the analysis of only one clone expressing CAT under the control of the 
350nt, 300nt, and 250nt 3’UTRs could be criticised, as it unknown whether any of 
these represented aberrant results too. Therefore, an analysis of more clones for each 
of these constructs was needed. To achieve this, each construct was re-transfected, 
again into the T. b. brucei monomorphic bloodstream form strain Lister 427, but 
selection of stable transfectant clones was with 2.5 µg/ml (instead of with 0.5 µg/ml 
previously) phleomycin. Two independently derived clones (biological replicates) of 
each of the 350nt, 300nt, and 250nt 3’UTR constructs were analysed. Hence, with 
the previous clones analysed (Section 3.3.1), a total of three biological replicates 
were analysed for each of these constructs. 
 
3.6.1 Additional 350nt construct clones 
The CAT protein expression obtained from the additional clones is shown in Figure 
3.13 (A) as a percentage of that obtained from the unmodified vector. The result 
presented in this graph for the 350nt construct is the mean of the two additional 
clones (D5 and C2) because, as can be seen when comparing Figure 3.6 (A) and 
Figure 3.13 (A), these two clones resulted in a much lower level of CAT protein 
expression than the original 350nt construct clone (clones of the D5 and C2 had a 
CAT protein expression level of 47% ±2.5% versus the original clone that had a 
level of 83%). The CAT mRNA expression for these two additional clones is shown 
in Figure 3.13 (B) and appears to be variable between the two clones. However, 
when the levels of CAT mRNA were quantified using the rRNA level, both clones 
were found to have a similar expression level, this being 48% and 42% of the 
expression from the unmodified vector (for clone D5 and C2, respectively). 
Therefore, both clones D5 and C2 had a lower CAT mRNA signal than that of the 
unmodified vector, in contrast to the original clone, which had a CAT mRNA 
expression level of 75%. Therefore, unfortunately it appears that the original 350nt 
construct clone may not have been representative, similarly to the eΔ construct clone 
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C2. It was for this reason that the original clone was excluded from the data 







Figure 3.13 Additional 350nt, 300nt and 250nt construct clone analysis using a CAT 
reporter gene assay. A. CAT protein expression from the constructs shown as a 
percentage of expression from one unmodified vector clone (control). Final results 
incorporating data obtained from all clones, excluding any odd results. Number of 
biological replicates (independently derived clones) used: Full-length: 5, 350nt: 2, 




standard error of biological replicates is shown on the graph. At the left of the graph 
are schematic representations of the sequence analysed in each construct, with the 
polyadenylation site location indicated with ‘A’ and regulatory element location 
indicated by the red line. B. Northern blot analysis using a digoxygenin-labelled 
RNA probe against the CAT coding region of RNA samples from the additional 
clones of the 350nt, 300nt, and 250nt constructs and one clone of unmodified vector 
as a control. Shown in the lower panel is the ethidium bromide-staining of the rRNA 
present in each sample to indicate the loading of each lane. 
 
3.6.2 Additional 300nt and 250nt construct clones 
Fortunately, the additional 300nt and 250nt construct clones gave similar CAT 
expression results to their respective original clones. Therefore, the data presented in 
Figure 3.13 (A) for each of these constructs is the mean of the three clones 
(biological replicates). The mean values are therefore, for the 300nt construct clones, 
32% of the CAT protein expression obtained from the unmodified vector (previously 
26% for the original clone alone), and for the 250nt construct clones, 77% 
(previously 73% for the original clone alone). Hence, none of the clones for either of 
these two constructs appeared to have produced an aberrant level of CAT protein 
expression and so the data for all these clones was included in the data presented in 
Figure 3.13. 
 
Analysis of the CAT mRNA levels for these additional clones is also shown in Figure 
3.13 (B). For each of the 300nt and 250nt constructs, the individual clones produced 
a similar level of CAT mRNA expression to each other. These levels are similar to 
the CAT protein expression level obtained for each construct and similar to that 
observed for the original clones of each construct (see Figure 3.6 B). 
 
The discovery that the original 350nt clone was generating an aberrant expression 
profile was disappointing since from the data presented in Figure 3.13 it now 
appeared that the loss of the predicted element structure in this construct was not 
responsible for the entire alleviation of repression seen with the 250nt construct. 
Instead, the predicted element structure may be responsible for some of this 
alleviation and possibly there is another negative regulatory region that is lost in the 
deletion to form the 250nt construct.  
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3.7 Is the ESAG9-EQ 3’UTR responsible for gene expression control in 
‘stumpy-like’ forms? 
 
Next, the question of whether the ESAG9-EQ 3’UTR is responsible for control of 
gene expression, i.e. release of repression, in stumpy forms was addressed. For this, 
the same CAT reporter gene assay approach could be used as to dissect the control of 
gene expression in slender forms. However, the cells used for the CAT reporter gene 
assays above were monomorphic and so these cells have lost the ability to 
differentiate to stumpy forms. The ideal experiment would be to analyse the same 
constructs in pleomorphic bloodstream form cells, where true slender and stumpy 
forms could be analysed. However, this would involve re-transfection of each 
construct and so re-generation of the cell lines, a huge task, given the inefficient 
transfection of pleomorphic trypanosomes. Therefore, experiments were performed 
on the existing monomorphic cell lines analysed above, which were driven to embark 
on stumpy formation by chemical induction.  
 
3.7.1 Generation of monomorphic ‘stumpy-like’ forms 
Treatment with a compound, 8-pCPT-2’-O-Me-cAMP, has been previously reported 
to turn monomorphic bloodstream form T. brucei into ‘stumpy-like’ forms (Laxman 
et al., 2006). Laxman et al. (2006) showed that 8-pCPT-2’-O-Me-cAMP, a 
hydrolysable cAMP analogue, has an anti-proliferative effect in bloodstream form T. 
brucei cells and that treated cells also have stumpy morphology and NADH 
diaphorase activity (a marker of intermediate and stumpy forms). Therefore, 
treatment with this compound was used to assess the control of CAT reporter gene 
expression in ESAG9-EQ 3’UTR based construct cell lines when ‘stumpy-like’ to 
give an idea of expression in stumpy forms. 
 
These experiments involved treatment of each cell line with 10 µM 8-pCPT-2’-O-
Me-cAMP (dissolved in DMSO) and, as a control, treatment with DMSO alone (see 
Section 2.2.3). CAT ELISA assay and northern blot analysis were performed in the 
same way described above in Section 3.1.2, using samples taken from both the 
treated and control cells 48 hours post-addition. The CAT protein expression results 
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are presented as the fold change in CAT protein levels between the treated, stumpy-
like, cells and the control cells. Moreover, for each construct there were 2 or 3 
biological replicates. For each cell line there were two experimental replicates, 
meaning that the CAT ELISA assays and northern blot analyses were performed with 
samples taken from two separate 8-pCPT-2’-O-Me-cAMP treatment experiments. 
This is with the exception of the unmodified vector clone, which had one biological 
replicate and four experimental replicates, this line being included in each 8-pCPT-
2’-O-Me-cAMP treatment experiment as a control. 
 
In each experiment involving treatment with 8-pCPT-2’-O-Me-cAMP, the cell 
number was determined (see Section 2.2.1) immediately prior to sample generation 
for CAT ELISA assay and northern blot analysis at 48 hours post-induction. This 
was to enable the values obtained from the CAT ELISA assay to be adjusted for the 
cell number for each sample. Also, this allowed confirmation of the anti-proliferative 
effect of the compound on trypanosomes. 
 
3.7.2 The ESAG9-EQ 3’UTR confers an alleviation of protein repression in 
stumpy-like forms 
8-pCPT-2’-O-Me-cAMP was used to treat the cell lines discussed in Sections 3.3, 
3.4, 3.5 and 3.6 to assess the contribution of the various 3’UTRs to control of CAT 
gene expression upon stumpy-like cell formation. The results for the various 3’UTR 
constructs are shown in Figure 3.14.  
 
The change in CAT protein levels in cells treated with 10 µM 8-pCPT-2’-O-Me-
cAMP compared to control cells is shown in Figure 3.14 (A). The data presented 
separately for each construct is the mean ± standard error of the biological replicates 
(unmodified vector and 350nt constructs: n = 1, full-length and eΔ constructs: n = 3, 





























Figure 3.14 Response of CAT reporter gene expression to 8-pCPT-2’-O-Me-cAMP 
treatment in ESAG9-EQ 3’UTR based constructs. A. Fold change in CAT protein 
expression levels between cells treated with 10 µM 8-pCPT-2’-O-Me-cAMP and 
control cells. Shown is the mean ± standard error of biological replicates; unmodified 
vector and 350nt: n = 1, full-length and eΔ: n = 3; other constructs: n = 2. At the left 
of the graph are schematic representations of the sequence analysed in each 
construct, with the polyadenylation site location indicated with ‘A’ and the 
regulatory element location indicated by the red line. B. and C. Northern blot 
analyses of RNA samples from two different 8-pCPT-2’-O-Me-cAMP treatment 
experiments using a digoxygenin-labelled RNA probe against the CAT coding 
region, each with the unmodified vector clone as a control. Samples are either from 
cells treated with 10 µM 8-pCPT-2’-O-Me-cAMP (+ drug) or control cells (- drug). 
Lower panels show the ethidium bromide-staining of the rRNA present in each 
sample analysed to indicate the loading of each lane. Shown below are the mRNA 
quantifications following normalisation to rRNA as a percentage of that obtained for 
the unmodified vector. 
 
 
As can be seen in Figure 3.14 (A), there was a small response of the unmodified 
vector to treatment with the compound (1.3 fold change), although the mRNA levels 
generated a lower fold-change (1.13 fold-change, Figure 3.14 B). This is unexpected 
because the truncated aldolase 3’UTR was not expected to be developmentally 
regulated (see Section 3.1.1). Nonetheless, as this construct was included as a control 
in all of the experiments performed, the values present in induced and untreated 




The full-length (400nt) ESAG9-EQ 3’UTR caused an increase in CAT protein 
expression in response to treatment with this compound by 2.2-fold compared to 
DMSO treatment. This was a larger increase in the fold change than was observed 
with the unmodified vector. This is significant because in stumpy forms there is a 
general repression of translation (Section 1.4.1), whereas for this construct there was 
increased expression, demonstrating that it was not translationally repressed. This 
increased expression supported a role for the ESAG9-EQ 3’UTR sequence in the 
release of gene expression repression in stumpy forms. It also implied that there are 
regulatory signal(s) within the ESAG9-EQ 3’UTR able to respond upon 
differentiation to stumpy-like forms.  
 
For the 350nt construct, the data presented in Figure 3.14 (A) is unfortunately only 
the result obtained for one clone. This is because initial experiments using this 
compound included the original clone for this construct, which later was discovered 
to give an aberrant level of CAT protein expression (see Section 3.6.1). The mRNA 
abundance obtained from this original clone is shown in Figure 3.14 (B), 
demonstrating that this clone also gives an aberrant result in this drug treatment 
analysis (5-fold increased mRNA level with drug treatment, see Section 3.7.3 also). 
Therefore, the results obtained for this clone in stumpy-like forms were not included 
in the data presented in Figure 3.14 (A). The results obtained from the one clone 
used for this analysis (clone D5) show that there was no difference in CAT protein 
expression upon treatment compared to the full-length construct; there was still a 
fold change of 2.2. Therefore, deletion of the first 50nt of ESAG9-EQ 3’UTR 
sequence did not affect the response to 8-pCPT-2’-O-Me-cAMP treatment observed 
with the full-length 3’UTR.  
 
Deletion of the next 50nt of the ESAG9-EQ 3’UTR sequence with the 300nt 
construct also did not affect the response to 8-pCPT-2’-O-Me-cAMP treatment (2.3 
fold change). However, further deletion of the sequence by 50nt more (i.e. the 250nt 
construct) did affect the response to 8-pCPT-2’-O-Me-cAMP treatment as the fold 
change decreased to 1.5-fold. This was almost a return to the value obtained for the 
unmodified vector, indicating a responsive element had been deleted.  
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Results obtained with the eΔ construct, where only the sequence of the predicted 
structural element is deleted (see Section 3.4), showed a fold change of 1.4, similar 
to that of the 250nt construct. Therefore, this suggests that it is the region containing 
the element sequence that is responsible for the response to 8-pCPT-2’-O-Me-cAMP 
treatment in the ESAG9-EQ 3’UTR sequence, because its deletion either within the 
eΔ construct or within the 250nt construct eliminated the response. 
 
To analyse if this element could also respond out of context, the eI construct, where 
the element sequence is inserted into the truncated aldolase 3’UTR (see Section 3.5), 
was analysed. This demonstrated a slight increase in the fold change upon treatment, 
matching the unmodified vector (1.6-fold). Similar to the results obtained from 
analysis of CAT reporter gene expression in slender monomorphic bloodstream form 
cells, this supported a small contribution of this sequence to gene expression in 
stumpy forms (see Section 3.5). Therefore, context is likely important for the 
functionality of this sequence element.  
 
3.7.3 Response of each construct at the RNA level in stumpy-like forms 
Analysis of the CAT mRNA levels in response to 8-pCPT-2’-O-Me-cAMP treatment 
for each of the cell lines is presented in Figure 3.14 (B and C). As mentioned above, 
treatment with 8-pCPT-2’-O-Me-cAMP resulted in an anti-proliferative effect as 
previously reported (Laxman et al., 2006). This generated low RNA yields for 
samples from the cells treated with this compound. Consequently, lower amounts of 
RNA than usual (typically 0.5 µg per sample) were analysed in northern blot 
analyses in these experiments. As shown in Figure 3.14 (B), there was a slight 
response of the unmodified vector to the treatment, this producing a small increase in 
CAT mRNA expression levels, similarly to that observed for the CAT protein 
expression for this clone (Figure 3.14 A). This was more pronounced in the 
experiments with the second group of cell lines analysed (Figure 3.14 C), as was the 
CAT protein expression response. The reason for this is unknown. However, when 
compared to the CAT mRNA expression levels for the full-length ESAG9-EQ clones 
(Figure 3.14 B), it is apparent that there was a much stronger response to treatment in 
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the test constructs bearing the ESAG9-EQ 3’UTR (1.93 fold-change, Figure 3.14 B). 
This matched the CAT protein expression response discovered for this construct, 
confirming that the ESAG9-EQ 3’UTR contributes to alleviation of gene expression 
repression in stumpy forms, likely through mRNA control. 
 
Similarly, the 3’UTR deletion series also respond to 8-pCPT-2’-O-Me-cAMP 
treatment with an elevated CAT mRNA expression level (Figure 3.14 B and C). This 
was greatest for the 350nt original clone (Figure 3.14 B), although this was the clone 
that produced an aberrant level of CAT expression and thus should be ignored from 
this analysis, as discussed above. Each of the remaining deletion series constructs 
generated an increase in CAT mRNA expression in stumpy-like forms, with these 
responses being comparable to each other (300nt fold-change: 2.72, 250nt fold 
change: 2.52). Therefore, the increased CAT protein expression observed for these 
constructs in stumpy-like forms (Figure 3.14 A) may be due to increased CAT 
mRNA expression. 
 
Interestingly, for the 250nt construct the fold-change of CAT protein was less (1.5-
fold, Figure 3.14 A) than the fold-change in mRNA quantification (2.5-fold, Figure 
3.14 B) between drug-treated and untreated cells, which indicates that this construct 
is subject to some translational repression. However, this interpretation is limited by 
the quantification of only the mRNA abundance obtained from one clone, indeed 
comparison of the mRNA levels obtained from another clone (Figure 4.13 C) 
suggests that this may yield a greater fold-change from quantification than the 
original clone. However, the dark area covering this section of the Northern blot 
would prevent meaningful quantification. Clearly further Northern blot analyses and 
quantifications would be required before any firm conclusions could be made, 
however, this was hampered by the low amount of RNA obtained from the drug-
treated cells. 
 
The eΔ 3’UTR clones also exhibited an elevated CAT mRNA expression in response 
to 8-pCPT-2’-O-Me-cAMP treatment (1.47 mean fold-change, Figure 3.14 B). Along 
with the CAT mRNA expression data obtained for the deletion series constructs this 
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suggests that the element sequence is not responsible for the alleviation of mRNA 
expression repression. Similarly, the eI 3’UTR construct did not generate a response 
to 8-pCPT-2’-O-Me-cAMP treatment by greatly increased CAT mRNA levels 
(Figure 3.14 C). Although there did appear to be some variation in the response 
between clones (e.g. clone D1 appears to respond more than clone C6), the response 
was of a similar level to that observed with the unmodified vector.  
 
From the results presented in Figure 3.14 (B and C) it can be concluded that the 
ESAG9-EQ 3’UTR is responsible for alleviation of RNA expression in stumpy 
forms. Also, we can conclude that the sequences responsible for this are present in all 
the ESAG9-EQ 3’UTR constructs analysed. Potentially, therefore, the sequence 
responsible must lie more than 250nt from the stop codon, beyond the region 
analysed in the deletion constructs used here.  
 
3.8 Analysis of additional unmodified vector cell lines 
 
The earlier results indicated that it was important to analyse multiple clones for a 
given construct to avoid individual cell artefacts. However, in all the earlier 
experiments it was the same unmodified vector clone that all experimental 3’UTR 
constructs were compared to. Therefore, further cell lines were generated to confirm 
the earlier analyses. Hence, linearised unmodified vector plasmid was re-transfected 
as described before (Section 3.6) to obtain four additional, independently derived 
clones (biological replicates), which were analysed alongside the original clone, 
meaning that in total five unmodified vector clones were analysed.  
 
3.8.1 Analysis of additional unmodified vector clones in slender monomorphic 
bloodstream form cells 
CAT mRNA and CAT protein expression was assessed in the slender monomorphic 
bloodstream form cells of the additional unmodified vector clones. The CAT protein 
expression results are presented as the percentage expression obtained for the 
original clone in Figure 3.15 (A). The data shown is the mean of two experimental 
replicates for each clone. Three out of the four additional clones, clones D2, D6 and 
133 
C5, show a similar level of CAT protein expression to the original clone (99%, 






Figure 3.15 Analysis of additional unmodified vector clones using a CAT reporter 
gene assay. A. CAT protein expression from the additional unmodified vector clones 
(clones D2, D6, C1 and C5) shown as a percentage of expression from the original 
unmodified vector clone (control). The mean ± standard error of two experimental 
replicates is shown on the graph. B. Northern blot analysis of the same clones as in 
A. using a digoxygenin-labelled RNA probe against the CAT coding region. The 
lower panel shows the ethidium bromide-staining of the rRNA present in each 





This, however, is probably not too dissimilar to the variability seen within different 
clones of the same construct for other constructs. It is also apparent here that clone 
C1 gave an aberrant expression profile, similar to eΔ clone C2 and the 350nt original 
clone. The expression level for this clone was 248% of the expression seen with the 
original clone. 
 
Analysis of the reporter gene mRNA levels revealed similar levels to that of the 
protein. The northern blot analysis for these clones is shown in Figure 3.15 (B). As 
can be seen, clones D2, D6 and C5, show a similar level of CAT mRNA expression 
to the original clone (90%, 88%, and 141% of the expression of the unmodified 
vector, respectively). In contrast, clone C1 exhibited a much greater level of CAT 
mRNA (230% of the expression of the unmodified vector), similar to the CAT 
protein expression level for this clone.  
 
From the data presented in Figure 3.15, it appeared as if the CAT reporter gene 
expression levels obtained from the original clone of the unmodified vector were 
consistent with other clones (D2, D6 and C5). Therefore, although the clones of the 
other constructs were only compared to this one clone, it seems as if this was an 
adequate control.  
 
3.8.2 Analysis of additional unmodified vector clones in ‘stumpy-like’ form cells 
It was also important to verify the response of the control construct when treated 
with 8-pCPT-2’-O-Me-cAMP. Therefore, the additional clones of the unmodified 
vector were tested in this assay alongside the original clone, with clone C1 being 
excluded. The assay was performed as described in Section 3.7 and the results are 
shown in Figure 3.16. 
 
The change in CAT protein levels detected in samples from cells treated with 10 µM 
8-pCPT-2’-O-Me-cAMP is shown in Figure 3.16 (A). As the data is presented 
separately for each clone, the data shown is the mean ± standard error of the 
experimental replicates (n = 2, except for the original clone where n = 4). 
Unfortunately, there was some variability in the results obtained from the original 
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clone in two of the CAT ELISA assays performed, resulting in a larger standard error 
than for the other clones. Nonetheless, the results demonstrated that between the 
different clones there was a similar level of change in CAT protein expression upon 
treatment in the original, D2, D6 and C5 clones (1.3, 1.2, 1.5, 1.3 fold changes, 
respectively). 
 
          
     
Figure 3.16 Response of CAT reporter gene expression to 8-pCPT-2’-O-Me-cAMP 
treatment in the unmodified vector clones. A. Fold change in CAT protein expression 
levels between cells treated 10 µM 8-pCPT-2’-O-Me-cAMP and control cells for 
each of the unmodified vector clones (the original clone and clones D2, D6 and C2). 
Shown is the mean ± standard error of experimental replicates; n = 2, except original 
clone n = 4. B. Northern blot analysis using a digoxygenin-labelled RNA probe 
against the CAT coding region with RNA samples from each clone shown in A. 




cells (- drug). The lower panel shows the ethidium bromide-staining of the rRNA 
present in each sample analysed to indicate the loading of each lane. 
 
CAT mRNA expression levels in each of the clones with and without 10 µM 8-
pCPT-2’-O-Me-cAMP is shown in Figure 3.16 (B). There was a slight increase in 
CAT mRNA expression in cells treated with the compound, similar to that seen for 
the CAT protein levels in Figure 3.16 (A). However, this appeared to be similar for 
all the clones. It was also similar to that seen with the original clone in Figure 3.14 
(C).  
 
Therefore, from the data presented in Figure 3.16 it appears to be acceptable that 
only one clone, the original clone, was used as a control in the 8-pCPT-2’-O-Me-
cAMP treatment experiments described in Section 3.7, because similar results were 
obtained for several additional unmodified vector clones. 
 
3.9 Is the ESAG9-EQ 3’UTR responsible for gene expression control in stumpy 
forms? 
 
The data obtained from the 8-pCPT-2’-O-Me-cAMP treatment experiments 
described in Section 3.7 suggested that the ESAG9-EQ 3’UTR was important for the 
control of gene expression upon development to ‘stumpy-like’ forms, and in 
particular that the element sequence identified was responsible for this response. 
However, this work was performed with monomorphic bloodstream form cells and 
so unable to differentiate to true stumpy forms. Consequently, it remained important 
to assess CAT gene expression from the same constructs in true slender and stumpy 
form cells to determine whether the regulatory element is also responsible for the 
control of gene expression in these life-cycle stages. Therefore, to further investigate 
this, four of the constructs were selected for transfection into pleomorphic 
trypanosomes (the AnTat 1.1 90:13 strain; see Section 2.2.4). These being the full-
length ESAG9-EQ 3’UTR, element deletion (eΔ), and element insertion (eI) 
constructs, with two independently derived cell lines being obtained for each 
construct. Additionally, two independently derived cell lines of the unmodified 
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vector were used as a control (these two cell lines were generated by Dr. Paula 
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Figure 3.17 Analysis of the ESAG9-EQ 3’UTR and associated element in true 
slender and stumpy forms using a CAT reporter gene assay. A. CAT protein 
expression from the constructs in slender form (grey bars) and stumpy form (white 
bars) cells, shown as a percentage of expression from cell lines of the unmodified 
vector slender form cells. The data shown is the mean ± standard error of two 
biological replicates (cell lines) for each construct. Therefore, because n = 2 for each, 
the standard error bars represent the data range. To the left of the graph are schematic 
representations of the sequence analysed in each construct, with the polyadenylation 
site location indicated with ‘A’ and regulatory element location indicated by the red 




CAT coding region of RNA samples from one cell line of each of the unmodified 
vector, full-length ESAG9-EQ 3’UTR, element deletion (eΔ) and element insertion 
(eI) constructs in slender (SL) and stumpy (ST) forms. Shown in the lower panel is 
the ethidium bromide-staining of the rRNA present to indicate the loading of each 
lane. Shown below are the mRNA quantifications following normalisation to rRNA, 
as a percentage of that obtained for the unmodified vector. 
 
The level of CAT protein expression obtained in true slender and stumpy forms for 
each construct are shown in Figure 3.17 (A). For the unmodified vector, there was no 
difference in the level of CAT protein expression observed upon differentiation to 
the stumpy form. In contrast, there was a very large increase in CAT protein 
expression for the full-length ESAG9-EQ 3’UTR construct in response to 
differentiation to the stumpy form. This was not observed for the element deletion 
construct upon stumpy form differentiation, therefore, demonstrating that it was the 
element sequence that was entirely responsible for the observed response to 
differentiation of the full-length construct. However, this element was not successful 
in functioning out of context in the element insertion construct, because no increase 
in CAT protein expression was found upon stumpy form differentiation in these 
cells.   
 
The CAT mRNA expression levels in slender and stumpy form cells for one of the 
cell lines obtained for each construct are shown in Figure 3.17 (B). For the 
unmodified vector, there was little change in the level of CAT mRNA upon stumpy 
form differentiation, similar to the CAT protein levels obtained for this construct (see 
Figure 3.17 A). Again, in contrast to this, the CAT mRNA level increases upon 
differentiation for the full-length ESAG9-EQ 3’UTR construct. For the element 
deletion construct, the level of CAT mRNA was similar in slender and stumpy forms, 
with both having a high level of expression. Like the full-length ESAG9-EQ 3’UTR, 
the CAT mRNA level increased in stumpy form differentiation with the element 
insertion construct. However, this was not reflected by an increased level of CAT 
protein in stumpy form cells for this construct (see Figure 3.17 A). The possible 
reasons for this inability of the element sequence to function out of context are 
discussed in Section 3.5.2. 
 
139 
Also observable in Figure 3.14 (B) are differences in the abundance of CAT mRNA 
processing intermediates. The greatest molecular weight band appears to be more 
abundant in slender forms than in stumpy forms, except for the full-length 3’UTR 
construct, where the higher molecular weight band is not visible. The reasons for 
these observations are not clear, 
The data presented in Figure 3.17 confirm that the full-length ESAG9-EQ 3’UTR is 
important for the control of gene expression upon development to the stumpy form, 
and that the identified element sequence was responsible for this response. 
Comparison of the CAT mRNA levels in slender forms for the full-length and eI 
constructs with the eΔ construct revealed that the presence of the element sequence 
appeared to result in the destabilisation of the CAT mRNA in slender forms (Figure 
3.17 B). However, comparison of the CAT protein expression levels for the full-
length construct with the eΔ construct demonstrated that the presence of the element 
sequence was required for increased translation in stumpy forms. Therefore, in 
slender forms the identified element sequence appeared to destabilise the mRNA, 
repressing gene expression, and in stumpy forms this sequence increased translation, 
thereby releasing the repression on gene expression. 
 
3.10 Is the ESAG9-EQ 3'UTR element found in other ESAG9 3'UTRs? 
 
Because all ESAG9 genes investigated have demonstrated the same stumpy form 
transcript enrichment (Barnwell et al., 2010), the conservation/presence of a similar 
predicted structure to the element identified here for ESAG9-EQ, in the 3’UTRs of 










Tb11.1000            AACTCATTGCTTGCGGATTCGTACATGAGTGTACAAATACTC-AGTAAATCGGGCGTTGT 59 
Tb927.1.5080         AACCCGTTGCT-ACAAGTCCGTGCATAAGTGTGCAAATGCCC-AGTAAGGCGGGCGATGC 58 
Tb09.v1.0330         AACTCATTGCC-CCATATCCGTGAAAAAGTGTGCAAGCTTTC-AGTGAAATTGGTAATAC 58 
Tb927.5.4620         AAATCATTACC-GCAATTCCATGGAATACTGTGAAAACGTCT-ATTGAGATTAACACCGC 58 
Tb427.BES122.10      AAATCATTACC-GCAATTCCATGGAATACTGTGAAAACGTCT-ATTGAGGTGAACACCGC 58 
Tb09.160.5400        TGTCTGTTGCT-TTACGCTGATGCATCAG-GTCACAACTGCTGAATAAAGTGAACGCCGC 58 
Tb927.1.5220         AAATCATTACT-TCAAATCTGTGAACGGGGATGCACACACCT-AATAAGGGCGGGGATGC 58 
Tb927.7.170          AGGCTATCACC-GCGGATCCATGCGTCGGCATGTGAATGTCT-AATAATGCTACCGATGT 58 
Tb09.160.5430        CACCAGTTTCT-GCAAACCCATATATGCACTTAAAATCGTTT-AACTGAGCAACAAGCGT 58 
Tb927.5.120          GACCG-----T-GCATAAC----TACGCAACTA------TCT-AATGAGATCAGAAAAGT 43 
                                                    *           *                 
 
Tb11.1000            ATAACACAAGAG--CTACCGCGGA-AGTCGGTAGCTAAATCATAACCACTTTTACGAAAG 116 
Tb927.1.5080         GTGACACAGGGG--CTGG-ACGGAGAGTCAGTAACTAAATCACAGCTTCGTTTACGAGAG 115 
Tb09.v1.0330         ATAACACAAGGG--ACAG-ATTGAGAATCAGTGGCCAAATGGCAACTTCTTTTACAAGAG 115 
Tb927.5.4620         ATGATGAGGAG---GAAGAGTTGAAAGTTGGAAACTAGCTTGCAACTGCTTTCAATGAAG 115 
Tb427.BES122.10      ATGATGCGGAG---GAAGAGTTGAAAGTTGGAAGCTATCTTGCAACTACTTTCACTAGGG 115 
Tb09.160.5400        ATAGGTCGAAG---TAAG-GCTGTGAATCAGTAACTAACTTGCAAGTGTTTTCATTAAGG 114 
Tb927.1.5220         ACAATGTGCATACTTCAGCGC-GAGAATCAGTAACTATTCTACAGCTTCGTTCACGGGAT 117 
Tb927.7.170          GTAACGCATGGG--TCAGAATGGA-AATTGGTACCTAACTCGAAACTTTCTTTACAAGAA 115 
Tb09.160.5430        CAAGTACAAAGA---CTG-GTGAAAAATACGTAACTACCTTGCAGCAGTTATTACAAAAG 114 
Tb927.5.120          ATGACACGGGTT---CGA-ATGGGAAACA-GTAACCAATTAACAACTTCTTTTACGAGAA 98 
                                              *    *   * *      *       * *       
 
Tb11.1000            -AA-TCACTTGTGAGGCATCACA---ACGGCATAATATTT-AAGGGACGACGTTGGAAGA 170 
Tb927.1.5080         -AA-ACACGTGTGAAGCGTGATA---ACGACATAATTTTTGAAAGGACAGTGTGACAACA 170 
Tb09.v1.0330         -AC-ACACTTCCGGAACGTTGCA---ACCACATACTATTTAAAATGGCGTTGCTGCAAAA 170 
Tb927.5.4620         -ATCATGTGGATGGAACGTTGTGG-AGAGACAAGAT-------AAGAGGAT-------CG 159 
Tb427.BES122.10      -ATCATGTGGATGGAACGTTGTGG-CGAGACATGCT-------AAGAGGAT-------CG 159 
Tb09.160.5400        -GATATGTGCATGGGCTGTTGTGG-CAAGTCATTGT-------AAGATGGT-------CG 158 
Tb927.1.5220         -AA-ACACTTATGGAACGTAGTA---AAGACATAATTTCCAGAAGGACGATGTTGCAACG 172 
Tb927.7.170          -AA-GCAGATGTGGAGCTACACA---ACATCATAATATTTTAGAGGATGATGCTGCAAGA 170 
Tb09.160.5430        -GGCTTGTTTAAGAAGTTCTAT---AGCGGCATT--------GAATGCGAT--------- 153 
Tb927.5.120          CAAAATTTTTGTGGTGTTTTAACGAAATAACACTTTAAAGGGGAATGCTATA-----ACA 153 
                                 *                 **                             
 
Tb11.1000            AGGTAGTATAATTCCGATGAAATCA-TAAGTAAGATGGAATGGTGAAGTGAATGATTTTC 229 
Tb927.1.5080         GGCGTGAATAACCCTAATGTAATCA-TGAGTAACGTGCAAGAGTGGAGTGAATGTCCTGA 229 
Tb09.v1.0330         GGTGTGGATAGCATCAACATATTTA-TCGGTAATGTGCAAAACTAAGGAGAATAGT-TGG 228 
Tb927.5.4620         A------ATAACACTAATGTAATCA-TAAGTAGCGTACATGAGTAAAACCAGTAACTGGA 212 
Tb427.BES122.10      A------ATAGCTCCAATGTAATCA-TAAGTAGAGTACATGAGTAAAACCAGTAACTGGA 212 
Tb09.160.5400        A------ATAACTCTGA---ATTAG-TAAG-AGCGAACATGC-TAAAATTAAAAGTCGCA 206 
Tb927.1.5220         AGTGTAGATAGCTCCAGCATAATCA-TAAGGAAAATGAAAAAGTAGAGCGAACGATTTTT 231 
Tb927.7.170          TGGGATGATAACCATAAT------A-TGAGTAGCATTCAAAGGCAAAGTTAATGATTTTA 223 
Tb09.160.5430        -GGATGAATAACTTTAATATAAAAAATAATTAACATACATTGGTAATTCGAATAATTGTA 212 
Tb927.5.120          GGGATGAACGACTCTGCCCTAATCA-TGAGTAAAATGAAAAGGTAAAACGAAAAGACAGA 212 
                            *                  *    *      *           *          
 
Tb11.1000            AAGTATGAAAAATAAAAAAAA-----TATTTTTA--------AAGT----CATAAT---- 268 
Tb927.1.5080         AAGGGAGGGAACCAAGTTAAAGTTCGTAATCTCATACAGCGAAAATG--ACACAATCGCA 287 
Tb09.v1.0330         AATGGAAAAAATCAAGTTAAA------ATTCTCGAGTGTATAAGGT-----AAAATGCAC 277 
Tb927.5.4620         ATGGAGGAAAAGCAGAATAAA------GTTGTT---AGCGCAAGAAGC-AAAAAATGTT- 261 
Tb427.BES122.10      ATGGAGGAAAAGCAGAATAAA------GTTAGG---CCCGCAAGGGG----AAAACGTC- 258 
Tb09.160.5400        AGAGAGGAAAAG-AAATTAAG------GCTATTTATCGTGTAAGCGG---AAAAGTACA- 255 
Tb927.1.5220         GTGGAAGAAGA-TAGGTTAAT------GGCTTCCAGACCAGAAGGGG----AAAGC---- 276 
Tb927.7.170          GGGGGTAAAGAATAAATAAAT------GATTTTAGGCATGTAAAGCA---TAGGGCGCC- 273 
Tb09.160.5430        AGACAGGAACTGTAACTCAAT------ATTTTAAAGCGTATAAAATGGCCCAAAATAGC- 265 
Tb927.5.120          AGGGAGGGAACGTAACTTAAA------GGTTTTGAGTGCGTAAAG--------AATACC- 257 
                                  *    **                      *                  
 
Tb11.1000            --AAAGTAAACA---GTTCGCAAGCTCAATA--AAA-TGATCATGGATAAGAAAGAGCTT 320 
Tb927.1.5080         AGGGAATAAGCA---GTAGACGGGTTCGATT--AAACTAATC--GGGTAAAA-----CTC 335 
Tb09.v1.0330         TAATAATAAAAG---GACTATAAATACGATATCAAA--AA----GAGTAAAC--GAACTG 326 
Tb927.5.4620         -CACATTAAGAA---CGACACGAG-GCAAGGTGAGA--AAC---AGGCGA-C--AACCTT 308 
Tb427.BES122.10      -GACATTGGGAA---ATACACCAATACAAAACT-GA--AGT---CGGCAAGC--GAAGTA 306 
Tb09.160.5400        -ACCATTAAAAA---ATGCAGAAATGTGATACAACA--AAC---GATTTA-C--GATCTC 303 
Tb927.1.5220         --CTATTAAAGGC--AGACAGGGTAACAA-ACGAGA--AAC---AGTTAA----GAGCAT 322 
Tb927.7.170          -ACCACTCAAAG---CACCGCCAGTACGAAATCAGA--AAC----AACAAGC--TAACTC 321 
Tb09.160.5430        -GTTG-TAAAAAAAAAAGCCCCACGACAAAAACAGA--AAC---GGTCAAT---GATCTT 315 
Tb927.5.120          -ATTAATGAGATCACAAGTATCA--AAAAAACCATG--GAC---AGTT--------CCAC 301 




Figure 3.18 continues on the following page 
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Tb11.1000            AACTTTAATGGTATTAAGGAAGCGGTGATTTATGGAGTT-----TTTAAAAGTGCAG-TG 374 
Tb927.1.5080         AGGTTCAATACTATTGGGAAGTTTGTGGTTGATGAACTT-----TTCAAAAGTGTAA-TG 389 
Tb09.v1.0330         AAA---AATGTTACTGCAAA---TGAGGTAAGAAAATTTAA--CTTCATTGGTATTA-AG 377 
Tb927.5.4620         AAC---AATATTATTATTAA---TTAAACAAGGAAATTTAA--CTTCAAAAGTATTA-AG 359 
Tb427.BES122.10      AAA---AATGCGGTCATGAA---CGCAACCGAGCAACTTAC--TTTCAAGAGTATTG-TG 357 
Tb09.160.5400        AAA---TAATTGATTTTAAA---TAGGAAAAGGAAATATGA--GGTTAATACTATCA-AA 354 
Tb927.1.5220         CAC---AAC---ATCTTTGA---TGAGGCAGGGAAAATAAA--ATTCGATTGTGTTG-AA 370 
Tb927.7.170          AAGAAAAATGTGATAGTAAA---TGGGTTAAGGAAACCTAA--CTTCAGTGGTACTG-GG 375 
Tb09.160.5430        ACG---AATGTTTTTATTAA----------AATGAACTTAA--CCTTAATGGAACTG-AG 359 
Tb927.5.120          AGG---ACCGTTGATAAGGC----------AAAGAATCTAAAATTTTAACGGTGTTGGAG 348 
                                                        *         *               
 
Tb11.1000            AAAGATGCCGTGTGGCGAAAGTTAGAGCCCT--------------CGAAAAG-TGC--C- 416 
Tb927.1.5080         GACGTTGCTGCATATCAAAAGTTAACCTTAT--------------TGCGAGGATGC--T- 432 
Tb09.v1.0330         AAAG-TAACACAC------AGTTGAATTTTT--------------CAAAAATGTAA--TA 414 
Tb927.5.4620         GACATCGTAGCATTGAA----TTTTTTTTTT--------AG------------------- 388 
Tb427.BES122.10      AAGACAGTAGAATTTAAAATATTTTTTCTTT--------AGT---TAAATGGACAAAGTA 406 
Tb09.160.5400        AA-ACCGCAATGAGGAG-------TTTCTTT--------AA-----AGATGTATAA--TA 391 
Tb927.1.5220         GAGTCCAT----TCCCG-----TTTTTCTTTTGCATTCAAAA---AAAAAACATAA--TA 416 
Tb927.7.170          GAAGGTGTAAC----CGAAGATTTTTTTTTTTA----ATGTA---AGGAAATTTGCTGCA 424 
Tb09.160.5430        AAATCCGCATCACATGAAGTATTC-------------AAAAA--AAAAAGGACCACTTTG 404 
Tb927.5.120          AGATCTTCTTCA-GTGAACTATTTTTTTTTGCGTTCTAAAAATTATAAAGAGCTGCCCCG 407 
                                                                                  
 
Tb11.1000            ----------GAAGGCA-----------------------GTCGTAAAGATGAA---CTT 440 
Tb927.1.5080         ----------GATGGCA-----------------------GTCGTGAGGGCAAG---CTG 456 
Tb09.v1.0330         ----------GAAGTTA-----------------------GT-GTGAGGATTAG---CTT 437 
Tb927.5.4620         ---------------------------------GG--AACGTGATAA------------- 400 
Tb427.BES122.10      ----------AGAACCACGTTGCATGCAGGGGGGA--AACTTGATACCAGAGAG---ACT 451 
Tb09.160.5400        ----------AGAGTCACTGAACACGCAAG---GGTTAACATACTGCAGAGCGG---CTT 435 
Tb927.1.5220         ----------GGAATCGCTTATCACTTGGG---GG---ATACATTATGAAGAGA---GTA 457 
Tb927.7.170          TATCC-----AAAGTCAGCG--------------------CTTTTGCAAAGGGA---GTG 456 
Tb09.160.5430        GTTCCGAATCGGAAAC-CGTCACAGCGAAGAT--GTAAATGGGTTAAGGAGGAGGGTCTT 461 
Tb927.5.120          -TGCCTAGAAGAAGGCACATTTCTAAGAGAGC--GAAAATGGTTTAA--AGCAGGA-CTT 461 
                                                                 *                
 
Tb11.1000            AACGGAATCGTTAATTTAAATTTTGGTGACGAT-ATTAATCGTTTTGTTAACAATACATA 499 
Tb927.1.5080         GATGAAATCGTAAATTTTAATTGTGGGGA------------ATTTAG---AGACCACCT- 500 
Tb09.v1.0330         AATAGCATTGCAAATTTAAATCTTTCTAAAGAA-GCTAACTATCTCTTTAAGCATGTGTG 496 
Tb927.5.4620         ------------------------------------------------------------ 
Tb427.BES122.10      AACGAAATCGTAGCGTCACGTTATGGGGGGGGGCACTGAATACTTTGAC----------- 500 
Tb09.160.5400        AACGGAAACGTAGGCTTGCGCTGCGTGGAAGAG-AGTGATTGTTTCAGCAGTCAAATGTG 494 
Tb927.1.5220         AATGTAGGTTACGAAGAATACTATGGAGATCACAAGCTAATAT----------------- 500 
Tb927.7.170          AGGATAGTCGTAAAGGTAAGCTTAACGGG-----ATCGTAAATTTAAAT----------- 500 
Tb09.160.5430        AGTGAAATTTTAAATTTAAATTGTGGGGAAGAA-ACTGAG-------------------- 500 
Tb927.5.120          ATTTAGATCATTAACTTAAA---TGAGGAAAAC-GCAGACGAT----------------- 500 
                                                                                  
 
Tb11.1000            A----- 500 
Tb927.1.5080         ------ 
Tb09.v1.0330         AAAT-- 500 
Tb927.5.4620         ------ 
Tb427.BES122.10      ------ 
Tb09.160.5400        AGATTA 500 
Tb927.1.5220         ------ 
Tb927.7.170          ------ 
Tb09.160.5430        ------ 
Tb927.5.120          ------ 
 
Figure 3.18 ClustalW2 alignment of sequences downstream of ESAG9 genes. For 
each ESAG9 gene, except Tb927.5.4620 (ESAG9-EQ) where 400nt was used, 500nt 
of sequence downstream of the coding region stop codon was aligned using the 
ClustalW2 Multiple Sequence Alignment tool 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) for DNA sequences and using the 
default parameters. Asterisks indicate positions of a single, fully conserved residue; 
pink highlight: mapped polyadenylation site (see Section 3.3.1); grey highlight: 
nearest adenosine nucleotide to mapped polyadenylation site for ESAG9-EQ in the 
alignment; the ESAG9-EQ element sequence is underlined; blue font: residues 
marked with asterisks in Figure 3.19.  
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Table 3.1 ClustalW2 scores from the alignment of sequences downstream of ESAG9 
genes shown in Figure 3.18. 
 
3.10.1 Sequence similarity for sequences downstream of ESAG9 genes 
Firstly, to discover how similar the downstream sequence of each identified ESAG9 
gene might be, these sequences were aligned to find regions of sequence 
conservation. Two genes that are annotated as ESAG9 pseudogenes (Tb927.3.5790 
and Tb927.5.100) were excluded from this analysis, because being pseudogenes they 
may not be functional and so not subject to the same regulation. In each case, 500nt 
of sequence downstream of the stop codon for the coding region of each ESAG9 
gene was downloaded using the Sequence Retrieval tool in the TriTryp database 
(http://tritrypdb.org/tritrypdb/), except for Tb927.5.4620 (ESAG9-EQ), where 400nt 
was used. These sequences were used as input in the ClustalW2 Multiple Sequence 
Alignment tool (http://www.ebi.ac.uk/Tools/msa/clustalw2/; see Section 2.1.1). The 
































































Tb11.1000 61 63 53 59 59 56 53 54 56
Tb927.7.170 58 55 64 56 56 58 56 56
Tb927.1.5080 56 60 60 58 58 53 55
Tb09.160.5430 61 53 46 60 56 54
Tb927.5.4620 62 60 54 66 80
Tb09.v1.0330 56 54 54 57





As can be seen in Figure 3.18 the sequences show a limited degree of similarity, 
there being few residues that were fully conserved between the downstream 
sequences (marked with asterisks in Figure 3.18), although some degree of sequence 
similarity can be observed between the sequences in the alignment. The most similar 
sequences to each other were ESAG9-EQ and Tb427.BES122.10, which had a score 
of 80 (see Table 3.1). The sequences least similar to each other were Tb09.160.5430 
and Tb927.1.5220, with a score of 46 (Table 3.1). The sequence of the ESAG9-EQ 
element is shown underlined in Figure 3.18. The residues of this sequence did appear 
to show some conservation again, but it was not highly conserved or more conserved 
than other regions of sequence within the downstream sequences. It was however 
well conserved in Tb427.BES122.10, which is not surprising as ESAG9-EQ and 
Tb427.BES122.10 were the sequences most similar to each other, and also 
Tb09.160.5400. 
 
3.10.2 Investigation of predicted RNA structure similarity 
Although there was not a high degree of conservation of the sequence of the ESAG9-
EQ element, it was possible that this region of each 3’UTR may still be able to form 
a similar structure. Therefore, the presence of a similar structure to that in the 
ESAG9-EQ 3’UTR was investigated in each ESAG9 downstream sequence using 
Sfold. Because the downstream sequences used above were relatively long, the PAS 
location was probably within each 500nt sequence. However, because the presence 
of extra sequence that is not part of the actual 3’UTR could affect the RNA structure 
predicted, each of the 500nt downstream sequences were also shortened to an 
adenosine residue that may represent the PAS location (based on its location in the 
ESAG9-EQ 3’UTR), in an attempt to improve accuracy.  
 
In order to achieve this the mapped PAS for ESAG9-EQ was used, which is shown 
in pink highlight on Figure 3.18. For each ESAG9 downstream sequence, the nearest 
adenosine nucleotide in the alignment to the ESAG9-EQ PAS was used to truncate 
the sequence to this residue. The residue chosen for each sequence is shown in 
Figure 3.18 in grey highlight. These truncated sequences were used as input for the 
Sfold programme, Srna, as was used in the Sections above.  
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Each of the centroid structures returned as output for each sequence were analysed 
for any structure that resembled the predicted ESAG9-EQ 3’UTR element structure. 
Three of the ESAG9 gene downstream sequences analysed possessed a structure 
within the predicted secondary structure that had resemblance and also contained 
sequence that aligned with the element by ClustalW2 alignment (see Figure 3.18). 




    
             
 
 
Figure 3.19 Predicted RNA structures of sequences downstream of ESAG9 genes 
bearing resemblance to that of the ESAG9-EQ element.  Section of secondary RNA 
structure predicted by the Sfold programme, Srna, for Tb427.BES122.10 (A), 
Tb09.v1.0330 (B), and Tb927.1.5220 (C). Asterisks indicate residues that aligned 





The most similar structure to that of the ESAG9-EQ element was found in the 
centroid of cluster 1 predicted folding for Tb427.BES.122.10, which is shown in 
Figure 3.19 (A). Comparison to the predicted structure of the element (see Figure 3.7 
E) reveals that the folding is almost identical, the differences being that there is an 
extra base pair (G and C) in between two of the loops in the Tb427.BES.122.10 
structure and also two unpaired nucleotides lower down the stem. Tb427.BES.122.10 
is the ESAG9 gene that had the highest similarity in downstream sequence to 
ESAG9-EQ, and the greatest similarity in the region of the element sequence (see 
Section 3.9.1). The residues that aligned in the region of the element sequence by 
ClustalW2 alignment are indicated in Figure 3.19 by asterisks. As can be seen, for 
the Tb427.BES.122.10 structure, the residues that make up this structure are the 
residues that aligned to the ESAG9-EQ element (Figure 3.19 A). 
 
Tb09.v1.0330 and Tb927.1.5220 also had stem-loop structures that were predicted to 
form with residues that aligned to the ESAG9-EQ element, but were much less 
similar in their predicted folding (Figure 3.19 B and C). For Tb09.v1.0330, the 
structure found was in the centroid of cluster 2 and also the mfold predicted 
structures; for Tb927.1.5220, the structure found was in the centroid of cluster 6 
predicted structure. The aligned residues that are indicated with asterisks in Figure 
3.19 are also indicated in the alignment in Figure 3.18 in blue font. For both, the 
residues that aligned were present at the beginning of the EQ element sequence and 
for Tb927.1.5220 this did not correspond to the start of the predicted structure.  
 
So, while it appears that the predicted structure found in Tb427.BES122.10 sequence 
is very similar to ESAG9-EQ, the structures found in Tb09.v1.0330 and 
Tb927.1.5220 could be only similar by coincidence. This is probably more likely for 
Tb927.1.5220, due to the residues of the alignment corresponding to a different 
region of the predicted structure than the ESAG9-EQ element predicted structure. 
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3.10.3 Other bioinfomatic analyses 
To determine if there was conservation of the element sequence in the rest of the 
sequences outside of the region aligned with the element, the RNA Regulatory 
Sequence Tool (RSAT) DNA-pattern matching tool was used (see Section 2.1.5). 
The sequence of the element was used as the query pattern and the same 500nt of 
sequences downstream of the ESAG9 genes as sequences for analysis (but, again, a 
400nt region was used for ESAG9-EQ). This resulted in only the element sequence 
in the ESAG9-EQ sequence being identified. The analysis was repeated with several 
variations on the query pattern, such as shortening the sequence at both ends and 
allowing purine/pyrimidine residues to be matched in the identification. Some 
searches resulted in identification of part of the region of Tb427.BES122.10 that 
aligned with the element in Figure 3.18 and therefore part of the structure predicted 
in Figure 3.19 (A), with a score of 0.88.  
 
The MEME suite (http://meme.sdsc.edu/meme/intro.html) is a collection of tools that 
can be used for motif-based sequence analysis, of which GLAM2 is one. GLAM2 
(http://meme.sdsc.edu/meme/cgi-bin/glam2.cgi) is a tool that can be used for 
identification of motifs in groups of related DNA sequences, using gapped 
alignments. So this was also used to determine if the element sequence would be 
identified as a conserved motif in the downstream ESAG9 sequences allowing for 
any insertions or deletions that may be present. The same downstream sequences of 
ESAG9 genes, truncated to the possible polyadenylation sites described in Section 
3.9.2, were used as input with the default settings. This resulted in the identification 
of a number of different conserved sequences, one of which consisted of part of the 
element sequence. The output for this sequence is shown in Figure 3.20. However, 
this was not a particularly high scoring motif (score: 197.696; the sixth highest), and 







Figure 3.20 Conservation of part of the element sequence in ESAG9 downstream 
sequences identified using GLAM2. Shown is the motif identified that consists of 
part of the ESAG9-EQ (Tb927.5.4620) element sequence. The upper graph shows 
aligned letters, the height of which refers to the frequency of the residue in that motif 
position in the sequences. Shown below is the motif in each ESAG9 downstream 
sequence, with the start and end nucleotide number, the strand the motif was found 
on, and a marginal score (a greater marginal score indicates better matches to the 
motif). Deletions in the alignments are shown with black dots. The part of the 
element sequence found in the motif is underlined.  
 
The bioinformatic analyses described above indicate that there is some conservation 
of the sequence, and to a lesser extent the predicted structure, of the ESAG9-EQ 
element within downstream sequences for other ESAG9 genes, but that this 
conservation is quite low. However, the lack of conservation of the predicted element 
structure may also be due to inaccurate folding predictions due to the unknown PAS 
locations for the other ESAG9 genes. The low conservation is surprising because the 
ESAG9 family of genes show the same developmental regulation, so it would be 







Previous studies to identify cis-acting sequences important to the control of T. brucei 
gene expression have focussed on the experimentally tractable, proliferative life-
cycle stages; these being the slender bloodstream and procyclic form stages (see 
Section 1.7). Using two genes previously identified as upregulated in stumpy forms, 
aconitase (TbACO; Saas et al., 2000) and ESAG9-EQ (Barnwell et al., 2010), the 
work presented in this chapter aimed to investigate if the 5' or 3'UTR belonging to 
each of these genes was responsible for the control of their expression in stumpy 
forms. 
 
3.11.1 Aconitase 5’ and 3’UTRs 
Regulation of the expression of the TbACO gene is believed to operate at the level of 
translation or post-translation (Saas et al., 2000). This is because the level of TbACO 
mRNA remains relatively constant throughout the lifecycle, however, the TbACO 
protein is enriched in stumpy forms compared to slender forms (Saas et al., 2000). 
Interestingly, in CAT reporter gene assays, the TbACO 3’UTR conferred gene 
repression in slender forms at the protein level, but not at the mRNA level (Figure 
3.3). In contrast, the TbACO 5’UTR only resulted in a small reduction in the level of 
CAT protein (Figure 3.3 B). This, therefore, suggested that the TbACO 3'UTR is 
responsible for the repression of TbACO protein expression in slender forms. 
 
Unfortunately, it was subsequently discovered that the TbACO 3’UTR sequence 
analysed in the CAT reporter assay did not possess either of the PASs identified for 
TbACO, these being located at positions +516 and +843 relative to the TbACO stop 
codon (Siegel et al., 2010). Thus, it is unclear whether the repression of gene 
expression observed for this construct was due to the presence of regulatory signals 
or the absence of a PAS. It would, therefore, be important to examine in the CAT 
reporter assay the TbACO 3'UTR sequence possessing both PASs, i.e. through 
examination of 850nt of downstream sequence.  
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The programme, Sfold, was used to predict the secondary RNA structure for the 5' 
and 3'UTR sequences analysed and there was a structure observed in the prediction 
for the 3’UTR that exhibited some resemblance to an IRE. This is particularly 
interesting because usually an IRE situated in a 3’UTR prevents mRNA degradation, 
and, consequently, promotes translation (reviewed in Volz, 2008). Therefore, if this 
structure were responsible for the repression of gene expression in slender forms, this 
would be unusual. It was not investigated here whether the 3’UTR is responsible for 
the alleviation of gene repression in stumpy forms, but if so, then it is possible that 
this IRE-like structure could be responsible.  
 
Also interestingly, TbACO accounts for the total aconitase activity in T. brucei and 
shows mitochondrial and cytoplasmic localisation (Saas et al., 2000). This contrasts 
with mammalian cells, which possess two aconitase enzymes, one mitochondrial and 
one cytoplasmic, which is also known as IRP1 (reviewed in Volz, 2008),. TbACO 
exhibits a high degree of conservation of the IRP RNA binding sequence, and 
therefore, it is possible that TbACO has a gene regulatory function (Saas et al., 
2000). If the IRE-like structure does contribute to the regulation of TbACO gene 
expression, then this could represent a self-regulatory mechanism. Therefore, if 
further analysis of the TbACO 3'UTR was made using CAT reporter gene assays, the 
IRE-like sequence would be particularly interesting to investigate. 
 
3.11.2 ESAG9-EQ 3’UTR 
The ESAG9 gene family mRNAs are strongly stumpy-enriched (Barnwell et al., 
2010). The 3’UTR of one member of this family, ESAG9-EQ, was investigated for 
its contribution to the control of gene expression using CAT reporter assays. The 
‘full length’ 3’UTR was found to confer reporter gene repression in slender forms at 
the levels of mRNA and protein (Figure 3.6). However, the reporter gene expression 
was not completely repressed in slender forms, as there was some CAT mRNA and 
protein present in these cells (Figure 3.6). Although, the reason for this is not clear, it 
could be that there are additional sequences required for complete repression that 
were not present in the sequence analysed. Alternatively, it could be due to the 
analysis being performed in monomorphic cells, which do not represent true slender 
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forms because of their culture adaptation. However, following transfection into 
pleomorphic cells, analysis of the full-length 3’UTR construct in true slender cells 
also found that there was not complete repression of the reporter gene expression 
(Figure 3.17 A). Although the level of CAT protein expression in slender cells with 
this construct was somewhat reduced compared to slender cells with the unmodified 
vector (Figure 3.17 A). Nonetheless, it does appear that the ESAG9-EQ 3’UTR 
makes a significant contribution to gene repression in slender forms. 
 
Initially, from the 3’UTR deletion series it appeared that the presence of the 
predicted structure of the element sequence (Figure 3.7) was responsible for gene 
silencing, as this correlated with gene repression (Figure 3.6). However, after 
analysing additional clones of the deletion series, it was apparent that the original 
350nt construct clone produced an aberrant result and that this initial conclusion was 
incorrect (Figure 3.13). Nonetheless, from the new data (Figure 3.13 A), it appeared 
that the 33nt element sequence could still be a significant contributor to slender form 
repression, as the sequence is present in the full-length, 350nt, and 300nt constructs 
which show repression and only 15nt of the sequence is present in the 250nt 
construct which shows alleviation of repression. This was supported by the reporter 
gene expression observed for the element deletion (eΔ) construct, which exhibited 
alleviation of gene repression (Figure 3.13). However, a greater alleviation of gene 
repression was obtained with the 250nt construct than the eΔ construct, indicating 
that although the element sequence was a significant contributor to gene repression 
in slender forms, it was not entirely responsible. Additionally, analysis of reporter 
gene expression in true slender and stumpy forms later demonstrated that although 
the element sequence appeared to result in mRNA destabilisation in slender forms, 
deletion of this sequence did not result in increased protein levels (Figure 3.17). 
 
It is possible that, as the structures obtained for the 3’UTR sequences used in the 
constructs are only predictions, the element structure does not actually form in vivo. 
If the two loops that comprise the top of the element structure do not form, they 
would create one larger loop, which was seen in the 350nt Sfold ensemble centroid 
structure for this region. Alternatively, it is possible that the element structure does 
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form in the 350nt 3’UTR sequence because, although it was not predicted in the 
ensemble centroid structure for this sequence, it was predicted to form in one of the 
two Sfold cluster centroid structures (data not shown). Either of these possibilities 
could explain why there was repression of gene expression with the 350nt construct 
when the element structure was not predicted to form. It would therefore be 
interesting to determine the structure of these 3’UTR sequences experimentally by, 
for example, RNase enzymatic digestion, to establish whether it is the element 
sequence or structure that is important for the control of gene expression.  
 
Following chemical induction of development to stumpy-like forms, it appeared that 
the full-length 3’UTR was also responsible for alleviation of repression in these cells 
(Figure 3.14). It also appeared that the presence of the element sequence was 
responsible for this, because the alleviation was observed with the 350nt and 300nt 
constructs which possess this sequence as well, but alleviation was lost with the 
250nt construct, which only possesses 15nt of the element sequence, and with the eΔ 
construct (Figure 3.14). This therefore, also indicates that it is the element sequence 
that is responsible, because the element structure was not predicted to form in the 
350nt sequence (Figure 3.7). However, as noted above, it is possible that this 
structure does not form in vivo in the other sequences, or alternatively, that it may be 
present in the 350nt sequence as well. The element sequence, therefore, represents 
the first identification of an mRNA sequence responsive to a chemical signal 
believed to intersect with the stumpy-induction signalling pathway. Thus, it was 
essential to next determine the importance of this regulatory sequence in true slender 
and stumpy forms, and so, in response to density-dependent development and SIF 
signalling, following pleomorphic transfection of these constructs. 
 
From analysis of reporter gene expression in stumpy-like forms it appeared that 
mRNA control was strongly contributing to increased expression in this development 
(Figure 3.14), in contrast to the results obtained for true slender and stumpy forms 
(discussed below). The reasons for this are unclear but could be attributable to 
differences in the cell types analysed, i.e. stumpy-like vs stumpy forms, given the 
incompleteness of stumpy form differentiation in the stumpy-like cells. Regardless, 
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the true slender and stumpy forms represent the most biologically relevant analysis 
and hence provide the most meaningful results. 
 
Analysis of a selection of the CAT reporter gene constructs in true slender and 
stumpy forms showed that the full-length ESAG9-EQ 3’UTR sequence was 
important for the control of gene expression upon development to the stumpy form, 
and that the element sequence was responsible for this response (Figure 3.17 A). 
Therefore, this element sequence also represents the first identification of an mRNA 
sequence responsive to density-dependent development and SIF signalling. Also 
shown in this analysis in true slender and stumpy forms was that the element 
sequence appeared to result in mRNA destabilisation in slender forms (Figure 3.17 
B), but that the presence of this sequence was required for increased translation in 
stumpy forms (Figure 3.17 A). These data lead to the proposal of the model shown in 
Figure 3.21 to describe the regulation of ESAG9-EQ expression in slender and 
stumpy forms. However, it remains unclear if the element sequence or predicted 




Figure 3.21 Proposed model for the mechanisms of regulation of ESAG9-EQ 
expression in slender and stumpy forms. In slender forms (left hand side), a negative 
regulator binds to the element sequence (depicted by the red bar) in the ESAG9-EQ 
3’UTR and causes mRNA degradation of the transcript, repressing the expression of 
ESAG9-EQ. In stumpy forms (right hand side), a positive regulator binds to the 
element sequence and increases translation of the transcript, resulting in the release 
of gene expression repression in this life-cycle stage. AAAn: poly(A) tail.  
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Nonetheless, whether the element sequence forms the predicted structure or whether 
the two loops comprising the top of the predicted structure do not form, it is possible 
that RNA-binding proteins bind to this sequence. In slender forms, this would result 
in repression of gene expression and in stumpy forms this would promote gene 
expression. Hence, it would be particularly interesting to identify any interacting 
proteins, specifically any that promote gene expression in stumpy forms. In 
particular, because the protein is responsive to SIF signalling in true stumpy forms 
this identification could provide a way to dissect the SIF signalling pathway from 
one of the end-points of the pathway and so from the opposite direction to signal 
transduction.  
 
A number of different approaches could be employed to identify any proteins 
interacting with the element sequence. For example, one approach would be to use a 
method similar to the RaPID (RNA-binding protein purification and identification) 
technique, whereby the bacteriophage MS2 coat protein, fused to green fluorescent 
protein (GFP) and streptavidin-binding protein (SBP), binds to an experimental 
mRNA engineered to contain MS2 loops. Thus, mRNA-protein complex purification 
can be achieved using streptavidin-conjugated beads (Slobodin and Gerst, 2010). 
Subsequently, identification of interacting proteins is made using mass-spectrometry. 
A second approach would be to use a yeast three-hybrid (Y3H) system, which 
identifies RNA-protein interactions via binding of an RNA to two hybrid proteins 
resulting in activation of reporter gene transcription (SenGupta et al., 1996). 
Additionally, another approach would be to use a recently described method 
consisting of attaching the experimental RNA sequence to a tRNA scaffold fused to 
a Streptavidin aptamer, and identifying bound proteins by mass spectrometry (Iioka 
et al., 2011).  
 
It was also investigated if the element sequence and predicted structure was found in 
other ESAG9 3’UTRs. The predicted structure was not detected by the methodology 
employed, except for in the 3’UTR of a very closely related ESAG9, 
Tb427.BES122.10 (Figure 3.19). However, the element sequence was more highly 
conserved among the ESAG9 3’UTRs (Figure 3.18) than the predicted element 
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structure. This could be important if the predicted element structure does not fold as 
































Investigation of upstream open reading frames and 




















In many eukaryotes, upstream open reading frames (uORFs) are used as a 
mechanism to regulate gene expression. For certain transcripts, such as GCN4 in 
Saccharomyces cerevisiae, uORFs can be used to escape the global translational 
repression imposed by phosphorylation of eIF2α (reviewed in (Hinnebusch, 1997). 
An uORF is a short ORF upstream from the main ORF, which can regulate 
translation of the main ORF either by causing translational repression through 
ribosome stalling or by enhancing translation through promoting ribosome 
reinitiation on the main ORF start codon. Additionally, uORFs have been found to 
cause destabilisation of the mRNA by ribosome termination (reviewed in (Vilela and 
McCarthy, 2003). Regulation of gene expression by an uORF has been demonstrated 
in another protozoan parasite, Plasmodium falciparum. The gene encoding one 
variant of the variant surface antigen, VAR2CSA, which is implicated in placental 
malaria, has a small uORF that represses its translation (Amulic et al., 2009).  
 
The aim of this part of the project was to assess if uORFs are used by T. brucei as a 
mechanism for controlling the expression of cohorts of co-regulated genes in stumpy 
forms. Namely, are uORFs used either as a mechanism for the escape from 
translational repression of stumpy form enriched genes, or as a mechanism of 
translational repression for repressed genes in stumpy forms. 
 
4.1 Genome-wide bioinformatic prediction of upstream open reading frames in 
T. brucei 
 
To investigate if uORFs are used as a mechanism to control the expression of 
stumpy-enriched transcripts, the presence of potential uORFs was first assessed 
globally in T. brucei genes by a bioinformatic genome-wide screen. This screen was 
used to predict the abundance of uORFs in sequences upstream of every annotated 
gene in T. brucei. The dataset generated from this analysis could then be used in 
cross-reference to genes identified as stumpy-enriched to identify if there was an 
overrepresentation of genes with potential uORFs expressed in stumpy forms. If so, 




The bioinformatic uORF genome-wide screen firstly involved retrieval of DNA 
sequence upstream of each annotated gene in the T. b. brucei TREU 927 genome 
(http://www.genedb.org/Homepage/Tbruceibrucei927), using the Sequence Retrieval 
tool (now available through http://tritrypdb.org/tritrypdb/). Then, the amino acid 
sequence was deduced for each sequence by translation of each of the three forward 
reading frames using an online tool available at 
http://searchlauncher.bcm.tmc.edu/seq-util/Options/sixframe.html. A Perl script 
(written and executed by Pankaj Barua, University of Edinburgh) was then used with 
the deduced amino acid sequences to identify all incidences of a methionine followed 
by a stop codon with 2 or more amino acids in between, for each amino acid 
sequence. These identified sequences may therefore represent an uORF.  
 
 
Table 4.1. Percentage of genes found to possess potential uORFs in the genome-
wide and other dataset analyses by bioinformatic prediction. 
a The prediction was for 100nt of upstream sequence for each gene and then further 
analysed for whether the identified potential uORF(s) location was within the 
upstream sequence up to the predicted splice site (Benz et al., 2005) for each gene 
(predicted 5’UTR) 
b nd: not determined; numbers in parentheses refer to the number of genes identified 
to possess a potential uORF(s) in the total number of genes in the dataset analysed  
c T. brucei, strain TREU 927 genome (downloaded from www.genedb.org; Berriman 
et al., 2005)  
d Kabani et al. (2009), Additional file 5 (genes exhibiting a -1,-1,-1,-1,-1 trinary code 
profile: genes elevated in stumpy-forms versus all other samples) 
e Kramer et al. (2008), characterised genes in Table S1 
 
 
Initially, 200nt of upstream sequence for each gene was used for uORF 
identification. However, 62.3% of genes were found to possess uORF sequence(s) by 
this analysis. As this number is relatively large it was believed that this was probably 
Dataset Criteria Percentage
T. brucei TREU 927 genome 100nt upstream sequence 25.38
within predicted 5'UTR nd
Stumpy-form upregulated genes 100nt upstream sequence 30 (12/40)
within predicted 5'UTR 20 (8/40)
Heat-shock regulated genes 100nt upstream sequence 19.67 (12/61)
within predicted 5'UTR 11.48 (7/61)
 










due to the result of false uORF assignments because the sequence length used was 
too long. Therefore, 100nt of upstream sequence for each gene was used instead. 
This should result in a more accurate prediction of uORF abundance, because this 
value is closer to the median length of T. brucei 5’UTRs, which was predicted to be 
68nt (Benz et al., 2005). 
 
Using this approach, 25.38% of T. brucei genes were found to possess uORF 
sequence(s) (Table 4.1). The maximum number of uORFs found for one gene was 
six, which was only the case for one gene, Tb09.244.0340. The number of uORFs for 
each gene ranged from 1 to 4, with a median number of 1 and mean number of 1.2. 
 
Interestingly, it was also noted that a low frequency of small sets of genes possessed 
predicted uORF(s) of identical amino acid sequence. In most of these sets the genes 
had the same gene product annotations and often were present on the same 
chromosome as each other. Thus, it appeared that these genes were probably the 
result of gene duplications where upstream sequence was also involved in the 
duplication event. This could mean that the predicted uORF is functional and 
important for control of gene expression so that the uORF sequence is conserved, or 
it may have no significance. However, further analysis of the upstream sequences for 
some of these sets of genes revealed that the whole 100nt upstream sequence was 
very well conserved between genes, suggesting that the uORFs within them were 
probably unimportant. 
 
4.1.1 GO term enrichment 
Next, an investigation was made to determine if there was any enrichment in 
different groups of genes in the dataset of predicted uORF-associated sequences. For 
this the Gene Ontology (GO) term annotations associated with each gene were 
analysed. GO terms are used to classify genes by their molecular function, 
involvement in a biological process, or cellular localisation. Therefore, a comparison 
of these associated annotations between the dataset of genes predicted to possess an 
uORF and the dataset of genes that are predicted to not, should reveal any 
enrichment in different classes of genes. 
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For each set of genes, the associated GO terms for each gene were obtained from the 
SQL environment of the Gene Ontology database 
(http://www.berkeleybop.org/goose) using the SQL query provided in Appendix 2. 
The frequency of each GO term was then compared between the results for the two 
datasets. Shown in Table 4.2 are the GO terms with a fold enrichment of 2 or greater 
in the dataset of genes predicted to possess an uORF. 
 
 
Table 4.2 Gene Ontology (GO) annotations enriched by greater than 2-fold in genes 
predicted to possess potential uORF(s) compared to genes not predicted to possess 
potential uORF(s). 
a Numbers in parentheses are the frequency of the GO term in the genes predicted to 
possess potential uORF(s) dataset because the frequency of the GO term in the genes 
not predicted to possess potential uORF(s) dataset was zero. 
 
 
GO ID GO description Fold enrichment
GO:0007009 plasma membrane organization (6)
GO:0005885 Arp2/3 protein complex 5
GO:0008194 UDP-glycosyltransferase activity 4.4
GO:0000315 organellar large ribosomal subunit (4)
GO:0006686 sphingomyelin biosynthetic process (4)
GO:0047493 ceramide cholinephosphotransferase activity (4)
GO:0004519 endonuclease activity 3
GO:0004185 serine-type carboxypeptidase activity (3)
GO:0019889 pteridine metabolic process (3)
GO:0006506 GPI anchor biosynthetic process 2.3
GO:0030629 U6 snRNA 3'-end binding 2
GO:0004497 monooxygenase activity 2
GO:0005507 copper ion binding 2
GO:0006725 cellular aromatic compound metabolic process 2
GO:0006816 calcium ion transport 2
GO:0006952 defense response 2
GO:0008094 DNA-dependent ATPase activity 2
GO:0015630 microtubule cytoskeleton 2
GO:0016462 pyrophosphatase activity 2
GO:0000113 nucleotide-excision repair factor 4 complex (2)
GO:0004998 transferrin receptor activity (2)
GO:0006259 DNA metabolic process (2)
GO:0008324 cation transmembrane transporter activity (2)
GO:0009103 lipopolysaccharide biosynthetic process (2)
GO:0030036 actin cytoskeleton organization (2)
   
 
  a 
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As can be seen, a number of different GO terms were found to be enriched in the 
dataset of genes predicted to possess an uORF. These appear to be largely unrelated 
and involve many different cellular processes. For example, there are terms 
associated with the plasma membrane, metabolic processes, DNA-related activities, 
the cytoskeleton, and possible cell signalling activities (for example, 
‘pyrophosphatase activity’). These enriched terms therefore, appear to be general and 
unspecific, indicating that the genes possessing an uORF sequence are probably not 
enriched for any specific functional groups. 
 
4.2 Is there an enrichment of potential uORFs in genes enriched in stumpy 
forms? 
 
To investigate if there was an enrichment of genes with predicted uORFs in stumpy-
enriched transcripts, a subset of genes identified as upregulated in stumpy forms by 
microarray analysis (Kabani et al., 2009) was investigated. This set of genes was 
found to be elevated in stumpy forms compared to all other samples investigated in 
that study (Additional file 5, genes exhibiting -1, -1, -1, -1, -1 trinary code; Kabani et 
al., 2009). This subset of genes was found to have an incidence of genes with 
predicted uORFs of 30% (12/40 genes), versus the overall genome frequency of 
25.38%. Therefore, this set of stumpy form upregulated genes showed a small 
enrichment in potential uORFs.  
 
Further analysis was made of the 12 stumpy form upregulated genes with predicted 
uORFs to determine whether the predicted uORF was likely to be within the 5’UTR 
of the gene. This further analysis was not performed on all genes with predicted 
uORFs found in the genome-wide study due to the large size of that dataset. To 
determine whether each predicted uORF was likely to be within the 5’UTR, the 
predicted 5’ splice sites predicted from a study by Benz et al. (2005) were used. That 
study used data obtained from known T. brucei 5’ splice sites to predict the splice 
site for each annotated gene in the T. brucei genome (Benz et al., 2005). To ascertain 
whether the uORF was within the predicted 5’UTR, each gene was viewed using 
Artemis software together with predicted 5’ splice sites and uORF sequences.  
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This resulted in the discovery that the predicted uORFs were not within the predicted 
5’UTR for 4 of these genes, leading to a decrease in the percentage of genes with 
predicted uORFs in this gene set to 20% (8/40 genes; Table 4.1). Therefore, the 
potential enrichment of genes with predicted uORFs in stumpy form upregulated 
genes compared to the genome-wide analysis appears to not be a true enrichment. 
However, this analysis of uORF location was not performed on the genome-wide 
analysis dataset, so it is unknown whether that percentage would also decrease 
through a similar analysis and how greatly. Of the 8 genes with predicted uORFs 
within the predicted 5’UTR, 4 are annotated as ‘hypothetical protein, unlikely’, 2 as 
‘hypothetical protein, conserved’, 1 as ‘varient surface glycoprotein (VSG)-related, 
putative’, and 1 as ‘ATP-dependent DEAD/H RNA helicase, putative’ (Table 4.3).  
 
 
Table 4.3 Genes identified as upregulated in stumpy forms or regulated during heat 
shock that have predicted uORFs within the predicted 5’UTR. 
 
a Either from microarray analysis (Kabani et al., 2009) or annotated ESAG9 genes  
b From Kramer et al. (2008; characterised genes in Table S1) 
a 
Gene ID Gene Product No. of uORFs
Upregulated in stumpy-forms
Tb927.1.390 hypothetical protein, unlikely 1
Tb09.160.4070 hypothetical protein, unlikely 1
Tb927.1.4510 hypothetical protein, unlikely 4
Tb09.211.1970 hypothetical protein, unlikely 1
Tb927.3.2540 variant surface glycoprotein (VSG)-related, putative 4
Tb11.47.0019 hypothetical protein, conserved 1
Tb09.211.2300 ATP-dependent DEAD/H RNA helicase, putative 1
Tb10.6k15.0300 hypothetical protein, conserved 3
Tb927.5.120 expression site-associated gene 9 (ESAG9) protein, putative 4
Tb927.7.170 expression site-associated gene 9 (ESAG9) protein, putative 1
Tb927.5.4620 expression site-associated gene 9 (ESAG9) protein, putative 1
Regulated in heat shock
Tb927.4.3110 tRNA-dihydrouridine synthase 4, putative 1
Tb927.3.5150 exonuclease, putative 1
Tb11.01.4750 elongation factor 1 gamma, putative 1
Tb927.4.2310 asparaginyl-tRNA synthetase, putative 1
Tb11.42.0003 t-complex protein 1 subunit beta 1
Tb11.02.1930 ATP-dependent RNA helicase 1
Tb10.70.6180 ATP-dependent DEAD/H RNA helicase 1
  b 
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4.2.1 Predicted uORF incidence in other stumpy-enriched genes 
Additional genes known to be upregulated in stumpy forms were also investigated 
for predicted uORFs and whether these were located within the predicted 5’UTR for 
each gene. One group of genes investigated were the PAD array of genes, which are 
upregulated in stumpy forms. None of the genes of this array were predicted to 
possess uORFs in the genome-wide prediction, and none had an uORF sequence 
within the predicted 5’UTR either. Another group of genes investigated were the 
ESAG9 family of genes, which are also enriched in stumpy forms. Of the 9 ESAG9 
genes analysed, 7 were found to possess a uORF by the genome-wide analysis. 
When investigation was made as to whether these were within the predicted 5’UTR 
however, it was discovered that this was the case for only 3 of the genes 
(Tb927.5.120, Tb927.7.170, and Tb927.5.4620; Table 4.3). Interestingly, 
Tb927.5.4620 is ESAG9-EQ, whose 3’UTR was investigated for contributions to 
gene expression control in this study (see Chapter 3). The analysis of the 5’UTR is 
presented in this chapter due to the presence of an uORF within the predicted 5’UTR 
for this gene.  
 
4.2.2 Investigation of predicted uORF incidence in another set of co-regulated 
genes 
As described above, there was a slight enrichment in the number of genes predicted 
to possess an uORF in the genes upregulated in stumpy forms compared to the 
genome-wide analysis. To further investigate if this represented a true enrichment, 
another set of co-regulated genes was analysed for uORF enrichment in the same 
way. This set of genes was the gene set identified as regulated during heat shock in 
the study by Kramer et al. (2008). The study involved an investigation of the global 
steady state levels of mRNAs following heat shock through microarray analysis, to 
identify transcripts upregulated or downregulated due to this treatment (Kramer et 
al., 2008). The set of genes that were identified (Table S1, Kramer et al., 2008) were 
used for uORF analysis. 
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The percentage of genes predicted to possess an uORF in the genome-wide 
prediction was 19.67% for the heatshock dataset (12 of 61 genes; Table 4.1). When 
the uORF localisation within the predicted 5’UTR was considered, this percentage 
decreased to 11.48%, as the predicted uORFs for 5 of the 12 genes were found not to 
be present within the predicted 5’UTR (Table 4.1). These percentages are lower than 
those obtained for the genome-wide analysis and for the stumpy form upregulated 
gene set. Therefore, there may be an under-representation of uORFs in the genes 
regulated during heat shock. 
 
Consequently, the small enrichment seen with the stumpy form upregulated gene set 
may be a true enrichment, even though this decreased with further analysis of uORF 
location. Additionally, when a set of genes found to be enriched in stumpy forms 
from a preliminary Illumina digital tag RNA sequencing experiment (Keith 
Matthews, unpublished data; the top 100 most highly enriched) was later analysed 
for potential uORF frequency within 100nt of upstream sequence, the incidence was 
found to be 18% of genes. Suggesting that there is not an enrichment of potential 
uORFs in stumpy-enriched genes compared to the genome-wide analysis. 
Nonetheless, following the original bioinformatic predictions, the next step was to 
investigate if the uORFs identified could be functional in stumpy forms and 
therefore, contribute to control of gene expression.  
 
4.3 Do the 5’UTRs of stumpy-enriched genes with potential uORFs control gene 
expression? 
 
The aim of this project part was to assess if uORFs are used by T. brucei as a 
mechanism for controlling gene expression in stumpy forms, either for the escape 
from translational repression of stumpy form enriched genes, or as a mechanism of 
translational repression for genes repressed in stumpy forms. To address this 
question the 5’UTRs of three stumpy-enriched genes which potentially possess an 
uORF were investigated. These were Tb09.211.2300 and Tb11.47.0019, found to be 
upregulated in stumpy forms by microarray analysis (Kabani et al. 2009) and 
ESAG9-EQ, which was found to be highly enriched in stumpy forms (Barnwell et 
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al., 2010), all of which were identified to possess an uORF sequence in their 
predicted 5’UTR (Section 4.2). Tb09.211.2300 was chosen because it is annotated as 
a putative ATP-dependent DEAD/H RNA helicase and so may play a role in gene 
expression control in stumpy forms. Tb11.47.0019 was chosen because although 
annotated as a conserved hypothetical protein, it possesses a predicted ubiquitin 
associated (UBA/TS-N) domain, and so may play a role in protein degradation in 
stumpy forms. Therefore, both looked potentially interesting for further study. 
ESAG9-EQ was chosen to complement the study of the 3’UTR for this gene (see 
Chapter 3). 
 
To assess if each potential uORF was responsible for control of gene expression, first 
the contribution of each 5’UTR to the control of gene expression was analysed. For 
this, the same CAT reporter gene approach was used as was used to assess the 
TbACO 5’UTR (see Section 3.2). Therefore, the same expression vector, CAT449 
(described in Section 3.1), containing the CAT reporter gene was used and the 
aldolase 5’UTR sequence was replaced with each experimental 5’UTR sequence. If 
the experimental 5’UTR was found to repress CAT reporter gene expression, then 
the potential uORF present in the 5’UTR sequence may be responsible for this effect. 
 
4.3.1 Generation of 5’UTR constructs 
To discover the 5’UTR sequences to be used for investigation, the annotated T. 
brucei TREU 927 genome sequence was viewed with Artemis software to identify 
the intergenic region upstream of each gene. For Tb09.211.2300 the nearest upstream 
annotated gene in the genome sequence is Tb09.211.2310. The intergenic region 
between the stop codon of Tb09.211.2310 and the annotated start codon of 
Tb09.211.2300 is 394 bp and is shown in Figure 4.1 (A). The genomic sequence of 
each chromosome can also be viewed with Artemis software together with the 
predicted splice addition sites (SAS) from Benz et al. (2005). For Tb09.211.2300, 
this revealed that the nearest predicted SAS was at position -125 relative to the 
annotated start codon of Tb09.211.2300 (see Figure 4.1 A). As can be seen in Figure 
4.1 (A) the potential uORF is therefore within the predicted 5’UTR sequence. As the 
upstream intergenic region for Tb09.211.2300 is relatively short in length, this entire 
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intergenic sequence was used to generate the ‘Tb09 5’UTR’ construct. To amplify 









  __________________________uORF___________________________ 
atatgtgtttggttggtgtattgtactctttgcataaagtttctattagcttcatgtgagcg 





















         EQ 5’UTR(s) 
TAA…(930bp)…gtttacaatccaacatatatatatataggtcgatcccccttttgtctctt 
             ____uORF____              EQ 5’UTR(e) 
agtggtattttgtatgatttgttagtttacgtcggggggaaaaATG 
 
Figure 4.1 Upstream intergenic regions of Tb09.211.2300, Tb11.47.0019 and 
ESAG9-EQ. A. and B. Upstream intergenic regions for Tb09.211.2300 (A) and 
Tb11.47.0019 (B). Shown are the nucleotide sequences from the stop codon of the 
nearest upstream annotated genes (Tb09.211.2310 and Tb11.47.0020 respectively) to 
the internal start codon (Siegel et al., 2010) of Tb09.211.2300 or Tb11.47.0019. The 
original start codon annotation is also indicated. C. Upstream intergenic region for 
Tb927.5.4620 (ESAG9-EQ). Shown is the genomic sequence from the stop codon of 
the nearest upstream annotated gene, Tb927.5.4610, to the annotated start codon for 
the coding sequence of ESAG9-EQ. Because this intergenic region is 1023 bp in 
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length, only the sequence immediately upstream, which was used to generate the ‘EQ 
5’UTR’ construct (93nt), is shown. All sequences are in the 5’ to 3’ direction and 
from the T. brucei TREU 927 genome sequence. The locations of potential upstream 
open reading frames (uORFs) are indicated with the line above each sequence. 
Lower and upper cases denote the 5’ intergenic region and nucleotide sequence of 
the original start codon annotation, respectively; red highlight: stop codon; red font: 
the original annotated and internal (also underlined) start codons; grey highlight: 
start (s) or end (e) of each sequence used to generate the construct named above that 
residue; ag: predicted SAS (Benz et al., 2005); AG: SASs found by RNA-sequencing 
(Siegel et al., 2010); blue font: 5’UTR identified by RNA-sequencing (Siegel et al., 
2010); bold font: sequence used for the microarray oligonucelotide in the study by 
Kabani et al. (2009). 
 
 
For Tb11.47.0019 the nearest upstream annotated gene in the genome sequence is 
Tb11.47.0020. The intergenic region between the stop codon of Tb11.47.0020 and 
the annotated start codon of Tb11.47.0019 is 113 bp and is shown in Figure 4.1 (B).  
Analysis of the predicted splice addition sites from Benz et al. (2005), as for 
Tb09.211.2300, revealed that the nearest predicted SAS was at position -84 relative 
to the annotated start codon of Tb11.47.0019 (see Figure 4.1 B). Therefore, again the 
potential uORF is within the predicted 5’UTR sequence (see Figure 4.1 B). As the 
upstream intergenic region for Tb11.47.0019 was again short in length, this entire 
intergenic sequence was used to generate the ‘Tb11 5’UTR’ construct. To amplify 
this region by PCR the primers 35 and 36 (see Table 2.1) were used. 
 
For ESAG9-EQ (Tb927.5.4620) the nearest upstream annotated gene in the genome 
sequence is Tb927.5.4610. The intergenic region between the stop codon of 
Tb927.5.4610 and the annotated start codon of ESAG9-EQ is 1023 bp and is shown 
in Figure 4.1 (C).  The nearest predicted splice addition site from Benz et al. (2005) 
was at position -42 relative to the annotated start codon of ESAG9-EQ. Again the 
potential uORF was within the predicted 5’UTR sequence (see Figure 4.1 C). As the 
upstream intergenic region for ESAG9-EQ was relatively long, a shorter region (93 
bp) that included the predicted SAS, its associated polypyrimidine tract, and the 
potential uORF was used to generate the ‘EQ 5’UTR’ construct. To amplify this 
region (the start and end of which is shown on the sequence in Figure 4.1 C in grey 
highlight) by PCR the primers 37 and 38 (see Table 2.1) were used. 
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Replacement of the aldolase 5’UTR in CAT449 used the XhoI and HindIII restriction 
enzyme sites as shown in Figure 3.1 (A). Construct generation was as described in 
Section 3.1. Therefore, as before stable transfectant cell lines were generated using T. 
b. brucei monomorphic bloodstream form strain Lister 427 and selected with 0.5 
µg/ml phleomycin. For each construct, two biological replicates (independently 
derived clones) were examined in CAT ELISA assays, the results being shown in 
Figure 4.2 (A). Three biological replicates for each construct were examined by 
Northern blot analysis and these results shown in Figure 4.2 (B). 
 
4.3.2 Analysis of the 5’UTR constructs with the CAT reporter gene assay 
In comparison to the unmodified vector, all three constructs with the Tb09 5’UTR, 
Tb11 5’UTR, or EQ 5’UTR gave a strong repression of CAT protein expression 
(Figure 4.2 A), where CAT protein was almost undetectable. As a percentage of 
CAT protein expression obtained for the unmodified vector these values were 0.91% 
(±0.39%), 1.3% (±0.77%), and 0.69% (±0.65%), for the Tb09 5’UTR, Tb11 5’UTR, 
and EQ 5’UTR constructs respectively. 
 
Analysis of CAT mRNA levels by northern blot analysis revealed that these 
constructs also resulted in almost undetectable CAT mRNA levels in comparison to 
the unmodified vector (Figure 4.2 B).  Even overnight exposures produced only very 
faint signals. However, for the EQ 5’UTR and Tb11 5’UTR constructs there was a 
strong signal obtained for a higher molecular weight band, that appeared in both 
cases to be a processing intermediate, similar in size to that seen for the unmodified 
vector (Figure 4.2 B). This was unlikely to be due to a shift in CAT mRNA size; the 






Figure 4.2 Analysis of Tb09.211.2300, Tb11.47.0019 and ESAG9-EQ 5’UTRs 
using a CAT reporter gene assay. A. CAT protein expression from the constructs 
indicated as a percentage of expression from one cell line of unmodified vector 
(control). For each of Tb09 5’UTR, Tb11 5’UTR and EQ 5’UTR the number of 
biological replicates was two, each having two experimental replicates. The mean ± 
standard error of biological replicates is shown on the graph. B. Northern blot 
analysis using a digoxygenin-labelled RNA probe against the CAT coding region. 
RNA samples: 3 biological replicates (independently derived clones) of each of Tb09 
5’UTR, Tb11 5’UTR, and EQ 5’UTR; one clone of unmodified vector as a control. 
The panel below the blot shows the ethidium bromide staining of the rRNA present 





From the data presented in Figure 4.2, it appears that each 5’UTR caused repression 
of gene expression in slender forms, at the levels of RNA and protein. Therefore, it 
was possible that the potential uORF in each 5’UTR sequence was responsible for 
this repression. If this were the case, the low CAT mRNA levels would suggest that 
this occurs through termination of translation of the uORF peptide stimulating 
mRNA decay. However, it could also be possible that these constructs were 
generating unstable CAT mRNA that was degraded due to the usage of incorrect 
splice addition sites upstream, within the vector sequence. Therefore, an 
investigation of the contribution of the potential uORF in each construct to the 
control of CAT gene expression was made.  
 
4.4 Is the potential uORF responsible for repression in slender forms? 
 
A functional analysis of the potential uORF in each 5’UTR sequence was made 
using the CAT reporter gene assay. The same constructs were used as used in the 
analysis in Section 4.3, except that the uORF was mutated. This mutagenesis was 
carried out using the QuikChange XL Site-Directed Mutagenesis kit from Stratagene 
(see Section 2.3.12) and involved introducing a single base pair mutation in the start 
codon for each potential uORF to change the sequence from ATG to ACG. As the 
start site for translation is therefore destroyed, a scanning ribosome will no longer 
recognise a start codon in this position, so will not be affected by an uORF sequence 
and should recognise the start codon of the downstream ORF. This approach has 
been used previously in a similar manner, to assess uORF function in malaria 
parasites by Amulic et al. (2009). 
 
Primers for mutagenesis using QuikChange XL Site-Directed Mutagenesis kit 
(Stratagene; see Section 2.3.12) were designed according to the manufacturer’s 
guidelines. For mutation of the Tb09 5’UTR, primers 39 and 40 were used; for 
mutation of the Tb11 5’UTR, primers 41 and 42 were used; for mutation of EQ 
5’UTR, primers 43 and 44 were used (see Table 2.1). After ensuring mutagenesis of 
the potential uORF start codon from ATG to ACG was successful by DNA 
sequencing, each of the resulting constructs, named ‘Tb09m’, ‘Tb11m’, and ‘EQm’ 
5’UTRs were used to generate stable transfectant cell lines. Again, T. b. brucei 
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monomorphic bloodstream form strain Lister 427 were used and selected with 0.5 
µg/ml phleomycin. For each construct, two biological replicates (independently 
derived clones) were examined using CAT ELISA assays; the mean of the biological 
replicates is shown in Figure 4.3 (A). Three biological replicates for each construct 
were examined by Northern blot analysis and these results shown in Figure 4.2 (B 
and C). 
 
          
 












Figure 4.3 Analysis of Tb09.211.2300, Tb11.47.0019 and ESAG9-EQ 5’UTRs with 
mutated uORF start codon using a CAT reporter gene assay. The start codon of the 
uORF present in each 5’UTR was mutated from ATG to ACG using site-directed 
mutagenesis (see Section 2.3.12). A. CAT protein expression from the constructs 
indicated as a percentage of expression from one cell line of unmodified vector 
(control). For each of Tb09m, Tb11m and EQm the number of biological replicates 
was two, each having two experimental replicates. The mean ± standard error of 
biological replicates is shown on the graph. B. and C. Northern blot analyses using a 
digoxygenin-labelled RNA probe against the CAT coding region, each with an RNA 
sample of one clone of unmodified vector as a control. RNA samples: 3 biological 
replicates (independently derived clones) of each of Tb09 5’UTR, Tb09m 5’UTR, 
Tb11 5’UTR, and Tb11m 5’UTR (B); and of EQ 5’UTR and EQm 5’UTR (C). The 
panel below each blot shows the ethidium bromide staining of the rRNA present in 
each sample analysed to indicate loading of each lane. Shown below are the mRNA 
quantifications following normalisation to rRNA, as a percentage of that obtained for 
the unmodified vector. 
 
As can be seen in Figure 4.3 (A), the loss of the potential uORF by mutation does not 
cause a release of repression of CAT protein expression. The levels of CAT protein 
expression from each of the three constructs as a percentage of the expression 
obtained for the unmodified vector were 0.88% (±0.12%), 0.72% (±0.69%), and 
0.94% (±0.29%) for Tb09m, Tb11m, and EQm 5’UTR constructs respectively. This 
was very similar to the CAT protein expression seen with the non-mutated 5’UTR 




The results of the CAT mRNA expression for these constructs and the previous non-
mutated 5’UTR constructs are shown in Figure 4.3 (B and C). With this northern blot 
analysis however, the levels of CAT mRNA from the Tb09 5’UTR clones appear to 
be marginally greater than previously (see Figure 4.2 B). The reasons for this are 
unclear. For Tb11 5’UTR and EQ 5’UTR, mutation of the uORF with the Tb11m 
and EQm constructs resulted in no detectable change in CAT mRNA levels. 
However, there was an increase in CAT mRNA levels with mutation of the uORF in 
the Tb09 5’UTR sequence, notwithstanding the overloading of Tb09m clone B5. 
Nonetheless, as mentioned above this did not result in an increase in the level of 
CAT protein expression. 
 
From the data presented in Figure 4.3, it appears that the potential uORF in each 
5’UTR does not contribute to the repression of gene expression seen in slender 
forms. This is because there was no increase in CAT protein expression levels upon 
mutation, and therefore loss, of the potential uORF. Even though mutation of the 
uORF did result in an increase in CAT mRNA expression levels for the Tb09 5’UTR, 
this did not correlate with an increase in CAT protein levels. If the uORF in this 
5’UTR were responsible for repression of gene expression by causing degradation of 
the transcript, it would be expected that loss of the uORF would result in increased 
RNA and therefore, protein levels. Since this was not observed, it appears that either 
there are other elements that are responsible for the repression of mRNA expression, 
or that the presence of these 5’UTR sequences in the vector somehow causes the 
generation of CAT transcripts that are rapidly degraded in a manner where the uORF 
is not functional. 
 
4.5 Is gene expression repression released in ‘stumpy-like’ forms? 
 
Despite the conclusion that the potential uORFs were not responsible for gene 
repression in slender forms (except possibly in the Tb09 5’UTR at the RNA level) it 
remained possible that they could be responsible for the release of gene repression in 
stumpy forms. Therefore, first it was necessary to determine if each 5’UTR sequence 
could drive gene expression in stumpy forms. If so, further analysis could be made 
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by analysis of the mutated uORF constructs in stumpy forms. As with the analysis 
made for the ESAG9-EQ 3’UTR (Chapter 3), the monomorphic cell lines analysed 
for CAT expression in slender forms discussed above were, therefore, treated with 8-
pCPT-2’-O-Me-cAMP to assess CAT expression in ‘stumpy-like’ forms. 
 
The experiments were performed as described in Section 3.7, with comparisons 
being made between treated and control cells. For each construct analysed, there 
were two biological replicates assessed. For each of these two experimental 
replicates were carried out, meaning that the CAT ELISA assays and northern blot 
analyses were performed with samples taken from two separate 8-pCPT-2’-O-Me-
cAMP treatment experiments. 
 
The CAT protein expression levels obtained for cells treated with 8-pCPT-2’-O-Me-
cAMP or control treated for each construct, are shown in Figure 4.4 (A). As can be 
seen, treatment with the compound resulted in a similar very low, almost 
undetectable, level of CAT protein expression, to the untreated cells. Note that the 
data are presented as a percentage of the expression level obtained for the 
unmodified vector control cells because calculations of the fold-change between 
treated and untreated cells appears misleading. This was due to the very low levels of 
CAT protein expressed from the constructs being tested, which meant that the 
variation between samples could produce misleading fold changes.  
 
The levels of CAT mRNA expression in the cells treated, or not, with 8-pCPT-2’-O-
Me-cAMP for each construct, is shown in Figure 4.4 (B). A quantification of the 
amount of the predominant band present for each sample was performed, but here the 
values are a percentage of the untreated cell sample instead of the untreated 
unmodified vector sample, this being due to the absence of a similar size band to the 
predominant band observed in lanes 7-14 in this sample. This quantification indicates 
that drug treatment reduced the mRNA abundance of the Tb11.47.0019 and ESAG9-
EQ 5’UTR construct transcripts (the situation for the Tb09.211.2300 5’UTR 
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Figure 4.4 Response of CAT reporter gene expression to 8-pCPT-2’-O-Me-cAMP 
treatment in 5’UTR containing uORF based constructs. A. CAT protein expression 
for each construct, shown as a percentage of expression from the unmodified vector 
control treated cells, for cells treated with 10 µM 8-pCPT-2’-O-Me-cAMP and 
control treated cells. Shown is the mean ± standard error of two biological replicates; 
except the unmodified vector where n = 1. B. Northern blot analysis of RNA samples 
from one 8-pCPT-2’-O-Me-cAMP treatment experiment using a digoxygenin-
labelled RNA probe against the CAT coding region, and the unmodified vector clone 
as a control. Samples are either from cells treated with 10 µM 8-pCPT-2’-O-Me-
cAMP (+ drug) or control treated cells (- drug). Lower panel shows the ethidium 
bromide-staining of the rRNA present in each sample analysed to indicate loading of 
each lane. Below is quantification of the mRNA band indicated by the arrowhead 





Because the endogenous transcripts are upregulated in stumpy cells, an increased 
level of expression would be expected if the 5’UTRs were responsible for alleviation 
of repression in stumpy forms, not the decrease observed in the mRNA 
quantification. The data shown in Figure 4.4 indicate that the 5’UTRs of 
Tb09.211.2300, Tb11.47.0019, or ESAG9-EQ are not responsible for a release of 
gene repression between slender and stumpy forms. However, this experiment does 
have the caveat that the reporter gene expression was assessed in stumpy-like cells 
and not true stumpy forms, which may produce a different result. 
 
4.6 Internal splice site identification and usage for both Tb09.211.2300 and 
Tb11.47.0019 genes 
 
Following the above analysis of the 5’UTR constructs and potential uORFs, it was 
discovered that both the Tb09.211.2300 and Tb11.47.0019 genes were members of a 
group of genes prediced to use an internal start codon (Siegel et al., 2010). As 
mentioned in Section 3.2.3 the Siegel et al. (2010) study used high-throughput RNA-
sequencing to identify 5’-splice addition sites (SAS) for ~7000 genes, using in vitro 
cultured bloodstream and procyclic forms. From this, it was found that for 488 genes 
the identified SAS was downstream of the originally assigned gene start codon, 
meaning that a subsequent in-frame start codon must be used instead. Both 
Tb09.211.2300 and Tb11.47.0019 genes were found to be included in these 488 
genes. These new start codon assignments and 5’UTRs identified are described 
below and shown in the sequences in Figure 4.1 (A and B). 
 
4.6.1 SAS positions identified by Siegel et al. (2010) 
The study by Siegel et al. (2010) found that the Tb09.211.2300 gene possessed one 
SAS only. This was located at position +261 relative to the original start codon 
annotation, generating a 5’UTR length of 17 bp downstream of this SAS (see Figure 
4.1 A). This meant that the coding sequence length for Tb09.211.2300 would be 282 
bp shorter than the original annotation and would generate a protein reduced by 94 
amino acids in length. It also meant that the Tb09.211.2300 transcript would not 
contain the sequence with the potential uORF sequence (see Figure 4.1 A).  
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The study by Siegel et al. (2010) found that the Tb11.47.0019 gene possessed two 
SASs; located at positions +322 and +345 relative to the original start codon 
annotation (see Figures 4.1 B and 4.5). The 5’UTR lengths found were 55 and 32 bp 
respectively, but both would mean the same internal start codon was used (see Figure 
4.1 B). This meant that the coding sequence length for Tb11.47.0019 would be 381 
bp shorter than the original annotation and would result in a protein reduced by 127 
amino acids in length. Again, it also meant that the Tb11.47.0019 transcript would 
not contain the potential uORF sequence (Figure 4.1 B).  
 
4.6.2 SAS positions identified by Nilsson et al. (2010) 
Another study also determined the 5’ splice sites of 85% of annotated T. brucei 
annotated genes, but used a spliced leader trapping (SLT) methodology rather than 
RNA-sequencing (Nilsson et al., 2010). As well as identifying the splice site, this 
methodology was also able to determine the gene expression profile for slender 
forms, stumpy forms and procyclic forms. The SAS locations for Tb09.211.2300 and 
Tb11.47.0019 were therefore determined from the dataset obtained from this study, 
through http://splicer.unibe.ch/.  
 
For the SAS location in Tb09.211.2300, only one SAS was found, which was present 
in each life-cycle stage and was the same as that found in the Siegel et al. (2010) 
study (see Figure 4.1 A). This therefore confirms the usage of an upstream splice site 
and an internal ATG used for this gene, and consequently, the absence of the uORF 














Figure 4.5 Schematic diagram showing the SAS locations identified for Tb11.47.0019. The SAS locations are indicated with ‘SAS’ and the 
position relative to the annotated ATG start codon (position 0). The black filled circles indicate the identification (or prediction from Benz et al., 
2005) of the use of the above SAS from studies by Siegel et al. (2010) and Nilsson et al. (2010). SL: slender form; ST: stumpy form; PC: 










For Tb11.47.0019, a number of different SAS locations were identified (see Figure 
4.5). Each of the three life-cycle stages investigated possessed a SAS that was the 
same as that identified by Siegel et al. (2010) at position +322. Slender forms and 
stumpy forms were also found to possess a SAS at position +345 that was identified 
by Siegel et al. (2010) as well. Additionally, all three life-cycle stages were found to 
possess a minor SAS further downstream at position +402 relative to the original 
start codon annotation. The nearest downstream start codon in-frame with the stop 
codon of the original gene annotation, is almost immediately after the splice site, 
which would produce a protein of 352 amino acids. Following that, the next nearest 
in-frame start codon would produce a protein of 332 amino acids. Another minor 
SAS was found in procyclic forms only and is the SAS predicted by the Benz et al. 
(2005) study. 
 
4.6.3 Determination of 5’UTRs using 5’RACE 
In order to determine the 5’UTR present in the transcripts of the Tb09.211.2300 and 
Tb11.47.0019 genes in slender, stumpy and procyclic forms, 5’RACE was used. This 
was performed as described in Section 2.5 and a schematic diagram is shown in 
Figure 4.6 (A). Firstly, this involved generation of cDNA from RNA samples from 
bloodstream form Lister 427, AnTat1.1 stumpy forms and procyclic form Lister 427-
449 cells using random hexamers as primers. To control for any amplification from 
contaminating genomic DNA, an identical reaction was set up for each RNA sample 
used, without reverse trancriptase. Additionally, as a negative control, an identical 
cDNA reaction was also performed (with reverse transcriptase present) but with the 
exception that water was added to the reaction instead of any RNA sample. The 
cDNA samples were then used as a template in PCRs, which were likewise used as 
template for a second nested PCR. This nested PCR approach was used because 
initial attempts using a single PCR reaction were unsuccessful for both genes.  
 
For each of the Tb09.211.2300 and Tb11.47.0019 genes, two sets of primers were 
used; one set to amplify only the transcript that would be generated from a trans-
splicing reaction at the predicted SAS (this region was named ‘a’) and one set to 
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amplify any transcripts that would be generated from downstream trans-splicing 
reactions, like that found by Siegel et al. (2010; this was named ‘b’). The reason for 
these different reactions was that the PCR amplification would favour the 
amplification of shorter sequences, potentially creating bias in the analysis. 
 
The first PCR used the splice leader primer (primer 45; Table 2.1) with either primer 
46, 47, 48 or 49; the second PCR again used the splice leader primer (primer 45) 
with either primer 50, 51, 52 or 53. As a positive control, a reaction was included 
that used primer 54 in the first PCR reaction to generate a product of ~340 bp, then 
primer 55 in the second (nested) PCR reaction to generate a product of ~290 bp; 
these were primer sequences used successfully to map the SAS for TbREL2 
(Tb927.1.3030) by Dr Achim Schnaufer (University of Edinburgh) using the same 
methodology. As a negative control, a PCR reaction with no template was included 
in each set of PCRs and contained the same primers as used for the positive control. 
 
Shown in Figure 4.6 (B) are the products from the second PCRs. The major products 
of each reaction shown indicated with asterisks were excised from the gel and 
purified for ligation into pGEM T-easy vector (see Section 2.3.9). Following 
bacterial transformation and small-scale plasmid preparation (see Section 2.3.10), 
DNA from two bacterial colonies obtained for each amplicon where sequenced with 
M13 forward and reverse primers (primers 1 and 2). The major band for Tb11 ‘a’ 
from slender and procyclic forms was not sequenced due to these products producing 
a much weaker signal in the initial experiment replicate. 
 
For the Tb09.211.2300 gene, if there was a transcript present generated from the 
predicted SAS (Benz et al., 2005), a product of ~447 bp should be produced in the 
PCR using primers for the ‘a’ region and a product of ~785 bp using primers for the 
‘b’ region. If there was a transcript present that was generated from the SAS 
identified at position +261, a product of ~126 bp should be produced in the PCR 
using primers for the ‘b’ region. From the sizes of main PCR product shown in 
Figure 4.6 (B), it would appear that only the transcript generated from the SAS 
identified at position +261 for this gene was present in each life-cycle stage. 
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Figure 4.6 continues on the following page 
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Figure 4.6 Results of 5’RACE for Tb09.211.2300 (‘Tb09’) and Tb11.47.0019 (‘Tb11’). A. Schematic diagram of PCR reactions using primers 
to amplify the ‘a’ and ‘b’ regions of each gene following generation of cDNA from RNA from each life cycle stage with random hexamers. Each 
PCR reaction used the spliced leader primer (primer number 45) as the forward primer and for each region two PCRs were performed, the 
second performed to form a nested PCR. Primer numbers are shown in italics and the sequences are given in Table 2.1. The expected PCR 
amplicon sizes are shown at the side of the diagram. B. Product from each of the second PCRs shown schematically in A. analysed on 1.5% w/v 
agarose gels. RT-: identical cDNA reaction performed with water instead of reverse transcriptase, neg. control: negative (water) control, pos. 
control: positive control using primers known to amplify Tb927.1.3030 (primer sequences provided by Dr Achim Schnaufer, University of 
Edinburgh) by 5’RACE. Asterisks mark bands used for sequencing, #s mark bands that were not sequenced. DNA sizes are shown in kilobases 
(kB). C. Schematic diagram showing the results of PCR product sequencing. In the grid on the right, positive identification of the ‘a’ or ‘b’ 
region 5’UTR depicted on the left, is indicated with a filled black circle. Filled grey circles indicate that a PCR product of the same size was 
identified for that sample, but that the 5’UTR sequence was not confirmed by sequencing. SL: splice leader; BSF: slender bloodstream form; ST: 






For the Tb11.47.0019 gene, if there was a transcript present that is generated from 
the predicted SAS (at position -86; Benz et al., 2005), a product of ~190 bp should 
be produced in the PCR using primers for the ‘a’ region and a product of ~625 bp 
using primers for the ‘b’ region. If there was a transcript present that was generated 
from the SASs identified at positions +322/+345, a product of ~186/~163 bp should 
be produced in the PCR using primers for the ‘b’ region. From the sizes of the main 
PCR products (indicated in Figure 4.6 B with asterisks), it would appear that two 
transcripts are generated for this gene in each life-cycle stage; one from the predicted 
SAS and one from the SASs identified at positions +322/+345. 
 
The results of sequencing of the main PCR products are given in Figure 4.6 (C). The 
identification of either the ‘a’ or ‘b’ region 5’UTR in each sample is indicated with a 
filled circle in the grid in Figure 4.6 (C). The sequencing confirmed that in each life-
cycle stage investigated the 5’UTR identified by Siegel et al. (2010) was the 
sequence generated from the main PCR product for Tb09.211.2300 transcripts, as 
suggested by the product size. For Tb11.47.0019 transcripts, the sequencing 
confirmed the use of the predicted SAS (Benz et al., 2005) in each life-cycle stage, 
and the 5’UTR sequence generated by usage of the SASs identified at position 
+322/+345 (Siegel et al., 2010), as suggested by the PCR product sizes. As 
mentioned above, the main product for Tb11 ‘a’ PCRs for slender forms and 
procyclic forms were not sequenced due to their much lower abundance in the first 
experimental replicate. Therefore, initially there was believed to be developmental 
regulation of alternative splice site usage for Tb11.47.0019, such that a longer 
transcript was generated with greater abundance in stumpy forms. 
 
4.7 Is there a developmental difference in transcript abundance? 
 
To further investigate the SAS location usage in the Tb09.211.2300 and 
Tb11.47.0019 genes in slender, stumpy and procyclic forms, northern blot analysis 
was used to analyse transcript abundance. Digoxygenin-labelled probes were 
generated against the ‘a’ and ‘b’ regions of each gene for this, which are shown in 















          
 
Figure 4.7 Detection of Tb09.211.2300 and Tb11.47.0019 transcripts by northern 
blot analyses. Digoxygenin-labelled probes were generated to detect the ‘a’ and ‘b’ 
regions of each gene transcript as shown in the schematic diagram in A. SL: splice 
leader; SAS: splice leader addition site; ATG: start codon. Northern blot analysis 
using the probes to the ‘a’ and ‘b’ regions of Tb09.211.2300 (B), and the probes to 
the ‘a’ (C only) and ‘b’ regions of Tb11.47.0019 (C, D, E, & F). C-E: used RNA 
samples from monomorphic slender bloodstream forms; F: RNA samples from 
pleomorphic slender forms, intermediate forms, and stumpy forms. BSF: 
bloodstream form; ST: stumpy form; PCF: procyclic form; SL: slender form; Int: 
intermediate form. Arrowheads in B mark bands detected, asterisk marks band of 
very feint signal. Arrowheads in C, D, E, & F mark upper and lower bands detected 
with Tb11.47.0019 ‘b’ region probe. Estimated molecular sizes of both transcripts is 
shown in kb (F). The panel below each blot shows the ethidium bromide staining of 





The probe to the ‘a’ region of each gene was designed against sequence of the gene 
that was downstream of the annotated start codon but upstream of the SAS identified 
by Siegel et al. (2010), Nilsson et al. (2010), and by 5’RACE above. To generate this 
for Tb09.211.2300, primers 56 and 57 (see Table 2.1) were used and for 
Tb11.47.0019 primers 58 and 59 were used in PCRs with T. b. brucei strain Lister 
427-449 genomic DNA being the template for the reaction.  
 
The probe to the ‘b’ region of each gene was designed against sequence of the gene 
that was downstream of the SAS identified by Siegel et al. (2010), Nilsson et al. 
(2010), and by 5’RACE above, and downstream of the next in-frame start codon 
following this SAS location. To generate this for Tb09.211.2300, primers 60 and 61 
(see Table 2.1) were used and for Tb11.47.0019 primers 62 and 63 were used in 
PCRs as described above. 
 
Each of the primers used to generate the probes mentioned in this section also 
contained BstXI restriction enzyme sites compatible for sub-cloning in the pQuadra 
set of plasmids for RNAi, however the pALC14 plasmid was used for RNAi instead 
(see Section 4.10). After sub-cloning into pGEM T-easy plasmid, the sequence of 
each amplicon was verified. These plasmids were then used to generate the probes as 
described in Section 2.4.4. 
 
4.7.1 Detection of Tb09.211.2300 transcripts 
The results of northern blot analysis with the probes to the ‘a’ and ‘b’ regions of 
Tb09.211.2300 described above are shown in Figure 4.7 (B). As can be seen, the 
probe to the ‘b’ region detected one main band, which is indicated with an arrowhead 
at the right side of the blot. The band detected by the probe is of stronger signal 
intensity in the RNA sample from stumpy form cells, demonstrating that this 
transcript is upregulated in stumpy forms, matching the analyses by Kabani et al. 
(2009). There were three additional minor bands detected, but these appear to be 
cross-reactivity with the triplet of rRNA bands. 
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The probe to the ‘a’ region detected a faint band in the RNA sample from procyclic 
form cells, indicated with the arrowhead at the left of the blot. However, this 
appeared to be a similar size to one of the minor bands detected with the ‘b’ region 
probe that were thought to be the result of cross-reactivity. Another, even more faint, 
band was detected, which is indicated in Figure 5.7 (B) with an asterisk. This could 
represent a transcript produced by usage of the Benz et al. (2005) predicted SAS. 
However, the signal was so weak that it might also represent unspecific binding of 
the probe. 
 
4.7.2 Detection of Tb11.47.0019 transcripts 
The results of the first northern blot analysis with the probes to the ‘a’ and ‘b’ 
regions of Tb09.211.2300 described above are shown in Figure 4.7 (C). No signal 
was detected with the probe to the ‘a’ region. This was true for subsequent attempts 
involving northern blot analysis with a lower stringency hybridisation temperature 
(60°C, instead of 68°C) and a probe generated from the other strand of DNA 
template in case the amplicon was present in the opposite orientation to that 
suggested by sequencing of the vector. However, the probe to the ‘b’ region detected 
two main bands, which are indicated in Figure 4.7 (C) by the arrowheads and termed 
the upper and lower bands. It was speculated that the upper band may represent the 
transcript produced from usage of the predicted SAS and the lower band may 
represent the transcript produced from usage of the SAS at position +322. The signal 
of both bands, but especially the upper band, was of a greater intensity in the stumpy 
form RNA sample, suggesting upregulation of these transcripts in stumpy forms. 
This supported the initial 5’RACE analysis where there appeared to be a greater 
abundance of the long transcript form in stumpy forms. 
 
However, when the northern blot analysis was repeated with the ‘b’ region probe a 
slightly different profile of expression was observed, this is shown in Figure 4.7 (D). 
Here the expression of both transcript forms appeared to be similar in both the 
slender and stumpy forms, but downregulated in procyclic forms. Two different 
slender form RNA samples were used for the blots shown in Figure 4.7 (C and D) 
and the cell concentration had been different at the time of sample generation. 
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Therefore, whether this difference in transcript abundance was caused by different 
cell density in the different samples was investigated. Shown in Figure 4.7 (E) is 
northern blot analysis performed with RNA samples generated from slender cells at 
different cell concentrations (2.4 x106 cells/ml and 5.8 x106 cells/ml) as well as a 
slender cell RNA sample used previously. Apparently, the cell concentration did not 
affect the abundance of either of the transcript forms. 
 
Due to the variation of the signal intensities of both bands in the northern blot 
analyses shown above, RNA samples were generated from pleomorphic slender, 
intermediate and stumpy forms. This was performed because the previous slender 
form samples had been obtained from monomorphic slender forms and it was 
considered that an assessment of levels in true slender forms might be more 
informative. The northern blot analysis using these RNA samples is shown in Figure 
4.7 (F). As can be seen, the abundance of both bands is greatly reduced in the slender 
form RNA sample. Intermediate and stumpy forms show increased abundance of the 
lower and upper bands compared to slender and procyclic forms. Therefore, the true 
slender forms appear to exhibit a lower abundance of the transcript forms than 
monomorphic slender forms. 
 
These RNA samples and Northern blot analysis was also used to estimate the 
molecular size of both transcripts, which was 2.1 kb for the upper band and 1.9 kb 
for the lower band (Figure 4.7 F). These estimates are smaller than the predicted 
transcript sizes using the 5’UTR and ORF lengths, and largest 3’UTR length from 
the study by Siegel et al. (2010) combined, which are 1823nt and 1414nt for the long 
and short form, respectively. The significance of these estimated sizes is therefore 
unclear. 
 
Because of the variation in transcript abundance observed between these northern 
blot analyses it is not possible to confidently conclude that there is developmental 
regulation of different splice site usage. However, taken all together they do seem to 
indicate that there might be upregulation of both transcripts in stumpy forms. 
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4.8 Potential functional consequences of alternative splice site usage for 
Tb11.47.0019 
 
From the results of the 5’RACE experiments (shown in Figure 4.6; and supported by 
northern blot analyses, shown in Figure 4.7) the generation of two transcripts were 
found to be produced from the Tb11.47.0019 gene, resulting in the potential usage of 
two different start codons. To assess the possible functional consequences of this, the 
amino acid sequences of both long and short forms of the predicted proteins were 
used in bioinformatic analyses (see Section 2.1).  
 
To identify any regions of the peptide sequences that may show homology to known 
conserved protein domains, the Pfam 24.0 database (http://pfam.sanger.ac.uk) was 
searched with the long (487 amino acids) and short (360 amino acids) form 
Tb11.47.0019 protein sequences. This returned one significant Pfam-A match and no 
Pfam-B matches for both forms. The significant result was a match to the UBA/TS-N 








    
 
 
Figure 4.8 Tb11.47.0019 long and short protein sequences contain a predicted 
UBA/TS-N domain. The Pfam 24.0 database (http://pfam.sanger.ac.uk) sequence 
searches predicted that the Tb11.47.0019 protein sequence contains a UBA/TS-N 
domain (ubiquitin associated/TS-N domain), which is present in both the long (487 
amino acids) and short (360 amino acids) form protein sequences at amino acids 
446-481 (E-value: 2.4e-09) and 319-354 (E-value: 1.6e-09) respectively. #HMM: 
consensus of the HMM (hidden Markov model); #MATCH: the match between the 
query sequence and the HMM; #PP: posterior probability, or the degree of 
confidence in each individual aligned residue; #SEQ: query sequence, coloured 
according to the posterior probability (a colour scale of 0-100% where 0% is red and 




































Figure 4.9 Prediction of transmembrane helix occurrence in long and short 
Tb11.47.0019 protein sequences. The graphical plot of posterior probabilities from 
the output generated by the transmembrane helice prediction tool, TMHMM2.0 
(http://www.cbs.dtu.dk/services/TMHMM/), using either the long (A) or short (B) 
peptide sequences for Tb11.47.0019 as input; red: transmembrane; blue: inside; pink: 
outside; at the top of each plot (between 1 and 1.2) the N-best prediction is shown. 
 
Figure 4.8 shows the output returned from the searches (both long and short 
sequences produced the same result). For the long protein form the E-value of the 
match was 2.4e-09 and for the short form was 1.6e-09, despite the two sequences 
only differing in the presence or absence of 127 amino acids at the N-terminal. 
A 
B 
amino acid number 
amino acid number 
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However, the posterior probability for each of the individual residues of the 
predicted domain are the same for both and are very high for most residues except 
the residues at each end of the potential domain. 
 
Additionally, a programme for the prediction of protein transmembrane helices that 
is based on a hidden Markov model, TMHMM2.0 
(http://www.cbs.dtu.dk/services/TMHMM/), was used. The results for both the long 
and short protein sequences are shown in Figure 4.9 (A and B respectively). For the 
long protein sequence it was predicted that there are two transmembrane helices near 
the N-terminus, with the N- and C-termini protein regions present on the non-
cytoplasmic side of the membrane. However, this programme should not be used to 
predict protein location. This programme also noted that there is a possible N-
terminal signal sequence and that predicted N-terminal region transmembrane helices 
often turn out to be signal peptides. For the short protein sequence, no 
transmembrane helices were predicted to be present, highlighting a potentially 
important difference between the forms. 
 
To investigate which known proteins each sequence might show similarity to, the 
protein-protein BLAST (blastp) programme 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) was used with the default 
settings and each amino acid sequence as input. The top 20 protein sequences 
identified with the highest percentage identity match to either the long or short 
protein form sequences are shown in Table 4.4. The most similar proteins identified 
for both protein sequences were the same hypothetical proteins within the ‘TriTryps’ 
(T. brucei, T. cruzi, and Leishmania sp.s). The other proteins identified were mostly 
hypothetical proteins in other species or proteins that from the gene annotations 
appear to have a role with ubiquitin-related processes. This is supportive of a role in 
ubiquitin-related processes for both the long and short protein forms, and is linked to 
the identification of the potential UBA/TS-N domain in each protein sequence.
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Table 4.4 Proteins (top 20) with the highest percentage identity match to the long or 
short protein form sequences using protein-protein BLAST (blastp; 
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins) analysis. 
Accession Description E value % identity
XP_828221.1 hypothetical protein [Trypanosoma brucei TREU927] 0 100
CBH17021.1 hypothetical protein, conserved [Trypanosoma brucei 
gambiense DAL972]
0 98.7
XP_810564.1 hypothetical protein [Trypanosoma cruzi strain CL Brener] 7.00E-73 43.19
XP_815088.1 hypothetical protein [Trypanosoma cruzi strain CL Brener] 1.00E-72 43.42
EFZ26585.1 hypothetical protein TCSYLVIO_7236 [Trypanosoma cruzi] 3.00E-72 42.45
XP_001565839.1 hypothetical protein [Leishmania braziliensis 
MHOM/BR/75/M2904]
1.00E-31 26.65
CAM45357.2 conserved hypothetical protein [Leishmania braziliensis 
MHOM/BR/75/M2904]
1.00E-29 26.47
CBZ35216.1 unnamed protein product [Leishmania donovani BPK282A1] 4.00E-28 32.33
XP_001467363.1 hypothetical protein [Leishmania infantum JPCM5] 1.00E-27 47.06
XP_848026.1 hypothetical protein [Leishmania major strain Friedlin] 2.00E-27 31.85
CBZ28167.1 conserved hypothetical protein [Leishmania mexicana 
MHOM/GT/2001/U1103]
1.00E-26 47.06
XP_003148386.1 ubiquitin family protein [Loa loa] 1.00E-12 29.85
XP_001902395.1 Ubiquitin family protein [Brugia malayi] 7.00E-11 33.75
EGD72894.1 hypothetical protein PTSG_04623 [Salpingoeca sp. ATCC 
50818]
2.00E-09 29.7
NP_740884.1 hypothetical protein F15C11.2 [Caenorhabditis elegans] 4.00E-09 48.65
NP_740885.1 hypothetical protein F15C11.2 [Caenorhabditis elegans] 5.00E-09 26.02
NP_740883.1 hypothetical protein F15C11.2 [Caenorhabditis elegans] 6.00E-09 25.5
AAF80171.1 A1U [Homo sapiens] 9.00E-09 24.41
XP_002715368.1 PREDICTED: ataxin-1 ubiquitin-like interacting protein 
[Oryctolagus cuniculus]
1.00E-08 29.63
EFB18473.1 hypothetical protein PANDA_016682 [Ailuropoda 
melanoleuca]
1.00E-08 28.65
XP_828221.1 hypothetical protein [Trypanosoma brucei TREU927] 0 100
CBH17021.1 hypothetical protein, conserved [Trypanosoma brucei 
gambiense DAL972]
0 99.17
XP_810564.1 hypothetical protein [Trypanosoma cruzi strain CL Brener] 5.00E-73 43.19
XP_815088.1 hypothetical protein [Trypanosoma cruzi strain CL Brener] 6.00E-73 43.42
EFZ26585.1 hypothetical protein TCSYLVIO_7236 [Trypanosoma cruzi] 1.00E-72 41.41
XP_001565839.1 hypothetical protein [Leishmania braziliensis 
MHOM/BR/75/M2904]
3.00E-32 26.65
CAM45357.2 conserved hypothetical protein [Leishmania braziliensis 
MHOM/BR/75/M2904]
5.00E-30 25.74
CBZ35216.1 unnamed protein product [Leishmania donovani BPK282A1] 7.00E-29 31.58
XP_001467363.1 hypothetical protein [Leishmania infantum JPCM5] 2.00E-28 47.06
XP_848026.1 hypothetical protein [Leishmania major strain Friedlin] 4.00E-28 31.2
CBZ28167.1 conserved hypothetical protein [Leishmania mexicana 
MHOM/GT/2001/U1103]
2.00E-27 47.06
XP_003148386.1 ubiquitin family protein [Loa loa] 2.00E-13 29.85
XP_001902395.1 Ubiquitin family protein [Brugia malayi] 3.00E-11 33.75
EGD72894.1 hypothetical protein PTSG_04623 [Salpingoeca sp. ATCC 
50818]
1.00E-09 29.7
AAF80171.1 A1U [Homo sapiens] 4.00E-09 50
XP_001163250.1 PREDICTED: ubiquilin-4 isoform 3 [Pan troglodytes] 4.00E-09 26.02
NP_740883.1 hypothetical protein F15C11.2 [Caenorhabditis elegans] 4.00E-09 25.44
NP_740884.1 hypothetical protein F15C11.2 [Caenorhabditis elegans] 4.00E-09 24.41
BAG64068.1 unnamed protein product [Homo sapiens] 5.00E-09 25




XP_828221.1      MCVCLCCQSFIGKWVVVYPREGLLLLLLLLSYWGRSQRIEFFLKEKMVANLGNILFLSIS 60 
CBH17021.1       ------------------------------------------------------------ 
XP_810564.1      ------------------------------------------------------------ 
                                                                              
 
XP_828221.1      LKRKKRYYNNISARVYIYMYITSNVPSRFVLLNLYIYLSVLFFMPYPTSYHIALCQATKR 120 
CBH17021.1       -------------------------------------------MPYPTSYHIALCQATKR 17 
XP_810564.1      ------------------------------------------------------------ 
                                                                              
 
XP_828221.1      KERGSLRMNVFDSNSMLCQVVSNITDPVELFIEPEMTVGEVRALVAEMTVDSNDWNVRLT 180 
CBH17021.1       KERGWLGMNVFDSNSMLCQVVSNITDPVELFIEPEMTVGEVRALVAEMTVDSNDWNVRLT 77 
XP_810564.1      ---------------MLFQIVSNVADKVDLFIEDEMTVGEVRVLIGQM-IDADEKTIRLT 44 
                                ** *:***::* *:**** ********.*:.:* :*::: .:*** 
 
XP_828221.1      FQGHTLEDDEETWSSVTQQYPVAQGVAPKLFSHASKKR-------EEKARRPVSLPLME- 232 
CBH17021.1       FQGHTLEDDEETWSSVTQQYPVAQGVAPKLFSHASKKR-------EEKARPPVSLPLME- 129 
XP_810564.1      FQGHVLEDDKATWELILRMYPLAEDTPRKLFAHVSERLRTGSASMEALRAALVSASGQED 104 
                 ****.****: **. : : **:*:... ***:*.*::        *      ** .  *  
 
XP_828221.1      EQKDRQQAKLMEPIIDTLVNDPNFSEMMISGQPSLRRLIDANPEVGRLFRNPETLKSLIM 292 
CBH17021.1       EQKDRQQAKLMEPIIDTLVNDPNFSEMMISGQPSLRRLIDANPEVGRLFRNPETLKSLIM 189 
XP_810564.1      EKAARVQARLMEPVIDLMVKDPSMLEMMLSSHPGLKQMLEKHPELKSHVCDPETLKTLMM 164 
                 *:  * **:****:** :*:**.: ***:*.:*.*::::: :**:   . :*****:*:* 
 
XP_828221.1      SQIDPDQRRAMNRNVQLQLAQISAIPGGEQLLERYTSGLMDDMDLNLDLVRNTKIKVPED 352 
CBH17021.1       SQIDPDQRRAMNRNVQLQLAQISAIPGGEQLLERYTSGLMDDMDLNLDLVRNTKTKVPED 249 
XP_810564.1      SQIDPDQRRSLNRGMGLQLAQLSALPGGEQLFEHLTSEYLNDMAA-LTETNVSSSSDNVD 223 
                 *********::**.: *****:**:******:*: **  ::**   *  .. :. .   * 
 
XP_828221.1      EKDDNSESVRGVNSEALPNPWSQSTNTAD--------SGNTN----TFS-----NAAMNL 395 
CBH17021.1       EKDDNSESVRGVNSEALPNPWSQSTNTAD--------SGNTN----TFS-----NAAMNL 292 
XP_810564.1      EAQARPDPTKEANSEALPNPWERQSSSLQGASGLNSMNGNTNNLFSAFGGLGAFGGSMPF 283 
                 * : ..:..: .*********.:.:.: :        .****    :*.     ..:* : 
 
XP_828221.1      FGIPGNVGHPSLGN-LFGSGLGGP--FPFMSPGISIPQTGVTASQRGDDAT-RWSQQLAM 451 
CBH17021.1       FGIPGNVGHPSLGN-LFGSGLGGP--FPFMSPGISIPQTGVTASQRGDDAT-RWSQQLAM 348 
XP_810564.1      AGLPGNIASLGHTNPVTAASFLPPRMLPSSHEGNHVPTTDPTHTREASANTGEWASQLAT 343 
                  *:***:.  .  * : .:.:  *  :*    *  :* *. * ::...  * .*:.***  
 
XP_828221.1      LKDMGFMDEELCLDALRMTNGDVDMAVNFIVNKDSS 487 
CBH17021.1       LKDMGFMDEELCLEALRMTNGDVDMAVNFIVNKDSS 384 
XP_810564.1      LREMGFDNEALCLEALRASNGDIDGAVNYIADKDK- 378 
                 *::*** :* ***:*** :***:* ***:*.:**. 
 
Figure 4.10 ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) multiple 
alignment using the default settings with the protein sequence for Tb11.47.0019 
(accession: XP_828221.1) and two protein sequences in T. brucei gambiense 
(accession: CBH17021.1) and T. cruzi  (accession: XP_001565839.1) found to be 
similar by BLASTP analysis. Asterisk (*): single, fully conserved residue; colon (:): 
conservation between groups of strongly similar properties; period (.): conservation 
between groups of weakly similar properties. The potential UBA/TS-N domain 
identified by Pfam search (Figure 4.8) is shown underlined; the downstream 
methionine in the sequence produced from usage of the downstream SAS is shown in 
grey highlight.  
 
Following this, the annotated protein sequence for Tb11.47.0019 (the long protein 
form, accession: XP_828221.1) was used in a multiple alignment with the two 
protein sequences showing the greatest sequence identity, hypothetical proteins from 
T. brucei gambiense (accession: CBH17021.1) and T. cruzi  (accession: 
XP_001565839.1). This was performed with the ClustalW2 programme 
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(http://www.ebi.ac.uk/Tools/msa/clustalw2/) with the default settings and the 
alignment is shown in Figure 4.10. These protein sequences demonstrate a 
reasonably high degree of similarity in protein sequence. Some regions of sequence 
show a higher degree of conservation, such as the sequence identified as a potential 
UBA/TS-N domain in the Pfam searches (see Figure 4.8; underlined in Figure 4.10).  
 
Interestingly, neither of the other protein sequences used for alignment was found to 
possess similarity to most of the N-terminal region of Tb11.47.0019 that is missing 
in the short form of the protein (the methionine residue produced from usage of the 
downstream SAS is shown in grey highlight in Figure 4.10). This was also found to 
be true in alignments using additional protein sequences identified by blastp analysis 
to show similarity (accessions: XP_001565839.1, AAF80171.1, XP_002810087.1, 
XP_001902395.1; data not shown). This could suggest that the N-terminal extension 
in Tb11.47.0019 is specific to this T. b. brucei gene. The locations of the domains 
predicted by the bioinformatic analyses for each protein sequence is shown in a 






















Figure 4.11 Schematic diagram of the generation of long and short protein forms from two SAS locations identified for Tb11.47.0019 with the 
locations of regions predicted by bioinformatic analyses. The arrowhead marks the position of putative signal peptide cleavage site in between 
amino acids 36 and 37 (probability: 0.798; SignalP). Blue boxes indicate locations of transmembrane helices (although the one nearest the N-
terminal is likely to be a signal peptide); yellow boxes indicate location of the UBA/TS-N domain; dileucine motif is marked by ‘LL’; numbers 




The presence or absence of predicted transmembrane helices in the long or short 
protein forms identified above suggest that these proteins may have different cellular 
localisations. Therefore, additional bioinformatic analyses were also performed using 
each of the long and short form protein sequences to attempt to predict the cellular 
localisation for each protein. The tools used were the SignalP 
(www.cbs.dtu.dk/services/SignalP), iPSORT, WoLF PSORT, PSORTII (each 
through http://psort.hgc.jp/), SecretomeP 
(http://www.cbs.dtu.dk/services/SecretomeP/), and TargetP 
(http://www.cbs.dtu.dk/services/TargetP/) programmes, the results of which are 
summarised in Table 4.5. 
 
As can be seen, very different predictions were made for each of the protein 
sequences. The long protein form was predicted to contain a cleavage signal peptide 
sequence, whereas the short protein form was not (SignalP, iPSORT and WoLF 
PSORT predictions). The long protein form was predicted to possess one 
transmembrane helix in addition to the signal peptide (PSORTII) as suggested by the 
TMHMM2.0 prediction above. This meant that the long protein sequence was 
predicted to have a membrane topology of Type 1a, where the N-terminus is present 
in the exoplasmic space and the C-terminus is cytosolic.  
 
Neither protein was predicted to be mitochondrial by iPSORT. The long protein form 
was predicted to be either present in the plasma membrane, endoplasmic reticulum, 
or extracellular environment by WoLF PSORT analysis; cytoplasmic rather than 
nuclear, and present in the Golgi, plasma membrane, or endoplasmic reticulum by 
PSORTII; and to be part of the secretory pathway (SP), rather than to have a 
mitochondrial targeting peptide (mTP) or other location by TargetP, with high 
reliability (reliability class, RC, of 1; scale of 1 to 5, where 1 is the strongest 
prediction). SecretomeP predicted that this protein possibly enters the classical 
secretory pathway, due to the presence of the signal peptide predicted by SignalP and 




Table 4.5 Summary of bioinformatic predictionsa for the long and short peptide 
sequences of Tb11.47.0019. 
 
a The bioinformatic tools listed were accessed through the following URLs: 
http://pfam.sanger.ac.uk; www.cbs.dtu.dk/services/SignalP; http://psort.hgc.jp/; 
http://www.cbs.dtu.dk/services/SecretomeP/; 
http://www.cbs.dtu.dk/services/TargetP/. UBA/TS-N: ubiquitin associated domain; 
TMS: transmembrane sequence; NN-score: a value greater than 0.5 predicts that the 
protein enters the secretory pathway; mTP: mitochondrial targeting peptide; SP: 
secretory pathway; other: other location; RC: reliability class, scale of 1 to 5 where 1 
is the strongest prediction. 
 
 
The short protein form was predicted to be either present in the cytoskeleton, cytosol, 
or have a nuclear location by WoLF PSORT analysis; nuclear rather than 
cytoplasmic, and to be either nuclear, mitochondrial, cytoplasmic, or cytoskeletal by 
PSORTII; and to have another location other than secretory or mitochondrial by 
Bioinformatic software programme Long peptide sequence Short peptide sequence
Pfam UBA/TS-N domain (2.4e-09) UBA/TS-N domain (1.6e-09)
SignalP Signal peptide: YES Signal peptide: NO
Prediction: Signal peptide Prediction: Non-secretory protein
Signal peptide probability: 0.842 Signal peptide probability: 0.001
Max. cleavage site probability: Max. cleavage site probability: 
0.798 between positions 36 & 37 0.001
iPSORT Signal peptide: Yes (1.61333) Signal peptide: No (0.60667)
Mitochondrial: No (0.03333) Mitochondrial: No (-0.06667)
WoLF PSORT Plasma membrane: 18.0 Cytoskeleton: 19.0
Endoplasmic reticulum: 8.0 Cytosol: 7.0
Extracellular: 4.0 Cytosol/nuclear: 7.0
Nuclear: 5.0
PSORTII Cleavable signal peptide (1 to 36) No N-terminal signal peptide
Number of TMS(s) predicted: 1 Number of TMS(s) predicted: 0
Membrane topology: Type 1a 
(cytoplasmic tail 106 to 487)
Dileucine motif in the tail: Dileucine motif in the tail: 







k -NN prediction:                         k -NN prediction:
  33.3%: Golgi   69.6%: nuclear
  33.3%: plasma membrane   21.7%: mitochondrial
  33.3%: endoplasmic reticulum   4.3%: cytoplasmic  
  4.3%: cytoskeletal
Secretome P NN-score: 0.837 NN-score: 0.384
TargetP mTP: 0.014 mTP: 0.063
SP: 0.957 SP: 0.136
other: 0.114 other: 0.863
RC: 1 RC: 2
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TargetP (RC: 2). SecretomeP predicted that this protein would not enter the secretory 
pathway, due to an NN-score of less than 0.5. 
 
Interestingly, a dileucine (LL) motif was identified in the long protein form sequence 
but not in the short protein form sequence (PSORTII), despite the sequence being 
present in this sequence too. This is interesting because these motifs exhibit a wide 
range of functions in endocytosis and membrane receptor/protein trafficking 
(reviewed by (Pandey, 2010). The dileucine residues of the identified motif are 
preceded by a polar residue (Q) and a negatively charged amino acid (E), which is 
characteristic of these motifs (reviewed by Pandey, 2010). However, why this motif 
was not detected in the short protein form, as the motif sequence is also present here, 
is unknown.  
 
These bioinformatic prediction tools, however, are not optimised for prediction with 
trypanosome protein sequences and so these predictions could be incorrect. 
Nonetheless, it does appear that the consensus of the predictions is that these proteins 
would have different cellular localisations to each other.  
 
4.9 Do ectopically expressed long and short Tb11.47.0019 peptides have a 
different cellular localisation? 
 
Due to the potential for different cellular localisations predicted for each of the long 
and short protein forms of Tb11.47.0019, the location of each of these proteins was 
investigated. This involved expression of either the long or short as an ectopic tagged 
copy.  
 
4.9.1 Generation of long and short tagged-peptide expressing cell lines 
For expression of either protein form, the plasmid, pHD451 was used. Sub-cloning 
of the DNA sequences for the protein forms is shown in the schematic diagram in 
Figure 4.12 (A). Either sequence was inserted into a region immediately preceding 
the sequence encoding a Ty epitope tag followed by a stop codon. Upstream of this 
region in the plasmid is the tetracycline repressor sequence containing an EP-
199 
procyclin promoter. Therefore, expression of the protein with a Ty epitope tag is 
inducible with addition of tetracycline. The plasmid also contains a ribosomal spacer 
sequence, such that linearization of the plasmid with NotI restriction enzyme 
digestion allows integration into the T. brucei genome in this region. The plasmid 
possesses a hygromycin resistance gene to allow selection of cells that have 
successful integration of the plasmid. 
 
For sub-cloning of the long protein sequence, the XhoI and BamHI restriction 
enzyme sites of pHD451 were used, as this sequence contains the HindIII restriction 
site sequence. Primers 64 and 65 were used to amplify the sequence of Tb11.47.0019 
from the annotated start codon to the nucleotide preceding the annotated stop codon 
(excluding the stop codon sequence allowed incorporation of the Ty epitope tag at 
the C-terminus). There were difficulties in obtaining the long sequence for 
Tb11.47.0019 as PCR amplifications always resulted in amplicons containing a G 
residue at the same position as a C residue in the amplicon for the short protein 
sequence and the T. brucei TREU 927 genome annotation. This would mean that the 
encoded protein would have a glutamic acid residue here instead of an aspartic acid 
residue as in the short protein form. Even though this is a conservative amino acid 
substitution, because these constructs were to be used for assessment of cellular 
localisation it was important that the only difference in the sequences was the N-
terminal extension in the long protein form. However, repeated PCRs produced the 
same outcome and it was discovered from genome analysis that the Tb11.47.0019 
gene is G/C polymorphic at this residue (Dr Paul Capewell, University of 
Edinburgh). Of 16 sequencing reads for the T. brucei TREU 927 genome, seven 
contained C at this position and nine contained G; in contrast the strain STIB247 was 
homozygous for G and the STIB386 strain was heterozygous for G/C. Therefore, it 
was assumed that this residue difference would not affect the function or localisation 




      
 
Figure 4.12 Ectopic overexpression of each of the long and short peptide forms of 
Tb11.47.0019 with a Ty epitope tag. A. Schematic diagram of construct generation 
using the expression vector, pHD451-Ty. Either the long or short form sequence was 
amplified by PCR (arrows depict primer binding regions) for ligation into pHD451-
Ty through the XhoI/BamHI or HindIII/BamHI restriction enzyme sites (long or short 
form, respectively). Shown at the bottom is a representation of the pHD451-Ty 
vector showing the ribosomal spacer, tetracycline repressor (TetR), Ty epitope with 
stop codon (Ty-stop), hygromycin resistance gene (HygroR), EP-procyclin promoter 
(pEP), VSG promoter (pVSG), and restriction enzyme site locations. B. Western blot 
analyses using a primary antibody that recognises the Ty epitope (BB2) and a 
secondary antibody of anti-mouse IgG with a horse radish peroxidase (HRP) 
conjugate. Cell lysate samples were either from the parental cell line, or cells 
ectopically expressing the long form of Tb11 (clones C2 and C4) or ectopically 
expressing the short form of Tb11 (clones D51 and D52) at the times indicated (hr: 
hours after induction). The arrowhead marks the ectopically expressed peptide; the 





For sub-cloning of the short protein sequence, the HindIII and BamHI restriction 
enzyme sites of pHD451 were used. Primers 66 and 65 were used to amplify the 
sequence from the start codon at position +378nt relative to the annotated start 
codon, to the nucleotide preceding the annotated stop codon, as for the long sequence 
above. Both of the pHD451 plasmids containing either the sequence for the long or 
short protein sequences were then transfected into T. b. brucei bloodstream form 
strain Lister 427-449 (meaning that these cells express the tetracycline repressor 
protein from transfection with pHD449 plasmid). Successful transfectants were 
selected with 2 µg/ml hygromycin B and two independently derived clones were 
assessed for each transfected construct. 
 
4.9.2 Inducible ectopic expression of long and short form proteins 
The cell lines obtained were tested for the ectopic overexpression of the tagged-
proteins. Cell lysate samples were made from each of the cell lines (and the parental 
427 449 cell line, as a control), then they were either induced for overexpression with 
tetracycline or uninduced and further cell lysate samples were made 24 hours later. 
These cell lysate samples were then probed by western blot analysis (see Section 2.7) 
with a primary antibody that recognises the Ty epitope tag (BB2) and a secondary 
antibody of anti-mouse IgG with a horse radish peroxidase (HRP) conjugate. The 
results of these western blot analyses are shown in Figure 4.12 (B).  
 
All the cell lines tested inducibly overexpressed an ectopic tagged-protein copy 
(marked by arrowheads in Figure 4.12 B). Although, for each of the cell lines there 
was expression of the tagged proteins in the absence of induction (see the 0hr and – 
tet lanes), this was at a much lower expression level than when induced with 
tetracycline (see + tet lanes). As expected, there was no tagged protein expressed in 
the parental cell line. These antibodies also detected a higher molecular weight band 
of ~60-70 kDa. This however, is a cross-reactive band, being present in all the cell 
lysate samples tested. Thus, it serves as a useful loading control. 
 
Interestingly, it was observed from the western blot analyses that the ectopically 
expressed proteins were present at the same molecular weight, despite transfection 
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with the sequences encoding the long or short protein forms. The length of the long 
protein sequence is 487 amino acids (excluding the length of the Ty epitope tag) and 
the short protein sequence is 360 amino acids long (again excluding the Ty epitope 
tag). The predicted protein molecular weight on the TriTryp database is 54 925 Da 
for the annotated Tb11.47.0019 gene (the long protein form). For the short protein 
form the molecular weight was determined as 39 870 Da 
(http://web.expasy.org/compute_pi/). The observed band is slightly larger than 40 
kDa and so is consistent with this being the short protein form. The slightly larger 
weight than estimated is contributed by the Ty epitope tag (10 amino acids; 
estimated molecular weight of 1 167 Da).  
 
4.9.3 Assessment of cellular localisation for long and short tagged-peptides 
When cell lysate samples were taken at 24 hours after induction with tetracycline (or 
from uninduced controls) for western blot analyses above, cells were also fixed for 
protein localisation analysis. For this the cells were fixed in paraformaldehyde on 
polylysine slides and stained with the BB2 antibody, then anti-mouse IgG labelled 
with FITC, and finally the DNA stain, DAPI (see Section 2.8.2). The slides were 
then analysed by fluorescence microscopy, representative results of one experimental 

























Figure 4.13 Immunofluorescence analysis. Cells were fixed in paraformaldehyde and stained with a primary antibody that recognises the Ty 
epitope tag (BB2), a secondary antibody (anti-mouse IgG labelled with FITC) and the DNA stain, DAPI. Micrographs show representative cells 
from two clones induced to ectopically express the long peptide form of Tb11.47.0019 (+ tet; A), two clones induced to ectopically express the 
short peptide form of Tb11.47.0019 (+ tet; B), or these same cells uninduced (- tet; C). Arrows indicate cells exhibiting more intense levels of 
FITC staining. Controls (D): the parental cell line treated or untreated with tetracycline; and cells induced to ectopically express the long or short 
peptide forms, but stained with secondary (2°) antibody only. Scale bar: 10 µm. 
C D 
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Figure 4.13 (A) shows four sets of micrographs obtained from cells induced to 
express the long protein form. In these cell populations there was only a low 
frequency of cells with bright FITC staining, most had a low level of staining, which 
through comparison with the controls was shown to be background staining (D). 
These cells with lower levels of FITC staining can be seen in these micrographs. For 
the cells that had more intense levels of FITC staining (indicated with arrows in 
Figure 4.13 A), the staining was observed to produce a punctate pattern throughout 
the cytoplasm. With the use of these antibodies often one or two intense spots of 
FITC staining were observed at the posterior end in close proximity to the DAPI-
staining of the kinetoplast. However, this was not specific to the expression of either 
protein form as the control cells also exhibited similar staining (see below). The 
punctate staining pattern did not appear to be excluded from the area of DAPI 
staining of the nucleus. Hence, either the tagged protein is present in both the 
cytoplasm and nucleus, or it is present on/near the cell surface, which would mean 
that it would appear to be present in the cytoplasm and nucleus by this methodology. 
Investigation of cellular localisation with these antibodies but using confocal 
microscopy could address this issue.  
 
Figure 4.13 (B) shows four sets of micrographs obtained from cells induced to 
express the short protein form. As can be seen, with comparison to the micrographs 
shown in Figure 4.13 (A), there was an identical pattern of FITC staining in this 
group of cells as in the cells induced to express the long protein form.  
 
Shown in Figure 4.13 (C) are four sets of micrographs obtained from one of each of 
the cell lines shown in A and B, but not induced for expression of the tagged protein 
copy. These cells exhibited a low level of fluorescent staining, consistent with the 
low level of tagged protein expression in these uninduced cells (Figure 4.12 B). 
However, this staining was only slightly more intense than that observed as the 
background level of staining in the parental cell line, with or without tetracycline 
(Figure 4.13 D).  
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Also shown in Figure 4.13 (D) is the non-specific FITC staining of cells induced to 
express either tagged copy when the secondary antibody was used alone. Under these 
conditions, the same low level of background fluorescence staining is observed 
similar to that observed when both antibodies were used, and often with the same 
one or two bright fluorescent spots of signal at the posterior cell end mentioned 
above. This indicates that this signal is the result of unspecific binding of the 
secondary antibody. Although, the parental cell line and analysis with secondary 
antibody only produced a low level of background fluorescence staining in the cells, 
the same punctate pattern of more intense fluorescence staining seen for the induced 
cells was not observed. 
 
In conclusion, both the cells induced to express tagged-copies of the long and short 
protein forms produced the same pattern of protein expression in the analysis shown 
in Figure 4.13. This is consistent with the observation that in both groups of cells the 
signal detected by western blot analysis of the tagged protein copies was of the same 
molecular size (Figure 4.12 B), and so these cells appear to express a tagged protein 
of the same molecular weight and localisation. 
 
4.10 RNAi-mediated ablation of the long Tb11.47.0019 transcript or both 
transcripts  
 
It was identified that there could potentially be differential expression across the 
lifecycle of the Tb11.47.0019 transcripts produced from trans-splicing at different 
locations (see Section 4.7.2 and Figure 4.7), generating a long and a short form of the 
transcript and, consequently, protein. Due to the potentially increased expression of 
the long form of the transcript in stumpy forms, it would be interesting to investigate 
if there was a functional consequence of this for differentiation. To study this, 
constructs for the RNAi-mediated ablation of transcripts containing either the ‘a’ or 
‘b’ regions of Tb11.47.0019 (described in Section 4.7) were generated. This would 
mean that only the long transcript form would be ablated upon RNAi involving the 
‘a’ region and both the long and short transcript forms would be ablated upon RNAi 
involving the ‘b’ region. It is not possible to ablate the short transcript form only, 
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because all the sequence should be identical to the long transcript form. Following 
construct generation and the creation of transfectant cell lines, the ability of cells to 
differentiate to procyclic forms could be tested after induction of RNAi. 
 
4.9.1 Generation of RNAi cell lines 
For generation of RNAi cell lines, the plasmid pALC14 (Bochud-Allemann and 
Schneider, 2002) was used. This plasmid contains a ‘stuffer’ region possessing 
HindIII, XbaI, XhoI, and BamHI restriction enzyme site sequences, downstream of a 
procyclin promoter and tetracycline operator sequences. A schematic diagram of the 
sub-cloning steps into this vector is shown in Figure 4.14 (A). Insertion of the same 
gene fragments in opposite orientations can be achieved through amplication of the 
same DNA sequence with primers containing HindIII and XbaI (forward and reverse 
primers, respectively) restriction site sequences, and another amplification with 
primers containing XhoI and BamHI (forward and reverse primers, respectively) site 
sequences. These DNA sequences were sequentially inserted into the vector by 
digestion with the appropriate restriction enzymes and ligation reactions. Therefore, 
inducible expression of double-stranded RNA would be produced with the addition 
of tetracycline. The pALC14 plasmid also contains the puromycin resistance gene for 
selection of cells containing the transfected plasmid.  
 
For sub-cloning of the Tb11.47.0019 ‘a’ and ‘b’ regions the plasmid preparations of 
these amplified regions in pGEM T-easy vector (which were used for generation of 
probes to these regions for northern blot analysis, see Section 4.7) were used as 
template in PCRs. For the ‘a’ region, PCRs contained either primers 67 and 68 or 
primers 69 and 70. For the ‘b’ region, PCRs contained either primers 71 and 72 or 
























Figure 4.14 Preliminary analysis of RNAi-mediated ablation of Tb11.47.0019 ‘a’ or 
both Tb11.47.0019 transcripts. A. Schematic diagram of the sub-cloning of the ‘a’ or 
‘b’ regions of Tb11(Tb11.47.0019) into pALC14. For each of ‘a’ and ‘b’, two PCRs 
were performed with primers (depicted by bent arrows) containing the sequences of 
the restriction enzyme sites indicated to give two products; one for insertion between 
the HindIII and XbaI sites in pALC14, and one for insertion between the XhoI and 
BamHI sites. Shown at the bottom is a representation of the pALC14 vector showing 
the puromycin resistance gene (PuroR), tetracycline operators (Tet Op.s), stuffer 
region (stuffer), rDNA spacer, procyclin and T7 promoters, and restriction enzyme 
site locations. B. Growth analysis following induction of RNAi-ablation of either the 
‘a’ or ‘b’ regions of Tb11.47.0019. Shown are cell concentrations (x106 cells/ml) at 
various time points (in hours) either after induction (+ tet; 1 µg/ml tetracycline) or in 
non-induced cells (- tet). At 48 hours, the cell concentrations were returned to 
~0.1x106 cells/ml. C. Northern blot analyses of RNA samples taken every 24 hours 
from cells shown in B. using a digoxygenin-labelled RNA probe against the ‘b’ 
region of Tb11.47.0019. Arrowheads indicate the upper (U) and lower (L) bands 
detected by this probe previously (Figure 4.7). Shown below each blot is the 
ethidium bromide staining of rRNA present in each sample to indicate loading. 
 
 
4.9.2 Preliminary assessment of effect of RNAi-mediated ablation of transcripts 
As a preliminary analysis of the effect of RNAi-mediated ablation of the 
Tb11.47.0019 transcripts, cell growth after induction was analysed in one clone of 
cells obtained from transfection with either the ‘a’ or ‘b’ construct described above. 
For the first analyses, the cells used for transfection were T. b. brucei single marker 
C 
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monomorphic bloodstream form cells, due to initial attempts at transfection of 
pleomorphic cells with these constructs being unsuccessful. Successful transfectant 
cells were selected using 0.5 µg/ml puromycin using the clonal selection described in 
Section 2.2.3. 
 
The growth of cells containing either the Tb11.47.0019 ‘a’ or ‘b’ RNAi constructs 
was assessed every 24 hours in cells either following induction of RNAi (+ tet; 
treated with 1 µg/ml tetracycline) or uninduced (- tet). The resulting cell 
concentrations measured at each time point are shown in Figure 4.14 (B). As can be 
seen, similar growth rates were observed for the induced and uninduced cells 
whether either the long transcript form (‘a’) or both transcript forms (‘b’) were 
targeted for RNAi. There was however a small increase in growth rate for cells at 96 
hours after induction of RNAi for both sequences analysed, with respect to 
uninduced cells. Further analysis would be needed to confirm or disprove this, but 
the slight decrease in growth rate in these conditions observed at 46 hours makes it 
appear unlikely that this is due to RNAi induction. 
 
Figure 4.14 (C) shows northern blot analyses of RNA samples taken from cells at the 
time points shown in Figure 4.14 (B). In these northern blot analyses the probe to the 
‘b’ region of Tb11.47.0019 (discussed in Section 4.7) was used, as it should detect 
both the long and short transcript forms. From the northern blot analyses, it was 
observed that there was effective transcript ablation with induction of the 
Tb11.47.0019 ‘b’ RNAi. This reduced both the upper and lower bands previously 
detected (see Figure 4.7), indicating that it is likely the upper band does contain the 
Tb11.47.0019 ‘b’ region sequence and represents the long transcript form. It would 
be expected that RNAi using the ‘b’ region would ablate both the long and short 
transcript forms and this appears to be observed. For the induction of Tb11.47.0019 
‘a’ RNAi, ablation of the long transcript form should result and so it would be 
expected that the intensity of upper band signal would decrease specifically. 
However, this did not appear to be the case. This could indicate that the RNAi 
ablation was not effective in this cell line. 
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The results shown in Figure 4.14 of this preliminary analysis, indicate that ablation 
of either of both transcript forms of Tb11.47.0019 generated little affect on the 
cellular growth rate in monomorphic slender cells. A specific effect from targeting 
the longer form only, however, could not be determined due to the failure of the 
Tb11.47.0019 ‘a’ RNAi cell line. Further analyses of any effects attributable to either 































In other eukaryotes, one mechanism for transcripts to escape global translational 
repression, such as during stress conditions, is uORFs. Therefore, it was investigated 
whether uORFs are used as a mechanism for stumpy-enriched transcripts to escape 
translational repression in stumpy forms.  
 
In T. cruzi, a 22-codon uORF present in the tuzin 5’UTR has been reported to 
substantially reduce reporter gene expression (Teixeira et al., 1999). Additionally, in 
T. cruzi, another four genes were reported to possess uORFs (Jaeger and Brandao, 
2011), although no functional analysis was made. Also, a functional uORF has been 
identified in Plasmodium falciparum, another protozoan parasite, which represses 
translation of var2csa (Amulic et al., 2009). Therefore, it appears possible that 
functional uORFs may also be present in T. brucei, although to the best of my 
knowledge, none have been identified to date. 
 
Using a bioinformatic approach to predict the occurrence of uORFs in the T. brucei 
genome revealed that 25.38% of annotated genes had one or more potential uORFs 
(Table 4.1), with a median uORF number of 1 and mean of 1.2. This analysis was 
performed using the definition of an uORF as a methionine codon followed by a stop 
codon with at least 2 amino acid residues in between and analysed 100nt of upstream 
sequence for each annotated gene. This length was chosen because the median and 
mean lengths of known 5’UTRs were previously found to be 68nt and 129nt, 
respectively (Benz et al., 2005). Therefore, using this method, the identified uORF 
sequences are potential uORFs because it is not known whether each uORF sequence 
is within the actual 5'UTR sequence for each gene (i.e. there could be many false 
positive assignments) and additionally, whether the uORF is functional (i.e. whether 
it affects the expression of the main ORF).  
 
For vertebrate and human 5’UTRs, estimates regarding the frequency of uORFs in 
the genome vary greatly, being between 11-48% of genes (Meijer and Thomas, 
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2002). However, for mice and human mRNAs, about 25% were found to have one or 
more uORFs, with an average of about 1.9 uORFs (Crowe et al., 2006). This is 
similar to the frequency that was identified here for T. brucei. However, the 
methodology used by Crowe et al. (2006) differed substantially. Firstly, the authors 
examined mature mRNA sequences obtained from each organism, and restricted 
their analysis to uORFs of 20 to 99 codons in length. At the time the analysis of 
uORF predictions in T. brucei was performed, the actual SAS locations had not been 
identified on a genome-wide scale. However, with data available from RNA-seq 
studies, performed by for example, Siegel et al. (2010), the identification of uORF 
sequences in true 5’UTR sequences would be possible. For further work, it would be 
interesting to repeat the uORF analyses using the data of the 5’UTRs obtained from 
these studies. 
 
An additional criticism that could be made of this approach could be that many 
potential uORFs could be missed, these being any uORFs where: i) the start codon 
precedes the 100nt of upstream sequence, and/or ii) the stop codon is within the main 
ORF coding sequence, and therefore, the uORF overlaps the main ORF. However, 
my analysis was performed to obtain a genome-wide prediction of the abundance of 
potential uORFs and unless each gene was analysed individually, which would be a 
huge task on a genome-wide scale, these inaccuracies are inevitable. 
 
Analysis of potential uORFs in two datasets of coregulated genes, those upregulated 
during heat shock and in stumpy forms, suggested that there might be a slight 
increase in the abundance of potential uORFs in stumpy forms (Table 4.1). 
Therefore, two genes were chosen for further analysis, these being Tb09.211.2300 
and Tb11.47.0019. The ESAG9-EQ 5'UTR was also included in these same analyses 
as it was found to also possess a potential uORF (Table 4.3). 
 
Using a CAT reporter gene assay, each of the 5'UTRs from these three genes 
(Tb09.211.2300, Tb11.47.0019 and ESAG9-EQ) was found to repress gene 
expression in slender forms, at the levels of mRNA and protein (Figure 4.2). This 
was not due to the replacement of the aldolase 5'UTR present in the reporter gene 
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plasmid alone because replacement with the TbACO 5'UTR resulted in only a small 
decrease in CAT expression (Figure 3.3 B). This suggested that the 5'UTR sequences 
were responsible for the repression of gene expression in slender forms. However, 
the potential uORF present in each 5'UTR was not responsible for this repression, 
because when each uORF was deleted through mutation of the uORF start codon this 
did not alleviate repression (Figure 4.3). Additionally, the 5'UTR sequences were not 
responsible for release of gene expression repression upon development to stumpy-
like forms with 8-pCPT-2’-O-Me-cAMP treatment (Figure 4.4). However, it is 
possible that alleviation of repression was not observed because gene expression was 
analysed in stumpy-like forms and not true stumpy forms, where repression may be 
relieved, but reporter gene expression in true stumpy forms was not examined in this 
study. 
 
For ESAG9-EQ, the main SAS location was confirmed by Nilsson et al. (2010) to be 
that predicted by Benz et al. (2005). Therefore, the EQ 5’UTR sequence analysed in 
the CAT reporter gene assays should contain a functional SAS. Hence, it is unclear 
why the CAT mRNA produced from the EQ 5’UTR construct was of a much larger 
molecular weight than predicted (Figures 4.2 B, 4.3 C, and 4.4 B) when the SAS in 
the EQ 5’UTR sequence would produce a short 5’UTR (41nt). This, combined with 
the low CAT protein expression levels obtained with this construct in each 
experiment (Figures 4.2 A, 4.3 A, and 4.4 A), suggests that the EQ 5’UTR was not 
functional in these experiments. It is possible that additional sequence is required 
from the endogenous context for correct mRNA processing. But, additionally, it is 
also possible that stumpy-specific factors may be required for correct mRNA 
processing, these not being present in slender forms or in the stumpy-like forms 
analysed. Although, arguing against this second possibility is the observation that the 
same SAS was identified as the main SAS in slender and stumpy forms in the 
Nilsson et al. (2010) study, suggesting that this SAS is used in both life-cycle stages. 
 
4.11.2 Different trans-splicing sites 
As mentioned in Section 4.4, it was discovered in previous studies (Siegel et al., 
2010; Nilsson et al., 2010) that the Tb09.211.2300 and Tb11.47.0019 genes were 
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members of a group of genes identified to use alternative SAS locations to those 
predicted by genome annotation (Benz et al., 2005), and therefore, were predicted to 
use an internal start codon.  
 
For Tb09.211.2300, both studies identified only one SAS, located at position +261 
relative to the original start codon annotation (Siegel et al., 2010; Nilsson et al., 
2010). Using northern blot analysis or 5'RACE, Tb09.211.2300 transcripts produced 
from trans-splicing reactions using the predicted SAS were not detected (Figures 4.5 
and 4.6 B). The SAS that was used in the Tb09.211.2300 transcript detected by 
5'RACE was determined to be that at position +261. Therefore, it appears likely that 
the Tb09.211.2300 5'UTR sequence used in the CAT reporter gene assays did not 
contain a functional SAS. Consequently, this may explain why this sequence did not 
support CAT gene expression (Figures 4.2, 4.3, and 4.4).  
 
The Tb09.211.2300 transcript was originally identified as stumpy-enriched by 
microarray analysis (Kabani et al., 2009) performed using an oligonucleotide 
sequence (marked in bold font in Figure 4.1 A) that was complementary to sequence 
upstream from the SAS at position +261. However, as mentioned above, the RNA-
seq studies, and northern blot analysis and 5'RACE results presented here, only 
detected usage of the SAS at position +261. This would suggest that Tb09.211.2300 
was a false-positive result in the microarray analysis. Confounding this, however, is 
the observation that the Tb09.211.2300 transcript was slightly enriched in stumpy 
forms in the northern blot analysis (Figure 4.6 B). Therefore, perhaps an explanation 
might be that the Tb09.211.2300 transcript detected in the microarray study was a 
processing intermediate, present prior to transcript trans-splicing, which was not 
detected in the northern blot analysis.  
 
For Tb11.47.0019, two main SAS locations were identified by RNA-seq (Siegel et 
al., 2010; Nilsson et al., 2010), one at position +322 relative to the original start 
codon annotation and the other at position +345. The analysis of Tb11.47.0019 
transcripts by 5'RACE identified three SASs (Figure 4.5), however, not all SASs 
used may be identified by the methodology employed. The SASs identified were 
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those at position +322/+345 and also the SAS predicted by Benz et al. (2005). The 
identification of the predicted SAS was interesting because in the RNA-seq studies 
(Siegel et al., 2010; Nilsson et al., 2010), it was only identified as a minor SAS in 
procyclic forms, but it appears to be used in slender, stumpy, and procyclic forms by 
5’RACE analysis (Figure 4.5). The usage of these SAS locations was also interesting 
because it could possibly result in the production of different length proteins from 
the Tb11.47.0019 gene. This was also supported by the identification of two bands in 
the northern blot analysis using a probe to a region of the transcript present in both 
alternatively spliced forms (Figure 4.6 C). The intensity of the signal for these two 
bands suggested that the two alternatively spliced transcript forms might have been 
present with differential abundance in the life-cycle stages analysed. However, 
unfortunately, variability in the results obtained from northern blot analyses meant 
that the life-cycle abundance was unable to be determined.  
 
From the northern blot analyses of Tb11.47.0019 transcripts with the 'b' region 
probe, (Figure 4.6) it was assumed that the upper band represented the longer 
transcript form (produced from usage of the predicted SAS), but this was not 
confirmed. Unfortunately, northern blot analyses using a probe to a region present 
only in the longer transcript form (probe to region 'a') did not result in the detection 
of any signal (Figure 4.6). However, RNAi-mediated transcript ablation against the 
'b' region, which should ablate the long and short transcript forms, resulted in a 
decrease in the abundance of both bands (Figure 4.13 C). Therefore, it appears that 
the upper band contains the 'b' region sequence and so would support the assumption 
that the upper band detected was the long transcript form. 
 
The use of the predicted SAS and those at position +322/+345 would be expected to 
produce encoded proteins of two different lengths, a long (487aa) form (from the 
predicted SAS) and a short (360aa) form (from the SASs at +322/+345). The long 
protein form sequence was found to include a predicted signal peptide and one or 
two predicted transmembrane helices, which were absent from the short protein form 
sequence (Figures 4.8 and 4.10), but both were predicted to contain an UBA/TS-N 
domain (Figures 4.7 and 4.10). Bioinformatic predictions regarding the cellular 
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localisation for these two protein sequences resulted in very different results (Table 
4.5). Presumably due to the presence of the signal peptide and transmembrane 
helices, the long protein form was predicted to be localised to the plasma membrane, 
Golgi, extracellular space, or endoplasmic reticulum. In contrast, the short protein 
form was predicted to localise to the cytoskeleton, cytoplasm, mitochondrion or 
nucleus. Additionally, a dileucine motif was found in the long protein sequence but 
not the short protein sequence, however, the motif was still present in the short form 
sequence. As mentioned in Section 4.8, a limitation of these bioinformatic 
predictions is that the tools used are not optimised for use with trypanosome protein 
sequences. 
 
In T. brucei, the production of two different length proteins with different 
localisations has been demonstrated for aminoacyl-tRNA synthetases, which exhibit 
alternative transcript splicing (Rettig et al., 2011). The isoleucyl-tRNA synthetase 
(IleRS) is encoded by a single gene but shows dual localisation to the mitochondria 
and cytosol, which is achieved through the inclusion/exclusion of a mitochondrial 
targeting signal in long/short protein forms, respectively, obtained by trans-splicing 
at two different locations (Rettig et al., 2011). However, the life-cycle abundance of 
each transcript isoform was not investigated in that study. Therefore, it is possible 
that in a similar manner, the generation of different protein isoforms with different 
cellular localisations, through alternative splicing may also occur for Tb11.47.0019. 
 
In contrast to the predicted localisations for the Tb11.47.0019 long and short protein 
forms, ectopic overexpression of a Ty epitope tagged copy of either protein form 
resulted in the same punctate pattern of staining when using immunofluorescence 
analysis to detect the Ty epitope tag (Figure 4.12). Additionally, western blot 
analysis of the ectopically expressed tagged proteins produced from either the long 
or short protein form sequences revealed that both resulted in expression of the short 
protein form only (Figure 4.11). Therefore, it would appear that even when the 
upstream ATG is present, the downstream ATG is used preferentially. It was not 
determined for ectopic expression of the long Tb11.47.0019 protein sequence, 
whether the SAS present upstream in the pHD451 plasmid or the SAS at position 
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+322/+345 was used. Therefore, it is possible that the short protein form was 
produced from the long protein form sequence because the originally annotated ATG 
is not used or because trans-splicing occurred using the SAS at position +322/+345. 
 
The possibility that the use of the predicted SAS does not permit production of the 
long protein form (beginning at the originally annotated ATG start codon) would be 
consistent with the observations from the CAT reporter gene assay with this 5’UTR 
sequence (Figure 4.2 A). Additionally, the homologous proteins of the long protein 
form identified by protein-protein BLAST analysis (see Table 4.4) showed no 
homology to the N-terminal extension of the long form. Rather, in most cases the 
homology began at a downstream methionine residue (most commonly M136), 
which corresponded to the start of the homologous protein (data not shown). Even 
the protein that exhibited the most similarity, CBH17021.1 from T. brucei 
gambiense, did not share the N-terminal extension (Figure 4.9). These observations 
would support the possibility that only the short protein form of Tb11.47.0019 is 
produced. However, this would need to be determined experimentally, for example, 
by western blot analysis using an antibody raised against the Tb11.47.0019 protein 
sequence common to both protein forms.  
 
It is also possible, however, that the long protein form is not produced in slender 
form cells but is produced in stumpy form cells only. The stumpy form was the life-
cycle stage that the long transcript form originally appeared to be enriched, and it 
might be that additional/different factors, present in stumpy forms and not slender 
forms are required for expression of the long protein form. The ectopically expressed 
tagged long/short protein forms were only analysed in slender forms in this study. 
Therefore, to determine if this is the case, the experiment of western blot analysis 
using a Tb11.47.0019-specific antibody mentioned above could be used to establish 


























Functional analysis of two stumpy-enriched 





















In addition to the analysis of gene expression regulation of individual transcripts that 
are enriched in stumpy forms, proteins involved in the process of translational 
regulation were analysed. In other organisms, the control of translation can be 
achieved through regulation of the activity of individual proteins involved in 
translation, such that global levels of translation are affected. The aim of this part of 
the project was to determine if any known proteins of translation are important for 
the global downregulation of translation in stumpy forms or for the escape from 
translational repression for genes that are expressed in stumpy forms. 
 
5.1 Are any translational proteins upregulated in stumpy forms?  
 
A few proteins known in other organisms to be important in the control of translation 
were selected to assess whether they could be important in control of translation in 
stumpy forms. These proteins were eIF4E, eIF2α kinases, eIF6 and a deoxyhypusine 
synthase. As a starting point to see if any of these proteins could be interesting for 
further study, their RNA expression across the T. brucei lifecycle was investigated 
by northern blot analysis. In particular, those that would be interesting for further 
study would be any which showed enrichment in stumpy forms, as this could 
indicate that they are contributing to translational control in this life-cycle stage. 
 
5.1.1 eIF4 homologues 
One of the components of the eukaryotic translational machinery, eIF4E, which 
binds to the mRNA cap structure and to another translational component, eIF4G, is 
the limiting initiation factor in most cells and is therefore significant for establishing 
global translation rates (reviewed in) (Raught and Gingras, 1999). There are four 
potential homologues of eIF4E identified in T. brucei (Clayton and Shapira, 2007). 
These were designated TbeIF4E1-4 (Tb11.18.0004, Tb927.10.16070, Tb11.01.3630, 
Tb927.6.1870 respectively). Digoxygenin-labelled probes against 300-500nt of the 
coding sequence for each of these genes were generated using the primers 75-82 (see 
Table 2.1). These were then used in northern blot analyses, the results of which are 







Figure 5.1 Life-cycle abundance of various translational protein homologue 
transcripts. Transcript abundance was assessed through northern blot analyses using 
digoxygenin-labelled probes against 300-500nt of the coding sequence for each gene 
indicated (A: TbeIF4E1-4; B: Tb927.10.5300 [TbeIF6] and Tb927.10.2750 [putative 
deoxyhypusine synthase]). Arrowheads indicate the main band detected, the asterisk 
indicates the other band detected with the Tb927.10.2750 probe. SL: slender form; 
ST: stumpy form; PC: procyclic form. The panel below each blot shows the ethidium 
bromide staining of the rRNA present to indicate loading of each lane.  
 
The transcripts of the four eIF4E homologues were found to show lifecycle 
regulation of abundance. The TbeIF4E1 transcript appeared to be enriched in the 
slender form, TbeIF4E2 and TbeIF4E3 transcripts were downregulated in procyclic 




against the TbeIF4E3 and TbeIF4E4 transcripts also resulted in the detection of 
cross-reactive bands that may be the rRNA transcripts. Hence, the main signal 
detected by these probes is marked by an arrowhead in Figure 5.1 (A); this being 
presumed to be the TbeIF4E3 or TbeIF4E4 transcript.  
 
5.1.2 eIF2α  kinase homologues 
eIF2α kinases mediate phosphorylation of the alpha subunit of eIF2, which causes an 
inhibition of protein synthesis but activates the translation of specific transcripts, as 
part of the stress-activated regulatory pathway. There are three eIF2α kinase 
homologues identified in T. brucei (Moraes et al., 2007); these were designated 
TbeIF2K1-3 (Tb11.02.5050, Tb927.4.2500, Tb927.6.2980 respectively). 
Digoxygenin-labelled probes against 300-500nt of the coding sequence for each of 
these genes were generated using the primers 83-88 (see Table 2.1), which were then 
used in northern blot analyses. However, unfortunately the signal achieved with the 
use of these probes was not great enough to conclusively determine transcript 
abundance.  
 
5.1.3 eIF6 and deoxyhypusine homologues 
Two other translational proteins where also investigated, a putative eIF6 
(Tb927.10.5300, the selection of this gene is discussed below in Section 5.3) and a 
putative homologue of deoxyhypusine synthase (Tb927.10.2750). Mammalian eIF6 
is required for efficient translational initiation and may be rate-limiting in translation 
and growth and acts downstream of extracellular signals (Gandin et al., 2008). 
Eukaryotic eIF5A promotes translation elongation and possesses a unique 
modification of lysine to hypusine, which is required for association of eIF5A with 
ribosomes (Saini et al., 2009; Merrick, 2009). The transcript for a putative 
deoxyhypusine synthase (Tb927.10.2750) was identified as enriched in stumpy 
forms by microarray analysis (Kabani et al., 2009). Therefore, both these proteins 
appeared to be potentially interesting and digoxygenin-labelled probes against 300-
500nt of the coding sequence for each of these genes were generated using the 
primers 89-92 (see Table 2.1). 
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The results of northern blot analyses with these probes are shown in Figure 5.1 (B). 
For the putative eIF6, Tb927.10.5300, the mRNA for this gene was found strongly 
enriched in stumpy form cells compared to slender and procyclic forms. The probe 
against the putative deoxyhypusine synthase (Tb927.10.2750) resulted in the 
detection of two bands; the main band is indicated in Figure 5.1 (B) with an 
arrowhead and a higher molecular weight band is indicated with an asterisk. The 
transcript of the main band was somewhat enriched in stumpy forms and the other 
band was enriched in procyclic forms. Interestingly, three different 5’UTR lengths 
were identified for this gene, 624, 604, and 118 bp (Siegel et al., 2010). Therefore, it 
is possible that the two bands detected here could represent the transcripts with 
624/604 bp length 5’UTRs and the transcript with the 118 bp length 5’UTR. 
However, the abundance of the transcripts observed in the Siegel et al. (2010) study 
do not match the abundances shown in Figure 5.1 (B). 
 
The enrichment of the TbeIF4E4 and TbeIF6 transcripts in stumpy forms highlighted 
them as interesting for further study, as they may be contributing to the global 
repression of translation in stumpy forms and/or the escape from translational 
repression of stumpy-expressed transcripts. Therefore, further characterisation was 
made of these proteins. 
 
5.2 Preliminary analysis of TbeIF4E1-4 
 
Due to the presence of four homologues of the eIF4E protein, it was possible that 
these proteins may have different functions. One such possibility could be that one of 
the homologues functions as a negative regulator, similarly to the 4E homologous 
protein (4EHP) which binds to the mRNA cap but not to eIF4G, thereby preventing 
translation initiation. Therefore, the protein sequences of the eIF4E homologues were 
analysed for conservation of the residues found to be important in cap or eIF4G 
binding in other organisms. 
 
Firstly, a ClustalW2 multiple sequence alignment was performed with the protein 
sequences of TbeIF4E1-4, human eIF4E (accession: P06730), S. cerevisiae eIF4E 
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(accession: P07260) and Drosophila melangaster 4EHP (accession: Q8T3K5; see 
Appendix 3 for the alignment). Conservation of important residues was determined 
by the presence or absence of the same residue in the aligned position. The 
conservation of residues important for binding to the mRNA cap or eIF4G is 
summarised in Table 5.1. 
 
All of the four eIF4E homologues show some lack of conservation of residues 
important for cap binding and binding of eIF4G. The levels of conservation are 
similar to that found for the 4EHP protein. Some residues important for cap binding 
are however conserved in all the sequences analysed (W102, W166, E103, G111). 
This was also true for two residues important for eIF4G binding, G139 and W75. 
Although in TbeIF4E1 W75 was not conserved and there is a phenylalanine (F) 
residue at this position, in yeast it was found that eIF4G binding was maintained with 
a W75F mutation (Ptushkina et al., 1998), so this could represent a conservative 
mutation. 
 
Of the 14 cap binding residues investigated, 11 were found to be conserved in 
TbeIF4E1, 10 in TbeIF4E2, 7 in TbeIF4E3, 7 in TbeIF4E4 and 8 in 4EHP. 
Therefore, this would suggest that TbeIF4E1 and TbeIF4E2 would be likely to bind 
the mRNA cap, with TbeIF4E3 and TbeIF4E4 less likely. However, 4EHP also 
lacked a similar number of these residues and yet can still bind to the mRNA cap. 
Therefore, all homologues may bind the mRNA cap, but perhaps with differing 
affinities. Of the 8 eIF4G binding residues investigated, 5 were found to be 
conserved in TbeIF4E1, 3 in TbeIF4E2, 6 in TbeIF4E3, 4 in TbeIF4E4 and 5 in 
4EHP. Hence, this would suggest that TbeIF4E3 would be likely to bind to the cap. 
However, all homologues have a similar number of conserved residues to the 4EHP 
protein, which does not bind to eIF4G. Overall, therefore, prediction of eIF4G 






Table 5.1 Conservation of eIF4E residues important for cap binding or eIF4G binding in TbeIF4E1-4 and 4EHPa 
a Presence (Y) or absence (N) of residue at aligned position; in parentheses are the single letter amino acid codes for non-conserved residues, 
asterisk here indicates that this residue was found to maintain binding 
b Asterisk indicates numbering for the yeast eIF4E protein 
c 1: Morino et al. (1996), 2: Altmann and Trachsel (1989), 3: Marcotrigiano et al. (1997), 4: Ptushkina et al. (1998), 5: Marcotrigiano et al. 
(1999)
Residue Function Details Reference TbeIF4E1 TbeIF4E2 TbeIF4E3 TbeIF4E4 4EHP
Cap binding:
W43 Cap binding W43L: complete loss 1 Y N (G) Y Y N (Y)
W46 Cap binding W46L: complete loss 1 Y N (K) N (Y) N (F) Y
W56 Cap binding W56L: ~80% loss 1 Y Y N (L) N (S) N (Y)
W102 Cap binding W102L: complete loss 1 Y Y Y Y Y
W166 Cap binding W166L: complete loss 1 Y Y Y Y Y
W113 Cap binding W113L: ~80% loss 1 N (L) Y N (I) N (V) Y
W130 Cap binding W130L: complete loss 1 Y Y N (F) Y Y
E103 Strenghtens cap binding E103A: >80% loss 1 Y Y Y Y Y
G111 Cap-binding G111D: reduces affinity 2 Y Y Y Y Y
H200 Required for cap binding 1 Y Y Y N (R) Y
H37 Required for cap binding 1 N (G) N (T) N (S) N (S) N (G)
K/R112 Interacts with the cap 3 N (K) Y N (T) N (I) N (Q)
R157 Interacts with the cap 3 Y N (Q) Y Y N (K)
R/K162 Interacts with the cap 3 Y Y N (T) N (M) N (S)
eIF4G binding:
E72 * Involved in eIF4G binding Mutation reduced binding 4 Y N (E) Y N (S) N (Q)
H37 * Involved in eIF4G binding Mutation reduced binding 4 N (G) N (T) N (S) N (S) N (G)
V71 * Involved in eIF4G binding Mutation reduced binding 4 Y N (A) Y N (I) Y
G139 * Involved in eIF4G binding Mutation reduced binding 4 Y Y Y Y Y
W75 * Involved in eIF4G binding Mutation reduced binding 4 N (F*) Y Y Y Y
L131 Involved in eIF4G binding 5 N (E) N (E) N (M) Y N (E)
L/M135 Involved in eIF4G binding 5 N (I) N (V) Y N (C) Y
E140 Involved in eIF4G binding 5 Y Y Y Y Y
b  c 
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In conclusion, the residue comparison predicted no obvious differential binding to 
eIF4G of the homologues, which may result in the protein functioning as a negative 
regulator. The protein structure for each homologue was also predicted with 
homology modelling using SwissModel (http://swissmodel.expasy.org/). However, 
an interpretation of whether any of the homologues should bind to the cap or eIF4G 
could not be made from these structures. Moreover, it should be noted that 
trypanosomes possess a highly modified cap structure, termed cap-4, and four eIF4G 
homologues. Hence different interactions may be important for the binding to these 
molecules. Consequently, functional characterisation of the TbeIF4E proteins would 
be needed to determine cap binding and eIF4G binding ability. 
 
5.2.1 TbeIF4E RNAi-mediated ablation 
Due to the enrichment of the TbeIF4E4 transcript in stumpy forms (Figure 5.1 A), 
this protein appeared to be a good candidate for further study, despite the inability to 
predict whether this protein may be a negative regulator of translation through 
bioinformatic methods. Therefore, to analyse the function of TbeIF4E4, the 
transcript was ablated through RNAi. 
 
For tetracycline-inducible RNAi, the pQuadra set of plasmids (Inoue et al., 2005) 
was used. A schematic diagram of construct generation is shown in Appendix 2. The 
same amplicon used to generate the TbeIF4E4 probe for northern blot analysis 
(Section 5.1) was used for the insertion into the pQuadra 3 plasmid. Two 
independently derived stable transfectant cell lines were generated using T. b. brucei 
Lister 427 ‘single marker’ bloodstream form cells; clones B2 and B4. 
 
Unfortunately, it was subsequently discovered that another laboratory was 
investigating the TbeIF4E proteins. Therefore, work on the TbeIF4E4 protein was 
ceased. However, a preliminary analysis was made of the RNAi cell lines before this 







Figure 5.2 TbeIF4E4 RNAi-mediated ablation. A. Growth analysis following 
induction of TbeIF4E4 RNAi-mediated ablation at 0 hours with 10 µg/ml 
tetracycline, in two independently derived clones (B2 and B4). The growth of the 
parental cell line treated with 10 µg/ml tetracycline (Tet), or untreated, is shown as a 
control. The data shown is from a representative experiment. B. Northern blot 
analysis of RNA samples from induced (+ Tet) and uninduced (- Tet) cells using a 
digoxygenin-labelled probe against part of the TbeIF4E4 coding region. Shown 
below the blot is the ethidium bromide staining of rRNA present to indicate loading 
of each lane. 
 
 
Figure 5.2 (A) shows the cell growth after induction of TbeIF4E4 RNAi in each 




treated with tetracycline from a representative experiment. Inhibition of cell growth 
rate was apparent by 48 hours after the induction of RNAi with tetracycline with a 
further decrease in cells induced for TbeIF4E4 RNAi at 96 hours (22.7% and 27.5% 
of the cell concentration of uninduced cells for clone B2 and B4 respectively). 
 
Figure 5.2 (B) shows the northern blot analysis of RNA samples taken from one of 
the TbeIF4E4 cell lines induced or uninduced for RNAi and parental cells, with the 
same probe used for the northern blot analysis shown in Figure 5.1 (A). The signal 
detected of the TbeIF4E4 transcript is clear in the parental and TbeIF4E4 cell line 
RNA from 0 hours and the uninduced (- Tet) RNA samples, and is marked in Figure 
5.2 (B) with an arrowhead. At 24 hours after induction of TbeIF4E4 RNAi with 
tetracycline (+ Tet lanes), the transcript was significantly reduced in abundance. This 
was maintained throughout the duration of the experiment, although it should be 
noted that for the 72 and 96 hour ‘+ Tet’ lanes less RNA was present compared to 
the ‘- Tet’ control lanes due to the decreased cell concentration of the induced cells. 
 
Therefore, Figure 5.2 shows that induction of TbeIF4E4 RNAi results in an 
inhibition of bloodstream form cell growth rate starting at about 48 hours but 
apparent by 72 hours, and confirms knockdown of the TbeIF4E4 transcript by 
treatment with tetracycline. A preliminary investigation to assess whether the 
inhibition of cell growth rate was attributable to a block in the cell cycle was made 
(as described below in Section 5.5). However, an accumulation of cells in a 
particular phase of the cell cycle after induction of RNAi was not observed. 
 
Next, it was investigated whether TbeIF4E4 is involved in translation. If so, then this 
would suggest that it does indeed bind to the mRNA cap and eIF4G protein. 
Therefore, the polysome profiles were compared from cells induced for TbeIF4E4 
RNAi and control, uninduced, cells. 
 
This experiment involved obtaining cell lysate from TbeIF4E4 RNAi cells either 
uninduced, or induced, for 48 hours with 10 µg/ml tetracycline. Then lysates were 
layered on to a 15-50% sucrose gradient, centrifuged at 40 000 rpm for 2 hours, and 
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fractions made of a certain size (see Section 2.9.3). The absorbance was measured at 




Figure 5.3 Polysome analysis after TbeIF4E4 RNAi-mediated ablation. Cells were 
harvested for polysome analysis either from control cell populations (uninduced; A) 
or 48 hours after induction of TbeIF4E4 RNAi (B) after treatment with 100 µg/ml 
cycloheximide. Cell lysate was layered on to a 15-50% sucrose gradient, centrifuged 
at 40 000 rpm for 2 hours, and fractions taken at a set number of drops (see section 
2.9). Absorbance was measured at 254 nm throughout fractionation. Shown are the 
absorbance traces with red vertical lines separating the fractions generated. The 
control was processed in parallel with the polysome analysis of the induced cells. 
The absorbance peaks corresponding to the assumed 40S, 60S, 80S and polysome 






Unfortunately, the polysome profile of the control cells (Figure 5.3 A) did not appear 
to be very successful as the peaks of the 40S and 60S monosomal subunits, and 80S 
monosomes are not very well resolved. In contrast, the polysome analysis of induced 
cells was more successful, with the monosomal subunits, monosomes and polysomes 
being well defined on the absorbance trace (Figure 5.3 B). From comparison to 
absorbance traces from other successful polysome analyses, it appeared that there 
was a reduction in the abundance of polysomes in the induced sample. This is 
consistent with the function of eIF4E in translation initiation, because an inhibition 
of translation initiation would cause a decrease in the number of ribosomes 
associated with mRNAs. Although further confirmation would be necessary, this 
supports the function of TbeIF4E4 as an eIF4E protein. 
 
5.3 A putative eIF6 protein in T. brucei 
 
The eukaryotic translation initiation factor, eIF6, appeared to be an interesting 
candidate protein to investigate because it was upregulated in stumpy forms. Also, it 
has been found that the expression of this protein is upregulated in archaea during 
cold shock (Benelli et al., 2009) and cold shock is a trigger involved in 
differentiation in T. brucei (Engstler and Boshart, 2004). Therefore, the presence of a 
potential eIF6 homologue in T. brucei was investigated. 
 
The protein sequence for an archaeal IF6 (Sulfolobus solfataricus; accession: 
Q980G0) was used as query in a protein BLAST search against the T. brucei genome 
entries in the TriTryp database (http://tritrypdb.org/tritrypdb/). This returned one 
significant hit in the T. brucei TREU 927 genome (Tb927.10.5300; e value: 7.4 x10-
26). The same result was obtained using human eIF6 as query (accession: P56537, e 
value: 2.0 x10-80). In the TriTryp database this gene is annotated as encoding a 
putative eIF6 protein and a reciprocal BLASTP search using the protein sequence 






human  MAVRASFENNCEIGCFAKLTNTYCLVAIGGSENFYSVFEGELSDTIPVVHASIAGCRIIG 60 
TbeIF6  MTLRTRFESSDDVGVFARLTNAYCLVAAGASQNFYSVFEQELASHIPVVYTSIGGSRVVG 60 
        *::*: **.. ::* **:***:***** *.*:******* **:. ****::**.*.*::* 
 
human   RMCVGNRHGLLVPNNTTDQELQHIRNSLPDTVQIRRVEERLSALGNVTTCNDYVALVHPD 120 
TbeIF6  RLTIGNRHGLVVPSITTDQELQHLRNSLPDSVKVQMVEERLSALGNCVVCNDHVALIHTD 120 
        *: :******:**. ********:******:*::: ********** ..***:***:*.* 
 
human   LDRETEEILADVLKVEVFRQTVADQVLVGSYCVFSNQGGLVHPKTSIEDQDELSSLLQVP 180 
TbeIF6  LSRETEEVIRDTLQVQTFRTSIAENALVGSYAAVTNKGCMVHPKTPAQDMDEIASLLQVP 180 
       *.*****:: *.*:*:.** ::*::.*****...:*:* :*****. :* **::****** 
 
human   LVAGTVNRGSEVIAAGMVVNDWCAFCGLDTTSTELSVVESVFKLN---EAQPSTIATSMR 237 
TbeIF6  VVAGTINRGNAAIGSGLVVNDWAAFCGLNTTATEITVVERIFQLRRDLGGDESNLLQQLR 240 
        :****:***. .*.:*:*****.*****:**:**::*** :*:*.    .: *.:  .:* 
 
human   DSLIDSLT 245 
TbeIF6  DTLVDELA 248 
        *:*:*.*: 
 
Figure 5.4 Conservation of eIF6 sequence and structure in TbeIF6. A. ClustalW2 
alignment of the human eIF6 protein sequence (accession: P56537) and T. brucei 
eIF6 homologue (TbeIF6, Tb927.10.5300) protein sequence. Asterisk (*): single, 
fully conserved residue; colon (:): conservation between groups of strongly similar 
properties; period (.): conservation between groups of weakly similar properties. 
Underlined: region of purified mouse anti-eIF6 antibody immunogen (BD 
Biosciences). B and C. Structure model of S. cerevisiae eIF6 (from Miluzio et al. 




using SwissModel (http://swissmodel.expasy.org/) based on S. cerevisiae eIF6 PDB 
structure (1G62A), shown are the top (D) and side (E) views; blue: predicted beta 
sheets, red: predicted alpha helices. 
 
 
A ClustalW2 alignment of the human eIF6 protein sequence and the Tb927.10.5300 
protein sequence is given in Figure 5.4 (A). The sequences show a high degree of 
conservation, with most aligned residues being fully conserved, or possessing similar 
properties. 
 
The eIF6 proteins of archaebacteria and S. cerevisiae, have been shown to form a 
unique ‘pentein’ structure, formed by five quasi identical α/β subdomains arrayed 
around a five-fold axis of pseudosymmetry (Groft et al., 2000). A model of S. 
cerevisiae eIF6 is given in Figure 5.4, showing the top (B) and side (C) views (from 
(Miluzio et al., 2009). The tertiary structure of the Tb927.10.5300 protein sequence 
was predicted through homology modelling using SwissModel 
(http://swissmodel.expasy.org/) and the Protein Database (PDB) structure for S. 
cerevisiae eIF6 (accession: 1G62A).  The top and side views of the predicted model 
are shown in Figure 5.4 (D and E, respectively). 
 
Comparison of Figure 5.4 (B) with (D) and (C) with (E) reveals that the protein 
sequence of Tb927.10.5300 is predicted to form a highly similar teriary structure to 
that found for the S. cerevisiae eIF6 protein. The ‘pentein’ structure is predicted to 
form, but there are some minor differences in the exact folding. However, the 
predicted structure supports that Tb927.10.5300 may encode an eIF6 protein.   
 
In summary, the bioinformatic analyses demonstrate that there is a gene encoding a 
putative eIF6 protein in T. brucei, which shows a high degree of similarity to known 
eIF6 proteins in protein sequence and predicted structure. The protein encoded by 
Tb927.10.5300 will therefore be referred to as ‘TbeIF6’ hereafter.  
 
5.4 Analysis of TbeIF6 with RNAi-mediated transcript ablation 
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As a first step to assess the function of TbeIF6, the transcript was ablated through 
RNAi. For tetracycline-inducible RNAi, the pQuadra set of plasmids (Inoue et al., 
2005) was used, as for the TbeIF4E4 RNAi described above. Similarly, the same 
amplicon used to generate the TbeIF6 (Tb927.10.5300) probe for northern blot 
analysis (Section 5.1) was used for the insertion into the pQuadra 3 plasmid. Only 
one independently derived stable transfectant cell line was generated using T. b. 
brucei Lister 427 ‘single marker’ bloodstream form cells; additional transfectant cell 
lines could not be isolated despite multiple attempts. 
 
Figure 5.5 (A) shows the cell growth after induction of TbeIF6 RNAi compared to 
the parental cell line also treated with tetracycline, from a representative experiment. 
The data shown is the cell concentration as a percentage of that of uninduced cells 
and the mean ± standard error of two independent experiments. Inhibition of cell 
growth rate was apparent by 48 hours after the induction of RNAi with tetracycline, 
with complete growth inhibition leading to a further large decrease in the cell 
concentration of cells induced for TbeIF6 RNAi at 96 hours (9.9% of the cell 
concentration of uninduced cells). 
 
Figure 5.5 (B) shows a northern blot analysis of RNA samples taken from cells 
induced or uninduced for TbeIF6 RNAi or parental cells, using the same probe used 
for the northern blot analysis shown in Figure 5.1 (B). The signal detected of the 
TbeIF6 transcript was clear in the parental and TbeIF4E4 cell line RNA from 0 hours 
and the uninduced (- Tet) RNA samples, and is marked in Figure 5.5 (B) with an 
arrowhead. As with TbeIF4E4 RNAi, the growth inhibition of induced cells at 72 
and 96 hours resulted in a reduction in the amount of RNA collected from these cells. 
Nonetheless, at 24 hours after induction of TbeIF6 RNAi, the TbeIF6 transcript was 
significantly reduced in abundance compared to the RNA from uninduced cells. This 
was maintained throughout the duration of the experiment, although the apparent 
further decrease in transcript abundance at 72 and 96 hours is likely to be due to the 







Figure 5.5 TbeIF6 RNAi-mediated ablation. A. Growth analysis following induction 
of TbeIF6 RNAi-mediated ablation with 10 µg/ml tetracycline (Tet) at 0 hours. The 
growth of the parental cell line treated with 10 µg/ml tetracycline, or untreated, is 
shown as a control. The data shown is from a representative experiment. B. Northern 
blot analysis of RNA samples from induced (+ Tet) and uninduced (- Tet) cells using 
a digoxygenin-labelled probe against part of the TbeIF6 coding region. The 
arrowhead indicates the TbeIF6 mRNA and the asterisk indicates the higher 
molecular weight band observed with TbeIF6 RNAi induction. Shown below the blot 







5.4.1 TbeIF6 RNAi induction causes the appearance of a higher molecular weight 
RNA 
Also apparent in the RNA samples from the induced cells in Figure 5.5 (B) was an 
additional band detected by the TbeIF6 probe. This band was of a higher molecular 
weight and is indicated with an asterisk at the left of the blot in Figure 5.5 (B). 
 
To investigate whether the abnormal processing of RNAs was a general phenomenon 
for mRNAs with induction of TbeIF6 RNAi, these RNA samples were also probed 
with the TbeIF4E4 probe using northern blot analysis. This is shown in Figure 5.6 
(A) and the appearance of a higher molecular weight TbeIF4E4 transcript was not 
detected in the RNA from cells induced for TbeIF6 RNAi. This suggests that 
irregular RNA processing was not a general consequence of TbeIF6 RNAi. 
 
To determine if the higher molecular weight band was derived from the TbeIF6 
RNAi plasmid, a version of the TbeIF6 probe was generated complementary to the 
antisense strand of TbeIF6 RNA (TbeIF6 ‘sense’ probe). Again, this ‘sense’ probe 
was used in northern blot analysis with the same TbeIF6 RNAi induced and 
uninduced RNA samples, the result being shown in Figure 5.5 (B). As expected, 
there was no signal detected using the ‘sense’ probe with RNA from the parental cell 
line. or uninduced RNA samples. However, a band (indicated with an arrowhead) 
and smear was detected using this probe in the RNA from induced cells (Figure 5.6 
B). This was not detected in the RNA from uninduced cells, which is consistent with 
the tight tetracycline induction seen in Figure 5.5 (B). This main band appeared to be 
a similar size to the higher molecular weight band in Figure 5.5 (B), suggesting that 















Figure 5.6 Abundance of various transcripts following TbeIF6 RNAi induction. 
Northern blot analyses with digoxgenin-labelled probes against part of the TbeIF4E4 
coding region (A), or to detect the anti-sense strand of TbeIF6 RNA (B; ‘sense’ 
probe), or against part of the INGI sequence (C). RNA samples are from the parental 
cell line and TbeIF6 RNAi cell line either induced (+ Tet) or uninduced (- Tet) at the 
times indicated in hours. The arrowheads indicate the main bands detected by the 
probes. The panel below each blot shows the ethidium bromide staining of the rRNA 
present to indicate loading of each lane. 
 
 
As eIF6 has been reported to be involved in miRNA silencing and RNAi in other 
organisms (see Section 1.5.4), it was investigated whether TbeIF6 plays a role in 
RNAi in T. brucei. Therefore, a transcript known to be subject to RNAi in T. brucei, 
the INGI retroposon, was also investigated using RNA from the TbeIF6 RNAi cell 
line. It has previously been demonstrated that RNAi deficiency through the 
generation of AGO1 knockout (ago1-/-) cells resulted in the increase in high 
molecular INGI transcripts (Janzen et al., 2006). A digoxygenin-labelled probe 
against the INGI sequence was generated via amplification of that region by PCR 
with primers 93 and 94 (see Table 2.1) on genomic DNA. The region of the INGI 
sequence selected was that used previously for an INGI probe (Janzen et al., 2006) 




The northern blot analysis using this INGI probe is shown in Figure 5.6 (C). In the 
RNA samples from the cells induced for TbeIF6 RNAi there may be an increase in 
high molecular weight INGI transcripts at 24 and 48 hours compared to the 
uninduced cells. However, the detection over some regions of the blot is obscured 
and comparison of the 48 hour induced lane to the 24 hour uninduced lane reveals 
similar detection levels of INGI transcripts. Comparison between RNA samples from 
induced and uninduced cells is also hindered in the 72 and 96 hour samples due to 
the low amounts of RNA present for the induced cells at these time points. 
 
The data presented in Figure 5.6 suggest that the induction of TbeIF6 RNAi inhibits 
the processing of the antisense TbeIF6 transcript produced from the RNAi construct, 
which does not appear to be a transcript-wide phenomenon. Also, TbeIF6 RNAi 
induction might affect the RNAi pathway as there may be some accumulation of 
high molecular weight INGI transcripts, however, further experiments would be 
needed to confirm this. 
 
5.5 Analysis of TbeIF6 through ectopic overexpression 
 
The enrichment of the TbeIF6 transcript in stumpy forms suggests that the protein 
expression may be upregulated in this lifecycle stage. Therefore, the effect of TbeIF6 
overexpression was investigated in slender form cells, to determine any effects on 
translation.  
 
The TbeIF6 protein was overexpressed though tetracycline inducible expression of a 
Ty epitope tagged ectopic copy using the pHD451 plasmid modified to insert a Ty 
tag at the C terminus of the expressed protein (see Section 4.9.1). The TbeIF6 coding 
region (excluding the stop codon) was amplified by PCR using primers 95 and 96 on 
genomic DNA. Thereafter, two independently derived stable transfectant cell lines 
(clones C5 and C1) were generated using T. b. brucei Lister 427 ‘single marker’ 




      
 
 






Figure 5.7 Ectopic expression of TbeIF6 protein with a Ty epitope tag. A. Growth 
analysis following induction of TbeIF6 ectopic expression with 10 µg/ml or 1 µg/ml 
tetracycline (+ Tet) at 0 hours and control, untreated (- Tet), cells. B. Growth of the 
parental cell line treated with 10 µg/ml or 1 µg/ml tetracycline and control, untreated, 
cells. The cell concentration of each culture was returned to ~1 x 105 cells/ml every 
48 hours. C. Western blot analysis of RNA samples from uninduced (- Tet) and 
induced (+ Tet) cells of one TbeIF6 overexpression clone, using a mouse monoclonal 
antibody to the Ty epitope tag (BB2 antibody) and anti-mouse IgG-HRP secondary 
antibody. Arrowhead indicates the ectopic Ty epitope tagged TbeIF6 protein; 
asterisk indicates a cross-reactive band. D and E. Cell cycle analysis of 250 
uninduced (D) and induced (E) cells at each time point, through staining of DNA 
with DAPI to determine nuclei and kinetoplast number (1K1N, 2K1N, 2K2N or odd 
number, where K is kinetoplast number and N is nuclei number).  
 
 
Figure 5.7 (A) shows the cell growth after induction of TbeIF6 overexpression for 
one clone with two concentrations of tetracycline (10 µg/ml and 1 µg/ml), due to 
concerns that the 10 µg/ml concentration used in earlier experiments was too high. 




that induction of TbeIF6 overexpression caused an inhibition of cell growth, present 
to a smaller extent at 48 hours but increasingly apparent after 96 and 144 hours. The 
inhibition of cell growth with TbeIF6 protein overexpression was greater in the cells 
treated with 10 µg/ml tetracycline compared to those treated with 1 µg/ml. However, 
this is unlikely to be due to an unspecific effect of tetracycline because, except for at 
the 96 hour time point, the parental cells did not show the same growth difference 
with the different tetracycline concentration treatments (Figure 5.7 B). Therefore, it 
seems likely that this was due instead to a greater induction of ectopic TbeIF6 
protein expression.  
 
The inducible expression of the TbeIF6 ectopic copy possessing a Ty epitope tag was 
verified through western blot analysis using an antibody that recognises the Ty 
epitope tag (mouse monoclonal BB2 antibody) and an anti-mouse-FITC secondary 
antibody. Representative western blots from one experiment are shown in Figure 5.7 
(C).  
 
The predicted molecular weight of the protein encoded by Tb927.10.5300 in the 
TriTryp database is ~27 kDa. The ectopic Ty epitope tagged protein migrates a little 
heavier than this, presumably due to the presence of the Ty epitope (which has an 
estimated molecular weight of 1.167 kDa), and is indicated in Figure 5.7 (C) with an 
arrowhead. The expression of the ectopic copy was very tightly inducible with 
tetracycline because expression was not detected in any of the samples from 
uninduced cells. A cross-reactive band was also detected with these antibodies (see 
also Figure 4.11) migrating at around 70 kDa. However, its presence served as a 
useful control for the presence of protein in each lane.  
 
An investigation into whether the inhibition of cell growth rate was attributable to a 
block in the cell cycle was made through analysis of cells at each time point. Cells 
were fixed with methanol, stained with the DNA stain, DAPI (4,6-diamidine-
2,phenylindole), and the number of kinetoplasts and nuclei present in each cell 
scored to determine the cell cycle stage. The categories made were 1K1N (G1 and 
S), 2K1N (G2 and mitotic), 2N2N (post-mitotic; where K is kinetoplast and N is 
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nuclei), and any other configurations were classified as ‘odd’. The frequency of each 
category in the samples of uninduced cells is shown in Figure 5.7 (D) and for 
induced cells in Figure 5.7 (E). As can be seen by comparison between the 
uninduced and induced cells, the accumulation of cells in a particular phase of the 
cell cycle after induction of ectopic protein overexpression was not observed. 
 
5.6 Is TbeIF6 upregulated during cold shock? 
 
As mentioned above, the investigation of this protein was initiated because the 
transcript was enriched in stumpy forms (Figure 5.1 B) and in archaeabacteria IF6 
was found to be upregulated during cold shock (Benelli et al., 2009). Therefore, an 
investigation was made of whether TbeIF6 can be likewise upregulated during cold 
shock.  
 
5.6.1 Detection of TbeIF6 protein with an anti-eIF6 monoclonal antibody 
For the analysis of the expression of eIF6 protein, determination of the levels of the 
endogenous protein would be most informative; therefore, an antibody to detect the 
TbeIF6 protein was sought. A monoclonal antibody raised in mice against an 
immunogen peptide of human eIF6 is commercially available (BD Biosciences). The 
peptide sequence of the immunogen is underlined in the human eIF6 sequence in 
Figure 5.4 (A) and demonstrated a good level of conservation with respect to the 
trypanosome sequence. Hence, this antibody was tested with T. brucei cell extracts 
and after some refinement a western blot protocol to successfully detect TbeIF6 was 



























Figure 5.8 Use of a monoclonal mouse anti-eIF6 antibody to detect TbeIF6 protein 
expression during cold shock. Western blot analyses to detect ectopic Ty epitope 
tagged TbeIF6 protein and endogeneous TbeIF6 protein using a monoclonal mouse 
anti-eIF6 antibody raised against a human eIF6 immunogen (BD Biosciences) and 
anti-mouse IgG-HRP secondary antibody. Cell extracts are from the TbeIF6 RNAi 
cell line (A) or the parental cell line (B), either treated (+) or untreated (-) with 
tetracycline (Tet) at the times indicated in hours; or from bloodstream form cells 
incubated at 37°C, or transferred to 27°C, or 20°C for the time indicated in hours 
(C). Cell extract previously determined to be ectopically expressing TbeIF6 is 
included in each blot (‘overexpression’ or ‘+ve control’ lanes). Ponceau staining of 
the membrane presented in A is to show protein loading. Asterisks indicate ectopic 




Western blot analyses showing the use of this antibody with an anti-mouse IgG-HRP 
secondary antibody are shown in Figure 5.8. Present on the blots shown in Figure 5.8 
(A and B) is cell extract where expression of the ectopic Ty epitope tagged TbeIF6 
protein was previously confirmed (‘overexpression’ lane) and it can be seen that the 
Ty epitope tagged TbeIF6 was clearly detected, the band migrating at the same size 
as detected with the BB2 antibody (Figure 5.7 C). This band is marked with an 
asterisk in Figure 5.8. A number of other bands were detected, but it would appear 
that endogenous TbeIF6 protein is the band that migrates just below the epitope 
tagged version (marked with an arrowhead in Figure 5.8). The additional cross-
C 
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reactive bands detected by these antibodies provided a useful means to assess protein 
loading. 
 
Figure 5.8 (A) shows cell extracts from the TbeIF6 RNAi cell line treated or 
untreated with tetracycline. Although the signal for the endogeneous TbeIF6 was 
always low, it can be seen that there was a reduction in this signal in the extracts 
from cells induced for TbeIF6 RNAi. Figure 5.8 (B) shows cell extracts from the 
parental cell line treated or untreated with tetracycline. Here, it was apparent that 
there was no reduction in the signal of the band believed to be endogeneous TbeIF6.  
 
Therefore, as this antibody successfully detects TbeIF6 protein, it could be used to 
assess TbeIF6 protein levels in response to cold shock treatment. 
 
5.6.2 TbeIF6 protein expression during cold shock treatment 
To assess the response of TbeIF6 protein expression in cells during cold shock, 
protein cell extracts were taken from T. b. brucei Lister 427 bloodstream form cells 
after growth at 37°C (0 hours) and at 30 minutes, 1, 2, and 5 hours following transfer 
of third of the cell population to 27°C or 20°C or continuation at 37°C.  
 
This experiment was performed twice, and a representative western blot analysis of 
protein cell extracts with the human anti-eIF6 antibody is shown in Figure 5.8 (C). 
Again a positive control of cell extract where expression of the ectopic Ty epitope 
tagged TbeIF6 protein was previously confirmed (‘+ve control’ lane) was included. 
The ectopic TbeIF6 protein was detected in the western blot and is indicated with an 
asterisk in Figure 5.8 (C); this provides reassurance that the band detected migrating 
below this ectopic copy above the 25 kDa marker is endogeneous TbeIF6. Although 
the detected TbeIF6 signal is faint, it was observed in both experimental replicates 




Therefore, unlike the archeaebacteria IF6, TbeIF6 protein does not appear to be 
significantly upregulated during cold shock, at least not under the conditions 
investigated. 
 
5.7 Is TbeIF6 involved in translation? 
 
To determine whether TbeIF6 is involved in translation, two types of experiment 
were performed using the RNAi and overexpression cell lines described above. 
Firstly, the synthesis of new proteins after induction of TbeIF6 overexpression or 
RNAi was determined through radiolabelling with [35S]-methionine. Secondly, the 
polysome profiles of cells were analysed following TbeIF6 overexpression or RNAi 
induction, as described above in Section 5.2.1.  
 
5.7.1 Polysome profiles of cells following TbeIF6 RNAi or protein overexpression 
The effect on translation of induction of TbeIF6 protein overexpression was assessed 
through analysis of polysome profiles (see Section 2.9). For this, after 48 hours 
growth either induced for TbeIF6 overexpression or uninduced, cells were treated 
with 100 µg/ml cycloheximide and harvested. 
 
The uninduced control sample was always processed in parallel to the induced 
sample. However, unfortunately there were problems of an unknown technical 
reason meaning that each time only one of the samples produced a successful 
absorbance trace. Absorbance traces obtained from two uninduced cell samples are 
shown in Figure 5.9 (A), and from two induced cell samples are shown in Figure 5.9 
(B). The absorbance traces at the right of Figure 5.9 (A and B) were obtained from 
samples processed together but are from cells harvested on different days. 
Confirmation of the induction, or not in the case of the uninduced cells, of ectopic 
TbeIF6 expression is shown in Figure 5.9 (E; left blot), with the samples 
corresponding to the absorbance traces marked with an asterisk at the base of the 
blot. The ponceau staining of the membrane is also shown to confirm the presence of 




Comparison of absorbance traces shown in Figure 5.9 (A) with (B) suggests a 
decreased level of 60S subunits, 80S monosomes and possibly polysomes in the 
induced cells. However, for a firm conclusion to be made this experiment would 
need to be repeated and absorbance traces obtained from uninduced and induced 
cells processed in parallel compared.  
 
Additionally, the cells were analysed 48 hours after induction of TbeIF6 
overexpression and at this time point there was a difference in the growth rate of 
uninduced and induced cells, which could affect the polysome profiles obtained. 
Therefore, cells were instead harvested at 24 hours following induction. 
Unfortunately, however, there was an unknown technical problem resulting in the 




















        








     


















Figure 5.9 Polysome analysis after TbeIF6 ectopic overexpression or RNAi. Cells 
were harvested for polysome analysis either from control cell populations 
(uninduced; A), 48 hours after induction of TbeIF6 ectopic expression (B), or 24 
hours after induction of TbeIF6 ectopic expression (C), or 48 hours after induction of 
TbeIF6 RNAi (D), after treatment with 100 µg/ml cycloheximide. Cell lysate was 
layered on to a 15-50% sucrose gradient, centrifuged at 40 000 rpm for 2 hours, and 
fractions taken at a set number of drops (see Section 2.9). Absorbance was measured 
at 254 nm throughout fractionation. Shown are the absorbance traces with red 
vertical lines separating the fractions generated. The absorbance peaks corresponding 
to the assumed 40S, 60S, 80S and polysome locations are indicated. E. Western blot 
analyses of cell extracts taken at the time of cell harvest, stained with BB2 antibody 
(left panel) or anti-eIF6 antibody (right panel). Ponceau staining of the membrane 
presented in the left panel is to show protein loading. Asterisks at the base of the left 
blot indicate samples corresponding to the absorbance traces in the right panels of A 
and B. Asterisk at the base of the right blot indicates sample corresponding to 
absorbance trace in C. Arrowhead: ectopic Ty epitope tagged TbeIF6; Tet: 
tetracycline; ‘+ve control’: cell extract previously determined to express ectopic Ty 
epitope tagged TbeIF6; protein marker is in kilodaltons (kDa). 
 
 
Figure 5.9 (C) shows the absorbance trace obtained from the induced cell sample. 
This may suggest that there is a decrease in the 80S monosomes present in these 
cells. This would be consistent with the role of eIF6 in other organisms as a molecule 
that prevents association of 40S and 60S subunits and therefore, the formation of 80S 
monosomes. The expression of the ectopic TbeIF6 protein was again confirmed by 




The effect of TbeIF6 RNAi induction on translation was also investigated through 
polysome analysis. Again, unfortunately there were problems with the control, 
uninduced, polysome analysis. Therefore, only the absorbance trace obtained from 
the induced cells (48 hours after induction) is shown in Figure 5.9 (D). In 
comparison to absorbance traces from other successful polysome analyses, it would 
suggest that here there was a reduction in the abundance of 60S monosomal subunits, 
80S monosomes, and polysomes. This would be consistent with the proposed 
function of eIF6 in 60S biogenesis. However, this experiment would need to be 
repeated before any such conclusions could be made. 
 
5.7.2 Protein synthesis following TbeIF6 RNAi or protein overexpression  
The experiment of [35S]-methionine radiolabelling was performed as described in 
Section 2.10 (performed by Dr. Terry Smith, University of St. Andrews). Each cell 
line investigated was either treated with 1 µg/ml tetracycline to induced protein 
overexpression/RNAi or left untreated and, ~24 hours later, following transfer into 
methionine-free media, incubated with 10 mCi [35S]-methionine for 1 hour. Cell 
lysate was analysed by SDS-PAGE, stained by fluorography or with Coomassie. 
 
This experiment was performed twice and the results from one representative 
experiment are shown in Figure 5.10 (A). As can be seen, induction of TbeIF6 RNAi 
or induction of TbeIF6 protein overexpression caused a decrease in protein synthesis 
compared to the uninduced controls. This decrease was not observed with the 
control, parental cell line treated with tetracycline. 
 
In addition to SDS-PAGE analysis, radiolabel incorporation in triplicate samples 
taken from each cell line +/- tetracycline was quantified through by scintillation 
counting. The mean counts ± standard error are presented in Figure 5.10 (B) along 
with the radiolabel incorporation in cells treated with tetracycline as a percentage of 











   
Figure 5.10 Analysis of protein synthesis following TbeIF6 RNAi or ectopic 
overexpression induction. A. TbeIF6 RNAi or TbeIF6 protein overexpression (clones 
C5 and C1) cell lines were either treated with 1 µg/ml tetracycline (+ Tet) to induce 
RNAi/protein overexpression or left untreated (- Tet) and ~24 hours later, following 
transfer into methionine-free media, incubated with 10 mCi [35S]-methionine for 1 
hour. The parental cell line was included as a control. Cell lysate was analysed by 
SDS-PAGE, stained by fluorography or with Coomassie. B. Mean scintillation 
counts ± standard error of triplicate samples taken from each cell line +/- 
tetracycline. Above is shown the radiolabel incorporation in cells treated with 
tetracycline as a percentage of that for the respective control, uninduced cells. C and 
D. Western blot analyses with extracts from cells prior to induction (0 hours), prior 
to radiolabelling (20 hours) and 48 hours following induction for the radiolabelling 
experiment presented in A and B. A mouse anti-eIF6 antibody and anti-mouse IgG-
HRP secondary antibody were used to detect the ectopic Ty epitope tagged TbeIF6 
protein (indicated with an asterisk) and endogeneous TbeIF6 protein (indicated with 
arrowheads). Protein size is shown in kilodaltons (kDa). 
 
 
tetracycline exhibited a similar incorporation of radiolabel. This was also true for the 
parental cell line treated with tetracycline (96.72% of the incorporation of untreated 
cells), demonstrating that treatment with tetracycline does not significantly affect 
radiolabel incorporation. However, induction of TbeIF6 RNAi caused a reduction of 
radiolabel incorporation to 72.17% of the uninduced control. Likewise, induction of 
TbeIF6 overexpression resulted in a reduction of radiolabel incorporation to a greater 




In this experiment, the induction of TbeIF6 RNAi or protein overexpression at 20 
hours and 48 hours after induction was confirmed through western blot analysis 
using a mouse anti-eIF6 antibody raised against the human eIF6 protein (BD 
Biosciences) and an anti-mouse IgG-HRP antibody. Shown in Figure 5.10 are the 
resulting western blots for TbeIF6 RNAi (C) and for one of the TbeIF6 
overexpression clones (D). In both blots the endogenous TbeIF6 protein is indicated 
with the arrowhead and the ectopic Ty epitope tagged TbeIF6 is indicated with an 
asterisk. Although the signal of the endogeneous TbeIF6 protein is weak in the blot 
of the RNAi samples, there was clear depletion in the tetracycline treated samples. 
The ectopic expression of TbeIF6 was apparent in the tetracycline treated samples in 
the blot shown in Figure 5.10 (D) and absent from the untreated samples. Here, a 
positive control of sample from cells previously determined as ectopically 
overexpressing the TbeIF6 protein was included. The parental cells showed no 
change in TbeIF6 protein expression, as expected.  
 
Despite the difficulties with these polysome analyses, from the data presented in 
Figure 5.10 it is apparent that TbeIF6 is involved in protein synthesis, as induction of 
RNAi and protein overexpression result in greatly reduced levels of protein 
synthesis. Analysis of the polysome profiles of induced cells (Figure 5.9) suggests 
that this may be due to decreased levels of ribosomal subunits/monosomes, leading 
to a decrease in polysomes. However, at this stage firm conclusions cannot be drawn 
from these experiments, these would need to be resolved and the experiments 
repeated to identify the mechanisms by which TbeIF6 is involved in protein 
synthesis.  
 
5.8 Is TbeIF6 involved in differentiation? 
 
Due to the strong enrichment of the TbeIF6 (Tb927.10.5300) transcript in stumpy 
forms compared to other life-cycle stages (Figure 5.1 B), it was postulated that this 
protein might play a role in differentiation to the procyclic form. To investigate this 
possibility, the differentiation ability of cells induced for TbeIF6 RNAi or 
overexpression was tested. If the TbeIF6 protein is involved in differentiation then 
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the cells induced for RNAi should exhibit a reduced ability to differentiate and those 
induced for protein overexpression might exhibit an increased ability. 
 
For this experiment, cells were either induced (treated with 1 µg/ml tetracycline) or 
uninduced and both populations were either treated with 6mM cis-aconitate or 
untreated. After tetracycline/cis-aconitate addition, all cells were transferred to 27°C 
and differentiation was assessed through EP-procyclin expression 72 hours later. As 
a control, the differentiation of the parental cells under the same conditions was also 
assessed. EP-procyclin expression was determined by fluorescence-activated cell 
sorting after staining with an EP-procyclin antibody, a FITC-labelled secondary 
antibody and a DNA stain, DAPI (see Section 2.8.3). A sample of procyclic cells was 
also stained to serve as a positive control for EP-procyclin expression. 
 
The results obtained from fluorescence-activated cell sorting were analysed in 
comparison to the procyclic cell sample. The strategy used for analysis of each 
sample is given in Figure 5.11. For the procyclic form cell sample two cell 
populations were gated on the plot of forward and side scatter (Figure 5.11 A). These 
were of the ‘intact’ cells (94% of the total population) and ‘compromised’ cells 
(3.93%), determined by the cell size and together with the DAPI staining of each 
population. The ‘intact’ population was further analysed through selection of 
‘singlet’ cells (87.7% of the ‘intact’ population) to exclude any aggregated cells 
(Figure 5.11 B). The DAPI and FITC staining of this population was then analysed 
for cells positive for FITC staining (98.3% of the ‘singlet’ population; Figure 5.11 
C). Therefore, 98.3% of the intact, singular material in the procyclic form sample 
















































































Figure 5.11 Pseudo-colour dot plots obtained from fluorescence-activated cell 
sorting analysis. Cells were analysed after staining with an EP-procyclin antibody, 
FITC-labelled anti-mouse IgG antibody and a DNA stain, DAPI (see Section 2.8.3). 
A-C: procyclic forms cell sample (positive control); D-F: one replicate of parental 
cells in the absence of tetracycline but treated with 6mM cis-aconitate. Pink boxes 
(gates) represent cell populations selected and percentages of cells within that 







These gating parameters were transferred on to the other samples and the suitability 
of the gates for analysis of the other samples was assessed. As an example, one 
replicate of the parental cells untreated with tetracycline but treated with cis-
aconitate is shown with the ‘intact’ and ‘compromised’ gates (Figure 5.11 D), 
‘singlet’ gate (Figure 5.11 E), and cells positive for FITC staining (Figure 5.11 F). 
Each experimental condition of each cell lines was performed in triplicate. The mean 
for each of the percentage of intact, singular material positive for EP-procyclin 
expression is shown in Table 5.2. 
 
 
Table 5.2 Percentage of cells positive for EP-procyclin expression in the intact, 
singular material, as determined by fluorescence-activated cell sortinga. 
 
 
a Tet: 1 µg/ml tetracycline; CA: 6mM cis-aconitate; percentages are the mean 
obtained for triplicate cultures 
 
 
Notably, the TbeIF6 overexpression cell line had a very low level of differentiation 
competence (17.7% of cells positive for EP-procyclin expression in uninduced cells 
treated with cis-aconitate). The parental cell line had a greater differentiation 
competence (38.4%) and the RNAi cell line even greater (66.1%). All cell lines 
exhibited a minimal differentiation competence when untreated with cis-aconitate. 
However, induction of TbeIF6 RNAi or overexpression did not greatly affect the 
differentiation ability of the respective cell line. In both cases there was a minor 
reduction in the percentage of EP-procyclin positive cells (66.1% to 63.8% and 
17.7% to 15.5% respectively), but this was also observed for the parental cell line 
treated with tetracycline (38.4% to 33.7%).  
 
Therefore, the result of this experiment suggests that induction of either TbeIF6 
RNAi or overexpression does not detectably affect the ability of cells to differentiate 
to the procyclic form.  
Cell line + CA - CA + CA - CA
Parental 33.7 0.4 38.4 0.5
RNAi 63.8 3.9 66.1 4.0
Overexpression 15.5 0.2 17.7 0.2




Translational activity is often controlled through regulation of components of the 
translational machinery. Commonly regulated proteins include a member of the cap-
binding complex, eIF4E, and eIF2α by phosphorylation. Additionally, other proteins 
such as eIF6 can regulate the formation of functional 80S ribosomes. As an initial 
assessment of whether any of these proteins may be involved in translational control 
in stumpy form T. brucei, the expression profiles of some regulatory protein 
homologues were investigated with northern blot analysis. Because stumpy forms 
exhibit translational repression (Brecht and Parsons, 1998), any transcripts enriched 
in this lifecycle stage are likely to be interesting for further study. 
 
5.9.1 TbeIF4Es 
It was particularly interesting that one of the four T. brucei eIF4E homologues, 
TbeIF4E4, was identified as enriched in stumpy forms by northern blot analysis 
(Figure 5.1 A). It has been previously suggested that the multiple trypanosomatid 
eIF4F isoforms could be associated with the different lifecycle stages (Dhalia et al., 
2005), however, Freire et al. (2011) reported that there was little variation in the 
mRNA levels of each TbeIF4E between slender and procyclic forms. In contrast, 
here it was observed that TbeIF4E1 was enriched in slender forms, TbeIF4E2 and 
TbeIF4E3 downregulated in procyclic forms, and TbeIF4E4 enriched in stumpy 
forms (Figure 5.1 A). It is also possible that these homologues may exhibit different 
functions, such as acting as a negative regulator of translation by binding to the 
mRNA cap but not eIF4G, similarly to the binding pattern of 4EHP. However, an 
investigation of potentially conserved cap-binding or eIF4G-binding residues in each 
homologue (Table 5.1) indicated that each homologue exhibited varying degrees of 
conservation and, therefore, did not help identify any such function. Additionally, 
this analysis was hampered by the possibility that different residues may be involved 
in T. brucei eIF4E interactions, due to the use of a highly modified mRNA cap 
structure, cap 4, and the presence of multiple eIF4G homologues (Yoffe et al., 2009).  
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As TbeIF4E4 was enriched in stumpy forms it was selected for further analysis using 
RNAi-mediated transcript ablation. A preliminary analysis of the effect of RNAi-
mediated transcript ablation revealed that TbeIF4E4 knockdown produced a decrease 
in cell growth rate that was apparent at 72 hours but also present to a smaller degree 
at 48 hours after induction (Figure 5.2). This result was very similar to the effect on 
cell growth of TbeIF4E4 RNAi in slender bloodstream forms reported elsewhere 
(Freire et al., 2011). Freire et al. (2011) also reported decreased protein synthesis 
following induction of TbeIF4E1/TbeIF4E4 double RNAi. Consistent with this, 
polysome analysis of cells induced for TbeIF4E4 RNAi indicated a decrease in 
polysome abundance and, therefore, a role in translation (Figure 5.3). However, this 
polysome analysis was inconclusive due to a problem with the resolution of the 
profile obtained for the uninduced control (Figure 5.3). Only this preliminary 
analysis was made, due to the discovery that another group was working on these 
eIF4E homologues. 
 
5.9.2 TbeIF2Ks and putative deoxyhypusine synthetase 
Due to the identification that eIF2α kinases are involved in differentiation in T. cruzi 
and Leishmania (see Section 1.7.5), it is unfortunate that the northern blot analyses 
for the T. brucei eIF2α kinases were unsuccessful at determining lifecycle 
abundance. However, a later Illumina digital tag RNA sequencing experiment (see 
Chapter 6) indicates that the TbeIF2K2 (Tb927.4.5200) transcript is enriched in 
stumpy form polysome-associated RNA compared to slender form polysome-
associated RNA (4.01 fold-change, p = 0), and so this transcript might exhibit 
increased translation in stumpy forms. It seems likely that these proteins may be 
interesting for further study in stumpy form T. brucei, due to the recently discovered 
role for these proteins in differentiation in closely related organisms. Likewise, the 
putative deoxyhypusine synthetase (Tb927.10.2750) may also be interesting for 
further study, due to their slight enrichment in stumpy forms (Figure 5.1 B), and the 
reported drug target potential of deoxyhypusine synthetase proteins in Plasmodium 




One eIF6 homologue was identified in the T. brucei genome, this being 
Tb927.10.5300, and was, therefore, named TbeIF6. The sequence of this protein was 
also predicted to form the highly conserved pentein structure of eIF6 (Groft et al., 
2000) (Figure 5.4). Interestingly, it was discovered that the mRNA of this gene was 
strongly enriched in stumpy forms (Figure 5.1 B). Due to the anti-association factor 
property of eIF6, it provides a connection between 60S ribosome biogenesis and 
translation, which may be regulated by extracellular signalling (Miluzio et al. 2009). 
Therefore, this appeared to be an interesting protein to investigate further by RNAi-
mediated transcript ablation and ectopic overexpression of a Ty-epitope tagged 
protein copy. 
 
Induction of either TbeIF6 RNAi or ectopic overexpression resulted in a decrease in 
the growth rate of slender bloodstream forms (Figures 5.5 A and 5.7 A). Following 
induction, the decreased growth rates were present to a small degree at 48 hours post 
induction and growth inhibition steadily increased at later time points measured. The 
decreased growth rates were likely due to reductions in the level of protein synthesis 
in induced cells (Figure 5.10), indicating a role for TbeIF6 in translation. Polysome 
profiles indicated that the reduced protein synthesis was possibly due to 
perturbations of translation in induced cells (Figure 5.9), however, technical 
difficulties meant that profiles obtained from uninduced and induced cells could not 
be directly compared and, thus, firm conclusions could not be made. The indication 
that there was a decreased level of 60S subunits, 80S monosomes and possibly 
polysomes in the cells induced for TbeIF6 RNAi (Figure 5.9 D) has also been 
reported following eIF6 RNAi induction in yeast (Si and Maitra, 1999), supporting 
this suggestion. 
 
Due to the enrichment of TbeIF6 in stumpy forms, the effect of RNAi and protein 
overexpression on differentiation capacity was assessed. However, no effect on 
differentiation to the procyclic form was observed (Table 5.2). It should be noted, 
however, that the methodology used in this analysis was not optimal, because the 
cells were examined for differentiation 72 hours after induction of RNAi or protein 
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overexpression. At that time there is a significant decrease in the growth rate 
(Figures 5.5 A and 5.7 A), meaning that there may have been secondary effects on 
differentiation following induction. Also, there was a high level of cell death in each 
treatment condition, possibly due to the transfer of cells to 27°C. The mean 
percentage of each bloodstream form population assumed to represent dead cells was 
43.6, in contrast to 3.93% for the procyclic form population. The bloodstream form 
cells were believed to have a low differentiation capacity, so analysis was made at 72 
hours after cis-aconitate treatment to maximise the percentage of differentiated cells. 
However, the low percentages of differentiated cells observed indicate that this 
approach may not have been successful. To resolve this question, it would be 
necessary to analyse the effect of RNAi and protein overexpression on differentiation 
capacity in pleomorphic trypanosomes. However, there was great difficulty in 
obtaining the transfectant RNAi and protein overexpression cell lines using 
monomorphic cells, so these constructs would not be ideal for transfection using 
pleomorphic cells as this procedure is of a lower efficiency. 
 
The reason for the observation of the appearance of a higher molecular weight 
TbeIF6 RNA species upon induction of TbeIF6 RNAi (Figure 5.5 B) is unclear. 
Investigation of another mRNA, TbeIF4E4, in the cells induced for TbeIF6 RNAi, 
revealed that the mRNA was the same molecular weight as in uninduced cells 
(Figure 5.6 A), suggesting that the appearance of higher molecular weight mRNAs 
was not a general consequence of TbeIF6 RNAi induction. However, it could be 
possible that this effect only occurs in a subset of transcripts, that includes TbeIF6 
but not TbeIF4E4.  
 
A role for TbeIF6 in RNAi was also investigated and induction of TbeIF6 RNAi may 
affect the RNAi pathway because there was a possible increase in high molecular 
weight INGI transcripts at 48 hours after TbeIF6 RNAi induction (Figure 5.6 C). 
This would be consistent with some other studies, as eIF6 has been reported to be 
involved in miRNA silencing and RNAi in other organisms (see Section 1.5.4). 
However, further experiments are needed to confirm the involvement of TbeIF6 in 
the RNAi response. Firstly, the northern blot analysis to identify the high molecular 
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weight INGI transcripts needs to be repeated to obtain a more conclusive result. 
Also, SLACS transcripts could be investigated in a similar manner as these are 
normally suppressed through RNAi (Shi et al., 2004). RNAi function could also be 
tested through the ability of cells induced for TbeIF6 RNAi to produce the FAT 
phenotype following electroporation of α-tubulin dsRNA, similarly to the analysis 
performed for AGO1 RNAi (Shi et al., 2004).   
 
The successful use of the anti-eIF6 antibody (BD Biosciences) to detect TbeIF6 was 
particularly valuable. Although other higher molecular weight proteins were detected 
with the antibody, these appear to be de to cross-reactivity of the antibody, because 
only the signal believed to be TbeIF6 was lost upon induction of TbeIF6 RNAi 
(Figure 5.8 A). This antibody would be very informative for other analyses of 
TbeIF6, such as investigation of the lifecycle abundance of TbeIF6 protein, to 
determine whether there is enrichment in stumpy forms corresponding to the 
enrichment of TbeIF6 mRNA in this lifecycle stage. One analysis that this antibody 
allowed was an investigation as to whether TbeIF6 is upregulated during cold shock, 
similarly to aIF6 in Archaea (Benelli et al., 2009).  
 
For this experiment, the cold shock temperatures chosen were 27°C and 20°C, the 
temperature found to increase sensitivity to cis-aconitate (Engstler and Boshart, 
2004). The time-range of cold shock treatment ranged from 30 minutes to 5 hours, 
because in Archaea upregulation of aIF6 was observed at 30 minutes of treatment 
(Benelli et al., 2009), and additional time-points were made after that time to allow 
for a possible increased time for upregulation in T. brucei. However, no upregulation 
of TbeIF6 was observed in two experimental replicates at either cold shock 
temperature or at any time investigated (Figure 5.8 C).  
 
It appears possible that eIF6 may contribute to the translational repression observed 
in stumpy forms (Brecht and Parsons, 1998), due to the enrichment of TbeIF6 in this 
life-cycle stage (Figure 5.1 B) and the decreased protein synthesis observed with 
TbeIF6 protein overexpression (Figure 5.10) This might be unusual because 
increased levels of eIF6 have been associated with proliferating cells in other 
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organisms (Miluzio et al. 2009), but stumpy form cells are non-proliferative. 
Therefore, it would have been interesting if TbeIF6 RNAi or overexpression affected 
the ability of cells to differentiate to the procyclic form. In the experiments 










































































A comparison of the polysome profiles for different life-cycle stages has 
demonstrated that stumpy form T. brucei shows a dramatic decrease in translational 
competence compared to the slender form and the procyclic form (Brecht and 
Parsons, 1998). Through the comparison of 2D-PAGE with radiolabelled 
methionine-proteins for these life-cycle stages, stumpy forms also showed decreased 
protein synthesis (Shapiro and Kimmel, 1987). As stumpy forms are non-
proliferative but slender and procyclic forms are proliferative this decrease in 
translation and therefore, protein synthesis, is perhaps expected. However, there are 
some transcripts that are expressed and so translated in stumpy forms, for example, 
the ESAG9 family of proteins (Barnwell et al., 2010) and PAD1 (Dean et al., 2009). 
These must be part of a small subset of transcripts that escape the normal 
translational repression in stumpy forms. As stumpy forms are believed to be 
preadapted for transmission to the insect vector, these transcripts could be genes 
involved in parasite transmission or competence for differentiation to the procyclic 
form. Therefore, these genes could be of great interest and importance. The aim of 
the experiments outlined in this chapter was to identify these genes that escape the 
translational repression in stumpy forms. 
 
To investigate the global patterns of translation during differentiation and between 
life-cycle stages, analyses were made between the newly synthesised proteins during 
the differentiation of stumpy forms to procyclic forms and the polysome-associated 
transcripts in different life-cycle stages. These global analyses involved two 
experiments. The first experiment involved comparison of SDS-PAGE with [35S]-
methionine-labelled proteins collected at various time-points throughout 
synchronous differentiation to procyclic forms stimulated by addition of cis-
aconitate. This sought to identify any increase in the expression of different sets of 
proteins, or individual proteins, expressed in stumpy forms or throughout 
differentiation. To quantitate changes, radiolabelled proteins at each time-point were 
precipitated with TCA and radiolabel incorporation of the samples measured, to 
266 
investigate the overall amount of protein synthesis and the dynamics of this 
throughout differentiation.  
 
A second approach involved comparison of the abundance of mRNA transcripts in 
four cell samples: total RNA from bloodstream-form monomorphic cells, total RNA 
from stumpy form cells, polysomal mRNA from bloodstream form monomorphic 
cells, and polysomal mRNA from stumpy forms. The aim of this experiment was to 
identify which transcripts in stumpy forms showed polysome-association, and so 
were actively translated. It was hoped this would assist the identification of genes 
important for parasite transmission or competence for differentiation to procyclic 
forms. 
 
6.2 Radioactive methionine labelling throughout stumpy form to procyclic form 
differentiation 
 
To investigate if there are specific proteins or protein subsets that escape 
translational repression in stumpy forms and if this profile changes throughout the 
differentiation to procyclic forms, newly synthesised proteins were analysed by 
radiolabelling with [35S]-methionine. Trypanosomes of the pleomorphic T. b. brucei 
AnTat1.1 strain, were purified from mice 6 days post-infection (when the cells were 
>80% stumpy by morphology), resuspended in HMI-9 media and treated with 6mM 
cis-aconitate; except for a small volume which were left untreated as a control. The 
remainder of the experiment was performed by Dr. Terry Smith (University of St. 
Andrews), as described in Section 2.10. At 1, 2, 4, 6, 8, 12, and 24 hours after 
addition of cis-aconitate, cell lysate samples were made following incubation with 10 
mCi [35S]-methionine for one hour. Proteins in each sample were analysed by SDS-
PAGE, stained with Coomassie or analysed by fluorography. This experiment was 
repeated twice, with similar results observed both times; the results of one 
representative experiment are discussed below.  
 
In this experiment, cells were pulse labelled with radiolabelled methionine such that 
only newly synthesised proteins would be labelled. Therefore, by analysing the 
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profile of radiolabelled proteins by fluorography it was possible to examine the 
proteins synthesised at different time points throughout differentiation. As expected, 
there was an overall increase in the amount of radiolabelled protein, and therefore 
protein synthesis, in the time-course of differentiation from stumpy forms 
(represented by the 0 hour time-point) to procyclic forms (Figure 6.1 A; shown is 
only the 8 hour time-point). This was not accounted for by an increase in cell number 
because during differentiation with cis-aconitate the first cell divisions occur after 10 
hours, whereas here the increase in radiolabelled protein was observed at 8 hours. 
However, the resolution of the gels was limited and no differential expression of 
specific proteins or subsets of proteins was detected during the time course. Analysis 
of the total loaded protein by Coomassie-staining (Figure 6.1 B) revealed some small 
variations in the loading of protein between samples, however, this variation could 
not account for the observed increase in protein synthesis throughout differentiation 





Figure 6.1 Analysis of protein synthesis throughout differentiation by [35S]-
methionine labelling. 6mM cis-aconitate was added to pleomorphic stumpy form T. 
b. brucei AnTat1.1 cells, followed by labelling with [35S]-methionine for one hour at 
the time indicated post-addition of cis-aconitate (hr). The 0 hr time-point represents 
stumpy form cells. Monomorphic slender bloodstream form (BSF) and established 
procyclic form (PCF) cultures were also analysed. Protein samples were separated by 
SDS-PAGE and stained either by fluorography (A) to detect [35S]-labelled proteins 
or with Coomassie (B) to show loading.  
 
 
The radiolabelling of newly synthesised proteins in this experiment was also 
analysed by scintillation counting after TCA precipitation of the proteins in each 
sample. This allowed the quantification of the amount of incorporation of the 
radiolabel, and so the amount of new protein synthesis for each sample. After cells 
were incubated for one hour with [35S]-methionine, triplicate samples were taken for 




along with the mean count as a percentage of the mean count for established 





Figure 6.2 Mean scintillation counts of [35S]-methionine incorporation during 
differentiation from stumpy form to procyclic form. Triplicate samples of cells 
labelled with [35S]-methionine for one hour were TCA-precipitated and scintillation 
counts measured to determine protein synthesis. Shown is the mean scintillation 
count ± standard error. Samples were taken at various time-points, shown in hours 
(h), post-addition of cis-aconitate (6mM); 0 h represents stumpy form cells. 
Established procyclic form cells (427 449 strain; PCF) and slender bloodstream 
monomorphic cells (single marker strain; BSF) were also analysed for comparison. 
Shown on the right y-axis is the mean count as a percentage of the mean count for 
the established procyclic form cells (100%), these values also being shown above 
each data point. The experiment was performed twice and the numbers in 
parentheses are those obtained from the second experiment. 
 
 
Stumpy form cells, represented by the 0 hour time-point, showed a relatively low 
level of protein synthesis compared to both established procyclic form cells and 
bloodstream monomorphic cells. However, the amount of protein synthesis increased 
with time during differentiation of the stumpy forms to procyclic forms upon 
addition of 6mM cis-aconitate. At 8 hours post-addition, the level of protein 
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synthesis (88%) approached that seen for established procyclic forms. This showed 
that there was an increase in translation throughout differentiation and, hence, release 
from the translational repression seen in stumpy forms. Also shown in Figure 6.2 are 
the derived values of the mean incorporation expressed as a percentage of the mean 
for established procyclic form cells (100%) for the other of these two experiments. 
Moreover, for one of the experiments the mean count at 24 hour post-addition of cis-
aconitate was 117% of the established procyclic form mean, demonstrating that the 
level of protein synthesis in these cells becomes equivalent to established procyclic 
form cells (unfortunately, in one experiment contamination with bacteria prevented a 
24 hour sample from being assayed). Notably, the largest increase in protein 
synthesis between the time-points in both experiments was between 4 and 6 hours 
after the initiation of differentiation (Figure 6.2).  
 
It can be concluded from this experiment that stumpy form cells exhibit a low level 
of protein synthesis compared to the proliferative bloodstream and procyclic forms, 
matching earlier studies. However, the level of protein synthesis increases 
throughout differentiation to the procyclic form, particularly after 4 hours, revealing 
the release from translational repression. However, the upregulation of expression of 
individual proteins in either stumpy form cells or throughout differentiation was not 
sufficiently resolved using the methods employed. 
 
6.3 Investigation of stumpy form polysome-associated transcripts using Illumina 
digital tag RNA sequencing 
 
In order to resolve proteins that change in expression in stumpy forms or throughout 
differentiation, an investigation was made at the RNA level. Specifically, to identify 
which mRNA transcripts escape stumpy form global translational repression, and 
therefore, are actively translated, the polysome-associated mRNAs were compared 
with total mRNA from stumpy forms (AnTat1.1 strain) and with total mRNA and 
polysome-associated mRNA from bloodstream form monomorphic (427 strain) cells. 
The polysome-associated RNA should represent the actively translated mRNAs, as 





Figure 6.3 Schematic diagram of RNA sample generation for Illumina digital tag 
RNA sequencing. As outlined in Sections 2.9 and 6.2.1, monomorphic bloodstream 
form T. b. brucei Lister 427 were used for the slender form total RNA and polysome 
RNA samples (A) and pleomorphic AnTat1.1 were collected at 6 days post-infection 






6.3.1 Sample generation 
A schematic diagram depicting how each sample was generated for RNA analysis is 
shown in Figure 6.3. For the bloodstream form monomorphic cell total RNA 
(hereafter referred to as ‘Slender total’ RNA sample) six flasks of 50 ml of cells at 
about 2.5 x105 cells/ml were grown to about 2 x106 cells/ml. Each 50 ml was washed 
twice with 20 ml of filter-sterilised PSG to remove any traces of media and then cell 
lysis and RNA extraction was carried out, as described in Section 2.4.1. For each 50 
ml of cells a separate RNeasy column (Qiagen) was used to allow maximum retrieval 
of RNA from the samples. Some (20%) of each of these six samples was then pooled 
together to generate the slender total RNA sample for Illumina digital tag 
sequencing. The remainder was stored to allow transcript validation by northern 
blotting or quantitative reverse-transcription PCR.  
 
For the bloodstream form monomorphic cell polysome-associated RNA (hereafter 
referred to as ‘Slender polysome’ RNA sample) ten flasks of 50 ml of cells were 
grown to about 1-2 x106 cells/ml. Cell lysates were generated for polysome analysis 
as described in Section 2.9.1. Specifically, cells from five flasks were pooled after 
the first centrifugation step, so two lysate samples would be generated. Each of these 
lysate samples were then subjected to sucrose gradient fractionation as described in 
Section 2.9.3, with the resulting polysome profiles being shown in Figure 6.4. RNA 
was then extracted from fractions containing only the polysomes (fractions 10-13), 
with a separate RNeasy column (Qiagen) being used for each fraction to allow 
maximum retrieval of RNA from the samples. Half of the RNA extracted from each 
of the four polysome fractions from ‘slender cell lysate sample 1’ (since the 
fractionation appeared better for this lysate) was pooled together to generate the 















































   
 
    
 
Figure 6.4 Polysome profiles for slender form (A) and stumpy form (B) cells. 
Lysates from cells treated with cycloheximide were layered on to a 15-50% sucrose 
gradient, centrifuged at 40 000 rpm for 2 hours, and fractions taken at a set number 
of drops (each fraction is marked with red vertical lines). Absorbance was measured 
at 254 nm throughout fractionation. RNA was extracted and purified from polysomal 
A 
6 7 8 9 10 11 12 13 14 2 3 4 5 
Fraction number 
Slender-form cell lysate sample 1 
6 7 8 9 10 11 12 13 14 15 3 4 5 
Fraction number 
Slender-form cell lysate sample 2 
6 7 8 9 10 11 12 13 14 15 2 3 4 5 
Fraction number 
Stumpy-form cell lysate B 
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fractions (fractions 10-13 for each, shown in black boxed regions on profiles) for 
Illumina digital tag RNA sequencing. See sections 2.9 and 6.2.1 for details. 
 
 
For the stumpy form total RNA (hereafter referred to as the ‘Stumpy total’ RNA 
sample) and for the stumpy form cell polysome-associated RNA (hereafter referred 
to as the ‘Stumpy polysome’ RNA sample) five MF1 mice were infected with T. 
brucei AnTat1.1, then trypanosomes harvested 6 days post infection, when about 
95% of the trypanosome population were stumpy form by morphology. The parasites 
were purified over DEAE columns as described in Section 2.2.2, and RNA extracted 
from the cells purified from one of the mice. For this RNA sample, the resuspended 
cell pellet was divided into six, and aliquots purified using a separate RNeasy 
column (Qiagen) to allow maximum retrieval of RNA. Some (20%) of each of these 
six samples was also pooled together to generate the ‘stumpy total’ RNA sample for 
Illumina digital tag sequencing. 
 
Cells purified using two DEAE columns from the four remaining mice, plus some of 
the cells purified from the mouse used for the ‘total RNA’ sample, were then used to 
generate one cell lysate for polysome analysis. Cells from the two purifications were 
pooled for the wash step. Sucrose gradient fractionation was then performed as 
described in Section 2.9 with this lysate, the resulting polysome profile being shown 
in Figure 6.4. RNA was extracted from fractions containing only the polysomes 
(fractions 10-13) as described in Section 2.9.4. Again, for each fraction, a separate 
RNeasy column (Qiagen) was used to allow maximum retrieval of RNA from the 
samples. Some (42.5%) of the RNA extracted from each of the four polysome 
fractions was pooled together to generate the stumpy polysome RNA sample for 
Illumina digital tag sequencing. The remainder was stored for future validation 
experiments. 
 
An analysis using Illumina digital tag sequencing of total mRNA populations from 
different life-cycle stages had been performed previously (Keith Matthews, 
unpublished data), so the bloodstream-form monomorphic and stumpy form total 
RNA samples here also served as replicates for this previous experiment. To further 
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assist this, total RNA was also obtained from slender form and intermediate form 
(population ~ 70% intermediate by morphology) pleomorphic cells (AnTat1.1 
strain).  
 
The concentration of the RNA samples was verified and controlled for integrity by 
using nanodrop analysis, and by inspection of each sample (10%) on RNA gels 
(Figure 6.5), as described in Section 2.4.2. The quality of each RNA sample 
appeared very good, so the pooled samples were sequenced by Eurofins MWG 
Operon using Illumina HiSeq 2000 sequencing (see Section 2.11).  
 
The sequencing reads were returned as FASTA sequences, which were mapped to 
the T. brucei TREU 927/4 genome and statistically analysed as follows (with the 
assistance of Dr. Paul Capewell, University of Edinburgh). Initially, a transcript 
alignment database was created using all of the identified ORFs from TriTrypDB 
v3.3 release (http://tritrypdb.org/tritrypdb/), this including mapped UTR data from 
the Cross Laboratory (Siegel et al. 2010). Adapter sequences were trimmed from the 
reads using the CLC Genomics Workbench and aligned against the transcript 
database using Bowtie (Langmead et al., 2009) with 1 mismatch (for the four 
bloodstream monomorphic/stumpy total/polysome RNA samples) or 2 mismatches 
(for the four total RNA samples used with the results of the previous Illumina digital 
























































Figure 6.5 Ethidium bromide-stained RNA gels with RNA samples used for 
Illumina digital tag RNA sequencing. A: Total RNA samples for slender forms (6 
samples) and stumpy forms (6 samples). B: Polysome-associated RNA samples for 
slender forms (samples 1 and 2) and stumpy forms, fraction numbers 10-13 for each. 
The three major rRNA bands are indicated by their size in kilobases (kb). 




















Two datasets were prepared for each sample, one that discarded tags that aligned to 
multiple sites (for identification of unique genes of interest) and another allowing for 
up to 10 matches per tag (for identification of gene arrays that may also be 
differentially regulated). The number of tags aligning to a transcript was normalized 
to the coverage of each transcript (to take into account differing numbers of NlaIII 
sites in each gene) and reported as RPKM (reads per kilobase of exon model per 
million mapped reads). To identify transcripts with differential expression, the 
RPKM values for each transcript in each dataset were compared using the CLC 
Genomics Workbench with either a proportional statistical analysis for non-
replicated samples (i.e. comparisons with the four bloodstream monomorphic/stumpy 
total/polysome RNA samples), or Gaussian statistical analysis for samples with 
replicates (i.e. comparisons with the four total RNA samples used with the results of 
the previous Illumina digital tag RNA sequencing experiment mentioned above). A 
stringent p value cut-off of 0.01 (corrected for false discovery rate) was used to 
determine if a transcript was differentially expressed between samples. A p value 
reported as ‘p = 0’, means that this p value has a value of less than 4.9 x 10-324. 
 
Using the datasets that discarded tags that aligned to multiple sites, analysis was 
made of the fold change in slender or stumpy polysome RNA read counts compared 
with slender or stumpy total RNA read counts, to identify genes whose transcript was 
enriched by 2-fold or greater (all p ≥ 0.01). Also returned with each gene identified 
in each of these comparisons was any associated RNAi phenotype from the study by 
Alsford et al. (2011). Further, a dataset was generated which compared the fold 
changes for all genes using the datasets allowing for up to 10 matches per tag. The 
work outlined above, from alignment of reads to the generation of the four datasets 
and multiple alignment dataset (inclusive), was performed by Dr Paul Capewell 
(University of Edinburgh). 
 
The number of genes whose transcript was enriched by 2-fold or greater (p ≥ 0.01) in 
each comparison and the overlap of these genes between datasets is shown in Figure 
6.6. The rest of this chapter will concern analysis of the results of these datasets 




Figure 6.6 Venn diagram of enriched transcripts. Number of genes with transcripts 
enriched in either slender or stumpy form polysome-associated RNA samples 
compared to slender or stumpy form total RNA samples. Numbers in parentheses 
indicate the total number of genes with enriched transcripts in each dataset. 
 
 
6.4 Which transcripts are actively translated in stumpy cells? 
 
My hypothesis was that genes that are actively translated in stumpy cells would 
probably include genes important for transmission to the tsetse fly and differentiation 
competence. Therefore, to detect which transcripts were actively translated in stumpy 
cells the 508 genes identified as enriched in stumpy polysome RNA by 2-fold or 
greater (all p ≥ 0.01) compared to stumpy total RNA were analysed further. The 30 
genes showing the greatest fold change are shown in Table 6.1.  
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Table 6.1 Genes with the greatest fold change upregulation in stumpy form polysome-associated RNA compared to stumpy form total RNA 
Gene ID Fold change p-value ST Total RPKM ST Polysome RPKM Product Description
Tb11.02.3570 4.68 0 102.15 431.92 hypothetical protein, conserved
Tb927.8.1220 4.58 0 212.01 878.18 hypothetical protein, conserved (pseudogene)
Tb927.7.4060 4.51 0 158.64 647.13 calpain-like cysteine peptidase, putative,cysteine peptidase, 
Clan CA, family C2, putative
Tb09.160.0680 4.1 5.28E-07 17.58 65.12 sec1 family transport protein, putative (SLY1)
Tb927.10.11820 3.98 1.36E-08 23.13 83.27 hypothetical protein, conserved
Tb927.7.4070 3.97 0 214.96 770.42 calpain-like cysteine peptidase, putative,cysteine peptidase, 
Clan CA, family C2, putative
Tb927.5.2590 3.93 6.97E-07 18.66 66.26 hypothetical protein, conserved
Tb11.03.0250 3.77 0 60.15 205.18 cyclophilin a,cyclophilin type peptidyl-prolyl cis-trans 
isomerase (CYPA)
Tb927.6.4130 3.75 6.84E-15 45.71 155.05 hypothetical protein, conserved
Tb09.211.4513 3.73 0 112.04 377.22 kinetoplastid membrane protein KMP-11 (KMP-11)
Tb927.7.2070 3.73 0 262.78 885.25 heat shock protein DNAJ, putative
Tb927.10.10830 3.69 4.87E-03 8.3 27.66 HNRNPA (HNRNPA)
Tb09.211.0700 3.67 0 53.61 177.8 isopentenyl-diphosphate delta-isomerase, 
putative,isomerase, putative
Tb11.02.2860 3.64 3.87E-11 35.93 118.34 hypothetical protein, conserved
Tb927.8.1750 3.62 0 70.61 230.77 hypothetical protein, conserved
Tb11.02.0020 3.61 0 182.22 593.79 hypothetical protein, conserved
Tb927.10.13710 3.57 0 110.86 357.65 hypothetical protein, conserved
Tb11.02.3230 3.55 8.34E-10 33.14 106.32 hypothetical protein, conserved
Tb927.7.1470 3.54 0 127.78 408.98 ATPase subunit 9, putative
Tb927.7.4290 3.53 8.88E-05 15.34 48.9 hypothetical protein, conserved
Tb11.02.1290 3.5 0 98.77 312.65 hypothetical protein, conserved
Tb927.7.2780 3.5 0 1,139.12 3,605.16 hypothetical protein, conserved
Tb927.7.3590 3.49 0 458.09 1,445.48 hypothetical protein, conserved
Tb11.01.7740 3.48 0 202.05 634.54 hypothetical protein, conserved
a   b 
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a p-value is corrected for false discovery rate (FDR) 
















Tb927.10.15810 3.47 0 159.88 501.73 hypothetical protein, conserved
Tb11.42.0004 3.45 0 93.36 291.42 hypothetical protein, conserved
Tb927.8.4380 3.45 0 156.26 487.8 hypothetical protein, conserved
Tb11.01.7800 3.44 0 901.04 2,800.43 nucleoside diphosphate kinase (NDPK)
Tb11.01.1180 3.42 0 440.48 1,361.17 hypothetical protein
Tb927.10.6080 3.41 0 154.42 476.18 proteasome beta 5 subunit, putative,proteasome beta 5 
subunit (PRCE)
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6.4.1 Analysis of conserved hypothetical genes 
A high proportion (almost two-thirds) of enriched transcripts had an associated gene 
product annotation of ‘hypothetical protein, conserved’, and therefore, may represent 
interesting genes with novel functions or be kinetoplastid-specific genes. To gain 
more information about possible functions for these genes, initially, the 10 genes 
with the greatest fold change difference in this dataset were investigated through the 
information associated with its gene entry page on the T. brucei genome database 
(http://tritrypdb.org/tritrypdb/) (Table 6.2). This yielded more information for the 
conserved hypothetical proteins, Tb11.02.3570, Tb927.8.1220, Tb927.10.11820, 
Tb927.5.2590, and Tb927.6.4130.  
 
For Tb11.02.3570, the additional information was that it has an associated GO term 
indicating that it is a mitochondrial component, is predicted to possess 6 
transmembrane domains and an uncharacterised protein family domain (3.70E-06), 
and was found by mass spectrometry in the T. brucei palmitolyated and procyclic 
form proteomes. Therefore, this information indicates it might be a mitochondrial 
membrane protein. 
 
For Tb927.8.1220 the predicted protein sequence was found to contain several stop 
codons, and therefore, this is unlikely to be a functional ORF.  
 
For Tb927.10.11820, this gene was found to be expressed in procyclic forms, has an 
associated GO term indicating that it is a mitochondrial component, and a 
tetratricopeptide repeat (TPR)-like protein domain (1.30E-02). Using the protein 
sequence for this gene as query in a protein BLAST (blastp; 
http://blast.ncbi.nlm.nih.gov/Blast.cgi) search yielded several genes annotated as 
pentatricopeptide repeat-containing proteins. In a previous study in T. brucei, 
pentatricopeptide repeat proteins were found to stimulate mRNA 
adenylation/uridylation to activate mitochondrial translation (Aphasizheva et al., 
2011), however, neither of the proteins investigated in this study were 
Tb927.10.11820. Therefore, it appears this protein is a component of mitochondria 
which could possibly be involved in mRNA adenylation/uridylation. 
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Table 6.2 Information from the TriTryp database (http://tritrypdb.org/tritrypdb/) regarding the ten most highly enriched transcripts in stumpy 
polysome-associated RNA compared to stumpy total RNA.  
 a Gene ID Notes GO terms Protein features Phenotype Mass spec.-based expression evidence Similarities to PDB chains Additional information
Tb11.02.3570 conserved amongst 
eukaryotes and plants, 










- T. brucei palmitoylated proteome, T. 
brucei  procyclic form
-
Tb927.8.1220 - - - - - - the predicted protein 
sequence contains several 
stop codons
Tb927.7.4060 expressed in 
bloodstream form as 
detected by proteomic 
analysis, expressed in 
procyclic form as 
detected by proteomic 
analysis, detected in T. 
brucei  bloodstream 
plasma membrane 
fraction, detected in T. 
brucei  bloodstream 
cytoskeletal fraction, 




















T. brucei proteomics bloodstream form 
cytosolic phosphoproteome
small myristoylated protein 1 
from L. major  (48), 
hypothetical protein from L. 
major (35)














(SM) proteins, Sec1 
Sec1 family
- T. brucei palmitoylated proteome, T. 
brucei  procyclic form
Sec1 family domain 
containing protein 1 from 
Rattus norvegicus  (45)
Tb927.10.11820 expressed in procyclic 








Tb927.7.4070 expressed in procyclic 




















T. brucei procyclic form, T. brucei 
proteomics bloodstream form cytosolic 
phosphoproteome
small myristoylated protein 1 
from L. major  (49) and 
hypothetical protein from L. 
major  (36)






- - Macro domain-containing 
protein 1 from Homo sapiens 
(47), putative 
polyprotein/phosphatase from 
E. coli  (43), Hypothetical 
protein TTHA0132 from 
Thermus thermophilus HB8 
(38), Non-structural protein 3 
from Venezuelan equine 
encephalitis virus  (32)
Tb11.03.0250 expressed in procyclic 
form as detected by 
proteomic analysis, 
expressed in 
bloodstream form as 

























- T. brucei palmitoylated proteome, T. 
brucei  procyclic form
Peptidyl-prolyl cis-trans 
isomerase A from Homo 
sapiens  (73), Cyclophilin A 
from Homo sapiens  (74)
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Tb927.6.4130 - mitochondrial 
part
- - T. brucei procyclic form - One of the orthologs 
within TriTrypDB is 
succinate dehydrogenase 
cytochrome B subunit 
(SDH3) from T. cruzi CL 
Brener Non-Esmeraldo-
like
Tb09.211.4513 expressed in T. brucei 
bloodstream plasma 
membrane fraction, 




bloodstream form as 
detected by proteomic 
analysis, expressed in 
procyclic form as 




















Tb927.5.2590 is predicted to possess a Macro domain (1.50E-55), the Pfam 
annotation (PF01661; http://pfam.sanger.ac.uk) for which states that this is an ADP-
ribose binding module found in a range of unrelated proteins, such as the macro-H2A 
histone protein, with other domains and also alone in a protein family found in 
bacteria, archaebacteria and eukaryotes. This protein also has some potential 
structural similarity to PDB chains for human Macro domain-containing protein 1 (p 
= 7.4 x 10-39), a putative polyprotein/phosphatase from Escherichia coli (p = 1.6 x 
10-27), Hypothetical protein TTHA0132 from Thermus thermophilus HB8 (p = 2.1 x 
10-18), and Non-structural protein 3 from Venezuelan equine encephalitis virus (p = 
9.2 x 10-8; see Table 6.2). The protein with the greatest similarity, human Macro 
domain-containing protein 1 has been identified as an O-acetyl-ADP-ribose 
deacetylase (Chen et al., 2011). With the Macro domain present in a wide range of 
unrelated proteins it is difficult to make any predictions about what the function of 
this protein may be, however, it is possible that it could function as an O-acetyl-
ADP-ribose deacetylase like human Macro domain-containing protein 1. 
 
Tb927.6.4130 also has an associated GO term indicating that it is a mitochondrial 
component and was found by mass spectrometry in the T. brucei procyclic form 
proteome. Additionally, one of the syntenic orthologs within the TriTryp database 
listed is annotated as succinate dehydrogenase cytochrome B subunit (SDH3; 
Tc00.10470553511523.14 from T. cruzi CL Brener Non-Esmeraldo-like). The 
TriTryp database entry page for this gene has a user comment annotating it as the 
cytochrome b large subunit, and so Tb927.6.4130 may also be a cytochrome b 
subunit. 
 
6.4.2 Interesting annotated genes in the ten most highly enriched genes 
Several genes with more specific annotations also appear interesting, such as two 
proteins possibly involved in protein secretion or membrane signalling; these are 
Tb09.160.0680 (putative sec1 family transport protein, SLY1) and Tb09.211.4513 
(kinetoplastid membrane protein-11, KMP-11). From the information gained from 
the gene entry pages for these genes, the putative sec1 family transport protein was 
detected in the bloodstream plasma membrane, was found in the T. brucei 
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palmitolyated and procyclic form proteomes, and has associated GO terms 
implicating it in vesicle-mediated transport, exocytosis and protein transporter 
activity. The kinetoplastid membrane protein-11 was detected by proteomic analysis 
in the bloodstream plasma membrane and cytoskeletal fractions, and has associated 
GO terms implicating it in defence response and positive regulation of cell 
proliferation (Table 6.2). This protein has been determined to be present at much 
greater levels in procyclic forms than bloodstream forms and increases in abundance 
during bloodstream form to procyclic form differentiation (Stebeck et al., 1995) and 
in T. cruzi regulation of KMP-11 was suggested to be at the translational level 
(Thomas et al., 2000), both being consistent with the presence of this transcript in 
this dataset. Interestingly, KMP-11 from Leishmania and African trypanosomes was 
able to stimulate cellular immune responses, and so KMP-11 may be important for 
induction of host immune response (Tolson et al., 1994). This additional information 
confirms these two genes as interesting, as they could be involved in protein 
secretion or sensing the environment at the plasma membrane.  
 
Another potentially interesting gene is annotated as cyclophilin A (CypA; 
Tb11.03.0250), as it may be involved in host-parasite interactions. For T. cruzi it has 
been reported that a cyclophilin is secreted by non-dividing trypanomastigotes and is 
involved in mammalian host cell entry (Moro et al., 1995). A study of the T. brucei 
CypA found evidence for its secretion or release into the T. brucei culture medium 
(Pelle et al., 2002). This study also investigated the transcript and protein expression 
of CypA throughout the T. brucei lifecycle and found that while protein expression 
was constitutively expressed with little variation in the different developmental 
stages, the transcript expression was at least 2-fold higher in slender forms than the 
procyclic form, and low in intermediate and stumpy forms (Pelle et al., 2002). The 
identification of this gene in this dataset perhaps indicates that the CypA protein is an 
important protein that is constitutively expressed and so has a high level of 
association with polysomes, even in stumpy forms where the level of the transcript is 
lower than other life-cycle stages. This would also suggest that the control of 
expression for this gene is at the level of RNA decay in slender and procyclic forms 
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where transcript levels are greater than other life-cycle stages but protein levels are 
constant.  
 
Additionally, two genes annotated as encoding putative calpain-like cysteine 
peptidase proteins (Tb927.7.4060 and Tb927.7.4070) had transcripts found to be 
enriched in stumpy polysome-associated RNA compared to stumpy total RNA. 
These genes are potentially interesting because cysteine peptidases are involved in 
various parasite processes, such as virulence and pathogenesis (Caffrey et al., 2011). 
Tb927.7.4060 and Tb927.7.4070 are members of group 3 calpain-like proteins, 
termed small kinetoplastid calpain-related proteins (SKCRPs), and are also called 
TbSKCRP7.1 and TbSKCRP7.2, respectively (Liu et al., 2010). These two proteins 
have almost identical sequences but only TbSKCRP7.2 was found to be associated 
with the flagellar membrane (Liu et al., 2010). Moreover, TbSKCRP7.2 was 
upregulated in procyclic forms 9.8-fold over bloodstream forms as determined by 
quantitative RT-PCR, whereas TbSKCRP7.1 was not significantly upregulated (Liu 
et al., 2010). The identification of the TbSKCRP7.2 transcript as enriched in stumpy 
form polysome RNA is, therefore, consistent with a preparation of these forms for 
procyclic form differentiation. The detection of TbSKCRP7.1 could be due to high 
similarity between these gene sequences. 
 
6.4.3 Mitochondrial proteins 
A large number of mitochondrial proteins were found to be present in the 508 genes 
whose transcripts were enriched in stumpy polysome RNA compared to stumpy total 
RNA. Some putative mitochondrial genes are discussed above (see section 6.4.1), 
being identified via their mitochondrial GO term. However, also present are a 
number of genes with a known mitochondrial localisation or association. Due to the 
change in environment and a resulting switch between aerobic glycolysis and 
oxidative phosphorylation during the transition between bloodstream forms and 
procyclic forms, a large number of mitochondrial genes show developmentally 
regulated expression, being elevated in procyclic forms. A number of these genes are 
mitochondrially-encoded so will not be present in this analysis, due to alignment of 
reads with the sequenced TREU 927/4 genome, which does not include the 
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mitochondrial genome. However, some of these genes are nuclear-encoded and are 
present in this stumpy-polysome enriched dataset.  
 
For example, the cytochrome oxidase (COX) complex is developmentally regulated 
in trypanosomes, as it is absent in bloodstream forms but present in procyclic forms 
(Priest and Hajduk, 1994). Of the components that make the COX complex, at least 
10 are nuclear-encoded and for 7 of these the regulation of developmental expression 
is achieved through differential mRNA stability and translational control (Mayho et 
al. 2006). Two of these components were found in this study to be upregulated in 
stumpy form polysome RNA compared to stumpy form total RNA; these were 
cytochrome oxidase subunit VIII (Tb927.4.4620; 2.82 fold change, p = 2.24 x 10-6) 
and cytochrome oxidase subunit VII (Tb927.3.1410; 2.47 fold change, p = 0).  The 
mRNAs for these components show bloodstream stage-specific instability, and 
3’UTR analysis of other COX components showed regulation mainly at the 
translational level but also mRNA stability (Mayho et al. 2006). Therefore, from the 
results shown here it would appear that for COX VIII and COX VII, regulation of 
expression is also at the translational level. Also detected were cytochrome c (see 
section 6.3.3), a putative cytochrome b5 (Tb11.02.4485; 2.65 fold change, p = 0), 
and a putative cytochrome oxidase copper chaperone (Tb927.3.2650; 2.03 fold 
change, p = 0). It has previously been shown that the levels of cytochrome b and 
COX I and II transcripts, which are undetectable in slender forms, increase in stumpy 
forms, and mitochondrial rRNAs also increase at this stage (Michelotti and Hajduk, 
1987). These authors suggest that stumpy forms accumulate mitochondrial 
transcripts prior to developing a functional mitochondrion (Michelotti and Hajduk, 
1987). Although the transcripts investigated are encoded in mitochondria it would 
appear from the results presented here that the same is true for, at least some, 
nuclear-encoded transcripts. This, therefore, provides support for the assumption that 
stumpy forms are preadapted for transmission to the insect vector and differentiation 
to procyclic forms.  
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6.4.4 Other interesting annotated genes 
Interestingly, a putative mitogen-activated protein (MAP) kinase was also found in 
this dataset (2.28 fold change, p = 1.20 x 10-11). This was Tb927.10.16030, which is 
annotated as putative mitogen-activated protein kinase 4 but has also been named 
TbMAPK2 (Muller et al., 2002).  This protein was shown to be involved in 
differentiation to the procyclic form, as a null mutant (∆mapk2/∆mapk2) 
differentiated with delayed kinetics (Muller et al., 2002). The same study also 
investigated the steady-state levels of the MAPK2 transcript and found that it was 3-
fold higher in the bloodstream form than procyclic form. Further, they also report 
that in the pleomorphic AnTat1.1 strain the transcript expression levels were similar 
in the slender bloodstream form and the stumpy bloodstream form (Muller et al., 
2002). Therefore, the presence of this gene in this dataset is consistent with the 
previous report, i.e. the transcript is still expressed at high levels in the stumpy form 
and is also enriched in stumpy form polysomal fractions, due to the requirement for 
this protein during differentiation to the procyclic-form. This again provides support 
for the concept that stumpy form cells are preadapted for differentiation to the 
procyclic form and transmission to the insect vector, as the cells are already starting 
to express a protein required for differentiation. 
 
It was also noted that there appeared to be several proteins with annotations involved 
in gene expression, such as in RNA binding, RNA processing, and translation. For 
example, those involved in RNA binding included putative Y14 (Tb927.7.1170; 2.18 
fold change, p = 5.63x 10-8), putative La (Tb927.10.2370; 3.03 fold change, p = 3.87 
x 10-3), as well as RPB25, RBP39, and RBP22 transcripts (Tb927.7.880, 
Tb11.01.7000, and Tb927.5.1080, respectively). Also, a number of mitochondrial 
RNA binding proteins were present, these included GBP21, GBP25, and RBP16 
(Tb11.55.0009, Tb11.01.4860, and Tb11.02.5770, respectively). Those involved in 
RNA processing included a putative ribonuclease H (Tb927.10.5070; 3.07 fold 
change, p = 0), ALBA2 (Tb11.02.2030; 2.56 fold change, p = 0), ALBA3 
(Tb927.4.2040; 2.6 fold change, p = 2.69 x 10-4), and fibrillarin (NOP1, 
Tb927.10.7500; 2 fold change, p = 0). Of those involved in translation these included 
putative eukaryotic translation initiation factor (eIF) 1A (Tb927.8.5880; 2.9 fold 
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change, p = 0), putative eIF4G (Tb927.8.4820; 2.89 fold change, p = 1.14 x 10-6), 
putative eIF (Tb11.01.3420; 2.37 fold change, p = 6.10 x 10-10), putative eIF3B 
(Tb11.01.1370; 2.16 fold change, p = 3.64 x 10-6), putative eIF3D (Tb927.4.1930; 
2.29 fold change, p = 4.36 x 10-3), and putative eukaryotic peptide chain release 
factor subunit 1 (Tb927.7.1710; 2.32 fold change, p = 1.08 x 10-7). The presence of a 
large number of these types of proteins is expected because the control of gene 
expression is believed to be through post-transcriptional mechanisms and these 
protein types would be likely to have an important role in developmental events.  
 
6.5 Which transcripts are more actively translated in stumpy polysomes 
compared to slender polysomes? 
 
To identify transcripts showing stumpy-enriched translation, the datasets were also 
analysed for transcripts that were at higher abundance in the stumpy form polysome 
RNA sample compared to the slender form polysome RNA sample. This identified 
732 genes enriched by 2-fold or greater (all p ≥ 0.01). The top 30 genes showing the 
















Table 6.3 Genes with the greatest fold change upregulation in stumpy form polysome-associated RNA compared to slender form polysome-
associated RNA 
 
Gene ID Fold change p-value SL Polysome RPKM ST Polysome RPKM Product Description
Tb927.4.4990 977.52 0 0.51 496.84 ubiquinol-cytochrome c reductase, putative
Tb11.01.3860 943.09 0 2.63 2,494.26 hypothetical protein, conserved
Tb11.01.3840 138.38 0 3.12 433.13 hypothetical protein, conserved
Tb927.7.5400 133.72 1.59E-05 0.17 23.2 hypothetical protein, conserved
Tb927.8.690 120.61 2.07E-07 0.27 32.35 peptidyl-prolyl cis-trans isomerase/rotamase, putative,PPIase, 
putative (PIN1)
Tb927.3.5760 72.98 2.69E-04 0.24 17.66 hypothetical protein, conserved
Tb09.160.2320 52.44 0 1.76 92.46 hypothetical protein, unlikely (1L12.35)
Tb927.4.100 51.42 2.14E-03 0.26 13.46 retrotransposon hot spot protein (RHS, pseudogene), 
putative,retrotransposon hot spot protein 1 (RHS1), interrupted
Tb11.03.0920 29.5 6.36E-06 0.92 27.22 hypothetical protein, conserved
Tb11.01.4560 26.71 4.56E-15 2.87 76.96 variant surface glycoprotein (VSG)-related, putative
Tb927.10.15370 25.44 2.09E-10 2.01 51.36 DNA-directed RNA polymerase, alpha subunit, putative,RNA 
polymerase subunit, putative (RPC40)
Tb927.2.2400 25.13 1.58E-04 0.81 20.32 hypothetical protein, conserved (25N14.65)
Tb927.6.1430 20.68 0 10.06 208.87 hypothetical protein, conserved
Tb927.4.4430 17.3 2.81E-03 0.83 14.45 adenylyl cyclase (GRESAG 4.4)
Tb927.6.5020 14.41 4.56E-15 5.79 83.72 cyclin 7, putative,CYC2-like cyclin, putative (CYC7)
Tb927.6.3070 13.4 0 10.1 135.84 hypothetical protein, conserved
Tb11.01.0720 13.17 6.43E-10 4.13 54.62 cation transporter, putative
Tb927.4.4410 13.01 3.13E-05 2.06 26.93 adenylyl cyclase (GRESAG 4.4)
Tb927.4.3500 12.67 0 9.99 127.06 hypothetical protein, conserved
Tb927.10.9160 12.56 0 15.34 193.4 hypothetical protein, conserved
Tb11.02.5180 11.64 0 50.01 584.5 DNA-direcetd RNA polymerase II, subunit 9, putative (RPB9)
Tb11.47.0008 10.97 0 26.59 293.01 class I transcription factor A, subunit 3 (CITFA-3)
Tb09.142.0030 10.72 4.40E-11 6.03 64.85 expression site-associated gene (ESAG, pseudogene), 
putative,expression site-associated gene 3 (ESAG3), pseudogene






  c 
292 
a p-value is corrected for false discovery rate (FDR) 
b SL: slender form, RPKM: reads per kilobase of exon model per million mapped reads 














Tb927.7.6870 10.56 1.54E-09 5.24 55.54 hypothetical protein, conserved
Tb09.211.1620 10.48 0 18.42 193.83 hypothetical protein, conserved
Tb927.3.2750 10.35 0 28.09 291.98 hypothetical protein, conserved
Tb927.2.200 9.83 0 54.98 542.65 expression site-associated gene (ESAG, pseudogene), 
putative,expression site-associated gene 3 (ESAG3), degenerate
Tb927.6.3880 9.64 5.50E-04 2.2 21.26 hypothetical protein, conserved
Tb927.6.3260 9.54 0 18.48 176.91 hypothetical protein, conserved
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6.5.1 Analysis of conserved hypothetical genes 
Again, there were many genes encoding proteins annotated as ‘hypothetical, 
conserved’ so initially the top 10 of these genes were investigated through the 
information associated with each gene entry page on the T. brucei genome database 
(http://tritrypdb.org/tritrypdb/) (Table 6.4). This yielded more information for 
Tb11.01.3860, Tb11.01.3840, Tb927.7.5400, Tb927.3.5760, Tb09.160.2320, 
Tb11.03.0920, and Tb11.01.4560.  
 
For Tb11.01.3860, the additional information was that it has an associated GO term 
indicating that it is a mitochondrial component, is predicted to have a signal peptide 
and was found to be expressed in the procyclic form.  
 
Tb11.01.3840 has a predicted S15/NS1 RNA-binding domain (8.40E-03) implicating 
it in RNA-binding. Tb927.7.5400 is predicted to possess a signal peptide and 2 
transmembrane helices. Using the protein sequence for this gene as query in a protein 
BLAST (blastp; http://blast.ncbi.nlm.nih.gov/Blast.cgi) search using the ‘Reference 
proteins (refseq_protein)’ database yielded no further information. The three 
significant hits were hypothetical proteins from T. brucei (Tb927.7.5420; p = 0.0), 
and T. cruzi (Tc00.1047053510305.70 and Tc00.1047053509153.20; p = 1 x 10-27 












Table 6.4 Information from the TriTryp database (http://tritrypdb.org/tritrypdb/) regarding the ten most highly enriched transcripts in 





Gene ID Notes GO terms Protein features Phenotype Mass spec.-based expression evidence Similarities to PDB chains Additional information
Tb927.4.4990 expressed in procyclic 
form as detected by 
proteomic analysis







Tb11.01.3860 - mitochondrial part Signal peptide 
predicted
- T. brucei procyclic form -
Tb11.01.3840 - - S15/NS1 RNA-
binding domain
- - -




Tb927.8.690 expressed in procyclic 
form as detected by 
proteomic analysis, 
expressed in 
bloodstream form as 














- - Peptidyl-prolyl cis-trans 
isomerase from Arabidopsis 
thaliana  (49), peptidyl-
prolyl cis-trans isomerase 
from Candida albicans  (45), 
peptidyl-prolyl cis-trans 
isomerase NIMA-inte from 
Homo sapiens  (52)
Tb927.3.5760 - - Signal peptide 
predicted
- - - Only syntenic gene listed 
(T. b. gambiense, 
Tbg972.3.6390) is 
annotated as 'hypothetical 
protein, T. brucei spp.-
specific protein'; two 927 
homologues annotated as 











Tb09.160.2320 - - - - - - Annotated as 'hypothetical 
protein, unlikely'; 
predicted protein sequence 
of 42 amino acids








Tb11.03.0920 - - Prefoldin - - -





Tb927.3.5760 is also predicted to possess a signal peptide. Interestingly, the only 
syntenic gene listed for this gene is from T. b. gambiense and is annotated as a T. 
brucei species-specific protein. Additionally, two of the T. brucei 927 homologues 
are annotated as putative ESAG9 proteins. Therefore, the protein sequence for this 
gene was used as query in a protein BLAST (blastp; 
http://blast.ncbi.nlm.nih.gov/Blast.cgi) search using the ‘Reference proteins 
(refseq_protein)’ database to see if this could be an ESAG9 gene. This search 
returned 4 results; the top hit was its own protein sequence (p = 0.0), the others were 
Tb09.160.5400 (a putative expression site-associated gene 9 protein, p = 1 x 10-13), 
Tb09.142.0380 (a hypothetical protein, p = 4 x 10-11; the entry for this gene on 
TriTrypDB notes that it has low similarity to ESAG9), and Tb927.5.150 (a 
hypothetical protein, p = 6 x 10-11; of the orthologs on TriTrypDB two are putative 
ESAG9 proteins). Therefore, it appears that Tb927.3.5760 shows similarity to 
ESAG9 proteins and may be an ESAG9 or ESAG9-related gene.  
 
Tb09.160.2320 is annotated as ‘hypothetical protein, unlikely’ and analysis of the 
protein sequence on the TriTryp database entry for this gene revealed only a 42 
amino acid sequence. Therefore, it is unlikely that this gene is a functional ORF.  
 
Tb11.03.0920 is predicted to have a prefoldin domain (8.10E-04); the Interpro 
annotation for which states that these proteins are part of a molecular chaperone 
system which stabilise nascent polypeptide chains and which therefore, promotes 
their correct folding. Consequently, it is possible that this protein has a similar 
function. 
 
For Tb11.01.4560, this is predicted to possess a signal peptide, however, this gene is 
already annotated as a putative VSG-related protein and from the orthologs and 
paralogs within TriTrypDB listed, it appears that this might be the case, so no further 
information was gained. 
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6.5.2 Other interesting proteins 
Many mitochondrial proteins were also found to be present in the 732 genes enriched 
in the stumpy form polysome RNA compared to the slender form polysome RNA. 
Again, members of the COX complex were present. COX subunits VIII (2.14 fold 
change, p = 2.76 x 10-4) and VII (3.77 fold change, p = 0) were present here, as well 
as being enriched in the stumpy polysome RNA compared to the stumpy total RNA 
(see section 6.2.1). Additionally, COX V was enriched 4.03-fold (p = 0) as was a 
putative cytochrome oxidase assembly protein enriched 2.58-fold (p = 7.25 x 10-8). It 
was previously found from investigations of the COX V 3’UTR that this provided 
regulation of protein expression almost exclusively at the translational or post-
translational level (Mayho et al. 2006). This is supported by the enrichment seen 
here, as it demonstrates that the COX V transcript is more actively translated in 
stumpy forms than slender forms and so is consistent with regulation being at the 
level of translation. 
 
As with comparing stumpy polysomal with total RNA, there were several transcripts 
implicated in translation found enriched in the stumpy polysome material compared 
to slender polysome sample. Interestingly, one of these was a putative eIF6 
(Tb927.10.5300; 3.13 fold change, p = 0), which is supportive of the upregulation of 
this transcript (see Section 5.1.2) and protein in stumpy forms. Also, one of the 
eIF4E homologues eIF4E3 (Tb11.03.3630; 3.09 fold change, p = 3.66 x 10-8) was 
found enriched here too. However, this was not the homologue whose transcript was 
found enriched in stumpy forms by directed northern analysis (eIF4E4; see Section 
5.1.1). This may indicate that, although the level of eIF4E3 transcript expression was 
observed to be consistent in different life-cycle stages (see Section 5.1.1), there may 
be upregulation of the protein in stumpy forms through an increase in translation. 
Additionally, a putative deoxyhypusine synthase (Tb927.1.870) was also found 
enriched in this dataset (2.03 fold change, p = 3.18 x 10-4). However, again, this was 
not the putative deoxyhypusine synthase found previously found to be upregulated at 
the mRNA level in stumpy forms by microarray analysis (Kabani et al. 2009, see 
Section 5.1.2) and northern blot analysis (Figure 5.1 B). 
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It was also noted that many genes annotated as adenylyl cyclase (GRESAG, Genes 
Related to ESAG, 4/4.4) genes were found in this dataset of transcripts enriched in 
the stumpy polysome sample compared to the slender polysome sample 
(Tb927.4.4430, Tb927.4.3750, Tb927.4.4410, Tb927.4.4460; 17.3, 3.09, 13.01, 7.61 
fold changes respectively, p = 3.41 x 10-3 - 3.13 x 10-5). Another study reports that 
GRESAG 4.1 protein is expressed in both bloodstream and procyclic form cells and 
at a constant level throughout differentiation, although the absence of a loading 
control makes assessment of protein levels difficult (Rolin et al., 1993). However, 
this enrichment of GRESAG genes found here is interesting because transient 
stimulations in adenylate cyclase activity have been observed during differentiation 
to procyclic form (Rolin et al., 1993). 
 
Other interesting genes in this dataset include two putative cyclins, ‘cyclin 7, 
putative, CYC2-like cyclin, putative (CYC7, Tb927.6.5020; 14.41 fold charge, p = 
4.56 x 10-15) and ‘cyclin 3, mitotic cyclin, putative’ (CYC3, Tb927.6.1460; 3.52 fold 
charge, p = 1.43 x 10-8). It could be that these proteins play a role in the cell cycle 
arrest of stumpy form cells or re-entry into the cell cycle during differentiation, 
although a previous study reported that neither of these cyclins is likely to be 
involved in cell cycle control (Li and Wang, 2003). Therefore, it is unlikely that 
these proteins function in control of the cell cycle in stumpy forms or during 
differentiation and unclear what the significance of their presence in this dataset is.  
 
Again, MAPK4, also known as TbMAPK2, was found in this dataset as well as 
being enriched in the stumpy polysome compared to stumpy total RNA (see Section 
6.4.4). Another MAP kinase is present in this dataset as well, MAPK5 
(Tb927.6.4220; 4.95 fold change, p = 0). Like TbMAPK2, this MAP kinase has also 
been shown to have a role in differentiation (Domenicali Pfister et al., 2006). 
However, this MAP kinase was shown to be important for differentiation to stumpy 
forms, where it appeared to be a negative regulator of differentiation, possibly by 
lowering sensitivity to SIF (Domenicali Pfister et al., 2006). The identification of 
translation of this transcript in stumpy forms could be consistent with a role of 
MAPK5 inhibiting differentiation. If MAPK5 lowers responsiveness to SIF, cells 
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that have already differentiated to the stumpy form would be expected to no longer 
require responsiveness to SIF. Additionally, as this gene was found enriched in 
stumpy form polysome transcripts compared to monomorphic slender forms 
polysome transcripts, this could be because this protein is expressed at low levels in 
monomorphic slender forms. Again, this is consistent with previous findings that 
TbMAPK5 null mutants in a monomorphic (and so refractory to SIF) bloodstream 
form strain showed no phenotype in contrast to pleomorphic bloodstream form 
TbMAPK5 null mutants (Domenicali Pfister et al., 2006). However, the authors did 
not compare endogenous TbMAPK5 protein or mRNA levels in monomorphic cells 
with pleomorphic cells.  
 
6.5.3 Are there genes actively translated in stumpy forms and not slender forms? 
In addition to identifying genes which are upregulated in stumpy form polysomal 
RNA compared to slender form polysomal RNA, interesting genes might be 
discovered in a comparison of the genes present in the stumpy polysome RNA reads 
and absent in the slender polysome RNA gene reads. This is because genes that are 
highly important for differentiation are not likely to be expressed in the slender form 
stage. Therefore, the dataset containing all the read counts for each gene was 
analysed to exclude genes with a value of <1 RPKM in the stumpy polysome sample 
and then exclude genes with a value of ≥1 RPKM in the slender polysome sample. 
This yielded a new dataset of 210 genes. Most of these genes have low RPKM values 
across all sequenced samples and high associated p values. However, 6 genes have 
>20 RPKM value for the stumpy polysome sample; these were Tb927.4.4990 
(977.52 fold change, p = 0), Tb927.8.690 (120.61 fold change, p = 2.07 x 10-7), 
Tb11.03.0920 (29.5 fold change, p = 6.36 x 10-6), Tb09.160.1900 (∞ fold change, p 
= 6.10 x 10-6), Tb927.7.5400 (133.72 fold change, p = 1.59 x 10-5), and 
Tb927.2.2400 (25.13 fold change, p = 1.58 x 10-4). Each of these genes, however, 
had already been identified in the stumpy polysome compared to slender polysome 
analysis and all were present in that dataset within the 15 genes with the greatest 
enrichment. Therefore, no additional interesting genes were discovered with this 
method, although this does provide validation of the previous analysis of genes 
enriched in the stumpy polysome compared to slender polysome samples. 
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6.6 Is the data for genes with known expression profiles as expected? 
 
To investigate if the data obtained from this global RNA analysis experiment was in 
agreement with previously published data, the dataset was examined for the 
expression profile of several genes with known life-cycle expression profiles in T. 
brucei. 
 
6.6.1 Housekeeping gene 
Initially, the datasets were interrogated for a housekeeping (i.e. constitutively 
expressed) gene, β-tubulin. In T. brucei the β-tubulin genes are part of an array, 
being composed of α-tubulin and β-tubulin genes. When the dataset from alignment 
of reads which discarded tags that aligned to multiple sites was analysed for the read 
counts of the annotated β-tubulin genes (Tb927.1.2330, Tb927.1.2350, 
Tb927.1.2370, Tb927.1.2390), the read count for all RNA samples for each of the 4 
genes was zero. This result was due to the high degree of similarity between the β-
tubulin gene sequences, because when the data from the alignment of reads which 
allowed for up to 10 matches per tag was analysed, the read counts were very high. 
The four annotated β-tubulin genes showed very similar read count results to each 
other within each sample. For slender polysome RNA compared to slender total 
RNA there was about a 1.54 (range: 1.52 to 1.56, p = 0 for each) fold change for the 
four β-tubulin genes. For stumpy polysome RNA compared to stumpy total RNA 
there was about a -1.27 (range: -1.24 to -1.32, p = 0 for each) fold change. These data 
reflect that the β-tubulin transcripts are constitutively expressed and translated, with 
a greater level of translation in slender compared to stumpy forms. For slender 
polysome RNA compared to stumpy polysome RNA there was about an 8.82 (range: 
8.69 to 8.91, p = 0 for each) fold change. This appears to reflect the much greater 
abundance of β-tubulin transcripts present in the slender form compared to the 
stumpy form. This is as expected because an approximately 5-fold decrease in 
tubulin transcript levels has been previously reported for stumpy forms relative to 
slender forms and procyclic forms (Feagin et al., 1986). 
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6.6.2 Stumpy form upregulated genes 
Next, the datasets were interrogated for genes known to be upregulated in stumpy 
forms. The genes chosen were ESAG9 and the PAD array. None of the ten annotated 
ESAG9 genes in the genome database (Tb09.160.5400, Tb09.160.5430, 
Tb09.v1.0330, Tb927.1.5080, Tb927.1.5220, Tb927.3.5790, Tb927.5.100, 
Tb927.5.120, Tb927.5.4620, and Tb927.7.170) were present in the upregulated in 
stumpy polysome RNA compared to stumpy total RNA or the upregulated in stumpy 
polysome RNA compared to slender polysome RNA datasets.  
 
When the data from alignment of reads that allowed for alignment to multiple 
sequences was analysed for the ten ESAG9 genes, this showed that the read counts 
for all the ESAG9 genes were low in all four RNA samples. The reason for this is 
unclear, however, one contributing factor may be that many of the ESAG9 genes are 
present in telomeric regions. These regions are not sequenced and so are not included 
in the T. brucei TREU 927/4 genome that was used for read alignment, and so this 
would cause these sequences to be discarded from the analysis. This could explain 
the low read counts for ESAG9 sequences.  
 
Another possibility is that the ESAG9-like gene found upregulated in the stumpy 
polysome compared to slender polysome dataset (see Section 6.5.1) is a true ESAG9 
gene that was highly expressed at the time of sample generation. Alternatively, it 
could be a full ESAG9 gene in the AnTat1.1 strain but quite diverged in sequence in 
the TREU 927 strain.  
 
The PAD gene array was also analysed and the genes were also found to not be 
present in the upregulated in stumpy polysome RNA compared to stumpy total RNA 
or the upregulated in stumpy polysome RNA compared to slender polysome RNA 
datasets. The exception was PAD2, which was found to be upregulated in the stumpy 
polysome RNA compared to slender polysome RNA dataset (5.7 fold change, p = 
5.27 x10-10). PAD2 might have been identified because it has the most distinct 
3’UTR of the PAD genes and so reads are more likely to be uniquely assigned to this 
gene. As with β-tubulin, the absence of most PAD genes in the dataset is probably 
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due to these genes being part of a family with great similarity between the gene 
members. Analysis of the alignment of reads that allowed for up to 10 matches per 
tag for the eight PAD genes revealed few reads in all four RNA samples, although 
the read counts for PAD1, 2 and 3 were slightly higher. 
 
6.6.3 Other genes 
Cytochrome c is a nuclear-encoded mitochondrial protein that shows developmental 
regulation. The protein is not detected in bloodstream forms, which have an inactive 
mitochondrion and lack cytochrome-mediated respiration, but during differentiation 
to procyclic forms the protein accumulates, as cytochrome-mediated respiration 
occurs in the procyclic mitochondrion (reviewed in Priest and Hajduk, 1994). 
Despite the fact that the cytochrome c protein was undetectable in the bloodstream 
form, the transcripts are present in all life-cycle stages, and therefore, the authors 
concluded that regulation of cytochrome c protein expression occurs at the 
translational or post-translational level (Torri and Hajduk, 1988). From the data 
obtained here, cytochrome c (Tb927.8.5120) was one of the genes whose transcript 
was found to be upregulated in stumpy form polysome RNA compared to stumpy 
form total RNA (2.6 fold change, p = 0). This is consistent with the above conclusion 
that cytochrome c protein expression is regulated at the translational or post-
translational level. As the authors also found in the above study that the protein was 
not detectable in stumpy forms, protein turnover might also be occurring. 
 
During differentiation to the procyclic-form a histone H2B transcript was found to be 
upregulated at 8-12hr after initiation. Two studies have investigated the level of 
histone H2B transcript in slender and stumpy bloodforms, procyclic forms, and 
during differentiation by northern blot analysis. Both found that the transcript was 
enriched (by about 4-fold) in slender forms and procyclic forms compared with 
stumpy forms, and increased in abundance during differentiation (Matthews and 
Gull, 1998; Garcia-Salcedo et al., 1999). Interestingly, a putative histone 2B variant 
(Tb11.02.5250) was found enriched in stumpy polysome RNA compared to stumpy 
total RNA (3.16 fold change; p = 3.79 x 10-6). This could reflect that the level of the 
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transcript is low in the stumpy total RNA sample but the protein is still actively 
translated in stumpy forms.  
 
6.6.4 Analysis of microarray-identified stumpy form upregulated genes  
The data from this study was also compared with an analysis of genes found to be 
upregulated in stumpy forms by microarray analysis. One microarray analysis that 
identified transcripts upregulated in stumpy forms was the study by Kabani et al. 
(2009), which identified 65 upregulated genes (listed in Kabani et al. 2009 
Additional file 5). Comparison of these 65 genes in the RNA-sequencing analysis, 
revealed that a large proportion of the genes had no reads at all in the RNA samples, 
irrespective of whether multiple tag matches to different genes were considered or 
not. Most of the genes were mostly annotated as ‘hypothetical, unlikely’, and 
therefore, it is likely these are not functional ORFs and not expressed. Moreover, 
many of the genes had high p values associated with the calculated fold changes 
when comparing RNA samples due to their low read counts. Therefore, a comparison 
to the RNA-sequencing data was not possible for most genes. 
 
However, for a few genes there was an agreement of transcript upregulation in 
stumpy forms. These were Tb927.8.1270 (4.4 fold change, p = 2.29 x 10-8) and 
Tb09.211.2300 (2.79 fold change, p = 9.40 x 10-6) when comparing stumpy 
polysome to slender polysome RNA. Interestingly, Tb927.8.5670 (2.89 fold change, 
p = 2.65 x 10-5), Tb927.6.4180 (2.17 fold change, p = 1.35 x 10-14) and Tb927.8.1270 
(2.47 fold change, p = 1.28 x 10-4) where found upregulated when comparing stumpy 









Table 6.5 Information from theTriTryp database (http://tritrypdb.org/tritrypdb/) for genes found to be upregulated in stumpy form both by 
microarray analysis (Kabani et al. 2009) and by Illumina digital tag RNA sequencing analysis 












Gene ID Notes GO terms Protein features Phenotype Mass spec.-based expression evidence Similarities to PDB chains Additional information
Tb927.8.5670 - - - - - -











Tb927.8.1270 expressed in 






- T. brucei palmitoylated proteome, T. 





Tb927.8.5670, Tb927.6.4180 and Tb927.8.1270 are all annotated as ‘hypothetical 
protein, conserved’. To obtain more information that might reveal a possible function 
for these genes, the TriTryp database was interrogated as before, the results of which 
are shown in Table 6.5. As the TriTrypDB entry page for Tb927.8.5670 provided no 
useful information, a basic protein BLAST search was performed using the protein 
sequence as query. This returned 13 sequences producing significant alignments, all 
hypothetical proteins from trypanosomatids, except a hypothetical protein from 
Paenibacillus larvae (e-value = 6.8). Thus, it appears this could be a 
Trypanosomatid-specific protein. Tb927.6.4180 is predicted to contain a FUN14 
domain (e-value = 1.40 x 10-18). The Pfam (http://pfam.sanger.ac.uk) annotation for 
this domain (PF04930) states that this family are short proteins that may contain 
transmembrane helices and are found in eukaryotes and some archaea. This protein 
has also been detected in the bloodstream form plasma membrane fraction and is 
predicted to possess two transmembrane helices; hence it may be a transmembrane 
protein present in the bloodstream plasma membrane. Tb927.8.1270 contains a 
predicted Hsp20-chaperone domain (e-value = 1.00 x 10-2). The Interpro 
(http://www.ebi.ac.uk/interpro) entry for this domain (IPR0008978) states that the 
Hsp20 family is a small family of mammalian heat-shock proteins most abundant in 
skeletal muscle and heart. The TriTrypDB entry page states that this protein has been 
detected in the procyclic form and palmitoylated proteomes (Table 6.5). Therefore, 
this may be an Hsp20-related protein found in procyclic forms. Tb09.211.2300 is 
annotated as ‘ATP-dependent DEAD/H RNA helicase, putative’. For further 
information on Tb09.211.2300 see chapter 4. 
 
6.7 Gene Ontology (GO) analysis 
 
In order to obtain an overall view of the classes of genes enriched in each of the 
polysome RNA samples compared to their corresponding total RNA samples the 
Gene Ontology (GO) terms associated with the genes in both the comparison datasets 
were analysed. Gene ontology terms are divided into three domains; ‘molecular 
function’, ‘biological process’ and ‘cellular compartment’. Cellular compartment 
terms refer to the associated cell part or extracellular environment. This can be an 
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anatomical structure or a gene product group, such as ‘proteasome’. Molecular 
function terms refer to the molecular activities of the gene product, such as catalytic 
or binding activities. Biological process terms refer to a series of events completed 
by one or more molecular functions in a defined order, such as signal transduction or 
a cellular physiological process. Therefore, analysis of associated GO terms provides 
an overview of the processes or gene groups associated with a particular condition or 
state. 
 
6.7.1 Initial GO analysis 
The associated GO terms were obtained for the set of transcripts identified as 
upregulated in stumpy polysome RNA compared to stumpy total RNA and for the set 
of transcripts identified as upregulated in slender polysome RNA compared to 
slender total RNA as well (see Section 2.1.3). The GO terms returned from each 
gene set were then counted and the fold enrichment calculated by comparison of the 
count number between both datasets to find the GO terms enriched in either stumpy 
polysomal RNA or slender polysomal RNA.  
 
Tables 6.6 and 6.7 show the GO terms with a fold enrichment of greater-than 1.5, 
obtained for stumpy form polysomal enriched transcripts and slender form polysomal 
enriched transcripts, respectively. For the GO terms enriched in stumpy form 
polysomal enriched transcripts there are terms connected with the proteasome and 
mitochondrion cellular compartments, ubiquitin and translation initiation processes, 
and enzyme activities such as endopeptidase, as well as calcium ion and nucleic acid 





Table 6.6 Gene Ontology (GO) annotations enriched by greater than 1.5-fold in 
genes enriched in stumpy form polysomal transcripts compared to genes enriched in 





Table 6.7 Gene Ontology (GO) annotations enriched by greater than 1.5-fold in 
genes enriched in slender form polysomal transcripts compared to genes enriched in 
stumpy form polysomal transcripts. 
 
GO ID GO description Fold enrichment
Cellular component
GO:0019774 proteasome core complex, beta-subunit complex 2.45
GO:0005739 mitochondrion 1.74
GO:0005838 proteasome regulatory particle 1.63
GO:0005839 proteasome core complex 1.63
Molecular function
GO:0009055 electron carrier activity 3.27
GO:0003743 translation initiation factor activity 2.45
GO:0004175 endopeptidase activity 2.45
GO:0005509 calcium ion binding 2.45
GO:0003676 nucleic acid binding 1.63
GO:0003755 peptidyl-prolyl cis-trans isomerase activity 1.63
GO:0004197 cysteine-type endopeptidase activity 1.63
GO:0004221 ubiquitin thiolesterase activity 1.63
GO:0015042 trypanothione-disulfide reductase activity 1.63
Biological process  
GO:0006511 ubiquitin-dependent protein catabolic process 3.00
GO:0006464 protein modification process 2.45
GO:0019538 protein metabolic process 2.45
GO:0000398 nuclear mRNA splicing, via spliceosome 1.63
GO:0006413 translational initiation 1.63
GO ID GO description Fold enrichment
Cellular component
GO:0005840 ribosome 3.06
GO:0016021 integral to membrane 1.57
Molecular function
GO:0003735 structural constituent of ribosome 4.90
GO:0004672 protein kinase activity 4.90
GO:0004674 protein serine/threonine kinase activity 2.86
GO:0016491 oxidoreductase activity 2.45
GO:0005524 ATP binding 2.18
Biological process
GO:0006470 protein dephosphorylation 3.67
GO:0006412 translation 3.26
GO:0006468 protein phosphorylation 2.75
GO:0051726 regulation of cell cycle 2.45
GO:0008152 metabolic process 1.84
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The presence in this dataset of many genes with annotations associated with the 
mitochondrion has already been noted (see section 6.5.2; also in the dataset of genes 
upregulated in stumpy polysomal RNA compared to stumpy total RNA, see section 
6.4.3), so the presence of the ‘mitochondrion’ GO term here confirms this 
observation.  
 
Several of the enriched GO terms were associated with the proteasome. Although not 
noted elsewhere, the appearance of many genes with annotations associated with 
proteasome subunits was also observed in both this dataset and the dataset of genes 
upregulated in stumpy polysomal RNA compared to stumpy total RNA. This 
suggests that in stumpy forms there is a high level of protein degradation. One of the 
enriched GO terms is ‘proteasome regulatory particle’ and several genes with 
proteasome regulatory subunit annotations were found upregulated in stumpy 
polysomal RNA compared to stumpy total RNA, for example, Tb927.10.3030 (2.96 
fold change, p = 2.05 x 105) and Tb927.2.2440 (2.37 fold change, p = 8.05 x 105). It 
could be speculated that the change in abundance of these regulatory proteins 
provides a change in proteasome composition, and therefore, regulation of 
proteasome substrates in different life-cycle stages. Connected with this is an 
enrichment of the GO terms ‘ubiquitin-dependent protein catabolic process’ and 
‘ubiquitin thiolesterase activity’, which supports the suggestion of an increase in 
protein turnover in stumpy forms.  
 
A few of the enriched GO terms in this analysis were associated with gene 
expression; these were ‘translation initiation factor activity’, ‘translational initiation’, 
‘nucleic acid binding’, and ‘nuclear mRNA splicing, via spliceosome’. As noted in 
section 6.4.4 many genes with these and other types of annotations associated with 
gene expression were found in the dataset of genes upregulated in stumpy polysomal 
RNA compared to stumpy total RNA. This could suggest that in stumpy forms there 
is a change in the proteins involved in the gene regulation that are elevated to 
mediate a change in gene expression control. This could mediate gene expression to 
prepare the parasite for release of translational repression during the differentiation 
to procyclic form.  
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For slender form polysomal enriched transcripts the number of enriched GO terms is 
much less. This is perhaps reflective of an overall increase in many different types of 
processes, such that there are many low counts for various cellular compartments, 
processes and functions. In agreement with this, many of the enriched GO terms 
were general terms such as ‘integral to membrane’, ‘protein dephosphorylation’ and 
‘regulation of cell cycle’. Several terms, however, do appear to be associated with 
signalling pathways, as there are a number related to protein 
phosphorylation/dephosphorylation, as well as ATP binding. Again, there are a two 
related to translation, these being ‘ribosome’ and ‘translation’. Hence, the presence 
of similar translation-related terms in the results from the genes upregulated in 
stumpy polysomal RNA may be less specific to that dataset. 
 
Gene ontologies are designated as a hierarchy whereby there are three parental terms 
at the top of the hierarchy (‘molecular function’, ‘biological process’ and ‘cellular 
compartment’). As would be expected, for each of the three parent terms there is no 
fold enrichment (the fold changes are 0.92, 1.02 and 1.16) between the stumpy form 
and slender form datasets. Since these terms are equally represented in each dataset, 
any GO annotations with a large fold change should signify a true enrichment. 
 
6.7.2 GO-Stats analysis 
Since many GO term enrichments were based on relatively low underlying reads, 
there was the potential for false positive calls. For example, the terms with an 
enrichment of less than 2-fold may not be true enrichments. Therefore, a different 
analysis of the enriched GO terms was sought. ‘GO-Stats’ is a GO Toolbox 
(http://genome.crg.es/GOToolBox/) online tool for identifying statistically relevant 
over- and under-represented GO terms in gene datasets. This was used to identify 
GO terms enriched or depleted in either stumpy form polysomal enriched transcripts 
or slender form polysomal enriched transcripts. However, unlike the earlier analysis, 
comparison to the genomic frequency of each term was used, rather than between 
gene sets (see Section 2.1.4). The statistically significant enriched and depleted terms 
for stumpy form polysomal enriched transcripts and slender form polysomal enriched 
transcripts, are shown in Tables 6.8 and 6.9, respectively. 
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Table 6.8 Enriched and depleted Gene Ontology (GO) terms in genes upregulated in stumpy form polysomal RNA compared to stumpy form 
total RNA, as identified by GO-Stats analysis. 
 
GO ID GO TERM No. in Ref Frequency in Ref No. in Set Frequency in Set P value Fold change
Enrichment (p < 0.01)
GO:0044257 cellular protein catabolic process 39 0.0137 11 0.0821 0.0005109 5.99
GO:0043632 modification-dependent macromolecule catabolic process 39 0.0137 11 0.0821 0.0005109 5.99
GO:0006511 ubiquitin-dependent protein catabolic process 39 0.0137 11 0.0821 0.0005109 5.99
GO:0019941 modification-dependent protein catabolic process 39 0.0137 11 0.0821 0.0005109 5.99
GO:0051603 proteolysis involved in cellular protein catabolic process 39 0.0137 11 0.0821 0.0005109 5.99
GO:0000502 proteasome complex 32 0.0114 10 0.0735 0.0007826 6.45
GO:0005839 proteasome core complex 14 0.005 7 0.0515 0.0008594 10.30
GO:0043231 intracellular membrane-bounded organelle 433 0.1548 42 0.3088 0.0010563 1.99
GO:0043227 membrane-bounded organelle 433 0.1548 42 0.3088 0.0010563 1.99
GO:0044424 intracellular part 829 0.2963 65 0.4779 0.0013149 1.61
GO:0034962 cellular biopolymer catabolic process 43 0.0151 11 0.0821 0.0014657 5.44
GO:0044237 cellular metabolic process 1137 0.3994 79 0.5896 0.0014853 1.48
GO:0005622 intracellular 839 0.2999 65 0.4779 0.0020475 1.59
GO:0008152 metabolic process 1280 0.4496 85 0.6343 0.0029007 1.41
GO:0044265 cellular macromolecule catabolic process 67 0.0235 13 0.097 0.0046564 4.13
GO:0043170 macromolecule metabolic process 974 0.3421 69 0.5149 0.0064545 1.51
Enrichment (0.01 <  p < 0.05)
GO:0044260 cellular macromolecule metabolic process 908 0.3189 65 0.4851 0.0102599 1.52
GO:0043283 biopolymer metabolic process 948 0.333 67 0.5 0.0106588 1.50
GO:0005739 mitochondrion 163 0.0583 21 0.1544 0.010753 2.65
GO:0034960 cellular biopolymer metabolic process 884 0.3105 63 0.4701 0.0178198 1.51
GO:0009055 electron carrier activity 5 0.0018 4 0.028 0.0191346 15.56
GO:0044238 primary metabolic process 1146 0.4025 76 0.5672 0.0196879 1.41
GO:0009987 cellular process 1515 0.5321 93 0.694 0.0232564 1.30
GO:0044248 cellular catabolic process 90 0.0316 14 0.1045 0.0272371 3.31




   c 
 




a http://genome.crg.es/GOToolBox/ (see Section 2.1.4) 
b Ref: The reference gene set created by the GO-Stats programme from the Trypanosoma brucei genomic distribution of GO terms 
c Set: The gene set under analysis 















Depletion (p < 0.01)
GO:0031224 intrinsic to membrane 450 0.1608 6 0.0441 0.0077352 0.27
GO:0016021 integral to membrane 450 0.1608 6 0.0441 0.0077352 0.27
Depletion (0.01 <  p < 0.05)
GO:0016020 membrane 619 0.2212 12 0.0882 0.0107436 0.40
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Table 6.9 Enriched and depleted Gene Ontology (GO) terms in genes upregulated in slender form polysomal RNA compared to slender form 
total RNA, identified by GO-Stats analysis. 
 
a http://genome.crg.es/GOToolBox/ (see Section 2.1.4) 
b Ref: The reference gene set created by the GO-Stats programme from the Trypanosoma brucei genomic distribution of GO terms 
c Set: The gene set under analysis 













  c 
 
a  
 d GO ID GO TERM No. in Ref Frequency in Ref No. in Set Frequency in Set P value Fold change
Enrichment (p < 0.01)
GO:0044238 primary metabolic process 1146 0.4025 71 0.6455 4.36E-05 1.60
GO:0044237 cellular metabolic process 1137 0.3994 70 0.6364 8.37E-05 1.59
GO:0008152 metabolic process 1280 0.4496 75 0.6818 0.000146 1.52
GO:0034960 cellular biopolymer metabolic process 884 0.3105 57 0.5182 0.0009043 1.67
GO:0044260 cellular macromolecule metabolic process 908 0.3189 58 0.5273 0.0009313 1.65
GO:0043283 biopolymer metabolic process 948 0.333 59 0.5364 0.0017398 1.61
GO:0043170 macromolecule metabolic process 974 0.3421 60 0.5455 0.0018888 1.59
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Although the enriched GO terms resulting from the analysis using GO-Stats were 
different to those found with the previous analysis, there are similar types of GO 
terms in both sets (Table 6.8). For GO terms enriched in stumpy form polysome-
associated transcripts, ‘mitochondrion’, ‘proteasome core complex’, ‘electron carrier 
activity’, and ‘ubiquitin-dependent protein catabolic process’ are enriched in the 
results of both GO analyses. Many similar terms to these were identified by the GO-
Stats analysis too. Therefore, the enrichment of these GO terms appears reliable. 
Translation-related terms are absent from the results of this GO-Stats analysis and 
therefore, this is in agreement with the observation from the above GO analysis, that 
translation-related terms were found enriched in both datasets and so that these are 
probably not true enrichments in either dataset. Additionally, the GO-Stats analysis 
identified three depleted terms, all membrane-related. This may indicate a 
downregulation of membrane proteins in the genes enriched in stumpy form 
polysome-associated transcripts. 
 
The GO-Stats analysis also identified few enriched terms for the slender polysome 
associated transcripts (Table 6.9), similarly to the straightforward GO terms analysis. 
Nonetheless, the GO terms were similar, all being related to metabolic processes. In 
fact, comparison of Table 6.9 to Table 6.8 reveals that all the GO terms found 
enriched in slender form polysome-associated transcripts were also found enriched in 
stumpy form polysome-associated transcripts. This suggests that these metabolic 
processes could be generally upregulated in bloodstream-form cells rather than 
specifically upregulated in either slender or stumpy forms.  
 
6.8 RIT-seq analysis 
 
A T. brucei genome-wide RNAi-screen was recently been published by Alsford et al. 
(2011). This identified genes that caused the phenotypes of ‘defect in bloodstream 
form growth’, ‘defect in procyclic form growth’ and ‘defect in in vitro differentiation 
to procyclic form’, as well as an ‘overall loss-of-fitness’ through RNAi. As stumpy 
forms are preadapted for transmission to the tsetse fly, the genes they express are 
likely to be important for differentiation to the procyclic form. It was hypothesised 
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that there may be an increase in the occurrence of genes associated with a loss-of-
fitness in differentiation upon RNAi in the dataset of genes preferentially translated 
in stumpy forms. Hence, the presence of each RNAi phenotype was investigated in 
the expression datasets using the data generated by Alsford et al. (2011).  
 
The phenotypes observed in the study by Alsford et al. (2011) were associated with 
each gene from the expression analysis using their binary scoring system which 
produced five groups: significant loss-of-fitness in bloodstream form, in procyclic 
form, in differentiation, in all experiments, and no significant loss-of-fitness in any 
experiment. In each expression dataset the occurrence of each phenotype was then 
compared and shown in Table 6.10. As can be seen, there was no specific enrichment 
or depletion of any RNAi phenotype in either stumpy form polysome associated 
transcripts or slender form polysome associated transcripts. As would be expected, 
the percentage of genes in each dataset with a non-specific loss-of-fitness was almost 
identical.  
 
Although it was believed that there might be an increase in the occurrence of genes 
associated with a loss-of-fitness in differentiation upon RNAi among transcripts 
preferentially translated in stumpy forms, this was not observed. However, this could 
be due to the methodology used in the RNAi-screen to test for a loss-of-fitness in 
differentiation. To test for differentiation the authors used bloodstream monomorphic 
cells stimulated to differentiate with the addition of cis-aconitate in vitro. In contrast, 
the dataset of transcripts enriched in stumpy form polysomes used pleomorphic 
bloodstream cells. Genes associated with the biology of stumpy forms and their role 








Table 6.10 Percentage of genes upregulated in slender polysome RNA or stumpy polysome RNA with a phenotype from the genome-wide 
RNAi screen study by Alsford et al. (2011)a. 










Loss-of-fitness in BSF Loss-of-fitness in PCF Loss-of-fitness in DIF Loss-of-fitness all groups Non-specific loss-of-fitness
Slender 4.53% (21) 2.80% (13) 6.47% (30) 12.28% (57) 36.21% (168)
Stumpy 5.91% (30) 3.35% (17) 5.91% (30) 11.42% (58) 36.61% (186)
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Table 6.11 Genes upregulated in stumpy form polysome RNA which have a ‘loss-
of-fitness in differentiation’ phenotype from Alsford et al. (2011). 
a asterisks indicate genes which are present in both datasets of transcripts upregulated 
in slender form polysome RNA and transcripts upregulated in stumpy form 
polysome RNA 
b Fold change upregulation in stumpy-form polysome RNA compared to stumpy 
form total RNA 
c p value associated with the fold change; corrected for false discovery rate (FDR) 
 
 
It was observed that the number of genes with a loss-of-fitness in differentiation 
phenotype was the same in both datasets (Table 6.10). So to investigate if both 
datasets contained the same genes identified as important for differentiation, the 
Feature ID Product description Fold change p  value
Tb927.7.2070 * heat shock protein DNAJ, putative 3.73 0
Tb09.211.0700 isopentenyl-diphosphate delta-isomerase, 
putative,isomerase, putative
3.67 0
Tb927.10.15810 hypothetical protein, conserved 3.47 0
Tb927.6.2820 hypothetical protein, conserved 3.02 0
Tb09.211.3420 riboflavin kinase, putative 2.96 2.98E-07
Tb927.8.580 hypothetical protein, conserved 2.96 0
Tb09.211.3310 replication factor C, subunit 3, putative 2.93 1.64E-07
Tb09.160.2020 thioredoxin (trx) 2.92 0
Tb927.4.4620 cytochrome oxidase subunit VIII (COXVIII) 2.82 2.24E-06




Tb927.3.4680 RAB GDP dissociation inhibitor alpha, putative 2.8 5.91E-08
Tb927.5.2110 hypothetical protein, conserved 2.8 4.98E-09
Tb09.211.1610 * phosphatidylserine decarboxylase, putative 2.77 0
Tb11.01.1820 Biotin--acetyl-CoA-carboxylase ligase, putative, 
biotin--protein ligase, putative
2.68 1.69E-12
Tb09.160.3110 mitochondrial processing peptide beta subunit, 
putative,metallo-peptidase, Clan ME, Family M16 
(1L12.450)
2.64 1.18E-11
Tb927.7.630 hypothetical protein, conserved 2.62 3.85E-05
Tb09.160.0410 hypothetical protein, conserved 2.56 4.71E-07
Tb927.3.5150 * exonuclease, putative 2.56 1.15E-03
Tb09.211.0310 hypothetical protein, conserved 2.54 2.65E-05
Tb927.10.14860 hypothetical protein, conserved 2.37 8.54E-12
Tb927.7.3100 hypothetical protein, conserved 2.31 4.52E-12
Tb11.02.4900 hypothetical protein, conserved 2.26 1.13E-08
Tb927.7.2740 hypothetical protein, conserved 2.25 0
Tb927.6.4570 hypothetical protein, conserved 2.18 0
Tb11.02.2130 hypothetical protein, conserved 2.14 4.17E-04
Tb927.6.4990 ATP synthase, epsilon chain, putative 2.11 0
Tb927.5.1270 hypothetical protein, conserved 2.1 2.00E-05
Tb927.10.10160 hypothetical protein, conserved 2.08 2.28E-05
Tb927.10.10420 monothiol glutaredoxin, putative 2.02 0








genes with the differentiation RNAi phenotype were compared. Table 6.11 shows the 
genes in the dataset of transcripts enriched in stumpy polysomes that have a loss-of-
fitness in differentiation phenotype. With comparison to the transcripts enriched in 
slender form polysomes, only four genes were present in both datasets (marked with 
an asterisk in Table 6.11). Hence, genes important for procyclic form differentiation 
apparently differs between monomorphic and pleomorphic cells. 
 
6.9 Analysis of downstream sequences of enriched genes 
 
Those transcripts enriched in the polysomal fractions of stumpy form cells with 
regard to the total RNA were analysed for 3’UTR sequence that might control their 
translation. This involved analysis of the sequences downstream of the gene stop 
codon for each gene using the online tool, Regulatory Sequences Analysis Tool 
(RSAT; http://rsat.scmbb.ulb.ac.be/rsat/; see section 2.1.5), which identifies 
statistically over-represented oligomers in sets of DNA sequences.  
 
The RSAT oligo-analysis tool (van Helden et al., 1998) was used to identify 
regulatory elements, as this tool is designed to detect over-represented 
oligonucleotides in co-regulated gene sets, and therefore, to identify regulatory 
elements. Although used initially to identify DNA binding sites for transcription 
factors in yeast genes, it can be utilised to identify other regulatory elements (van 
Helden et al., 1998). 
 
Initially, the Markov model option was used as the background model in the oligo-
analysis tool to identify over-represented oligomers in the 300nt downstream-
sequences for genes enriched in either stumpy form or slender form polysomes. This 
length of downstream-sequence was used because it is close to the median length 
found for all mapped 3’UTRs (400 bp, Siegel et al. 2010). However, the results 
appeared to be fairly unspecific, with many of the oligomers identified present in 
both analyses. Therefore, to increase specificity the same approach was used as has 
been used previously, in that oligomer frequencies were compared to those obtained 
for the 300nt downstream-sequences of genes present on chromosomes 1 and 2 
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(Mayho et al. 2006). Genes present on chromosomes 1 and 2 were chosen as a 
representative set because it is unlikely that these are co-regulated and so should 
show no bias in oligomer frequency, except for that which is seen in sequences of 
300nt downstream of genes throughout the T. brucei genome. For this comparison, 
the 300nt of downstream-sequence for each of 475 genes present on chromosomes 1 
and 2 was retrieved, and used as input in the oligo-analysis tool to generate a 
frequency file of 8-mers, which was subsequently used as the background model in 
the oligo-analysis tool with 300nt downstream-sequences of genes in the test dataset. 
Again, most of the over-represented oligomers (8-mers) identified were present in 
both datasets, perhaps representing ‘bloodstream-form’-specific 8-mer sequences. 
After these were excluded, 8 unique 8-mers were present for each of the 300nt 
downstream-sequences of genes enriched in either stumpy form or slender form 
polysome-associated RNA. These are shown in Table 6.12. 
 
As can be seen in Table 6.12, within each set of 8-mers there appears to be some 
similarity. For example, in the ‘enriched in stumpy form polysomal transcripts’ the 
sequence ‘TTATT’ occurs in 3 of the 8-mers, and ‘TATT’ occurs in another. This 
sequence was not found in any of the unique 8-mers found over-represented in genes 
enriched in slender form polysomal transcripts. Interestingly, this ‘TTATT’ 5-mer, 
along with a ‘TTA’ 3-mer, ‘TATT’ 4-mer, and ‘TTATTA’ 6-mer were found to be 
over-represented using this same approach in T. brucei COX 3’UTRs, as well as in 
procyclic-enriched transcripts with similar AU-rich oligomers (Matthew Mayho, 
PhD thesis, University of Edinburgh). Therefore, this appears to confirm the 
presence of a large number of genes upregulated in procyclic forms in the stumpy 
form polysome enriched transcript dataset.  
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Table 6.12 Oligomer (8-mer) sequences, found by Regulatory Sequences Analysis 
Tool (RSAT; http://rsat.scmbb.ulb.ac.be/) oligo-analysis tool, over-represented in 
either 300nt of downstream-sequences of stumpy form or slender form polysomal 
transcriptsa. 
a Using RSAT oligo-analysis, a background model of oligomer (8-mer) sequence 
occurrence frequency was created from 300nt downstream-sequences for genes on 
Chromosomes 1 and 2. This was used to identify over-represented 8-mers in the 
300nt downstream-sequences of genes enriched in either stumpy form or slender 
form polysome-associated RNA. The over-represented 8-mers were then compared 
to find unique 8-mers present in each dataset. 
 
 
In the unique 8-mers over-represented in slender form polysomal transcripts many 
contain stretches of many T residues. One of these, ‘GTTTTGTT’ is very similar to 
one from the stumpy form polysomal transcripts 8-mers, ‘TTGTTTTG’. Therefore, 
these sequences are unlikely to be specific to either dataset. Except for one, each of 
the unique 8-mers in this dataset contains 4-5 consecutive T residues. Thus, it would 
appear that the sequence ‘TTATT’ is over-represented in the 300nt downstream-
sequences of genes enriched in stumpy form polysome-associated RNA and the 
sequence ‘TTTT/TTTTT’ is over-represented in the 300nt downstream-sequences of 
genes enriched in slender form polysome-associated RNA. These sequences could 
therefore be involved in the control of life-cycle stage-specific translation, either in 
Sequence Expected frequency Occurance E-value
Enriched in stumpy-form polysomal transcripts
attattat 3.0365E-07 39 7.00E-95
tttgtttg 3.0365E-07 39 7.00E-95
aagaaaag 3.0365E-07 38 6.10E-92
tattatta 3.0365E-07 38 6.10E-92
gtttttgt 3.0365E-07 37 5.20E-89
ttattgtt 3.0365E-07 37 5.20E-89
ttgttttg 3.0365E-07 37 5.20E-89
tatatatt 3.0365E-07 36 4.20E-86
Enriched in slender-form polysomal transcripts
ctcttttt 3.0365E-07 47 1.00E-120
tctctttt 3.0365E-07 47 1.00E-120
tccttttt 3.0365E-07 42 2.00E-105
tgtgtgtt 3.0365E-07 42 2.00E-105
ttcctttt 3.0365E-07 42 2.00E-105
tttttaaa 3.0365E-07 42 2.00E-105
gttttgtt 3.0365E-07 41 2.00E-102
actttttt 3.0365E-07 39 2.00E-96
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promotion of translation in the respective life-cycle stage in which it is over-
represented or in repression of translation in the other life-cycle stages.  
 
The ‘feature map’ tool (see section 2.1.5) allowed visualisation of the location of the 
over-represented unique 8-mers in the 300nt downstream-sequence of the respective 
dataset. This showed that they are relatively evenly distributed throughout the genes 
present and with no obvious bias to location along the 300nt for either dataset (see 




























6.10.1 Radioactive methionine labelling throughout stumpy form to procyclic form 
differentiation 
To investigate proteins that escape translational repression in stumpy forms and how 
this profile changes throughout differentiation to the procyclic form, the synthesis of 
new proteins was followed using radiolabelled methionine. The amount of protein 
synthesis was much lower in stumpy forms compared to slender and procyclic forms, 
and increased during differentiation (Figure 6.1 A). This was consistent with another 
study (Shapiro and Kimmel, 1987) and of translational repression in stumpy forms 
(Brecht and Parsons, 1998), and also demonstrated the release of translational 
repression during differentiation. However, the resolution of this methodology was 
not sufficient to determine individual proteins that escape repression in stumpy forms 
or throughout differentiation.  
 
The amount of protein synthesis was also analysed by quantification of radiolabel 
incorporation. This demonstrated the increasing amount of protein synthesis 
throughout differentiation with time, and that by 8 hours into differentiation the level 
of protein synthesis was approaching that observed for established procyclic forms 
(Figure 6.2). The greatest increase in the amount of protein synthesis throughout 
differentiation was between 4 and 6 hours after the initiation of differentiation 
(Figure 6.2). This is coincident with a previously reported dramatic increase in RNA 
synthesis between 4 and 10 hours into differentiation (Pays et al., 1993). 
 
Interestingly, this result is in contrast to a previous study that reported a decrease in 
protein synthesis at the onset of in vitro differentiation (Bass and Wang, 1992). 
However, the study by Bass and Wang (1992) differed in that differentiation to the 
procyclic form was initiated directly in monomorphic slender forms by a temperature 
decrease alone, whereas in the study presented here, stumpy forms and cis-aconitate 
were used. It is likely that the contrasting results reflect the different methodologies. 
For example, the decrease in protein synthesis observed in the Bass and Wang (1992) 
study could have resulted as a cold-shock response to the temperature decrease, 
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which occurred because the temperature decrease was unaccompanied by the cis-
aconitate signal. Alternatively, it may have represented a stumpy-like transitional 
phase needed for differentiation of monomorphic forms to the procyclic form, such 
that the cells passed through a stage of decreased protein synthesis similar to that 
observed in stumpy forms. 
 
6.10.2 Analysis of actively translated transcripts using Illumina digital tag RNA 
sequencing 
To identify which mRNA transcripts escape the translational repression in stumpy 
forms, the polysome-associated mRNAs were compared with total mRNA from 
stumpy forms (AnTat1.1 strain) and monomorphic slender forms (427 strain) using 
Illumina digital tag RNA sequencing. There are limitations of this approach, for 
example, the slender and stumpy populations used were from monomorphic and 
pleomorphic strains, respectively, and so may exhibit gene expression differences 
that may bias comparisons. Likewise, only one biological replicate was analysed, 
therefore, gene expression comparisons between different populations could also 
result in the identification of false positive transcript enrichments. It would, 
therefore, be necessary to confirm any transcript enrichment of genes identified for 
further study through regeneration of the infections and samples, followed by 
Northern blotting or qRT-PCR.   
 
Also, this approach used an RNA sequencing procedure reliant on the NlaIII 
restriction enzyme site sequence, which is not present in every gene sequence. 
Transcripts that do not possess this sequence will therefore be excluded from the 
analysis. However, this should not cause a problem because this analysis involved 
comparison between transcript abundance in different RNA samples rather than 
comparison between the abundance of different transcripts. Unless, for a given 
transcript there is differential RNA processing between the two life-cycle stages that 
results in the loss or gain of an NlaIII site sequence, and thus gives an apparent 




The transcripts identified as enriched in the stumpy polysomal RNA appeared to 
confirm this life-cycle stage as preadapted for transmission and differentiation to the 
procyclic form. This is because there was a large number of enriched transcripts 
encoding proteins associated with the mitochondrion or procyclic-enriched 
transcripts, such as COX VIII, VII and COX V. As noted in Section 6.4.3, it was 
previously suggested that stumpy forms accumulate mitochondrial transcripts before 
developing a functional mitochondrion in procyclic forms (Michelotti and Hajduk, 
1987) and the data presented here supports this suggestion. 
 
Enrichment of transcripts encoding proteins associated with other types of cellular 
processes/components was also noted, such as gene expression or the proteasome. 
This was also confirmed in comparisons of associated GO terms in the datasets of 
enriched transcripts in slender forms and stumpy forms (Tables 6.6, 6.7, 6.8 and 6.9). 
The enrichment of transcripts associated with the proteasome in stumpy forms is also 
consistent with their preadaptation for differentiation, because presumably, each cell 
will have a high protein turnover when it undergoes the great morphological change 
that this process involves, in addition to autophagy and glycosomal turnover.  
 
As noted in Section 6.7.1, there was enrichment in proteasome regulatory 
particle/subunit annotations observed in stumpy form enriched transcripts. The 19S 
proteasome regulatory particle is important for proteasome substrate binding, 
unfolding and translocation of the substrate into the proteolytically active core 
particle, and it therefore, confers substrate specificity (Tomko et al., 2011). Thus, it 
may be speculated that this enrichment indicates that there is a change in regulation 
of proteasome substrates in different life-cycle stages. For example, in Arabidopsis 
thaliana a proteasome regulatory particle subunit (RPT2) plays a critical role in plant 
development, with rpt2a null mutants exhibiting a range of developmental defects 
(Lee et al., 2011). In addition, yeast cells in a stationary phase exhibit increased 
proteasome subunit expression, altered proteasome composition and increased levels 
of individual proteasome proteolytic activites which may play a role in maintaining 
cell viability during stationary phase (Chen et al., 2004). Therefore, suggesting a link 
324 
between a non-proliferative cell state and altered proteasome regulation that may 
support a similar connection in stumpy form trypanosome cells.  
 
Analysis of the associated GO terms, therefore, was useful in confirming the 
observations of these enriched protein groups. However, one study reported that only 
38% of T. brucei annotated genes have associated GO terms (Alsford et al., 2011), 
meaning that a large number of genes are not represented in this analysis. Therefore, 
it is possible that enrichment of transcripts associated with particular cellular 
processes/components could have been overlooked in this analysis or that an 
identified enrichment may be a false positive result.    
 
Additionally, another criticism that could be made of the Illumina digital tag RNA 
sequencing study presented here is that the polysome fractions used for extraction of 
polysome-associated RNA may be contaminated with other mRNAs. This is because 
it is possible that other high-molecular weight complexes that contain mRNAs were 
present in these fractions. These could be, for example, P bodies or stress granules, 
and therefore, contain mRNAs for degradation or storage. Thus, some transcripts 
concluded here to be actively translated in stumpy forms could, in contrast, be 
degraded or stored in this life-cycle stage. 
 
The transcripts of a number of interesting genes were identified as enriched in the 
stumpy polysome RNA sample in this study. For example, Tb927.5.2590 which is 
predicted to possess a Macro domain (see Section 6.4.1); Tb09.160.0680 and 
Tb09.211.4513, which are annotated as putative sec1 family transport protein 
(SLY1) and kinetoplastid membrane protein-11 (KMP-11) respectively, 
Tb11.03.0250 which is annotated as cyclophilin A (see Section 6.4.2); Tb927.7.5400 
which is predicted to possess a signal peptide and two transmembrane helices and 
may be a trypanosomatid-specific gene, Tb927.3.5760 which showed similarity to 
ESAG9 sequences (see Section 6.5.1); Tb927.8.5670 which may also be a 
trypanosomatid-specific gene, Tb927.6.4180 which is predicted to contain a FUN14 
domain, and Tb09.211.2300 which is annotated as a putative ATP-dependent 
DEAD/H RNA helicase (see Section 6.6.4). However, analysis of the expression of 
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these transcripts in slender forms, intermediate forms, stumpy forms, procyclic forms 
and bloodstream monomorphic forms (from analysis performed by Dr. Paul 
Capewell of both Illumina digital tag sequencing experiments, see Section 6.3.1) 
revealed that of these genes only Tb927.7.5400, Tb927.8.5670, and possibly 
Tb927.3.5760 and Tb09.211.2300 are enriched in stumpy forms. 
  
The next necessary experiment in this work is to validate the Illumina digital tag 
sequencing results using quantitative PCR or northern blot analysis, to confirm the 
mRNA expression levels for a number of transcripts. This would be essential to 
verify the expression profile of any interesting genes selected for further study before 
that work commenced. For example, the upregulation of Tb09.211.2300 in stumpy 
forms has already been confirmed by northern blot analysis, as this transcript was 
investigated in another part of this project (Figure 4.7 B). The further study of 
interesting genes may involve RNAi-mediated transcript ablation or ectopic 

















































The question that was to be addressed in this project was how are translation and the 
escape from translational arrest in stumpy form T. brucei controlled? This 
encompassed four specific aims, each of which is addressed below with suggestions 
of further work. 
 
• What signals control the expression, or escape from translational arrest, of 
genes expressed in stumpy forms? 
 
For one stumpy-enriched transcript, ESAG9-EQ, a 33nt sequence, termed here the 
'element' sequence, in the 3'UTR was identified as contributing strongly to gene 
silencing in slender forms. This sequence was also determined to be the signal 
responsible for transcript enrichment upon development to stumpy-like forms in 
response to 8-pCPT-2’-O-Me-cAMP. Analysis of reporter gene expression in 
pleomorphic form cells confirmed that this sequence was responsible for the release 
of translational repression in true stumpy forms. Thus, this sequence represents the 
first identification of an mRNA sequence responsive to cell-density and stumpy-
induction factor signalling. Therefore, it would be interesting to investigate if an 
RNA-binding protein interacts with the ESAG9-EQ 3'UTR, and specifically the 
identified element, possibly through the use of an RNA EMSA (electromobility shift 
assay) before employing one of the techniques discussed in Section 3.10.2, such as 
tRNA tethering. As mentioned, this could enable dissection of the currently unknown 
SIF signalling pathway, in the opposite direction to signal transduction.  
 
Additionally, it would be interesting to determine the secondary structure of the 
element sequence in the full-length 3’UTR experimentally, by RNase enzymatic 
digestion, for example. If an RNA-binding protein does interact with the element 
sequence, then mutational analysis of this sequence could determine which 
nucleotides are important for the interaction and so, together with the experimentally 
determined element structure, may assist with the discovery of other transcripts 
bearing this regulatory motif.  
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• Do mechanisms such as uORFs control the escape from repression, or 
repression, of genes expressed in stumpy forms? 
 
Although it did appear initially that there was a slight enrichment in the abundance of 
potential uORFs in stumpy-enriched transcripts compared to heat-shock regulated 
transcripts or genome abundance (Table 4.1), upon analysis of predicted SAS 
locations and stumpy-enriched transcripts from an initial Illumina digital tag 
sequencing experiment, this slight enrichment was not present. This indicates that it 
is unlikely that uORFs are used as a general mechanism for the control of gene 
expression in stumpy forms, but this does not exclude the possibility that this 
mechanism is used to control the expression of some individual genes. However, of 
the three stumpy-enriched genes possessing potential uORFs that were investigated 
in this study (ESAG9-EQ, Tb09.211.2300 and Tb11.47.0019) none showed evidence 
of the identified potential uORFs contributing to the control of their expression. 
 
For Tb11.47.0019, the use of three SAS locations was discovered, potentially giving 
rise to encoded proteins of different lengths from the annotated ATG or an internal 
ATG. It has been previously hypothesised that in T. brucei the use of differential 
SAS and PAS could be used to regulate gene expression and also regulate the 
inclusion/exclusion of various properties in a protein (Siegel et al., 2011). Initially, it 
appeared that the different SAS locations in Tb11.47.0019 may have been used in 
different ratios during the life-cycle, but variability in the Northern blot analyses 
meant that these results were inconclusive. The possibility that different protein 
isoforms of Tb11.47.0019 with different localisations was investigated by ectopic 
expression of either isoform with a Ty epitope tag. However, it appeared that the 
short protein form was preferentially expressed, regardless of the presence of the 
long protein sequence, either due to preferential trans-splicing at the downstream 
location or to preferential recognition of the downstream ATG start codon. 
Therefore, it appears that differential splicing does not always result in the 
production of two protein isoforms, at least within slender and stumpy forms. If this 
project were to be continued, it would be necessary to determine whether the longer 
protein isoform of Tb11.47.0019 is naturally expressed (for example, in stumpy 
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forms), which could be achieved by western blot analysis using an antibody raised 
against the protein sequence common to both isoforms. 
 
• Are specific translational proteins involved in translational control in stumpy 
forms? 
 
The transcripts of a number of translation initiation factor homologues were 
investigated for enrichment in stumpy forms, which could be involved in 
translational control in stumpy forms. As such, the mRNA of one eIF4E homologue, 
TbeIF4E4, was identified as stumpy-enriched and so may contribute to translational 
control in this life-cycle stage. Preliminary experiments indicated that RNAi-
mediated transcript ablation of TbeIF4E4 resulted in a decreased growth rate and 
decreased polysome abundance, consistent with a previous study (Freire et al., 
2011). But this was not analysed any further than the preliminary experiments 
performed, due to the finding that another group was also researching these eIF4E 
homologues. 
 
Another translation initiation factor homologue that exhibited transcript enrichment 
in stumpy forms was the eIF6 homologue, TbeIF6. Either RNAi-mediated transcript 
ablation or protein overexpression of TbeIF6 resulted in decreased growth and 
dramatically decreased protein synthesis. This was possibly due to decreased levels 
of translation following both inductions, although the polysome analysis did not 
provide conclusive results. TbeIF6 did not appear to be involved in differentiation to 
the procyclic form, but it remains that the stumpy-enrichment suggests involvement 
of TbeIF6 in translational repression in stumpy forms. For further work of 
investigation of this protein, firstly it would be interesting to determine if the TbeIF6 
protein is also upregulated in stumpy forms. Additionally, it is necessary to repeat 
the polysome profiles of cells induced for TbeIF6 RNAi or overexpression alongside 
uninduced controls, and also to repeat the northern blot analysis to detect INGI 
transcripts using RNA samples from TbeIF6 RNAi-induced cells. Furthermore, it 
would be interesting to assess the effect of RNAi or overexpression of TbeIF6 in 
stumpy form cells on differentiation to the procyclic form, and therefore, following 
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transfection of the relevant constructs into pleomorphic cells. However, this 
experiment may still suffer from secondary effects due to the induction of either of 
these conditions resulting in a decreased growth and decreased protein synthesis. 
 
• Which transcripts escape translational repression in stumpy forms? 
 
Protein synthesis in stumpy forms and throughout differentiation to the procyclic 
form was assessed using radiolabelled methionine. This confirmed that stumpy forms 
exhibit a decreased level of protein synthesis compared to slender and procyclic 
forms, and also demonstrated the release from translational repression during 
differentiation as protein synthesis increased during this process. To identify which 
transcripts escape translational repression in stumpy forms, Illumina digital tag RNA 
sequencing was used with total RNA and polysome-associated RNA samples from 
slender and stumpy forms. Transcripts enriched in the stumpy form polysome-
associated RNA sample were determined and some interesting genes were identified 
for further analysis. These transcripts also appeared to confirm stumpy forms as 
preadapted for transmission and differentiation to the procyclic form, because there 
were many enriched transcripts that were associated with the mitochondrion. 
However, this expression data requires validation by northern blot analyses or 
quantitative PCR, and this would be the next step in the further work for this project 
area. Following this, interesting genes could then be investigated for their function 
and importance in stumpy form biology and differentiation through RNAi-mediated 
transcript ablation and protein overexpression. 
 
In conclusion, stumpy forms exhibit decreased protein synthesis in comparison to 
proliferative life-cycle stages and the control of translation in this life-cycle stage 
may involve translational proteins, such as the eIF6 homologue. For the escape from 
translational repression in stumpy form T. brucei, 3'UTR sequences appear to be 
important, such as the ESAG9-EQ 3’UTR element sequence. Therefore, stumpy 
forms are similar to other life-cycle stages studied, where the control of gene 
expression by cis-acting sequences is also important. uORFs do not appear to be a 
mechanism important for general translational control in stumpy forms, although 
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they may control the expression of individual genes, but not the three genes analysed 
in this study. The control of gene expression and production of different protein 
isoforms may be regulated by different trans-splicing locations, however, whilst 
different SAS locations appear to be used for one gene (Tb11.47.0019) studied, it 
was observed that this did not result in the production of different protein isoforms, 
at least in slender forms. Additionally, transcripts enriched in the polysome-
associated RNA of stumpy forms were identified in this study, and thus, should 
represent transcripts that escape the translational repression at this life-cycle stage.  
 
Because stumpy forms are preadapted for transmission to the tsetse fly, a 
trypanosomiasis treatment developed to target this life-cycle stage could potentially 
block or reduce parasite transmission. This strategy could, however, result in an 
increase in virulent slender forms in the host and so may not be a viable treatment 
strategy unless used in combination with an additional treatment. An alternative 
method of exploiting stumpy form biology could be the use of compounds to 
accelerate stumpy form differentiation leading to reduced transmission because of a 
reduction in parasite numbers through cellular quiescence and host immune system 
infection control (MacGregor and Matthews, 2010). Consequently, understanding the 
biology of stumpy forms is an important area for research. At the commencement of 
this project, nothing was known regarding the control of gene expression in stumpy 
forms. Therefore, the work presented here makes a significant contribution to 
understanding the control of translation and escape from translational arrest in this 
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Chemicals were purchased from Sigma unless otherwise stated. 
 
PSG (Phosphate-Saline-Glucose) buffer 
 
1 litre: 
NaH2PO4.2H2O 0.488 g  
NaCl   2.55 g 
Na2HPO4  8.08 g 
D-glucose  15 g 
pH to 7.8 with HCl 
 






pH to 7.4 
 
vPBS (Voorheis’s modified PBS) 
PBS   250 ml 
Sucrose  3.925g 




Mowiol 4-88 reagent (Calbiochem)  10% w/v 
Glycerol     25% w/v 




DL-Dithiothreitol dissolved in 10 mM sodium acetate (pH5.2), then sterilized by 











MOPS     46.26 g/l 
Sodium acetate, pH7.0  50 mM 
EDTA, pH8.0    10 mM  




NaCl     3M 
Tri sodium citrate   0.3M 
 
RNA gel loading buffer 
 
Formamide    150 µl 
Formaldehyde (37%)   83 µl 
Bromophenol blue   0.01% 
MOPS     1X 
Glycerol    10% 




20X SSC    12.5 ml 
Formamide    25 ml 
10% SDS    100 µl 
10% DIG block   10 ml 
 
Maleic acid buffer 
 
Maleic acid    100 mM 
NaCl     150 mM 




Blocking reagent (Roche)   10% (w/v) 
Maleic acid buffer, pH7.5 











Miniprep solution I 
 
Glucose   50 mM 
Tris-HCl, pH8   25 mM 
EDTA, pH8   10 mM 
Autoclaved 
 
Miniprep solution II 
 
SDS    1% 
NaOH    0.2 M 
 
Miniprep solution III 
 
5M Potassium acetate  60 ml 
Glacial acetic acid  11.5 ml 




Tris-acetate   40 mM 
EDTA    1 mM 
pH8 
 
6X DNA gel loading buffer 
 
Bromophenol blue  0.25% 
Xylene cyanol   0.25% 




Tris-HCl, pH8   10 mM 













WESTERN BLOT ANALYSIS SOLUTIONS 
 
Semi-dry transfer buffer 
 
Tris   2.5 mM 
Glycine  15 mM 
SDS   0.02% 




       10%   12% 
Running gel:  Water    3.12 ml  2.62 ml 
   TrisHCl buffer (pH8.8) 1.87 ml  1.87 ml 
   Acrylamide   2.5 ml   3.0 ml 
   10% APS   50 µl   50 µl 
   TEMED   10 µl   10 µl 
 
Stacking gel: Water    1.5 ml 
  TrisHCl buffer (pH6.8) 375 µl 
  Acrylamide   625 µl 
  10% APS   12.5 µl 
  TEMED   4 µl 
 
TrisHCl buffer (pH8.8): TrisHCl 1.5 M 
    SDS  0.4% 
 
TrisHCl buffer (pH6.8): TrisHCl 0.5 M 




























































SQL query (written by Christiane Hertz-Fowler, Wellcome Trust Sanger Institute, 
Hinxton) for retrieving Gene Ontology annotations (Gene IDs entered into the last 
set of parentheses): 
 
SELECT 
  gene_product.symbol, 
  gene_product.full_name, 
  dbxref.xref_dbname, 
  dbxref.xref_key, 
  species.genus, 
  species.species, 
  association.is_not, 
  evidence.code, 
  term.acc, 
  term.name 
 FROM   gene_product 
  INNER JOIN dbxref ON (gene_product.dbxref_id=dbxref.id) 
  INNER JOIN species ON (gene_product.species_id=species.id) 
  INNER JOIN association ON (gene_product.id=association.gene_product_id) 
  INNER JOIN evidence ON (association.id=evidence.association_id) 
  INNER JOIN term ON (association.term_id=term.id) 
 WHERE 
   dbxref.xref_key IN 
     ('Tb927.1.700','Tb927.1.710') 
 AND 





























pQuadra vector quadratic ligation with pQuadra1, pQuadra2, and pQuadra3 vectors, 
using the BstXI restriction enzyme sequence (depicted at the top of the diagram and 
shown in bold in other sequences). X: any nucleotide. Arrows indicate 5’-3’ 

























































human             ------------------------------------------------------------ 
S.cerevisiae      ------------------------------------------------------------ 
4EHP              ------------------------------------------------------------ 
4E2               ------------------------------------------------------------ 
4E1               ------------------------------------------------------------ 
4E3               MNPEAEEFVPKGNRTPGSGGRRGNGGGSRQIPVRGERQQPPPPPPPPQQQQQQVAPSSQT 60 
4E4               MQNLRADAVEYTPSWQKRSSAVAVTAPTPTTLPARATLPTPKTGFTTSMTSTNTITTHSG 60 
                                                                               
 
human             ------------------------------------------------------------ 
S.cerevisiae      ------------------------------------------------------------ 
4EHP              ------------------------------------------------------------ 
4E2               ------------------------------------------------------------ 
4E1               ------------------------------------------------------------ 
4E3               TLRASAEPFQPKGSQGFGLVGQVLPYVAGPPGGVPQAWESVEPVPPLSVWKSDSVQQAGA 120 
4E4               FSAQATTPQSPSCPPQGQQQQTVVPPPTRSPVSTHVIPTRMSPVHAPSAAFHMSPNAVSY 120 
                                                                               
 
human             ----------------MATVEPETTPTPNPPTTEEEKTE---------SNQEVANPEHYI 35 
S.cerevisiae      ----------------MSVEEVSKKFEENVSVDDTTATP---------KTVLSDSAHFDV 35 
4EHP              -----------MSMEKVANKQYETKNWPDIVDSDDSDVD---------NQIDVDNLPPLE 40 
4E2               -------------MQTLLRPRPGEPTLFGPPTNQCTQLWGVWEM----WCVLPDGHEAAT 43 
4E1               ----------------MMAESSAKEMEANQVSAAGDQTA-----------KADDRYVIID 33 
4E3               KPLSLSATPYTPTNPKISSKFPATPEAQRGPSTEFKDTTPASLQPQEKEVVEVGEKAVAI 180 
4E4               VPRGAAAGSLMPLPTSTADLAVEKELQRKQQSGSPSTSSWVTTCTKSNGVRSATSPVPKA 180 
                                                                               
 
human             KHP--------------------------------------------------------- 38 
S.cerevisiae      KHP--------------------------------------------------------- 38 
4EHP              VGPGEN------------------------------------------------------ 46 
4E2               ATPN-------------------------------------------------------- 47 
4E1               RGVKRH------------------------------------------------------ 39 
4E3               ASPPEEDAVAANGGSVDASGAPSTQNFTVGEIVENDFSGSMLPSLFQVEVLDKPAPAEPV 240 
4E4               GSTPIVAEISVDKTDEEVLEISRCSSLKASAPAFLPRRTLNRSNMTKPSPFTLTPDSGDM 240 
                                                                               
 
human             -LQNRWALWFFK--NDKSKT-WQANLRLISKFDTVEDFWALYNHIQLSSNLMPGCDYSLF 94 
S.cerevisiae      -LNTKWTLWYTKPAVDKSES-WSDLLRPVTSFQTVEEFWAIIQNIPEPHELPLKSDYHVF 96 
4EHP              RLQHTYCLWFSRKETQRAAADYSKSLHMVGRCASVQQWWSLYSHLIRPTALKPYRELLLF 106 
4E2               -VRGSGAKKGGMSKTKVKKATWLDQVRSIGLFDSAEGFWGIITCTLNPSQLPPGFNYYLF 106 
4E1               LLNRPWTLWYDSVSTYDCKQ-WELSLIEVMTVRTVEDFFAMLHYCKPPHVLRVSAQYHFF 98 
4E3               RFNTVWALYADEHPTPFGAP-LAYHPVLVHLVGDVECFWRLWRHLPPPSTLLPAFTYHWF 299 
4E4               RFGDPWCLFYLPVGGPDSTRESTYDPTLVFRMDCISSFWKVFNNIPEPTRMCAG-TLYLF 299 
                   .                          :      . :: :      .  :        * 
 
human             KDGIEPMWEDEKNKRGGRWLITLNK----------------------QQRRSDLDRFWLE 132 
S.cerevisiae      RNDVRPEWEDEANAKGGKWSFQLR------------------------GKGADIDELWLR 132 
4EHP              KQGIIPMWEDPANSKGGQWLIRLR--------------------------KNKVDRAWEN 140 
4E2               RRNIAPMWEHEANRRGGRWVMRFRVSQHDDSPATALDGAV----AAAAEGQLPVDRAWEA 162 
4E1               REGVKPMWEDPNNKAGGKLWVSLDDKTMTDKSGAAGGGKTRKDNGADADKKPELDTVWEN 158 
4E3               RRDIRPNWEHTRNKNGGTITFVIFDRDK-----------------PGLNNKQTMDDAFMA 342 
4E4               RDGINPKWEDLRNRDGGIVRAKVR--------------------------PQVVDDAWLH 333 
                  : .: * **.  *  **     .                              :*  :   
 
human             TLLCLIGE--SFDDYSDDVCGAVVN--VRAKGDKIAIWTTECENREA---VTHIGRVYKE 185 
S.cerevisiae      TLLAVIGE--TIDEDDSQINGVVLS--IRKGGNKFALWT-KSEDKEP---LLRIGGKFKQ 184 
4EHP              VCMAMLGE--QFLVG-DEICGVVLQ--TKYPEDSLSVWHRTATDMTS---TTRIRDTLRR 192 
4E2               LCVAMIGE--QLPGDETEICGAVVRRAERRRDWKLSLWTRTAADRCT---QERIGFFVKD 217 
4E1               VLIALVGEYLDYGVEGEHIMGVVLT--KRKYCNRIALWLKDASDSDA---VAAIEKQLVK 213 
4E3               MLMACSGE--SLAESTTNLNGVMLK-VRQNKPTTLQIWTASSDELKLRSLARSLRTLLEK 399 
4E4               LLCRTVGES-WSRSVRNSVNGIALK--VRAAAFMLEVWVTEQTSELMSDISELLHKFLGD 390 
                        **          : *  :    :     : :*     .         :       
 
human             RLGLPPKIVIGYQSHADTATKSGSTTKNRFVV----------- 217 
S.cerevisiae      VLKLTDDGHLEFFPHSSANGRHPQPSITL-------------- 213 
4EHP              ILNIPLTTALEYKIHCDSLKYVSINKGPLKS------------ 223 
4E2               LLHLE-DGSLQYFSHRELMQASEKGNWDVPPLYQL-------- 251 
4E1               EAGLLPATKPIFTAHGASKA----------------------- 233 
4E3               VIGPKPLQKLEYFSHQRTQVGAPGSLAGRMKGKPSRITPDFTL 442 
4E4               AFQVPYIPHSVAQERAATNAAALAVKEKKNRGNRRLW------ 427 
                                : 
 
ClustalW2 alignment of the protein sequences of four Trypanosoma brucei eIF4E 
homologues (‘4E1-4’), human eIF4E (‘human’; accession number: P06730), S. 
361 
cerevisiae eIF4E (‘S.cerevisiae’; accession number: P07260), and 4EHP from 
Drosophila melangaster (‘4EHP’; accession number: Q8T3K5). Residues 
highlighted in grey are those reported to be important for interactions with the 
mRNA cap or eIF4G (see Section 5.2) and were used for the generation of Table 5.1. 
Asterisk (*): single, fully conserved residue; colon (:): conservation between groups 












































































Feature map from RSAT oligo-analysis of genes enriched in stumpy form polysome 


































































































Feature map from RSAT oligo-analysis of genes enriched in slender form polysome 
associated transcripts, showing locations of over-represented unique 8-mer 
sequences. 
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